



REPUBLIQUE ALGERIENNE DEMOCRATIQUE ET POPULAIRE

MINISTRE DE L'ENSEIGNEMENT SUPERIEUR

ET DE LA RECHERCHE SCIENTIFIQUE

UNIVERSITE KASDI MERBAH-OUARGLA

FACULTE DES MATHEMATIQUES ET DES SCIENCES DE LA MATIERE

DEPARTEMENT DE CHIMIE

N° d'ordre:.....

N° de série:.....

**THÈSE DE L'OBTENTION D'UN DIPLÔME DE DOCTORAT 3ème
Cycle (LMD)**

**Spécialité : Electrochimie des substances bioactives d'intérêts
pharmaceutiques**

Intitulé :

**Etude ethnobotanique et phytochimique, evaluation des
activités biologiques de quelques plantes médicinales du
Sahara Septentrional**

Soutenue publiquement

Présentée par :

Wafa ZAHNIT

Le: 11/ 10/ 2023

Devant le jury composé de :

Mr. Hocine Dendougui	Professeur	U.K.M Ouargla	Président
Mr. Mohamed Yousfi	Professeur	U.A.T Laghouat	Examineur
Mr. Abdelkrim Rebiai	Professeur	U.E.H.L El-Oued	Examineur
Mrs. Sakina Khallef	M.C.A	U.K.M. Ouargla	Examineur
Mrs. Ouanissa Smara	Professeur	U.K.M. Ouargla	Rapporteur
Mr. Lazhar Bechki	Professeur	U.K.M. Ouargla	Co- Rapporteur

Année universitaire: 2022/2023



PEOPLE'S DEMOCRATIC REPUBLIC OF ALGERIA
MINISTRY OF HIGHER EDUCATION AND
SCIENTIFIC RESEARCH
KASDI MERBAH UNIVERSITY - OUARGLA

Order Number:.....

Serial Number:.....

FACULTY OF MATHEMATICS AND MATERIAL SCIENCES

DEPARTMENT OF CHEMISTRY

THESIS TO OBTAIN A DOCTORAL DIPLOMA (LMD)

**Specialty: Electrochemistry of Bioactive Substances of Pharmaceutical
Interest**

Entitled

**Ethnobotanical and phytochemical study, evaluation of the
biological activities of Some medicinal plants of The
Northern Sahara**

Publicly presented and supported

By:

Wafa ZAHNIT

The: 11/10 /2023

In front of the jury composed of:

Mr. Hocine Dendougui	Professor	U.K.M Ouargla	President
Mr. Mohamed Yousfi	Professor	U.A.T Laghouat	Examiner
Mr. Abdelkrim Rebiai	Professor	U.E.H.L El-Oued	Examiner
Mrs. Sakina Khallef	M.C.A	U.K.M Ouargla	Examiner
Mrs. Ouanissa Smara	Professor	U.K.M. Ouargla	Supervisor
Mr. M. Bechki Lazhar	Professor	U.K.M. Ouargla	Co-supervisor

Year Universitaire: 2022/2023

DEDICATION

*to the hopeless years gone by and the unknowns to be arrived
to the one who kneed me with notions and the one whose words rescued me
every day*

*To my Parents: **Mohamed Adnane & Dalila Benouakhir***

"I love you deeply with all my heart"

*To my Brothers: **Mohamed Riadh & Abelraouf***

"Both of you have been my best cheerleaders"

*To my Sister: **Raouia***

"I love you without measure"

*To my Son: **Ahmed Amine***

*"You made me stronger, better and more fulfilled than I could have ever
imagined. I love you to the moon "*

ACKNOWLEDGMENT

This study was conducted across multiple research facilities and necessitated the cooperation and participation of numerous individuals to prove the African saying "one hand cannot tie a package". I want to express my gratitude to all those who contributed in various capacities toward successfully completing this work.

*First and foremost, I would like to thank my academic supervisors, Pr. **Ouanissa Smara** and Pr. **Lazhar Bechki** at UKMO, for agreeing to supervise this work and for being so helpful and supportive throughout the years it took to complete it, as well as for the advice they gave me and the qualities they exhibited as humans. I want to thank you very much for everything.*

*I would like to express my deepest appreciation to the jury members: Pr. **Hocine Dendougui** at Kasdi Merbah University-Ouargla, for agreeing to act as jury chair. I am very sensitive to the honor given to me by the examiners of this work, Pr. **Mohamed Yousfi** at Amar Telidji Laghouat University and Pr. **Abdelkrim Rebiai** at University Echahid Hama Lakhdar El-Oued for agreeing to evaluate to review this thesis and to be part of my jury. I sincerely thank Dr. **Sakina Khallef** from Kasdi Merbah Ouargla for her kind attention to this project and for agreeing to review it.*

*This work was carried out at the Valorization and Promotion of Saharan Resources Laboratory (VPRS), UKMO, under the direction of Professor **Mohamed alakhder Belfar**, department of chemistry, faculty of science, The Centre for Scientific and Technical Research on Arid Regions (C.R.S.T.R.A) with the assistance of Pr. **Kechebar Mohamed**, and **Dr. Benouamane Ourida**, the Scientific and Technical Research Center in Physico-Chemical Analysis (CRAPC), with the assistance of Dr. **Belkhalifa Hakim**, Mr. **Boussebaa Walid** and Dr. **Sabah Menaâ**, and at the Laboratory of Valorisation and Technology of Sahara Resources (VTRS) El-Oeud University, Department of Chemistry, under the direction of Pr. **Touhami Lanez**, and Dr. **Elhafnaoui Lanez** to whom I extend my sincere and profound gratitude. I want to express my gratitude to the reactor chemistry team, as well as the technical and administrative staff of the Nuclear Research Centre (CRNB) and the NAA Department at the Draria Nuclear Research Centre (CRND) and the Laboratory of Biotechnology Research Center-Constantine (CRBT) under the direction of Dr. **Bensouici Chawki**.*

*I want to extend my profound gratitude and respect to Dr. **Mahdi Belguidoum** and Dr. **Mohamed Mesaoudi** for imparting their expertise and knowledge and instilling a research-oriented mindset that will prove invaluable throughout my life.*

A special feeling of gratitude to Asma Abid, Tatou Touahria, Dr. Imen Larkem, Pr. Benchikha Naima, Dr. Amira Boutarfaia, Dr. Chahrazad BAKKA, Amina Chouh, Sihem Boubekour , Dr. Chaima Bensaci, Dr. Zineb Rahmani, Dr. Abdeldjabbar Messaoudi , Saida Benferdia for their invaluable assistance, insightful guidance, unwavering encouragement, steadfast support, true friendship, and the multitude of experiences that we shared.

I would like to thank the various members of the Valorization and Promotion of Saharan Resources (VPRS) Laboratory and all professors of chemistry at the department of chemistry at UKMO, with whom I had the opportunity to work, they provided a friendly and cooperative atmosphere at work and also helpful feedback and insightful comments on my work.

I want to thank all my friends and colleagues for being supportive and kind throughout my work. Your hospitality, help, understanding, encouragement, and sympathy have been invaluable to me.

Thank you all

Abstract

Artemisia campestris L. and *Fagonia bruguieri* DC. are commonly used in folk medicine due to its antioxidant, anti-diabetic, anti-inflammatory, and neuroprotective properties.

Our study assessed the total phenolics and flavonoids contents, antioxidant, and pharmacological activities of various organic extracts prepared from the aerial parts of *Artemisia campestris* L. and *Fagonia bruguieri* DC. The two species were first collected from the mountainous Hoggar region in Tamanrasset town, southern Algeria. Furthermore, this study focuses on the isolation and structural elucidation of bioactive compounds originating from the polar extracts (n-Butanol) of *Artemisia campestris* L. and *Fagonia bruguieri* DC. aerial parts, as well as their mineral elements and chemical profile were analysed.

Two analytical techniques, namely inductively coupled plasma mass spectrometry (ICP-OES) and instrumental neutron activation analysis (INAA) were applied to determine the concentration of mineral elements. The phytochemical profiling in *A. campestris* L. and *F. bruguieri* DC was characterised using HPLC-UV and LC-MS/MS analysis. A variety of techniques are carried out to isolate secondary metabolites, including maceration, extraction, separation, and purification. Chromatographic strategies such as thin-layer chromatography (TLC), preparative thin-layer chromatography (PTLC), and chromatography column (CC) are utilised, with stationary phases including silica gel, reversed-phase C-18, and Sephadex LH-20. The compounds obtained were structurally identified using 1D and 2D NMR spectroscopic techniques.

An array of assays was conducted to evaluate the antioxidant properties of the samples, including DPPH, ABTS, beta-carotene, GOR free radical, reducing power, cupric reducing antioxidant capacity (CUPRAC), O-Phenanthroline assays and $O_2^{\cdot-}$ free radical scavenging assay.

The present investigation aimed to evaluate the potential inhibitory effects of *A. campestris* L. and *F. bruguieri* DC. extracts in vitro with regard to their anti-cholinesterase, anti-lipase, and anti-diabetic activities. The sun protection factor (SPF) of the plants was quantified to determine its photoprotective effect, whereas its anti-inflammatory potential was assessed through the protein denaturation technique.

The findings of our study indicate that *A. campestris* L. and *F. bruguieri* DC. exhibit a notable abundance of essential minerals, encompassing both macro and micro elements (such as Ca, Na, Fe, Mg, Cu, Zn, Li, Mn, Sr, Ti, Ni, Co, Mo, Cd, Pb and Cr), with concentrations that are in close proximity to the recommended values established by the FAO. The results obtained from LC/MS-MS and HPLC-UV analyses indicated that the AcEAE and FbBE extracts are the richest in phenolic acids and flavonoids. The investigation of chemical compounds in AcBE and FbBE led to the identification of three compounds, consisting of two derivatives of phenolic acid and one polysaccharide, all of which were characterised.

AcPEE and FbDE have been discovered as the most potent inhibitors of alpha-amylase. The extracts AcEAE, AcBE, and FbBE exhibited noteworthy inhibitory effects on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). In terms of anti-lipase activity, AcEAE and FbDE exhibited potent inhibition of the pancreatic lipase enzyme. The anti-inflammatory efficacy of AcBE and FbBE was found to be important. *A. campestris* L. and *F. bruguieri* DC. were found to have a robust photoprotective ability, absorbing UV radiations with SPF values ranging from $11.25 \pm 0,1$ to $43,86 \pm 0,12$. The findings demonstrate that polar extracts displayed remarkable antioxidant activity across multiple systems, with AcEAE and FbBE exhibiting the most optimal performance, except for the $O_2^{\cdot-}$ free radical scavenging assay, where AcEA and FbAE exhibited boosted antioxidant activity.

Due to their compositions and potent biological properties, *A. campestris* L. and *F. bruguieri* DC. have the potential to prove pharmaceutical formulations, medical research, and health.

Keywords: *A. campestris* L.; *F. bruguieri* DC.; antioxidant activity; Alzheimer's disease; LC-MS/MS, INAA; secondary metabolite.

Résumé

Artemisia campestris L. et *Fagonia bruguieri* DC. sont deux espèces couramment utilisées en médecine traditionnelle en raison de leurs propriétés antioxydantes, antidiabétiques, anti-inflammatoires et neuroprotectrices.

L'objectif principal de ce travail est l'étude phytochimique, pharmacologique des différents extraits des parties aériennes d'*Artemisia campestris* L. et de *Fagonia bruguieri* DC. Les deux espèces ont d'abord été collectées dans la région montagneuse du Hoggar dans la ville de Tamanrasset, au sud de l'Algérie. L'analyse quantitative des extraits de plantes a été évaluée à l'aide des méthodes colorimétriques, ainsi que les activités antioxydantes et pharmacologiques de divers extraits organiques d'*Artemisia campestris* L. et de *Fagonia bruguieri* DC. De plus, cette étude a porté sur l'isolement et l'élucidation structurale de composés bioactifs provenant des extraits polaires (n-Butanol) d'*Artemisia campestris* L. et de *Fagonia bruguieri* DC. ainsi que leur analyse qualitative et quantitative, et la mesure de leurs concentration en éléments minéraux.

Deux techniques analytiques, à savoir la spectrométrie de masse à plasma à couplage inductif (ICP-OES) et l'analyse instrumentale par activation neutronique (INAA) ont été appliquées pour mesurer la concentration des éléments minéraux. Dans le but d'évaluer la composition chimique d'*A. campestris* L. et *F. bruguieri* DC. l'analyse quantitative et qualitative a été caractérisée par l'analyse HPLC-UV et LC-MS/MS.

Afin d'isoler les métabolites secondaires, on a procédé à la macération, l'extraction, la séparation et la purification. Des techniques chromatographiques telles que la chromatographie sur couche mince (TLC), la chromatographie préparative sur couche mince (PTLC) et la chromatographie sur colonne (CC) ont été utilisées, avec des phases stationnaires comprenant du gel de silice, du RP C-18 et du Sephadex LH-20. Les composés isolés ont été structurellement identifiés à l'aide de techniques spectroscopiques RMN 1D et 2D.

Une série des tests a été menée pour évaluer les propriétés antioxydantes des différents extraits, y compris DPPH, ABTS, bêta-carotène, GOR, pouvoir réducteur, CUPRAC, O-Phenanthroline et $O_2^{\cdot-}$ par voie électrochimique.

En outre, La présente étude visait à évaluer les effets inhibiteurs potentiels de *A. campestris* L. et *F. bruguieri* DC. in-vitro en ce qui concerne leurs activités Anti-cholinestérase, Anti-lipase et Anti-diabétique. Le facteur de protection solaire (FPS) des plantes a été quantifié

pour déterminer leurs effets photo-protecteur, tandis que leur potentiel anti-inflammatoire a été évalué par la technique de dénaturation des protéines.

Les résultats de notre étude indiquent que *A. campestris* L. et *F. bruguieri* DC. présentent une abondance notable de minéraux essentiels, englobant à la fois des éléments macro et micro-nutritifs (tels que Ca, Na, Fe, Mg, Cu, Zn, Li, Mn, Sr, Ti, Ni, Co, Mo, Cd, Pb et Cr), avec des concentrations proches des valeurs recommandées établies par la FAO. Les résultats obtenus à partir des analyses LC/MS-MS et HPLC-UV ont indiqué que les extraits AcEAE et FbBE sont les plus riches en acides phénoliques et en flavonoïdes. L'étude de la composition chimique dans AcBE et FbBE a conduit à l'identification de trois composés, constitués de deux dérivés d'acide phénolique et d'un polysaccharide.

AcPEE et FbDE ont montrés l'effet inhibiteur le plus puissant contre l'alpha-amylase. Les extraits AcEAE, AcBE et FbBE ont révélé des effets inhibiteurs notables sur l'acétylcholinestérase (AChE) et la butyrylcholinestérase (BChE). En termes d'activité anti-lipase, AcEAE et FbDE ont présenté une puissante inhibition de l'enzyme lipase pancréatique. L'efficacité anti-inflammatoire de l'AcBE et du FbBE s'est avérée importante. *A. campestris* L. et *F. bruguieri* DC. se sont avérés avoir une capacité photoprotectrice robuste, absorbant les rayonnements UV avec des valeurs SPF allant de $11,25 \pm 0,1$ à $43,86 \pm 0,12$. Les résultats montrent que les extraits polaires présentent une activité antioxydante importante dans plusieurs systèmes, AcEAE et FbBE montrant les performances les plus optimales, excepté lors du test de piégeage des radicaux libres $O_2^{\cdot-}$, où AcEA et FbAE présentent une activité antioxydante très forte. En raison de la compositions chimiques et de la puissances des propriétés biologiques, d'*A. campestris* L. et *F. bruguieri* DC. ont le potentiel d'améliorer les formulations pharmaceutiques, la recherche médicale et la santé.

Mots clés : *F. bruguieri* DC.; *A. campestris* L.; activité antioxydante ; AChE; LC-MS/MS, INAA; métabolite secondaire.

ملخص

تستخدم النباتان المختارتان *Artemisia campestris* L. و *Fagonia bruguieri* DC. للدراسة بشكل شائع في الطب التقليدي نظراً لخصائصهما المضادة للأكسدة والسكري والالتهابات والوقاية العصبية.

الهدف من هذا العمل هو الدراسة الكيميائية النباتية والفعالية الدوائية (الفارماكولوجية) وكذلك المحتوى الفينولي و الفلافونويدى للمستخلصات العضوية المختلفة المحضرة من الأجزاء الهوائية للنبتين من الصحراء الجزائرية , اين تم جمع النوعين لأول مرة من المنطقة الجبلية الهقار لمدينة تمنراست، جنوب الجزائر. علاوة على ذلك، تركز هذه الدراسة على الفصل والكشف عن البنى للمركبات الفعالة بيولوجياً المستخلصة من المستخلصات القطبية (n- بيوتانول) من *Artemisia campestris* L. و *Fagonia bruguieri* DC. بالإضافة الى دراسة التحليل النوعي لمختلف المستخلصات للنبتين وكذلك العناصر المعدنية والملف الكيميائي.

طبقت تقنيتين تحليليتين ، وهما مقياس الطيف الكتلي للبلازما المقترن بالحث (ICP-OES) وتحليل التنشيط النيوتروني (INAA) لتحديد تركيز العناصر الكيميائية المعدنية. كما اجري التحليل الكمي و النوعى بهدف تحديد التركيب الكيميائي للنبتين في *A. campestris* و *F. bruguieri* باستخدام HPLC-UV و LC-MS / MS. قمنا بتطبيق العديد من التقنيات الكروماتوغرافية لعزل منتجات الايض الثانوية، بما في ذلك النقع، الاستخلاص، الفصل، والتنقية اين استخدامت تقنيات مختلفة مثل عمود هلام السيليكا، عمود C18 ، وكروماتوغرافيا الطبقة الرقيقة التحليلية والتحضيرية. حددت البنى الكيميائية للمركبات التي تم فصلها و الكشف عنها باستخدام تقنيات طيف الرنين المغناطيسي أحادي وثنائي البعد. اجريت مجموعة من الاختبارات لتقييم الخصائص المضادة للأكسدة للعينات، بما في ذلك DPPH , β -caroténe , ABTS , CUPRAC, GOR, و Phenanthroline و $Oz^{\cdot-}$.

هدفت هذه الدراسة ايضا إلى تقييم التأثيرات المثبطة المحتملة لمستخلصات *A. campestris* L. و *F. bruguieri* DC. فيما يتعلق بأنشطتها Anti-cholinesterase, Anti-lipase ومضاد السكري. بالإضافة إلى ذلك، تطرقنا الى قياس عامل الحماية من الشمس (SPF) للنباتات لتحديد تأثيرها الواقى من الضوء، في حين قمنا بتقييم إمكاناتها المضادة للالتهابات من خلال تقنية تمسخ البروتين.

سمحت الدراسة فيما يخص المحتوى المعدني للنبتين التي تم تحديدها بطريقتان هما: INAA و ICP-OES ، أنهما غنيتان بالمعادن الضرورية للكائن الحى، (مثل Ca و Na و Fe و Mg و Cu و Zn و Li و Mn و Sr و Ti و Ni و Co و Mo و Cd و Pb و Cr). بالإضافة إلى ذلك، كان تركيز العناصر السامة أقل بكثير من القيم المرجعية للسمية المحددة من طرف المنظمة للصحة العالمية. الدراسة الفيتو كيميائية للمستخلصين AcBE و FbBE باستخدام مختلف الطرق الكروماتوغرافيا، مكنتنا من تحديد ثلاث مركبات ، تتكون من 2 مركبات فينولية و 1 متعدد السكرات.

اظهر كل من المستخلصين AcPEE و FbDE على أنهما أكثر فاعلية اتجاه تثبيط ألفا أميلاز. كما تميزت المستخلصات AcEAE AcBE و FbBE بتأثيرات مثبطة على كل من Acetylcholinesterase (AChE) و Butyrylcholinesterase (BChE). فيما يخص النشاط المضاد للليباز، أظهر AcEAE و FbDE تثبيطاً قوياً لإنزيم الليباز البنكرياس. اما المستخلصات AcBE و FbBE أثبتت فعالية جد مهمة كمضادات للالتهابات. للنبتين قدرة قوية للحماية من الأشعة فوق البنفسجية بقيم SPF تتراوح من 11.25 ± 0.1 إلى 43.86 ± 0.12 . ووضحت النتائج

للمستخلصات القطبية نشاطاً مضاداً للأكسدة ملحوظاً من خلال استعمال أنظمة متعددة، حيث أظهر AcEAE و FbBE فعالية كبيرة، باستثناء $O_2^{\cdot-}$ حيث أظهر AcEA و FbAE نشاطاً مضاداً للأكسدة عالى.

نظراً للنتائج المتحصل عليها والخصائص البيولوجية القوية و التى اثبتت ان للنبتين: *A. campestris* و *F. bruguieri* القدرة على تحسين التركيبات الصيدلانية ، والبحوث الطبية ، والصحة.

الكلمات المفتاحية: *A. campestris* L; *F. bruguieri* DC. ; نشاط مضاد للأكسدة ; AchE; ; LC-MS / MS ; INAA; منتجات الايض الثانوية.

Acknowledgment

Abstract

List of Content	I
Abréviations and Symbols	VI
List of Tables	XV
List of Figures	VIII
Introduction	XXI

Part 1 : Bibliographic part

Chapter I: Literature overview

I.1. Asteraceae	1
I.1.1. Botany of the family Asteraceae.....	1
I.1.2. Geographic distribution of the family Asteraceae	3
I.1.3. Folk-medicinal and Pharmacology of the family Asteraceae	3
I.1.4. Chemistry of the family Asteraceae	4
I.1.5. The <i>Artemisia</i> genus	4
I.1.5.1. Botany of the genus <i>Artemisia</i>	5
I.1.5.2. Geographic distribution of the genus <i>Artemisia</i>	6
I.1.5.3. Folk-medicinal of the genus <i>Artemisia</i>	6
I.1.5.4. Pharmacology of the genus <i>Artemisia</i>	8
I.1.6. <i>Artemisia campestris</i> L.....	11
I.1.6.1. Botany of the <i>Artemisia campestris</i> L.....	12
I.1.6.2. Geographic distribution of <i>Artemisia campestris</i> L.....	13
I.1.6.3. Folk-medicinal of <i>Artemisia campestris</i> L.....	14
I.1.6.4. Pharmacology of <i>Artemisia campestris</i> L.....	15
I.1.6.5. Secondary metabolites isolated from the <i>Artemisia</i> genus.....	18
I.1.6.5.1. Flavonoids.....	18
I.1.6.5.2. Lignans.....	27
I.1.6.5.3. Coumarins.....	28
I.1.6.5.4. Chromones.....	29
I.1.6.5.5. Acetophenones.....	29
I.1.6.5.6. Terpenoids.....	31
I.2. Zygophyllaceae	34
I.2.1. Botany of the family Zygophyllaceae.....	34
I.2.2. Geographic distribution of the family Zygophyllaceae	34
I.2.3. Folk-medicinal and Pharmacology of the family A Zygophyllaceae	34
I.2.4. Chemistry of the family Zygophyllaceae	36
I.2.5. The <i>Fagonia</i> genus	36
I.2.5.1. Botany of the genus <i>Fagonia</i>	36

ABBREVIATIONS AND SYMBOLS

I.2.5.2.	Geographic distribution of the genus <i>Fagonia</i>	36
I.2.5.3.	Folk-medicinal of the genus <i>Fagonia</i>	37
I.2.5.4.	Pharmacology of the genus <i>Fagonia</i>	38
I.2.6.	<i>Fagonia bruguieri</i> DC.....	40
I.2.6.1.	Botany of the <i>Fagonia bruguieri</i> DC.....	41
I.2.6.2.	Geographic distribution of <i>Fagonia bruguieri</i> DC.....	42
I.2.6.3.	Folk-medicinal of <i>Fagonia bruguieri</i> DC.....	42
I.2.6.4.	Pharmacology of <i>Fagonia bruguieri</i> DC.....	43
I.2.6.5.	Secondary metabolites isolated from the <i>Fagonia</i> genus.....	44
I.2.6.5.1.	Flavonoïds.....	44
I.2.6.5.2.	Terpenoids.....	49
Chapter II: Valorisation of Bioactive Compounds		
II.1.	Introduction.....	58
II.2.	Phenolic compounds	58
II.2.1.	Phenolic acids	58
II.2.1.1	Biosynthesis	59
II.2.2.	Flavonoids.....	61
II.2.2.1.	Biosynthesis.....	61
II.2.3.	Tannins.....	63
II.3.	Biological properties of phenolic compounds.....	63
A/.	Phenolic acids.....	64
B/.	Flavonoids.....	64
C/.	Tannins.....	64
D/.	Terpenic compounds.....	64
E/.	Saponins.....	64
II.3.1.	Antioxidant properties	64
II.3.1.1.	Free radicals.....	64
II.3.1.2.	The different reactive oxygen species.....	65
II.3.1.3.	Oxidative stress.....	65
II.3.1.4.	Phenolic compounds as antioxidants.....	65
II.3.2.	Anti-inflammatory activity	67
II.3.3.	Anti-diabetic activities	67
II.3.3.1.	Reduction of the adsorption of sugars.....	68
II.3.3.2.	Inhibition of enzymes involved in the occurrence and complications of diabetes related to obesity.....	68
II.3.3.3.	Increase in Glucose Transport.....	68
II.3.3.4.	Increase in insulin secretion.....	68
II.3.4.	Anti-cholinesterase activity	69
II.4.	Mineral elements.....	70

Part 2: Experimental part

Chapter III: Extraction, Chemical Composition, Purification and Separation

III.1.	Plant Material	71
III.2.	Preparation of Extracts.....	71
III.3.	Qualitative Phytochemical Screening.....	74
III.3.1.	Flavonoids test.....	74
III.3.2.	Alkaloids Test.....	74
III.3.3.	Tannins Test.....	74
III.3.4.	Terpenoids Test.....	74
III.3.5.	Coumarins Test.....	75
III.3.6.	Reducing compounds Test.....	75
III.3.7.	Saponins Test.....	75
III.4.	Mineral Analysis using the INAA and ICP-OES techniques.....	75
III.4.1.	Instrumental Neutron Activation Analysis (INAA).....	75
III.4.1.1.	Irradiation and Measurement.....	76
III.4.1.2.	Quality Control and Quality Assurance (QC/QA).....	77
III.4.2.	Inductively Coupled Plasma ICP-OES Analysis.....	78
III.5.	Analytical Chromatography Techniques.....	79
III.5.1.	Quantitative analysis of phenolic compounds by High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV).....	79
III.5.1.1.	Preparation of extracts for HPLC-UV analysis.....	79
III.5.1.2.	Preparation of polyphenol standard.....	80
III.5.1.3.	Chromatographic instruments and HPLC analysis conditions.....	80
III.5.1.4.	LOD and LOQ.....	80
III.5.2.	Quantitative analysis of phenolic compounds by high-performance liquid chromatography coupled to tandem mass spectrophotometry (LC MS/MS).....	82
III.5.2.1.	Preparation of extracts for LC-MS/MS analysis.....	82
III.5.2.2.	Chromatographic instruments and LC-MS/MS analysis conditions.....	82
III.6.	Separation and purification.....	83
III.6.1.	Isolation of the constituents of the Butanol fraction of <i>Artemisia campestris</i> L. aerial part AcBE...	83
III.6.2.	Isolation of the constituents of the Butanol fraction of <i>Fagonia bruguieri</i> DC. Aerial part FbBE....	88
Chapter IV : Biological Activities		
IV.1.	Total bioactive components assessment.....	94
IV.1.1.	Total phenolic content (TPC).....	94
IV.1.2.	Total flavonoids content (TFC).....	95
IV.2.	Antioxidant Activity.....	96
IV.2.1.	DPPH [•] Scavenging Activity.....	97
IV.2.2.	ABTS Scavenging Activity	98
IV.2.3.	β -Carotene-Linoleic Acid Bleaching Activity.....	99
IV.2.4.	Cupric Reducing Antioxidant Capacity (CUPRAC) Activity.....	100
IV.2.5.	Reducing Power Assay.....	101

ABBREVIATIONS AND SYMBOLS

IV.2.6.	Galvinoxyl (GOR) Scavenging Activity.....	102
IV.2.7.	O-Phenanthroline Activity.....	103
IV.2.8.	Antioxidant Activity Evaluation via Electrochemical Method.....	103
IV.2.8.1.	OH ⁻ free radical scavenging assay.....	103
IV.3.	Enzymes Inhibitory Activity.....	105
IV.3.1.	Evaluation of anti-Alzheimer activity.....	105
IV.3.1.1.	Cholinesterase Inhibitory Activity.....	105
IV.3.2.	Evaluation of anti-diabetic activity.....	107
IV.3.2.1.	Alpha -amylase Inhibitory activity.....	107
IV.3.3.	Evaluation of anti-obesity activity.....	108
IV.3.3.1.	Pancreatic Lipase Inhibitory Activity.....	108
IV.3.4.	Anti-inflammatory Activity (BSA denaturation inhibition).....	109
IV.3.5.	Photoprotective Activity.....	109
IV.3.5.1.	Sun protection factor activity (SPF).....	109

Part 3: Results & Discussion part

Chapter V: Quantitative analysis and Structural Elucidation

V.1.	Qualitative phytochemical screening	112
V.2.	Mineral Analysis.....	114
V.2.1.	Calculation of Elementary (Mineral) Concentrations.....	114
V.2.2.	Evaluation of Results and Quality – Quality Assurance / Control (QC / QA).....	115
V.2.3.	Assessment of dietary intake of trace elements according to the RDA.....	117
V.2.5.	Potentially toxic elements and tolerable daily intake (TDI).....	123
V.3.	Quantitative analysis of phenolic compounds by High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV)	124
V.4.	Quantitative analysis of phenolic compounds by high-performance liquid chromatography coupled to tandem mass spectrophotometry (LC-MS/MS).....	131
V.5.	Structural Elucidation.....	144
V.5.1.	Identification of compounds isolated from of <i>Artemisia campestris</i> L. aerial parts (AcBE).....	144
V.5.1.1.	Compound I: (PN).....	144
V.5.2.	Identification of compounds isolated from of <i>Fagonia bruguieri</i> DC.aerial parts (FbBE).....	153
V.5.2.1.	Compound II: Pb.....	153
V.5.2.2.	Compound III: PV2.....	160

Chapter VI : Results and Discussion of Biological Activities

VI.1.	Total bioactive components assessment.....	169
VI.2.	Antioxidant Activity.....	173
VI.2.1.	DPPH [•] Scavenging Activity.....	173
VI.2.2.	ABTS Scavenging Activity.....	176
VI.2.3.	β -carotene-linoleic Acid Bleaching Activity.....	178
VI.2.4.	Cupric Reducing Antioxidant Capacity (CUPRAC) Activity.....	180
VI.2.5.	Reducing Power Assay.....	183

ABBREVIATIONS AND SYMBOLS

VI.2.6.	Galvinoxyl (GOR) Scavenging Activity.....	185
VI.2.7.	O-Phenanthroline Activity.....	187
VI.2.8.	Antioxidant Activity Evaluation via Electrochemical Method.....	192
VI.2.8.1.	O ₂ ^{•-} free radical scavenging assay.....	192
VI.3.	Enzymes Inhibitory Activity.....	202
VI.3.1.	Cholinesterase Inhibitory Activity.....	202
VI.3.1.1.	Acetylcholinesterase	202
VI.3.1.2.	Butyrylcholinesterase.....	204
VI.3.2.	Evaluation of anti-diabetic activity.....	208
VI.3.2.1.	Alpha -amylase Inhibitory activity.....	208
VI.3.3.	Evaluation of anti-obesity activity.....	211
VI.3.3.1.	Pancreatic Lipase Inhibitory Activity.....	211
VI.4.	Anti-inflammatory Activity.....	214
VI.5.	Sun protection factor activity (SPF).....	219

ABBREVIATIONS AND SYMBOLS

1D	one-dimensional
2D	two-dimensional
ABTS	2,2'-azinobis-(3-ethylbenzothiazolin-6-sulfonic)
AcAE	<i>Artemisa campestris</i> Aqueous Extract
AcBE	<i>Artemisa campestris</i> Butanol Extract
AcDE	<i>Artemisa campestris</i> Dichloromethane Extract
AcEAE	<i>Artemisa campestris</i> Ethyl Acetate Extract
AchE	Acetylcholine
AcME	<i>Artemisa campestris</i> Methanol Extract
AcPEE	<i>Artemisa campestris</i> Petroleum ether Extract
BchE	Butyrylcholinesterase
BHA	ButylHydroxyAnisol
BHT	ButylHydroxyToluen
BSA	Bovine serum albumin
COSY	correlated spectroscopy
CUPRAC	Cupric Reducing Antioxidant Capacity
<i>d</i>	Doublet
<i>dd</i>	Doublet of Doublet
DEPT	Distortionless Enhanced Polarization Transfer
DPPH	1,1-Diphényl-2-PicrylHydrazyl
DTNBA	5,5'-dithio-bis(2-nitrobenzoic) acid
FbAE	<i>Fagonia bruguieri</i> Aqueous Extract
FbBE	<i>Fagonia bruguieri</i> Butanol Extract
FbDE	<i>Fagonia bruguieri</i> Dichloromethane Extract
FbEAE	<i>Fagonia bruguieri</i> Ethyl Acetate Extract
FbPEE	<i>Fagonia bruguieri</i> Petroleum Ether Extract
HMBC	Heteronuclear Multiple Bond Coherence
HSQC	Heteronuclear Single Quantum Coherence
IC₅₀	Concentration Inhibitory at 50%
ICP-OES	Inductively coupled plasma - optical emission spectrometry
INAA	Instrumental neutron activation analysis
J (Hz)	Coupling constant (Hertz)

ABBREVIATIONS AND SYMBOLS

LC-MS/MS	Liquid Chromatography-Mass/Mass Spectrometry
<i>m</i>	Multiplet
<i>m/z</i>	Mass to charge ratio
NMR	Nuclear Magnetic Resonance
RP C-18	Reversed-phase C-18 column
SPF	Sun Protective Factor
TLC	Thin-layer chromatography
WHO	World health organization
δ (ppm)	Chemical shift
U	Unit
SF	Sub-fractions

List of Figures

N°	Chapter I	Page
Figure.I.1	Different types of flowers	2
Figure.I.2	Geographic distribution of the family Asteraceae	3
Figure.I.3	The synflorescences and leaves of different <i>Artemisia</i> species; A: <i>A. Absinthium</i> , B: <i>A. annua</i> , C: <i>A. dracunculus</i> , D: <i>A. vulgaris</i>	5
Figure.I.4	Geographical distribution of <i>Artemisia</i> species	6
Figure.I.5	<i>Artemisia</i> genus medicinal benefits	48
Figure.I.6	<i>Artemisia campestris</i> L.	12
Figure.I.7	<i>Artemisia campestris</i> L. illustrations (A) paniculate inflorescence, (B) Alternate-leaved capitula, (C) male flower, (D) female flower	13
Figure.I.8	Geographic distribution of <i>A. campestris</i> L. (A): Widespread geographic distribution of <i>A. campestris</i> L. ; (B): Geographical distribution of <i>A. campestris</i> L. in the Euro-Mediterranean region	14
Figure.I.9	<i>Fagonia</i> distribution map with endemism areas: (A): South America, (B): North America, (C): north of Mexico, (D): south of Africa, (E): Sahara-Sind includes Macaronesia, (F): the Horn of Africa, (G): Oman and Yemen, (H): west of Morocco, and (I): south of Iran	37
Figure.I.10	<i>Fagonia bruguieri</i> DC.	41
Figure.I.11	Drawing of <i>Fagonia bruguieri</i> DC.	41
Figure.I.12	Distribution of <i>Fagonia bruguieri</i> DC.	42
Figure.I.13	Oleanane saponins isolated from the genus <i>Fagonia</i> .	52
Figure.I.14	Ursan saponins isolated from the genus <i>Fagonia</i>	52
Figure.I.15	Triterpenes and saponins of the taraxastane type isolated from the genus <i>Fagonia</i>	53
Figure.I.16	Lupan-type triterpenes isolated from <i>Fagonia</i>	54
Chapter II		
Figure.II.1	Structure of principal phenolic acids	59
Figure.II.2	Biosynthesis of benzoic acid derivatives	60
Figure.II.3	Biosynthesis of cinnamic acid derivatives	60
Figure.II.4	Structure of a flavonoid	61
Figure.II.5	Flavonoid biosynthesis	62

LIST OF FIGURES

Figure.II.6	Basic structure of tanins. A : Condensed tannins ; B : Hydrolysable tannins	63
Figure.II.7	Oxidizing stress mechanism	65
Figure.II.8	Simplified presentation of antioxidant mechanisms of phenolic	66
Chapter III		
Figure.III.1	The geographical position of the collects, Tamanraasset (Hoggar) – Algeria	71
Figure.III.2	The protocol of extraction for different fractions of <i>A.campestris</i> L., and <i>F.bruguieri</i> DC.	73
Figure.III.3	Protocol for mineral element analysis using ICP-OES.	79
Figure.III.4	High-performance liquid chromatography (HPLC) chromatogram of phenolic compounds	81
Figure.III.5	Follow-up the TLC fractions silica gel column of AcBE after revelation with acidic solution	84
Figure.III.6	Scheme of the fractionation and isolation of pures compounds from AcBE aerial parts	85
Figure.III.7	Follow-up the separation of fraction A	86
Figure.III.8	Follow-up the separation of fraction B	87
Figure.III.9	TLC purification of JR1 and JR2 compounds	88
Figure.III.10	Follow-up the TLC fractions silica gel column of FbBE	89
Figure.III.11	Scheme the fractionation and isolation of pures compounds from FbBE aerial	90
Figure.III.12	Follow-up the separation of fraction A	91
Figure.III.13	Follow-up the separation of fraction B	92
Chapter IV		
Figure.IV.1	Gallic acid calibration curve for TPC quantification	95
Figure. IV.2	Quercetin calibration curve for TFC quantification	96
Figure.IV.3	Preparation of dilutions of different extracts	97
Figure.IV.4	The mechanism for reducing the DPPH ⁺ radical by an antioxidant	97
Figure.IV.5	Formation and trapping of the radical ABTS ⁺⁺ by an antioxidant donor of H [•]	98
Figure.IV.6	Reduction of the Cu ⁺² -Nc chromogenic complex	100
Figure.IV.7	Reduction of Fe ⁺³ by an antioxidant in the reducing power test	101
Figure.IV.8	Chemical structure of galvinoxyl	102
Figure.IV.9	Cyclic voltammogram for a reversible system	104

Figure.IV.10	Chemical mechanism of the Ellman method	106
Chapter V		
Figure.V.1	Comparison between measured values and the limit tolerance of essential elements	119
Figure.V.2	Comparison between measured values and the Tolerable Daily Intake of toxic elements	120
Figure.V.3	Phenolic compounds content identified by HPLC chromatogram in AcME. Detected Constituents are: GA: Gallic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.	125
Figure.V.4	Phenolic compounds content identified by HPLC chromatogram in AcPEE. Detcted compounds are: CGA: Chlorogenic Acid; V: Vanillin; p-CA: p-Coumaric Acid and RU: Rutin.	125
Figure.V.5	Phenolic compounds content identified by HPLC chromatogram in AcDE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin; NAR: Naringin and QC: Quercetin	126
Figure.V.6	Phenolic compounds content identified by HPLC chromatogram in AcEAE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.	126
Figure.V.7	Phenolic compounds content identified by HPLC chromatogram in AcBE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.	127
Figure.V.8	Phenolic compounds content identified by HPLC chromatogram in AcAE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin; NAR: Naringin and QC—Quercetin	127
Figure.V.9	Phenolic compounds content identified by HPLC chromatogram in FbDE. Detected compounds are: GA: Gallic Acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid. and NAR: Naringin	128

LIST OF FIGURES

Figure.V.10	Phenolic compounds content identified by HPLC chromatogram in FbEAE. Detected compounds are: GA: Gallic acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; NAR: Naringin and QC: Quercetin	129
Figure.V.11	Phenolic compounds content identified by HPLC chromatogram in FbBE. Detected compounds are: GA: Gallic Acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid and NAR: Naringin	129
Figure.V.12	Phenolic compounds content identified by HPLC chromatogram in FbAE. Detected compounds are: CGA : Chlorogenic Acid; CA: Caffeic Acid; p-CA: p-Coumaric Acid and RU: Rutin	130
Figure.V.13	Total ion current (TIC) profile of AcDE (A) AcEAE (B) and AcBE (C)	135
Figure.V.14	Mass spectra of detected compounds from <i>A. campestris</i> L. extracts	136
Figure.V.15	Total ion current (TIC) profile of FbDE (A) FbEAE (B) and FbBE (C)	140
Figure.V.16	Mass spectra of detected compounds from <i>F. bruguieri</i> DC.Extracts	141
Figure.V.17	¹ H NMR spectrum of compound PN (400 MHz, Methanol-d ₄)	146
Figure.V.18	¹ H NMR spectrum spread out (3.25-4.15 ppm) of compound PN (400 MHz, Methanol-d ₄)	146
Figure.V.19	¹³ C NMR Spectrum of compound PN (Methanol-d ₄ , 125 MHz)	147
Figure.V.20	DEPT 135 ° Spectrum of compound PN (Methanol-d ₄ , 125 MHz)	148
Figure.V.21	HMBC spectrum spread out of the first hexose	149
Figure.V.22	The HMBC correlations of the first hexose	149
Figure.V.23	HSQC spectrum spread out of first hexose	150
Figure.V.24	The HMBC correlations of the second hexose	151
Figure.V.25	HSQC spectrum spread out of second hexose	151
Figure.V.26	HSQC spectrum spread out of second hexose	152
Figure.V.27	Structure of α-D-glucopyranosyl-(1↔2)-β-D-fructofuranoside	152
Figure.V.28	¹³ C NMR Spectrum of compound Pb (400 MHz, MeOH-d ₄)	154
Figure.V.29	¹ H NMR spectrum of compound PN (400 MHz, Methanol-d ₄)	155
Figure.V.30	¹ H NMR spectrum spread out (6.00-7.10 ppm) of compound Pb (400 MHz, Methanol-d ₄).	156

LIST OF FIGURES

Figure.V.31	¹ H NMR spectrum spread out (3.1-5.0 ppm) of compound Pb (400 MHz, Methanol- <i>d</i> ₄).	156
Figure.V.32	HSQC spectrum spread out of compound Pb	157
Figure.V.33	COSY spectrum spread out of compound Pb	158
Figure.V.34	HMBC spectrum spread out of compound Pb	159
Figure.V.35	The HMBC and COSY correlations of compound Pb	159
Figure.V.36	Structure of Syringing	160
Figure.V.37	¹³ C NMR spectrum of compound PV2 (400 MHz, Methanol- <i>d</i> ₄)	161
Figure.V.38	DEPT 135° spectrum of compound PV2 (400 MHz, Methanol- <i>d</i> ₄)	162
Figure.V.39	¹ H NMR spectrum of compound PV2 (400 MHz, Methanol- <i>d</i> ₄)	163
Figure.V.40	¹ H NMR spectrum spread out (6.7-8.4 ppm) of compound PV2 (400 MHz, Methanol- <i>d</i> ₄)	164
Figure.V.41	¹ H NMR spectrum spread out (3.2-5.1 ppm) of compound PV2 (400 MHz, Methanol- <i>d</i> ₄).	164
Figure.V.42	HSQC spectrum of spread out of compound PV2	165
Figure.V.43	COSY spectrum of spread out of compound PV2	166
Figure.V.44	HMBC spectrum spread out of compound PV2	167
Figure.V.45	The HMBC and COSY correlations of compound PV2	167
Figure.V.46	Structure of 4-O-β-D-glucopyranosyloxy-1-hydroxybenzoic acid	168

Chapter VI

Figure.VI.1	Total phenolic and flavonoids contents of different extracts of <i>A.campestris</i> L.	170
Figure.VI.2	Total phenolic and flavonoids contents of different extracts of <i>F.bruguieri</i> DC.	172
Figure.VI.3	Comparison of DPPH capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	174
Figure.VI.4	Comparison of DPPH capacity between extracts of <i>F.bruguieri</i> DC. and BHA, BHT and α-Tocopherol	175
Figure.VI.5	Comparison of ABTS ^{•+} capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	177
Figure.VI.6	Comparison of ABTS ^{•+} capacity between extracts of <i>F.bruguieri</i> DC. and BHA and BHT	178
Figure.VI.7	Comparison of β-carotene capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	179
Figure.VI.8	Comparison of β-carotene capacity between extracts of <i>F.bruguieri</i> DC. and BHA and BHT	180

LIST OF FIGURES

Figure.VI.9	Comparison of CUPRAC capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	181
Figure.VI.10	Comparison of CUPRAC capacity between extracts of <i>F.bruguieri</i> DC.and BHA and BHT	182
Figure.VI.11	Comparison of reducing power capacity between extracts of <i>A.campestris</i> L. and BHA, BHT and ascorbic acid	184
Figure.VI.12	Comparison of reducing power capacity between extracts of <i>F.bruguieri</i> DC.and BHA, BHT and ascorbic acid	185
Figure.VI.13	Comparison of galvinoxyl radical (GOR) scavenging capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	186
Figure.VI.14	Comparison of galvinoxyl radical (GOR) scavenging capacity between extracts of <i>F.bruguieri</i> DC.and BHA and BHT	187
Figure.VI.15	Comparison of O-Phenanthroline capacity between extracts of <i>A.campestris</i> L. and BHA and BHT	188
Figure.VI.16	Comparison of O-Phenanthroline capacity between extracts of <i>F.bruguieri</i> DC.and BHA and BHT	189
Figure.VI.17	Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of Ascorbic acid , recorded at 0.1V s ⁻¹ potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF ₄ 0.1 M.	193
Figure.VI.18	Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of <i>A. campestris</i> L. extracts (A): AcPEE; (B): AcDE; (C): AcEAE (D): AcBE; (E): AcAE, recorded at 0.1V s ⁻¹ potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF ₄	195
Figure.VI.19	Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of <i>F.bruguieri</i> DC.extracts (A): FbPEE; (B): FbDE; (C): FbEAE (D): FbBE; (E): FbAE, recorded at 0.1V s ⁻¹ potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF ₄ 0.1 M	197
Figure.VI.20	Comparison of superoxide anion radical O ₂ ^{•-} according to I % values between extracts of <i>A.campestris</i> L. and Ascorbic acid	198
Figure.VI.21	Comparison of superoxide anion radical O ₂ ^{•-} according to I % values between extracts of <i>F.bruguieri</i> DC.and Ascorbic acid	199
Figure.VI.22	Plots of (A ₀ -A) / A ₀ *100 verses the concentration for diffrents extracts of <i>A.campestris</i> L. and <i>F.bruguieri</i> DC.	201

LIST OF FIGURES

Figure.VI.23	Comparison of acetylcholinesterase inhibition according to I % values between extracts of <i>A.campestris</i> L. and Galantamine.	203
Figure.VI.24	Comparison of acetylcholinesterase inhibition according to I % values between extracts of <i>F.bruguieri</i> DC.and Galantamine.	204
Figure.VI.25	Comparison of Butyrylcholinesterase inhibition according to I % values between extracts of <i>A.campestris</i> L. and Galantamine.	205
Figure.VI.26	Comparison of Butyrylcholinesterase inhibition according to I % values between extracts of <i>F.bruguieri</i> DC.and Galantamine	206
Figure.VI.27	Comparison of alpha-amylase inhibition according to I % values between extracts of <i>A.campestris</i> L. and Acarbose	209
Figure.VI.28	Comparison of alpha-amylase inhibition according to I % values between extracts of <i>F.bruguieri</i> DC.and Acarbose	210
Figure.VI.29	Comparison of Antilipase inhibitory according to I % values between extracts of <i>A.campestris</i> L. and Orlistat	212
Figure.VI.30	Comparison of Antilipase inhibitory according to I % values between extracts of <i>F.bruguieri</i> DC.and Orlistat	213
Figure.VI.31	Effect of different extracts of <i>Artemisia campestris</i> L. and Diclofenac sodium on the inhibition of protein denaturation	215
Figure.VI.32	Effect of different extracts of <i>Fagonia bruguieri</i> DC.and Diclofenac sodium on the inhibition of protein denaturation	217

List of Tables

N°	Chapter I	Page
Table.I.1	Ethnobotanical use of <i>Artemisia</i> species.	7
Table.I.2	Pharmacological studies of <i>Artemisia</i> species	9
Table.I.3	Traditional medicinal uses of <i>Artemisia campestris</i> L.	15
Table.I.4	Pharmacological studies of <i>Artemisia campestris</i> L.	16
Table.I.5	Flavonoïds compounds isolated from <i>Artemisia</i> species	18
Table.I.6	Lignans compounds isolated from <i>Artemisia</i> species	27
Table.I.7	Coumarins compounds isolated from <i>Artemisia</i> species	28
Table.I.8	Chromones compounds isolated from <i>Artemisia</i> species	29
Table.I.9	Acetophenones compounds isolated from <i>Artemisia</i> species	30
Table.I.10	Triterpenoids isolated from <i>Artemisia</i> species	32
Table.I.11	Traditional medicinal uses of <i>Fagonia</i> species	38
Table.I.12	Pharmacological studies of <i>Fagonia</i> species	38
Table.I.13	Traditional medicinal uses of <i>Fagonia bruguieri</i> DC.	43
Table.I.14	Pharmacological studies of <i>Fagonia bruguieri</i> DC.	43
Table.I.15	Quercetin derivatives isolated from the genus <i>Fagonia</i>	45
Table.I.16	Kaempferol derivatives isolated from the genus <i>Fagonia</i>	46
Table.I.17	Isorhamnetin derivatives isolated from the genus <i>Fagonia</i>	47
Table.I.18	Herbacetin derivatives isolated from the genus <i>Fagonia</i>	48
Table.I.19	Flavonols isolated from the genus <i>Fagonia</i>	49
Table.I.20	Triterpenes and saponins isolated from the genus <i>Fagonia</i>	50
Table.I.21	Steroids isolated from <i>Fagonia</i> genus	54
Table.I.22	Diterpenes isolated from <i>Fagonia</i> genus	55
Table.I.23	Sesquiterpene isolated from <i>Fagonia</i> genus	56
Table.I.24	Monoterpene isolated from <i>Fagonia</i> genus	57
Chapter III		
Table.III.1	Yield of different fractions of <i>Artemisa campestris</i> L. and <i>Fagonia bruguieri</i> DC.	72
Table.III.2	Optimum experimental conditions and nuclear data employed in this study	77
Table.III.3	Retention times (Rt), calibration curves, regression coefficients, Detection and quantification limits for phenolic compounds	81

Chapter IV

LIST OF TABLES

Table.IV.1	The Normalized product function used in the calculation of sun protection factor (SPF)	110
-------------------	--	-----

Table.IV.2	Protection categories displayed on solar products according to the measured protection factors, as recommended by the European Commission, 2006	111
-------------------	---	-----

Chapter V

Table.V.1	Phytochemical screening results of <i>Acampestris</i> L.	112
------------------	--	-----

Table.V.2	Phytochemical screening results of <i>F.bruguieri</i> DC.	113
------------------	---	-----

Table.V.3	Concentrations in mg/kg of the chemical elements in the plant <i>A. campestris</i> L. and <i>F.bruguieri</i> DC.	114
------------------	--	-----

Table.V.4	Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of NIST-SRM 1570a	116
------------------	---	-----

Table.V.5	Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of WEPAL-IPE 172	116
------------------	--	-----

Table.V.6	Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of WEPAL-IPE 189	117
------------------	--	-----

Table.V.7	Intake values (mg/day, person) of certain essential elements and tolerable daily intake for adults (70 kg) (Tolerable Daily Intake) of certain toxic elements according to the food and agricultural organization (FAO/WHO)	118
------------------	---	-----

Table.V.8	Identification and quantification of phenolic compounds in <i>A. campestris</i> L. extracts by HPLC analysis.	124
------------------	---	-----

Table.V.9	Identification and quantification of phenolic compounds in <i>F.bruguieri</i> DC. extracts by HPLC analysis	128
------------------	---	-----

Table.V.10	Phenolic profile determined by LC-MS-MS in fractions from <i>A. campestris</i> compared with literature	132
-------------------	---	-----

Table.V.11	Phenolic profile determined by LC-MS-MS in fractions from <i>F. bruguieri</i> DC. compared with literature	137
-------------------	--	-----

Table.V.12	¹³ C NMR and ¹ H NMR spectral data of compound PN (400 MHz, 125 MHz, Methanol-d ₄)	153
-------------------	--	-----

Table.V.13	¹³ C NMR and ¹ H NMR spectral data of compound Pb (400 MHz, 125 MHz, Methanol-d ₄)	160
-------------------	--	-----

LIST OF TABLES

Table.V.14	^{13}C NMR and ^1H NMR spectral data of compound Pb (400 MHz, 125 MHz, Methanol-d4)	168
-------------------	---	-----

Chapter VI

Table.VI.1	Total phenolics of different extracts of <i>A.campestris</i> L.	169
Table.VI.2	Total flavonoids contents of different extracts of <i>A.campestris</i> L.	170
Table.VI.3	Total phenolics of contents of different extracts of <i>F.bruguieri</i> DC.	171
Table.VI.4	Total flavonoids contents of different extracts of <i>F.bruguieri</i> DC.	171
Table.VI.5	DPPH radical scavenging activity of different extracts of <i>A.campestris</i> L.	174
Table.VI.6	DPPH radical scavenging activity of different extracts of <i>F.bruguieri</i> DC.	175
Table.VI.7	ABTS scavenging activity of different extracts of <i>A.campestris</i> L.	176
Table.VI.8	ABTS scavenging activity of different extracts of <i>F.bruguieri</i> DC.	177
Table.VI.9	β -carotene-linoleic acid bleaching activity of different extracts of <i>A.campestris</i> L.	178
Table.VI.10	β -carotene-linoleic acid bleaching activity of different extracts of <i>F.bruguieri</i> DC.	180
Table.VI.11	Cupric reducing antioxidant capacity activity of different extracts of <i>A.campestris</i> L.	181
Table.VI.12	Cupric reducing antioxidant capacity activity of different extracts of <i>F.bruguieri</i> DC.	182
Table.VI.13	Reducing power assay of different extracts of <i>A.campestris</i> L.	183
Table.VI.14	Reducing power assay of different extracts of <i>F.bruguieri</i> DC.	184
Table.VI.15	Galvinoxyl scavenging activity of different extracts of <i>A.campestris</i> L.	185
Table.VI.16	Galvinoxyl (GOR) scavenging activity of different extracts of <i>Fagonia bruguieri</i> DC.	186
Table.VI.17	O-Phenanthroline Activity of different extracts of <i>A.campestris</i> L.	188
Table.VI.18	O-Phenanthroline Activity of different extracts of <i>F.bruguieri</i> DC.	189
Table.VI.19	Superoxide Anion $\text{O}_2^{\bullet-}$ Scavenging of different extracts of <i>A.campestris</i> L.	198
Table.VI.20	Superoxide Anion $\text{O}_2^{\bullet-}$ Scavenging of different extracts of <i>F.bruguieri</i> DC.	199
Table.VI.21	Acetylcholinesterase inhibitory activity of different extracts of <i>A.campestris</i> L.	202
Table.VI.22	Acetylcholinesterase inhibitory activity of different extracts of <i>F.bruguieri</i> DC.	203

LIST OF TABLES

Table.VI.23	Butyrylcholinesterase inhibitory activity of different extracts of <i>A.campestris</i> L.	204
Table.VI.24	Butyrylcholinesterase inhibitory activity of different extracts of <i>F.bruguieri</i> DC.	205
Table.VI.25	Alpha-amylase inhibitory activity of different extracts of <i>A.campestris</i> L.	208
Table.VI.26	Alpha -amylase inhibitory activity of different extracts of <i>F.bruguieri</i> DC.	209
Table.VI.27	Pancreatic lipase inhibitory activity of different extracts of <i>A.campestris</i> L.	211
Table.VI.28	Pancreatic lipase inhibitory activity of different extracts of <i>F.bruguieri</i> DC.	212
Table.VI.29	Inhibition percentage in Anti-Inflammatory activity of different extracts of <i>A.campestris</i> L.	215
Table.VI.30	Inhibition percentage in anti-inflammatory activity of different extracts of <i>F.bruguieri</i> DC.	216
Table.VI.31	Photoprotective Activity of different extracts of <i>A.campestris</i> L.	220
Table.VI.32	Photoprotective Activity of different extracts of <i>F.bruguieri</i> DC.	220
TABLE.VI.33.	Chemical structure of the compounds Isolated from <i>A.campestris</i> L. & <i>F.bruguieri</i> DC.	

GENERAL

INTRODUCTION

Introduction

In recent years, multiple fields, including the valorisation of the use of plants in natural remedies and scientific research that enriches medical knowledge, have contributed to the allure of returning to nature. In fact, the treatment with plants, which had lost the upper hand in the therapeutic arsenal since the dawn of the pharmaceutical industry, is currently being enhanced due to recent advances in chemical research.

Only half of the world's 500,000 plant species have been identified by botanists. The World Health Organisation (WHO) has catalogued 22,000 distinct plant species that are traditionally utilised in medical treatment. Only 3,000 have been subjected to scientific assessment [1]. According to the WHO, nearly 6,377 plant species are utilised in Africa, of which over 400 are medicinal plants that account for 90% of traditional medicine [2].

Medicinal plants contain a vast array of biomolecules that are of significant interest for the development of pharmaceuticals against a variety of pharmacological targets. For millennia, humans have used substances derived from plants to prevent or treat many kinds of illnesses. A broad spectrum of compounds derived from plants is relevant to a wide range of disorders affecting humans, including analgesics (aspirin, morphine extracted from opium, codeine, etc.), anti-cancer drugs (vinblastine, taxol, etc.), anaesthetics (tropane-ring alkaloids including cocaine), cardio-stimulants (digitalis), psychostimulants (caffeine, theophylline), antimalarial drugs (quinine, artemisinin, etc.), and immunosuppressants (cyclosporine, etc.) etc... [3]. Actually, secondary metabolites have been and will continue to be the focus of a great deal of in vitro and in vivo study, which includes searching for novel naturally occurring components such as phenolic compounds [4].

The Algerian Sahara is known for its extended floral variation. There are 650 species in the Algerian Sahara, 162 of which are endemic; endemism constitutes about 25% of the species. This vast floristic richness has helped advance scientific study in Algeria in a variety of fields, including ethnomedicine, traditional pharmacopoeia, and the valorisation of natural substances. Species in this environment usually offer molecules with intriguing biological activities [5].

Within this context, and in continuation with our axis's research program on Algerian Saharan plants, this work aims to research and characterize novel compounds with biological activity. Thus, two plants native to Algerian Sahara, one belonging to the family Asteraceae named *Artemisia campestris* L. and the other belonging to the family Zygophyllaceae named

Fagonia bruguieri DC. which were chosen for the purpose of researching their respective chemical compositions and the biological activities they engage in and determining the concentrations of different mineral elements in the studied plant's. In addition, to isolating and identifying their secondary metabolites. The selection of both species was selected for their respective endemism and pharmacopoeia interest. Interestingly, *Fagonia bruguieri* DC. has not been examined in terms of its chemical composition, pharmacological effects (anti-cholinesterase, anti-lipase, BSA denaturation, and dermatoprotector), as well as mineral profile. *Artemisia campestris* L., on the other hand, has yet to be previously investigated for its numerous pharmacological activities (lipase inhibitory and dermatoprotective) and mineral composition.

This present manuscript describes our work in three distinct parts:

PART 1: Bibliographical part contains two chapters

- ✚ Chapter I: Literature studies on the plants studies (family, genus, and species). It overviews their chemical composition, pharmacological uses, and phytotherapeutic uses.
- ✚ Chapter II: An overview of secondary metabolites and their pharmacological activity.

PART 2: Experimental part contains two chapters

- ✚ Chapter III: This chapter planned to include the phytochemical and chemical study of *Artemisia campestris* L. and *Fagonia bruguieri* DC. by presenting all experimental steps, starting with maceration, separation, and purification of isolated compounds using different chromatographic techniques, as well as protocols used for mineral and chromatographic analysis (LC-MS/MS, HPLC-UV, ICP-OES, INAA).
- ✚ Chapter IV: Protocols of the experimental biological evaluation (antioxidant, anti-lipase, anti-inflammatory, anti-cholinesterase, anti-alpha amylase, and dermatoprotector activities) and quantified the total phenol and flavonoid content of different extracts from two species studied.

PART 3: Results & Discussion contains two chapters

- ✚ Chapter V: The results and discussions in this chapter focus on the structural elucidation of isolated compounds using NMR 1D and 2D (^1H , ^{13}C , DEPT, COSY, HSQC, HMBC) and chemical composition (Chromatographic and Mineral Analyses).
- ✚ Chapter VI: Results & Discussion of Quantitative analysis and biological activities.

PART 1:

BIBLIOGRAPHIC

PART

Chapter I: Literature

Overview

I.1. Asteraceae

Asteraceae, commonly known as Compositae, the scientific name for this family is the Asteraceae Martynov (1820); it is also referred to as the Compositae Giseke(1792). It is one of the most prominent dicotyledonous angiospermic plant families based on the number of species (1500 genus and 13000 species) that comprise this cosmopolitan plant family [6].

Asteraceae, which includes approximately 10 % of the world's flowering plants, is typically divided into 12 subfamilies. About 109 genus of plants and more than 408 species promote plant growth in Algeria [7]. It includes edible, medicinal, harmful, invasive, and endangered species [6].

I.1.1 Botany of the family Asteraceae

A wide variety of morphological characteristics can be found in this family of Asteraceae, including evergreen shrubs, subshrubs, perennial herbs (rhizomatous and tuberous), annual herbs or biennials, giant herbs, epiphytes, and aquatic plants that are in extreme cases [8].

Vegetative apparatus

- ✓ **Roots:** typically pivotal and sometimes fibrous.
- ✓ **Stems:** generally straight but sometimes droop on rising. Some species have underground stems in the form of rhizomes; these can be fleshy or woody, depending on the species. In Asteraceae, there are different morphological variations of the stem:
 - Cylindrical stems like the Arnica of the Mountains, *Arnica montana*.
 - Angular stems as for *Jacobean Seneçon*, *Senecio jacobaea*.
 - Winged stems, with small wings on each side as for Black Thistle, *Carduus nigrescens*.
 - Fistulous stems, meaning hollow stems [9].
- ✓ **Leaves:** the arrangement is alternate, often appearing in a basal rosette formation, and the leaves are devoid of stipules, sometimes opposite, simple, pinnate or palmate, sessile cut, lacinated, and sometimes they can be succulent [10].

Producing apparatus

✓ **Flowers:** The arrangement of flowers unique to this plant family, with a single flower, called a capitulum, that looks like a head. The morphology related to the reproduction of tiny flowers clustered together in tight heads, called capitula, that give the appearance of single, enormous flowers. Flowers can be regular (actinomorphic), or they can be severely actinomorphic, in which case the corolla tube will be extended into a long, strap-shaped extension known as a ligula. There are three basic types of composite heads [11]:

- The flowers will be tube-shaped and regular (Figure.I.1).
- Exceptionally bilabiate, the flower will have two lips formed by the petals.
- With only one lip, the flowers are ligulated (Figure.I.1).




Figure.I.1. Different of some types of flowers [11].

✓ **Fruits:** Achenes are the most common type of Asteraceae fruit. It is considered that the particular design of the flowers and inflorescence promotes fertilization and the process of cross-pollination. Pappus, which are bristles or scaly structures, typically take the

role of calyx in this family. The pappus is well-known for its role in the wind-borne dissemination of ripe seeds throughout an area [12].

I.1.2. Geographic distribution of the family Asteraceae

The plants of the family Asteraceae are found on the entire surface of the earth (Figure.I.2). It is a cosmopolitan family with a greater diversification at the level of dry regions and responds well to semi-arid tropical and subtropical zones; for example, in the Mediterranean basin, southern Africa, Mexico and South America, as well as the southwestern United States. They can be found in meadows, valleys, grassy plains, rolling plateaus, and mountain slopes [13].




Figure.I.2. Geographic distribution of the family Asteraceae [13].

I.1.3. Folk-medicinal and Pharmacology of the family Asteraceae

The Asteraceae plant family is one of the most diverse and complex in the plant kingdom, with almost 1500 genera and approximately 13000 species. Around 7,000 chemicals were isolated and identified from 5,000 species reported by ZDERO and BOHLMANN [14]. A substantial amount of bioactivity complements this astonishing variety. It has been established that the plants and the secondary metabolites possess diverse pharmacological properties. The aforementioned phenolic compounds and saponins were isolated from the aerial parts of *Centaurea melitensis* L., making it an acknowledged source; anti-inflammatory [15], antimicrobial [16, 17], antioxidant [17], antidiabetic, and neuroprotective effects are among these compound's numerous known biological activities [17]. Several biological activities of species belonging to the *Lychnophorinae* subtribe have been investigated, the most frequently reported activities are antibacterial, analgesic, antinociceptive, anti-inflammatory, and poisonous [18]. Traditional medicinal practices significantly use the plants that belong to this

family, In traditional Chinese medicine, *Bidens pilosa* L. is used as antirheumatismal, a whole plant decoction that is claimed to be effective once taken orally as a remedy for Snake bites, Pulmonary tuberculosis [19], Cuts, burns, skin problems [20], and Renal infection [21]. Even in folk medicine, a decoction prepared from the seeds of *Helianthus annuus* has been used to decrease the severity and frequency of asthma attacks and migraines, as well as the danger of heart attack [22]. This practise originated in traditional indian medicine.

Perennial *Arnica montana* grows wild in Europe, Russia's Alps, and the Caucasus Mountains, european pharmacopoeias define it as a therapy for minor injuries such as hematomas, which it has been used to treat. In traditional herbal medicine, this plant is used to help relieve pain and swelling in muscles and joints (such as from sprains, bruises, and joint pain) [22, 23]

In China, *Inula Britannica* L. is recommended for the treatment of asthma, whereas *Inula Grantioide* L. is used for treating bronchitis and other inflammatory disorders [24].

Tanacetum Parthenium's dry leaves are made into fresh healthcare used to treat arthritis and migraine [25]. It has been shown that *Ambrosia Maritima* L. is utilised as an antispasmodic diuretic to treat and prevent bilharzia [26]. Whereas the aqueous and alcoholic extracts of the plant *Marticaria Chamomilla* L. have been used orally and topically for wound healing and anti-inflammatory properties, notably that *Matricaria Chamomilla* L. is one of the oldest medicinal herbs [27].

I.1.4. Chemistry of the family Asteraceae

In regards to their contribution to phytochemistry, the species of the Asteraceae family are abundantly present with secondary metabolites, specifically Flavonoids [28, 29], phenolic compounds [30, 31], diterpenes [32], sesquiterpenes [33], coumarins [29], Lignans and alkaloids [34] and other chemicals isolated from Asteraceae have all been the focus of research due to their potential biological activity.

I.1.5. The *Artemisia* genus

Artemisia is among the largest and most extensively distributed genus in the Asteraceae family (Compositae); it is a heterogeneous genus with approximately 500 species, mainly widespread in all of the world's half-northern [35]. In the Algerian flora, there are 11 different species of *Artemisia*: *A. herba-alba* , *A. campestris* ssp. *eu-campestris* , *A. campestris* ssp. *gIutinosa*, *A. Absinthium*, *A. atlantica*, *A. ar-borescens* L., *A. judaica* L., *A. atlantica*, *A. Verlotorum*, *A. vulgaris* L., and *A. alba* [7]. The genus can be divided into the *Artemisia* and *Dracunculus*

categories. Species that belong to the genus *Artemisia* have therapeutic properties; they are not only used in traditional medicine but also in industry food and pharmaceuticals [36].

I.1.5.1. Botany of the genus *Artemisia*

Vegetative apparatus

Roots: *Artemisia* has two types of fibrous roots [37]:

- Coarse lateral roots that grow near the soil surface and use surface moisture
- Deep tap roots that can grow quickly to large depths

Leaves: The *Artemisia*'s leaves are scattered or arranged in pairs. With a few notable outliers like *A. dracunculus* L., they can be found in a broad variety of sizes, forms, and textures, some of which are shown in Figure.I.3 .




Figure.I.3. The synflorescences and leaves of different *Artemisia* species; **A:** *A. Absinthium*, **B:** *A. annua*, **C:** *A. dracunculus*, **D:** *A. vulgaris* [38].

Producing apparatus

- ✓ **Flowers:** The flowers heads, also known as capitula, are some of the most distinctive features of this genus. These capitula are small, spheroidal, ovoid, or cylindrical in shape, and they contain only flosculose florets that are implanted on a tomentose or glabrous receptacle. The receptacle is protected by an involucre that contains herbaceous or partly scarios bracts. The corollas are pale, yellow, or purple and not very showy, and the number of florets per capitulum varies from 4-7 to more than 40 [38].

- ✓ **Fruits:** Most of the fruits in this genus are achenes (also called cypselas) that lack a pappus and are obovoid, laterally compressed, very tiny, and light. These traits are a direct result of anemochory, the most prevalent dispersion process [39].
- ✓ **Grains:** The microechinate exine ornamentation on the pollen grain sculpture is very typical of the genus and has been used as a systemic marker in front of most Anthemideae representatives. Indeed, *Artemisia* and the taxa that are more strongly linked to it are distinguished from one another by their pollen grains, which constitute the *Artemisia* pollen type and are adorned with a simple pattern . In this regard, we assume that the term microechinate is more appropriate than the term psilate. whereas *Artemisia* pollen grains exhibit microechini when viewed through a light microscope [38, 40].

I.1.5.2. Geographic distribution of the genus *Artemisia*

Artemisia is one of the most extensive and widely distributed genus in the Astraceae (Compositae) family. It is a heterogeneous genus with approximately 500 species mainly distributed in the subtropical and tropical regions of Europe, Asia, North America (Mexico, United States, and Canada), Africa, and Australia (Figure.I.4)



Figure.I.4. Geographical distribution of *Artemisia* species [41].

I.1.5.3. Folk-medicinal of the genus *Artemisia*

Different parts of *Artemisia* species, such as seeds, fruit, leaves, and roots, have been used for a wide range of uses. These applications cover a broad spectrum of realms. *Artemisia*, in particular, has a long history of effective treatment for various illnesses related to the digestive

tract and intestinal parasites, asthma, anthelmintic, and antispasmodic [42-44]. Treatment for malaria in Europe and Africa is successful by using several different species of *Artemisia* [45-47] (Table.I.1).

Table.I.1. Traditional medicinal uses of *Artemisia* species.

Region	Plant/ part used	Ethnopharmacology reports	Ref
Kazakhstan	<i>A.cina</i> / Leaves	Sudden cardiac arrests, esophagus, duodenum and cancers of the stomach,	[48]
	<i>A.cina</i> / Seeds	Inflammation and bronchitis diseases, treatment of asthma	[48]
	<i>A. cina</i> / (seeds,raisins)	Lung illnesses	[49]
	<i>A.tincture</i> / Aerial part	Epilepsy, unpleasant odors of mouth, caecum, hemorrhoids, and stomach ulcers	[50]
Iran	<i>A. vulgaris</i> / aerial parts	Cervicitis	[51]
Iran	<i>A.dracunculus</i> / Leaves	Anticoagulant and antidiabetic	[52]
South Africa	<i>A. afra</i> / (leaves, roots)	Medication for diabetes	[53]
Russia	<i>A.juice</i> / (leaves, roots)	Renal stones, anti-inflammatory drug, and insomnia	[42]
England	<i>A. absinthium</i> / Leaves	Improve memory, mental function, and liver inflammation	[54]
Italy	<i>A.absinthium</i> /Leaves	Lack of appetite, helminthiasis	[55]
China	<i>A. annua</i> / Aeaves	Malaria, various types of fevers	[56]
China	<i>A. vestita</i> / (leaves,resins)	Inflammatory illnesses	[57]
Korea	<i>A. asiatica</i> / Aerial parts	Infections ulcerogenic, cancer and inflammatory illnesses	[58]
India	<i>A. vulgaris</i> /Leaves	Skin diseases, intestinal issues, dysentery, Urinary issues, and haemorrhage	[59]
Egypt	<i>A. judaica</i> / Aerial part	Gastrointestinal diseases	[60]
Italy	<i>A. verlotorum</i> /Leaves	Hypertension	[61]
Pakistan	<i>A.vulgaris</i> / Aerial parts	Liver illnesses , analgesic, antispasmodic and anti-inflammatory	[62, 63]

I.1.5.4. Pharmacology of the genus *Artemisia*

Artemisia species are excellent sources of a wide variety of biologically active chemicals, which are responsible for a wide range of pharmacological effects (Figure.I.5). *Artemisia* has a broad bioactivity spectrum due to its many active components or secondary metabolites, which function through diverse modes of activity.

Artemisia species are often used to treat diseases like malaria, inflammation, wounds, arterial hypertension, hepatitis, and free radical damage [64]. Table.I.2 provides a comprehensive summary of some of the biological activities that are carried out by different species of *Artemisia*.




Figure.I.5. *Artemisia* genus medicinal benefits [48].

Table.I.2. Pharmacological studies of *Artemisia* species

Plant / Tested sample	Model	Dose / concentration	Results	Ref
Anthelmintic activity				
<i>A. absinthium</i> / crude aqueous, crude ethanol extracts	-In-vitro /Haemonchus contortus -In-vivo /Effect on faecal egg count	25 mg/mL	Ethanolic extracts and Crude aqueous exhibited in-vivo and in-vitro anthelmintic effectiveness against ovine nematodes.	[65]
Neuroprotective effects				
<i>A. absinthium</i> / Methanol extract	In vivo / Middle cerebral artery occlusion (MCAO) for 90 minutes was followed by reperfusion for 24 hours to generate focal ischemia and reperfusion.	100 - 200 mg/kg	Pretreatment with the methanol extract of <i>A.absinthium</i> significantly reduced oxidative stress and damage in the brain, as well as cognitive abnormalities.	[66]
<i>A. judaica</i> / Ethanol extract	In-vivo / High-fat diet (HFD) and streptozotocin (STZ, 30 mg/Kg) in rats produce neuronal impairments in a diabetes model.	300 mg kg ⁻¹ day ⁻¹	Cognitive abilities in diabetic rats was significantly enhanced by administration with <i>A.judaica</i> .	[67]
Antimalarials effect				
<i>A. annua</i> / artemisinin	In vitro/ Artemisinin's interaction with Hb and Mb, both free and protein-bound.	200 Mm	Artemisinin predominantly reacts with haem in Hb instead of free haem.	[68]
Antiulcerogenic activity				
<i>A. annua</i> / Dihydro-epideoxyartemisinin B, deoxyartemisinin	In vivo / Models of ulceration in rats produced by ethanol and indomethacin.	100 mg /Kg	Based on the dose-response analysis performed on the ethanol-induced ulcer model, it was determined that dihydro-epideoxyartemisinin B is more effective than deoxyartemisinin.	[69]
Toxicity of artemisinin				
<i>A. annua</i> / artemisinin	In vivo/ The toxicity of artemisinin on development and reproduction in Wistar rats treated during	35-75 mg/kg	Impact after pregnancy and post-implantation development in rats.	[70]

Table.I.2 continued....

	gestational days (GD) 7–13 and 14–20.		
Antiviral activity			
<i>A.arborescens</i> / Essential oil	<i>in vitro</i> / Inhibition of HSV-1 and HSV-2 plaque development, attachment, penetration, and post-attachment virus neutralizing experiments	100 – 6.25 µg/mL	<i>A. arborescens</i> essential oil inhibits the lateral diffusion of both HSV-1 and HSV-2, as indicated by an inhibition of plaque development test. The IC50 values for HSV1 and HSV-2 were 2,4 and 4,1 µg/ml, respectively. [71]
<i>A. capillaris</i> Tablets	<i>in vitro</i> / Hepatitis B virus replication	3.75-600 mg / mL	The levels of HBsAg and HBeAg in 2.2.15 cells that had been treated with <i>A. capillaris</i> Tablets were significantly lower compared to the control. [72]
Antimicrobial activity			
<i>A.douglasiana</i> / leaves	<i>In vitro</i> / - <i>B.cereus</i> - <i>S. aureus</i> - <i>E.coli</i> - <i>P.aeruginosa</i> - <i>C.albicans</i> - <i>A.niger</i>	100 µg/mL	Neither <i>A. douglasiana</i> leaves oil nor its components protected bladder cells against <i>P. aeruginosa</i> . [73]
<i>A.annua</i> / Essential oil	<i>In-vitro</i> / - <i>E. coli</i> - <i>P. aeruginosa</i> - <i>S.cerevisiae</i> - <i>C. albicans</i>	2-32 mg/ mL	The oil had antimicrobial effect against all of the microorganisms that were examined, apart from <i>Pseudomonas aeruginosa</i> . [74]
Inflammatory activity			
<i>A. asiatica</i> / ethanol extract	<i>In-vitro</i> / Nitric oxide generation, as well as the expression of inducible nitric oxide synthase and inflammatory cytokines	0.5–1 µg/ mL	<i>A. asiatica</i> extract inhibits the inflammatory activation of microglia and preserves PC12 cells against microglial neurotoxicity. [58]
<i>A. dracunculus</i> / ethanol extract	<i>In-vivo</i> / Mice with xylene-induced ear edoema were used to assess the effect of the ethanolic extract on acute inflammation.	50 mg/Kg	Throughout a xylene ear edoema test, the ethanolic extract shown substantial efficacy (ED ₅₀ = 78.20 mg/kg). [75]
Anticarcinogenic activity			
<i>A. capillaris</i> / Chloroform extract	<i>In-vivo</i> / Carcinogenesis of the skin in mice caused by	-	<i>A.capillaris</i> chloroform fraction reduced tumors/mouse and incidence. [76]

Table.I.2 continued....

exposure to 7,12-dimethylbenz[a]anthracene (DMBA).

		Hepatoprotective activity	
<i>A. capillaris</i> / 6,7-dimethylesculetin	In-vivo / Galactosamine (D-GalN) and lipopolysaccharide (LPS) induced hepatitis in mice.	150–600 mg/kg	The hepatoprotective efficacy of 6,7-dimethylesculetin isolated from <i>A. capillaris</i> was confirmed by liver histology. [62]
		Anti-diabetic activity	
<i>A. vulgaris</i> / Aqueous and Methanol Extract	In-vitro/ α -Glucosidase inhibition activity - In vivo / Activity of aldose reductase inhibiting enzyme in rat lenses	-	-Capillinol's IC50 for inhibiting α -glucosidase activity was 464.53 ± 2.69 mM, indicating moderate activity. [77] -The IC50 value for capillin's RLAR inhibiting activity was 55.34 ± 0.28 mM, indicating that it was a potent inhibitor.
<i>A. judaica</i> / water and alcoholic extracts	In-vivo/ Single and Multiple <i>A. judaica</i> Extracts Doses on Diabetic Rat Blood Glucose	-0.25-0.5 g/kg b.wt. for the water extract. - 0.5 - 1 g/kg b.wt for the alcoholiextract	Following oral administration of aqueous extract of <i>A. judaica</i> up to 50 to 5g/kg, the obtained results demonstrated no mortalities in mice; nevertheless, the LD for the alcoholic extract was 9.17g/kg. [78]
		Insecticidal activity	
<i>A. sieberi</i> / Essential oil	Fumigant toxicity - <i>C. maculatus</i> - <i>S. oryzae</i> - <i>T. castaneum</i>	37-926 uL per L	<i>S. oryzae</i> (LCso: 4.41 uL per L) and <i>T. castaneum</i> (LCso: 20.31 IJ.L per L) were found to be more resistant to the fumigant toxicity of <i>A. sieberi</i> than <i>C. maculatus</i> (LCso: 1.64 IJ.L per L uL per L). [79]

I.1.6. *Artemisia campestris* L.

Artemisia campestris L. is a chamaephyte plant classified systematically in the tribe Asteraceae and the genus *Artemisia*. *A. campestris* L. is most frequently known by its common names, including dgouft, beach wormwood, oum nafsa, field wormwood, field sagewort, tall wormwood, and field sagebrush. It is known as tedjok in Tamahaq, the indigenous language of the Touareg inhabitants in the South of Algeria, and as oum nafsa in Arabic [7, 80]. This species is divided into various subspecies and varieties. In Tunisia, Pottier-alapetite is classified into three different subspecies, the *A. eu-campestris* subspecies includes two varieties: *Vulgaris Marss* and *odoratissima (Desf) Bonn* and *Barr. Battandier* and Quezel have described additional varieties in Algeria, including *A. clausonis pomel*, *A. glutinosa (Jgay) Batt*, and

A. glutinosa (Pomel) Batt. *canescens* LH. Several interesting biological properties of the *Artemisia campestris* L. species have been researched [81]. They are currently the focus of attention from the phytochemical field due to the biological and chemical richness of the species as well as the production of essential oil.

✓ **Systematic classification** [82, 83].

Kingdom: Plantae

Subkingdom: Tracheobionta

Superdivision: Spermatophyta

Division: Magnoliophyta

Class: Dicotyledones

Subclass: Magnoliidae

Superorder : Asteranae

Order: Asterales

Family: Asteraceae (Compositae)

Tribe : Anthemideae Cass.

Genus: *Artemisia* L.

Species: *Artemisia campestris* L.

Vernacular names: Field sagewort

Local name: tedjok



Figure.I.6. *Artemisia campestris* L.

I.1.6.1. Botany of the *Artemisia campestris* L.

Artemisia campestris L. consists of small shrubs that are perennial, biennial, or annual, hermaphrodite, almost odorless, and grow to around 1 m in height.

Vegetative apparatus

- ✓ **Roots:** The root structure comprises a fibrous taproot or caudex and a woody taproot or caudex .
- ✓ **Stems:** Subligneous stems that stay flat at the base and rise vertically; reddish and glabrescent at the genitalia; branching trees with spreading limbs.
- ✓ **Leaves:** Alternate and green leaves, not fleshy, keeled beneath, more or less silky in adolescence, becoming glabrescent afterward, the lower petioles with 2-3 pinnatipied blades, the other sessile with less divided blades, with narrowly linear segments, mucronulated

Producing apparatus

- ✓ **Flower:** Individual flower heads (capitulum) are green or yellowish green in color, about 2-4 mm long, void and heterogeneous. Each flower head has 8–30 perfect inner disc florets and 5–20 pistillate outer disc florets. Male flowers (which are tubular, yellow, calyx-less, with five fused petals and five fused filaments, and secretion sacs on the corolla lobes) have a different structure than female flowers. The disc flowers are functionally male with decreased abortive ovaries, whereas the ray flowers are female, pistillate, and fertile (Figure.I.7) [81, 84].
- ✓ **Fruit:** The fruit is an achene in the shape of an ovoid without a pappus [85].




Figure.I.7. *Artemisia campestris* L. illustrations (A) paniculate inflorescence, (B) Alternate-leaved capitula, (C) male flower, (D) female flower [86].

I.1.6.2. Geographic distribution of *Artemisia campestris* L.

Concerning the geographical distribution of *A.campestris* L., it has been indicated that this plant is widely distributed in Europe, in European Russia from the Urals to Siberia, and is considered an exotic species in North America [87]. It also occurs predominantly in the arid regions of the countries of North Africa, particularly the countries in the Mediterranean region, where it prefers a semi-arid habitat and constitutes good land cover, in addition to being a source of litter production and having the surface property of providing protection [88]. Morocco [89],

Algeria, Tunisia [90], and Libya [91] are the leading countries in which the dominance of this plant is found. *A.campestris* L grows naturally along the shoreline of Ryukyu Island in Japan [92]. However, it represents a native herbaceous species that persists at reference sites of restored dunes on North America's Great Lake [93] (Figure.I.8).




Figure.I.8. Geographic distribution of *A.campestris* L.

I.1.6.3. Folk-medicinal of *Artemisia campestris* L.

A.campestris L. is a plant that has a long history of use as a traditional medicine in a variety of countries, including Algeria, Libya, Tunisia, Morocco, Spain, Turkey, Italy, India, the United States, Canada, Iraq, and Argentina. It has been shown to be effective in treating skin problems, respiratory, and gastrointestinal [94-97]. In the Algerian region of Hoggar, the local populations of Tamanraasset use a infusion, decoction prepared of aerial parts, leaves as a treatment for gastrointestinal illnesses, fever, after childbirth, and loss of hair [98].

Additionally, it is recommended in Japan, Algeria, and Tunisia for the treatment of urinary and hepatic problems [83, 99, 100]. In Algeria, Iraq, and Tunisia, *Artemisia campestris* L. is recommended for the treatment of fever, and in Algeria [101] and India, it is used as an antivenom [102]. It is advised for the treatment of ocular disorders, and baldness, as an aid to

weight loss and hyperthyroidism [103-105]. Additional traditional applications are listed in the literature (Table.I.3).

Table.I.3. Traditional medicinal uses of *Artemisia campestris* L.

Region	Preparation method	Part used	Ethnopharmacology reports	Ref
Algeria	Infusion, decoction, poultice, powder	Leaves, fruits, aerial part, stems	gastrointestinal, analeptic, cutaneous, antidiabetic, antihypertensive, anthelmintic, diuretic, vulnerary, circulation regulator, antitussive, for post-partum, accommodation, antivenom, baldness.	[106] [107] [100] [101]
Morocco	Infusion, poultice, decoction	Flowers, leaves, aerial part, seeds	Treatments for diabetes, metabolic disease, eye disease, skin disease (melasma), digestive disease, lung disease, and allergy.	[108] [105]
Japon	Decoction	-	Renal, Liver disease, and antidiabetic.	[99] [92]
Spain	Decoction	Flowers	Baldness therapy	[104]
India	Decoction	Leaves	Antivenom	[109]
Argentina	Maceration, infusion	Stems, leaves	Treatment of bronchitis, medication for cough, and treatment for bruising	[96]
Italy	-	-	Fever lowering and ulcer treatment	[110]
Canada	Infusion, poultice	Roots, leaves	Digestive, respiratory, and Cutaneous	[97]
Serbia	-	Leaves	Antiseptic, anthelmintic, tonic	[110]
Libya	Decoction	Leaves, flowers	Anthelmintic treatment	[111]
Iraq	-	Whole plant, leaves	Fever reducer, and cough reducer	[104]
Tunisia	Decoction	Whole plant, leaves	Anti-inflammatory, Antivenom, anti-eczema, anti-rum, anthelmintic, cough suppressant, febrifuge, against digestive problems and urinary tract infections	[112]

I.1.6.4. Pharmacology of *Artemisia campestris* L.

The species *Artemisia campestris* L. has been the focus of a significant variety of scientific studies that investigate a wide range of pharmacological activities. The majority of them focused on antivenom, anti-inflammatory, antidiabetic, spasmolytic, vasorelaxant, antioxidant, and neuroprotective effects. Table.I.4 comprehensively examines the diverse pharmacological effects of *Artemisia campestris* L.

Table.I.4. Pharmacological studies of *Artemisia campestris* L.

Testd sample / Part used	Model	Dose / concentration	Results	Ref
Antivenom activity				
Essential oil / Aerial part	-In vivo / Indirect anti-hemolytic impact of phospholyase A2 inhibition on egg yolk red blood cells	1.0–10 mg/mL	Suppression of hemolysis from both <i>Cerastes cerastes</i> and <i>Macrovipera lebetina</i> venoms (27-31%)	[113]
Decoction / Leaves	In vivo/ Hypertension induced by subcutaneous injection of <i>Buthus occitanus tunetanus</i> scorpion venom in pregnant and nonpregnant rats	200 mg/mL	Reduced venom-induced lung hypertrophy (1.33 g versus 1.47 g). Reduced (30%) MAP in pregnant and (10%) non-pregnant rats with extract only. Absence of a hypertensive increase in pregnant and non-pregnant rats following extract+envenomation.	[114]
Anti-inflammatory activity				
2',4',5,7-tetrahydroxy-5',6-dimethoxyflavone, Cirsiliol/ Leaves	In vivo / Inhibition of lipoxygenase	30 Mm	Simultaneous inhibition on cirsiol (48.51%) and lipoxygenase by 2',4',5,7-tetrahydroxy-5',6- dimethoxyflavone (46.85%)	[115]
Aqueous extract / Leaves	In vivo / Mice paw inflammation following subcutaneous carrageenan injection	200 mg/Kg, b.w.	Edema volume reduction, inflammatory cell count reduction, and tissue repair following edoema .	[116]
Antidiabetic activity				
Aqueous extract/ Aerial part, roots	In vivo/ Inhibition of α -glucosidase	-	Aqueous extracts (roots and aerial organs) inhibit microbial α -glucosidase, and a root tincture inhibits mammalian α -glucosidase	[117]
Aqueous extract/ Leaves	In vivo / Diabetes induced by alloxan in rats	200 mg/Kg	-Reduced serum glucose levels (147 mg/dl). -Elevation in serum insulin concentration by 30% -Reduction in glucose concentration by 63% after 120 minutes of the tolerance test for glucose.	[118]
Neuroprotective activity				
Essential oil / Aerial part	In vitro / Inhibition of AChE (acetylcholinesterase)	-	Important ibition of acetylcholinesterase (IC ₅₀ =0.02 mg/ml)	[119]
Antihypertensive activity				
Aqueous extract/ Aerial part	In vivo/ Blood pressure was measured using the tail-cuff technique in L-	50 mg/kg, b.w.	Protection of the rise of arterial blood pressure produced with L-NAME	[120]

Table.I.4 continued....

	NAME-induced hypertensive rats for a duration of 4 weeks.			
Vasorelaxant activity				
Aqueous extract , Essential oil / Aerial part	in vivo / Vasorelaxant effect on normotensive rat aorta	-2 mg/ml (aqueous extract) -10-1 mg/mL (essential oil)	Both the essential oil and the aqueous extract exhibit significant vasorelaxation.	[119, 120]
Antinociceptive activity				
Aqueous extract/ Aerial part	In vivo / Mice sense pain following formalin injection, pain mice due to the heat, and acetic acid induces stomach pain in mice after injection.	200- 400 mg/kg, b.w.	Late and early nociceptive reflexes decrease, Attenuation of the central pain sensation.	[121]
Antileishmaniasis activity				
Essential oil / Aerial part	In vitro/ Leishmania infantum L eishmania major	10^{-3} - 10^3 µg	Growth of both Leishmania infantum and Leishmania major promastigotes was inhibited (IC ₅₀ =3.24 and 4.59 µg/ml, respectively).	[122]
Antioxidant activity				
Aqueous extract/ Aerial part	In vivo / Rats exposed to oxidative stress caused by Lagocephalus puffer fish liver extract	5 mg/mL	Improvement in antioxidant enzymatic (GSH-Px in kidney SOD, and CAT, brain, and liver) and suppression of lipid peroxidation (TBARS inhibition in the kidney, brain, and liver).	[123]
Essential oil / Stems, leaves	In vivo / Deltamethrin-induced oxidative stress in rats	200 mg/kg, b.w.	Reducing conjugated dienes and MDA prevents lipid peroxidation, CAT, GSH-Px in the kidney and SOD, liver, and brain enhance	[123]
Aqueous extract/ Leaves	In vivo / Gastroesophageal reflux in rats induces oxidative stress over six hours.	100 - 400 mg/kg, b.w.	Reduced MDA inhibits lipoperoxidation, thiol enhance, reduction in hydrogen peroxide calcium and free iron, CAT, SOD, and GSH-P normalisation.	[124]
Essential oil / Aerial part	In vitro / DPPH assay	Essential oil (5 mg/ml)	IC ₅₀ : 94,5 mg/ml	[125]
Aqueous extract/ Leaves	In vitro / ABTS assay	0.5 mg/mL	IC ₅₀ = 26.01 ± 5.74 mg/ml	[126]
Essential oil / Aerial part	In vitro / Ferric Reducing Antioxidant Power assay (FRAP)	1-10 mg/mL	IC ₅₀ = 17.79 ± 0.08 mg/ml	[127]
Aqueous extract/ Aerial part	In vitro / β-carotène/ linoleic acid	50 mg/mL	% of inhibition of blanchiment of carotene= 64.81 %	[116]
Aqueous extract/ Aerial part	In vitro / Trapping peroxide anion	5-100 mg/mL	IC ₅₀ = 47,5 mg/ml	[99]
Gastro - esophageal protection				
Aqueous extract/ Leaves	In vivo / Six hours of gastroesophageal reflux-	100- 400 mg/kg, b.w.	78% reduction in ulcer index, prevention against esophageal epithelium damage,	[124]

Table.1.4 continued....

induced esophageal
ulceration in rats.

reduced inflammatory infiltration and
epithelial hyperemia

I.1.6.5. Secondary metabolites isolated from the *Artemisia* genus

I.1.6.5.1. Flavonoids

A. campestris L. is a species that has several subspecies. Three of these subspecies, *ssp. glutinosa*, *ssp. campestris*, and *ssp. Maritima*, have been studied considerably for their flavonoid profiles. It has been reported that the plant genus *Artemisia* has a significant quantity of flavonols such as quercetin, apigenin, patuletin, acacetin, and luteolin, as well as their derivatives. The presence of flavones marked a significant abundance, including Hispidulin, Cirsiliol, and Eupatilin, among many others. *A. absinthium*, *A. campestris*, *A. glutinosa*, and *A. pygmaea* were the sources of the isolated flavanones, flavanonols, chalcones and derivatives. The Flavonoids isolated from *Artemisia* species are reported in Table.I.5.

Table.I.5. Flavonoids compounds isolated from *Artemisia* species.










Isolated Compound	Structure	Species	Ref
	<i>Flavonols</i>		
Quercetin		<i>A. vulgaris</i> , <i>A. dracunculus</i> <i>A. absinthium</i>	[128]
		<i>A. monosperma</i> <i>A. herba-alba</i>	[129]
Quercetin 3-glucoside		<i>A. monosperma</i> <i>A. herba-alba</i>	[130]
Quercetin 3-rutinoside		<i>A. monosperma</i> <i>A. herba-alba</i>	[130]

Table.I.5 continued....

Quercetin 5-glucoside		<i>A. monosperma</i>	[130]
Isorhamnetin		<i>A. vulgaris,</i> <i>A. dracunculus</i> <i>A. absinthium</i>	[128]
		<i>A. monosperma</i> <i>A. herba-alba</i>	[129]
Isorhamnetin 5-glucoside		<i>A. monosperma</i>	[130]
Patuletin		<i>A. absinthium</i>	[128]
		<i>A. herba-alba</i>	[129]
Patuletin 3-glucoside		<i>A. monosperma</i>	[130]
Patuletin 3-rutinoside		<i>A. monosperma</i> <i>A. herba-alba</i>	[130]







Acacetin		<i>A. pygmaea</i>	[131]
Acacetin 7-glucoside		<i>A. monosperma</i>	[129] [130]
Acacetin 7-rutinoside		<i>A. monosperma</i>	[129] [130]
Vicenin-2		<i>A. monosperma</i> <i>A. judaica</i>	[130]
		<i>A. transiliensis</i>	[132]
Lucenin-2		<i>A. monosperma</i>	[130]
Kaempferol 3-glucoside		<i>A. vulgaris</i> , <i>A. dracunculus</i> <i>A. absinthium</i>	[128]
		<i>A. monosperma</i> <i>A. herba-alba</i>	[129]

Table.I.5 continued....








Kaempferol 3-rutinoside		<i>A. vulgaris</i> , <i>A. dracunculus</i> <i>A. absinthium</i>	[128]
		<i>A. monosperma</i> <i>A. herba-alba</i>	[129]
Apigenin		<i>A. ludoviciana</i>	[133]
		<i>A. frigida</i>	[134]
Apigenin 7-glucoside		<i>A. japonica</i>	[135]
Luteolin		<i>A. ludoviciana</i>	[133]
		<i>A. tridentata</i>	[136]
Luteolin 7-glucoside		<i>A. japonica</i>	[135]
		<i>A. tridentata</i>	[136]
Flavones			
Hispidulin		<i>A. campestris</i>	[137]
		<i>A. ludoviciana</i>	[133]
		<i>A. frigida</i>	[134]
5,7, 2',3'-tetrahydroxy-6, 5'-dimethoxy-flavone		<i>A. campestris</i>	[115]
Cirsiliol		<i>A. campestris</i>	[115]
		<i>A. heba-alba</i>	[138]

Table.I.5 continued....

		<i>A. mesatlantica</i> <i>A. capillaris</i>	[139]
Eupatilin		<i>A. campestris</i>	[115]
		<i>A. ludoviciana</i>	[133]
		<i>A. frigida</i>	[134]
Dimethoxycentaureidin		<i>A. campestris</i>	[115]
5,7-dihydroxy-3,4'-dimethoxyflavone		<i>A. campestris</i>	[100]
5,7-dihydroxy-3,4',5'-trimethoxyflavone		<i>A. campestris</i>	[100]
3,5,7,4'-tetrahydroxy-3'-methoxyflavone		<i>A. campestris</i>	[100]
5,7,4'-trihydroxy-3,6,8-trimethoxyflavone		<i>A. ludoviciana</i> <i>A. grayi</i>	[133] [140]

6,7,3',4'-tetramethoxy Quercetagenin		<i>A. ludoviciana</i>	[133]
Casticin		<i>A. annua</i>	[140]
Jaceosidin		<i>A. ludoviciana</i> <i>A. princeps</i> <i>A. frigida</i>	[133] [141] [142]
5,7,4'-trihydroxy-3,6- dimethoxyflavone		<i>A. ludoviciana</i>	[133]
Tricin		<i>A. ludoviciana</i>	[133]
Chrysoeriol		<i>A. ludoviciana</i>	[133]
Axillarin		<i>A. ludoviciana</i> <i>A. incanescens</i>	[133] [143]
Eupafolin		<i>A. ludoviciana</i> <i>A. tridentata</i>	[133] [136]








Selagin		<i>A. ludoviciana</i>	[133]
Cirsimaritin		<i>A. scoparia</i>	[144]
		<i>A. capillaris</i>	[139]
5,7,4'-trihydroxy-6,3',5'-trimethoxyflavone		<i>A. ludoviciana</i>	[133]
		<i>A. frigida</i>	[142]
5,7,3'-trihydroxy-6,4',5'-trimethoxyflavone		<i>A. ludoviciana</i>	[133]
		<i>A. frigida</i>	[142]
5,7,3',4'-tetrahydroxy-3,6,5'-trimethoxyflavone		<i>A. ludoviciana</i>	[133]
		<i>Artemisia frigida</i>	[142]
5,7,2',4'-tetrahydroxy-6,5'-dimethoxyflavone		<i>A. ludoviciana</i>	[133]
Flavanones, Flavanonols			
Naringenin		<i>A. campestris</i>	[137]
		<i>A. campestris</i>	[145]
		<i>A. campestris</i>	[146]
		<i>A. Glutinosa</i>	[147]

Table.I.5 continued....











Artemisetin		<i>A. absinthium</i>	[148]
5,4'-dihydroxy-7-methoxyflavanone (Sakuranetin)		<i>A. campestris</i>	[145] [146]
5,7-dihydroxy-4'-methoxyflavanone (isosakuranetin)		<i>A. campestris</i>	[145] [146]
7-methoxy-Eriodictyol		<i>A. campestris</i>	[146]
7, 3'-dimethoxy-Eriodictyol		<i>A. campestris</i>	[146]
5,8,4'-trihydroxyflavanone		<i>A. campestris</i>	[149]
5,6-dihydroxy 4'-methoxyflavanone		<i>A. campestris</i>	[149]
5,4'-dihydroxy-7,3'-dimethoxyflavanone		<i>A. campestris</i>	[149]

Table.I.5 continued....

3,7-dimethoxy-,5 3',4'-trihydroxyflavanone		<i>A. campestris</i>	[149]
5,4'-dihydroxy-6,7-dimethoxyflavone		<i>A. campestris</i>	[149]
Padmatin		<i>A. campestris</i>	[145]
7-O-methoxy aromadendrin		<i>A. campestris</i>	[137]
Pinostrobin		<i>A. campestris</i>	[137]
Pinocembrin		<i>A. campestris</i>	[137]
Homoeriodictyol		<i>A. campestris</i>	[137]
<i>Chalcones</i>			
4,2'-dihydroxy-4'-methoxychalcone		<i>A. campestris</i>	[100]

Table.I.5 continued....

2',5'-dihydroxy-4-methoxychalcone		<i>A. campestris</i>	[100]
Isoliquiritigenin		<i>A. campestris</i>	[100]

I.1.6.5.2. Lignans

Various studies have been conducted on the lignans of *A. sieversiana* and *A. absinthium*, both of which contain cyclolignans. The Table.I.6 present an overview of the different structures of lignans that have been isolated.

Table.I.6. Lignans compounds isolated from *Artemisia* species.







Isolated Compound	Structure	Species	Ref
Diayangambin		<i>A.sieversiana</i>	[150]
		<i>A. absinthium</i>	[151]
Epiyangambin		<i>A.sieversiana</i>	[150]
		<i>A. absinthium</i>	[148] [151]
Epiashchantin		<i>A.sieversiana</i> <i>A. absinthium</i>	[150] [151]

Table.I.6 continued....

Sesartemin		<i>A.sieversiana</i>	[150]
		<i>A. absinthium</i>	[148] [151]
Caruilignan A		<i>A.sieversiana</i>	[150]
		<i>A. absinthium</i>	[151]
(+)-Phylligenin		<i>A.sieversiana</i>	[150]

I.1.6.5.3. Coumarins

Coumarin is a natural organic aromatic heterosidic oxygenated substance with the chemical formula $C_9H_6O_2$. It is also referred to as 1,2-benzopyrone or 1, benzopyrane-2-one in the international nomenclature. There are few isolated coumarins from the genus *Artemisia*. We list 7 coumarines from 5 different species (Table.I.7).

Table.I.7. Coumarins compounds isolated from *Artemisia* species.








Isolated Compound	Structure	Species	Ref
Scopoletin		<i>A.campestris</i>	[146]
		<i>A. herba alba</i>	[152]
Umbelliferone		<i>A. anomola</i>	[153]
Dracunculin		<i>A. kieskiana</i>	[154]




Table.I.7 continued....

Herniarin		<i>A. glutinosa</i>	[147]
Artemidinal		<i>A. campestris</i>	[100]
E-artemidin		<i>A. campestris</i>	[100]
(+) epoxyartemidin		<i>A. campestris</i>	[100]

I.1.6.5.4. Chromones

Two chromones were isolated from an acetone extract of *A. campestris* L. *ssp. maritima*, and artemisenol was isolated from *A. campestris* L. *ssp. glutinosa* (Table.I.8).

Table.I.8. Chromones compounds isolated from *Artemisia* species.

Isolated Compound	Structure	Species	Ref
5-Hydroxy-7-methoxychromone		<i>A. campestris</i>	[146]
5,7-dimethoxychromone		<i>A. campestris</i>	[146]
Artemisenol (6-acetyl-2-methyl-2-hydroxymethylchromene)		<i>A. campestris</i>	[155]

I.1.6.5.5. Acetophenones

Acetophenones have been thoroughly examined by De Pascual *et al.*, and their occurrence has been limited to the weakly acidic fraction of the hexane extract of *A. campestris* L. *ssp. glutinosa*; the main isolated acetophenones are presented in Table.I.9.

Table.I.9. Acetophenones compounds isolated from *Artemisia* species.

Isolated compounds	Structure	Species	Ref
3-[4-acetoxyisopent-2(Z)-enyl]-4-hydroxyacetophenone		<i>A.campestris</i>	[156]
3-[4-acetoxyisopent-2(E)-enyl]-4-hydroxyacetophenone		<i>A.campestris</i>	[156]
3-(3-acetoxymethyl-2-hydroxybut-3-enyl)-4-hydroxyacetophenone		<i>A.campestris</i>	[156]
3-(isopent-2-enyl)-4-hydroxyacetophenone		<i>A.campestris</i>	[149]
3-[4-Hydroxyisopent-2(E)-enyl]-5-(isopent-2-enyl)-4-hydroxyacetophenone		<i>A. campestris</i>	[157]
3-[4-Hydroxyisopent-2(Z)-enyl]-5-[4-hydroxyisopent-2-(E)-enyl]-4-hydroxyacetophenone		<i>A. campestris</i>	[157]
4, 6-di methoxy acetophenone-2-O-β-D-glucopyranoside		<i>A. Spicigera</i>	[158]
Glutinosol		<i>A. glutinosa</i>	[147]

Table.I.9 continued....

I.1.6.5.6. Terpenoids

Terpenes are compounds formed from 2-methylbutadiene branching pentacarbonyl units. Depending on the number of units, monoterpenes (2 units), sesquiterpenes, diterpenes, triterpenes, steroids, and carotenoids are formed. α -Santonin and 8 α -Hydroxytaurin were both isolated from the air-dried *Artemisia santonicum*.

Ridentin, Ridentin-3-acetate, and Artemorin were isolated from the aerial part of *A. verlotorum* and *A. lerchiana* using chloroform and the crude extract, respectively, and Pallensin was obtained using the acetone fraction from the aerial part of *A. pallens*. Table.I.10 shows several different terpenoid compounds that belong to this genus.

Table.I.10. Terpenoids isolated from *Artemisia* species.







Monoterpenes						
Isolated Compound	Structure			Species	Ref	
Lyratyl acetate				<i>A. schimperi</i>	[159]	
Artemisyl acetate				<i>A. schimperi</i>	[159]	
1,5-Octadien-3-hydroxy-3-methyl-7-one				<i>A. schimperi</i>	[159]	
Sesquiterpenes						
						
Germacranolides						
Isolated Compound	R ₁	R ₂	R ₃	R ₄	Species	Ref
Herbolide F	H	OH	H	OH	<i>A. herba alba</i>	[160]
Herbolide H	H	OH	H	H	<i>A. herba alba</i>	[160]
Shonachalin	OH	H	OH	H	<i>A. herba alba</i>	[161]
Dihydroridentin	H	H	OH	OH	<i>A. herba alba</i>	[162]
11β,13-dihydroridentin-3-acetate	H	H	OH	OAc	<i>A. desertii</i>	[162]

Table.I.10 continued...



Germacranolides


Isolated Compound	R1	R2	R3	Species	Ref
Ridentin	OH	H	OH	<i>A. lerchiana</i>	[163]
Artemorin	OH	H	H	<i>A. verlotorum</i> <i>A. lerchiana</i>	[163] [164]
Ridentin-3-acetate	OH	H	OAc	<i>A. verlotorum</i> <i>A. lerchiana</i>	[163] [164]



Eudesmanolides

Isolated Compound	R1	R2	R3	R4	Species	Ref
Santamarin	CH ₂	H	H	OH	<i>A. hispanica</i>	[165]
α -Santonin	CH ₃	H	H	=O	<i>A. santonicum</i>	[166]
8 α -Hydroxytaurin	CH ₃	OH	H	=O	<i>A. santonicum</i>	[166]
8 α -Acetoxytaurin	CH ₃	OCH ₃	H	=O	<i>A. santonicum</i>	[166]

Pallensin

*A. pallens* [167]

Neozoguaianin



*A. montana* [168]

Table.I.10 continued....

Oyomoginin

*A. montana*

[168]

I.2. Zygophyllaceae

The Zygophyllaceae is a flowering family that includes the bean-escapade and the caltrop. It was classified as a dicot family (angiosperms)[169]. Around 27 genera and 285 species belong to the Zygophyllaceae family, further divided into five subfamilies. Therefore, approximately 3% of the Algerian desert comprises Zygophyllaceae [170].

I.2.1. Botany of the family Zygophyllaceae

Vegetative apparatus

- ✓ **Stems:** Swollen nodes are a common characteristic of stems.
- ✓ **Leaves:** The leaves can be paripinnate, trifoliolate, geminate, or simple, depending on the species. They are often opposite (less frequently spiral), stipulate and resinous, and the stipules are permanent and spiky in certain taxa [171].

Producing apparatus

- ✓ **Flowers:** The flowers are always bisexual, actinomorphic or zygomorphic, terminal or axillary, and single or clustered in racemes or cymes. The 4 or 5 sepals, valvaires or imbricate, are lanceolate, oblong, oval, or obovate, with an acute or obtuse apex and a glabrous or hairy surface. 4 or 5 valvaires or nested petals are white, creamy, yellow, pink, purple, or purple. Oblong, spatulate with 4-5 stamens up to 3 times the number of petals [172].
- ✓ **Fruits:** The fruit is typically a schizocarp or lobed capsule (each carpel is divided into 2 mericarps in certain taxa) and is rarely a berry or drupe.
- ✓ **Seeds:** the seeds might be ellipsoid, oblong, obovoid, ovoid, or flat. They can also be smooth, tuberculous, or crustaceous [171, 172].

I.2.2. Geographic distribution of the family Zygophyllaceae

The family of Zygophyllaceae is distributed in the old and new world but predominately in arid, semiarid, and saline regions in all warm areas of the world, particularly in seasonally dry deserts, in tropical and subtropical regions [7, 173].

I.2.3. Folk-medicinal and Pharmacology of the family Zygophyllaceae

Zygophyllaceae is a family of plants with many different species, many of which have remarkable therapeutic properties and are utilized in traditional medicine. The following are several examples of species that are very important from a therapeutic:

In traditional Iranian medicine, *Peganum harmala* L is known to as "Esfand," "Espand," and "Harmal" due to its wide range of medicinal uses, including as a carminative, vermifuge, aphrodisiac, galactagogue, diuretic, emménagogue, and antithrombotic [174].

In traditional Egyptian medicine, the fruits of the *Balanites aegyptiaca* Del. plant are used as an oral hypoglycemic. On the other hand, in traditional Indian medicine, the species was used to treat epilepsy and rheumatism [175]. Besides treating digestive problems such as constipation and heartburn, it can also help in treating helminthiases, jaundice, spleen illness, herpes, skin problems, malignant wounds, gonorrhea, lice, and syphilis [176].

Zygophyllum gaetulum is widely known for the anti-diabetic characteristics that it possesses [177]. In addition to those properties, it is anti-spasmodic, anti-eczema, and a helpful cure for the stomach and the *Zygophyllum album* L., which is Saharo-Mediterranean species, is used to treat diabetes and diarrhea. Its aqueous preparations are carminative, antiseptic, and stimulating [178].

In Argentina, the species *Larrea divaricata* is widely used to treat various diseases, including tumours, inflammation, arthritis, and fever [179]. In addition to the use of Zygophyllaceae in traditional pharmacopeias, a variety of studies have been carried out to validate their traditional uses and to look for novel biological potentials in these plants.

Several plants of the family Zygophyllaceae, including *Guaiacum officinale* [180], *Fagonia schweinfurthii* [181], *Peganum harmala* L. [182] and *Balanites aegyptiaca* L. [183], have been shown to exhibit antioxidant potential in recent studies.

Zygophyllaceae species are natural anti-inflammatory sources, including *Zygophyllum album* Desf. [184], *Peganum harmala* L. [182], *Balanites aegyptiaca* L. [183] and *Larrea divaricata* Cav. [185].

Zygophyllum album Desf. and *Peganum harmala* L have both been examined for their potential to replenish anticancer and antitumor compounds [182, 184].

Additional research on different species in this family has revealed a wide range of biological effects, including those that are antihyperglycemic (*Zygophyllum album* L.) and antihyperlipidemic (*Zygophyllum album* L.) [186], anticonvulsant (*Balanites aegyptiaca* L.) DeL.) [175] , antinociceptive (*Balanites aegyptiaca* L.), cytotoxic (*Larrea tridentate* DC.) [183].

I.2.4. Chemistry of the family Zygophyllaceae

In light of their contribution to phytochemistry, Zygophyllaceae species include an abundance of secondary metabolites, notably flavonoids and alkaloids [187], triterpenoids, sterols, and saponins [173], and other compounds isolated from Zygophyllaceae owing to their potential pharmacological activity.

I.2.5. The *Fagonia* genus

The genus *Fagonia*, a member of the Zygophyllaceae family, is noteworthy since it has 35 species native to various regions of Africa, the Mediterranean Basin, the Middle East, and Asia, which is classified as eurosid I (APG II, 2003). these species are generally Shrub or herbaceous plants up to 60 cm tall. Ethnobotanically, numerous species of *Fagonia* have been utilized for the treatment of a wide variety of illnesses by traditional practitioners adhering to Ayurveda and other healing regimens [188].

I.2.5.1. Botany of the genus *Fagonia*

Vegetative apparatus

- ✓ **Stems:** Stems with glabrous, pubescent, or glandular characteristics.
- ✓ **Leaves:** Depending on their complexity, the leaves are either opposite or simple (1-, 2- or 3-foliolate., rarely up to 7 foliolate.). Folioles are typically linear to oval or obovate in form, frequently mucronate, and can have a petiole. The stipules are free and have spiny.

Producing apparatus

- ✓ **Flowers:** The five sepals have an acute-attenuated apex. The five petals are obovate, pink, or purple. There are 10 stamens and filaments without basal appendages. The ovary is (5-) locular, glandular and pubescent.

- ✓ **Fruits:** Obconical capsules assist in circumscribing *Fagonia*.
- ✓ **Seeds:** The exterior seed testa is mucilaginous without internal structures, and the aril lacks [189, 190].

I.2.5.2. Geographic distribution of the genus *Fagonia*

The disjunct distribution of *Fagonia* includes arid regions of the New and Old World. In the New World, it is found in the southwestern United States, the southwestern USA, Peru, Chile, and Mexico. In the Old World, it is found in Macaronesia, northern Africa, south of the Sahel regional transition area, southern Africa, as well as the southern regions of Europe, comprising the islands in the Mediterranean. *Fagonia* is also found in Kenya, western Asia (Turkey, Lebanon), western India, Afghanistan, and Arabian Peninsula. Several different species of *Fagonia* can be found in the Old or New World [190] (Figure.I.9). Among the 17 species of this genus found in Algeria are the *F. bruguieri*, *F.arabica*, *F.longispina*, *F. kahirina*, and *F. olivieri* [191].




Figure.I.9. *Fagonia* distribution map with endemism areas: (A): South America, (B): North America, (C): north of Mexico, (D): south of Africa, (E): Sahara-Sind includes Macaronesia, (F): the Horn of Africa, (G): Oman and Yemen, (H): west of Morocco, and (I): south of Iran [190].

I.2.5.3. Folk-medicinal of the genus *Fagonia*

There are extensive and intriguing lists of illnesses that reportedly can be treated traditionally using *Fagonia* species. Depending on the type of disease being treated, the recommended therapy approach may include both an internal or exterior treatment. Due to its widespread use

in both India and Pakistan, it is widely utilized in folk medicine by the native inhabitants. Some examples are presented in the Table.I.11.

Table.I.11. Traditional medicinal uses of *Fagonia* species.

Region	Plant/ part used	Ethnopharmacology reports	Ref
Pakistan	<i>F.cretica</i> / leaves, flowers, aerial parts	Stomach aches, urinary, vomiting, fever, asthma, liver disorders, typhoid, toothaches, and stomach aches.	[192]
	<i>F.cretica</i> / whole plant	Treatment for cancer	[193]
	<i>F.arabica</i> L / Ns	Typhoid, vomiting, leukemia, boils, dysentery, and asthma. Their infusions treat mouth pain, stomatitis, and constipation.	[194, 195]
	<i>F.arabica</i> L / Twigs	treat snake bites and are applied externally as a paste on tumors and swellings	[194]
	<i>F. Olivieri</i> / Shoot	Diabetes and cough treatment, blood purifier, and cooling agent	[196]
	<i>F. olivieri</i> / Ns	Vascular, early-stage cancer, and digestive diseases.	[177]
India	<i>F.arabica</i> L / Leaves, aerial parts	smallpox, skin diseases, and endothermic body reactions	[193, 195]
	<i>F.schweinfurthii</i> / whole plant	Poisoning, smallpox, diabetes, pain, jaundice, cough, asthma, skin rashes, liver tonic for many liver conditions	[181]
Algeria	<i>F. longispina</i> / aerial plant	digestive diseases	[189]

Ns : Not specified

I.2.5.4. Pharmacology of the genus *Fagonia*

Several investigations have been conducted to validate traditional uses of the genus *Fagonia* and investigate novel biological potentials concerning their therapeutic utilizes. The majority of these studies concern anticancer and antitumor effects, microbial resistance, antidiabetic effect, anti-inflammatory, and healing (Table.I.12).

Table.I.12. Pharmacological studies of *Fagonia* species.

Plant / Tested sample	Model	Dose / concentration	Results	Ref
Cytotoxic, Anti-tumor activity				
<i>F.cretica</i> / methanolic extract	-In-vivo / Brine shrimp toxicity assay -In-vivo / Potato disc assay	-0.5-10,000 ppm for Cytotoxic assay -10-1000 ppm for anti-tumor activity	- At LD50 118.89 ppm, a significant cytotoxic effect was recorded against brine shrimps - All of the tumor-inducing Agrobacterium strains tested showed significant antitumor activity (At6, At10, and At77), with At10 showing the highest tumour inhibition (77.04%).	[192]
<i>F. indica</i> / crude water extract	In-vivo / Tumors in male and female rats were induced experimentally	-	Significantly greater tumorostatic activity in females than in males	[197]
Thrombolytic agent activity				
<i>F. Arabica</i> / Aqueous extract	In vivo / The clot lysis efficacy of <i>F. Arabica</i> was tested using a thrombolytic model with Streptokinase as a positive control.	10 mg/mL	<i>F.arabica</i> demonstrated a substantial % of clot lysis (75.6%) compared with Streptokinase (86.2%) (reference).	[198]
Anti-Diabetic effect				
<i>F.indica</i> / (hexane, chloroform, methanol, and water extracts)	-In vitro / Potential hypoglycemic effects were examined using an alpha inhibitory method. -In vivo / Wistar albino rat models were used to test the chloroform fraction's anti-hyperglycemic potential.	-20-100 ug/mL for the test in vitro -250-500 mg/kg b.w. for the test in vivo	-In vitro / The chloroform extract showed substantial activity, with an IC ₅₀ of 93.61±4.44 µg/mL compared to the acarbose (standard) value of 52.99±4.88 µg/mL followed by ethyl acetate, n-hexane, and n-butanol extracts. -In vivo / at 30 min after a meal, chloroform extract lowered postprandial blood glucose levels less than the reference acarbose.	[199]
Anti microbial activity				
<i>F.indica</i> / Ethanollic extract	In vivo / Inhibition zones against gram-negative and positive bacteria: <i>E.coli</i> , <i>S. aureus</i> , <i>P. aeruginosa</i> and <i>B. cereus</i>	25- 100 mg/mL	The ethanollic extract had a strong inhibitory effect against all bacterial strains, with the best impact observed against <i>B.cereus</i> .	[200]
Hepatoprotective activity				
<i>F. schweinfurthii</i> / ethanollic extract	In vivo/ The hepatoprotective effect of <i>F. schweinfurthii</i> ethanollic extract was evaluated in the male wistar albino rats model	200-400mg/kg/day/ p.o.	<i>F.schweinfurthii</i> ethanollic extract effectively reduced CCl ₄ -induced alterations in HepG2 cells	[181]

Table.I.12 continued....

	of CCl ₄ -induced hepatotoxicity			
Anti-inflammatory and wound healing activity				
<i>F.schweinfurthii</i> / Herbal gel	In vivo/ Carrageenan induced rats paw edema and excision wound	0.5 g	Gel formulations have a gradual anti-inflammatory effect and expedite wound healing	[201]
Clot lytic activity				
<i>F. Arabica</i> / Aqueous extract	In vitro/ Blood coagulation and Fibrinolysis by Microtiter plate clot lysis method	50 ug/mL	<i>F.arabica</i> lysed clots have a similar effect to streptokinases (reference =60 ug /ml) in an MPCL technique.	[198]
Antioxidant activity				
<i>F. arabica</i> / Total extract	In vitro/ Prevention of Oxidative Stress in PC12 Cells Due to Chemical Ischemia	1000 ug/mL	The antioxidant activity of <i>F.arabica</i> protect cells from being damaged by oxidative stress by ischemia.	[202]
<i>F.Longispina</i> / Ethanol extract	In vitro/ DPPH scavenging assay	0.5-0.001 mg/ml	The ethanolic extract had a scavenging efficacy (IC ₅₀ = 0.22±0.0075 mg/ml) comparable to that of ascorbic acid (IC ₅₀ = 0.24±0.0081 mg/ml)	[203]
<i>F.mollis</i> / (Aqueous and methanolic extracts)	In vitro/ ABTS scavenging activity	-	IC ₅₀ = 72.5 ±0.6 µmol TE g ⁻¹ dry weight for Aqueous and 31.4± 4.5 µmol TE g ⁻¹ dry weight for methanolic extracts which exhibited a moderate effect compared with the reference trolox.	[204]

1.2.6. *Fagonia bruguieri* DC.

The genus *Fagonia* species possess a wide variety of active chemical constituents, which have been speculated to be accountable for the pharmacological effects of the *Fagonia* species. These studies have shown the accumulation of various secondary metabolites including flavonoids and terpenes [205]. Plants belonging to this genus have been the subject of significant attention in phytochemistry for an extended period. *Fagonia bruguieri* DC. species Saharo-arabic is most frequently known by its common name *F. echinella* Boiss. It is known as afessour in Tamahaq, the indigenous language of the Touareg inhabitants in the South of Algeria [98]. This choice was influenced mainly by the endemism of this plant in the southern Sahara, which has a distinct climate and unique environment. These factors, particularly the latter, are likely to influence the chemical composition of the vegetation.

✓ **Systematic classification [7, 191]**

Kingdom: Plantae

Subkingdom: Viridaeplantae

Division: Magnoliophytae

Class: Magnoliopsidae

Order: Zygophyllales

Family: Zygophyllaceae

Sub-family: Zygophylloideae

Tribe : Zygophylleae

Genus: *Fagonia* L.

Species: *Fagonia bruguieri* DC.

Vernacular names: *F. echinella* Boiss

Local name: *afessour*



Figure.I.10. *Fagonia bruguieri* DC.

I.2.6.1. Botany of the *Fagonia bruguieri* DC.

Fagonia bruguieri DC. is a small perennial (Shrub or shrublet), pale-green plant, procumbent, reaches a maximum height of 20 cm and is thickly branched [188] (Figure.I.11).



Figure.I.11. Drawing of *Fagonia bruguieri* DC.[206].

Vegetative apparatus

- ✓ **Stems:** thickly or sparsely glandular, frequently viscid, broadly angular and with ridges of varying sizes; internodes measuring between 3 and 35 mm in length.
- ✓ **Stipules:** 1.5-25 mm long, spinescent, erect or deflexed, shorter or longer than the leaves, basal stipules longer than upper stipules, glandular.

- ✓ **Leaves:** Lower leaves 3-foliolate or sometimes 2-foliolate, upper leaves (3)-foliolate, linear to elliptic, rarely obovate, glandular, flat, with up to 0.8 mm mucro, lateral leaveslets smaller than center

Producing apparatus

- ✓ **Sepal:** persistent, ovate, apiculate, and glandular. *Fagonia bruguieri* DC. has longer-lasting sepals than most species.
- ✓ **Petal:** Petals varied from 3.5 to 5 mm, 1.7 mm claw, apiculate and soon deciduous. Violet-purple petals.
- ✓ **Fruit:** Fruit-calyx persistent, a capsule with five sides is covered in hairs, 4 mm long and 3 to 4 mm wide [188].

I.2.6.2. Geographic distribution of *Fagonia bruguieri* DC.

Fagonia bruguieri is a northern Sahara-endemic species found all over the Sahara desert. In Africa, *F. bruguieri* is distributed in Mauritania in the west, East Egypt, and the transition zone of the Sahel area in the south. It has a continuous distribution across Afghanistan and Pakistan to the east and reaches Yemen to the south (Figure.I.12) [188, 207].




Figure.I.12. Distribution of *Fagonia bruguieri* DC.[188].

I.2.6.3. Folk-medicinal of *Fagonia bruguieri* DC.

Fagonia species are widely utilized in folk medicine as popular treatments for a wide range of skin diseases. In the Algerian region of Hoggar, the local populations of Tamanraasset use a decoction prepared of leaves as a treatment for jaundice as well as digestive problems, anemia, and kidney diseases [98]. Additional traditional applications are listed in the literature (Table.I.13).

Table.I.13. Traditional medicinal uses of *Fagonia bruguieri* DC.

Region	Preparation method	Part used	Ethnopharmacology reports	Ref
Algeria	Décoction, infusion, Powder	Leaves, aerial parts	Jaundice, Digestive diseases, anemia kidney diseases.	[98]
	Powder (internal use)	Aerial parts	Jaundice, liver insufficiency, Palpitations, anxiety	[176]
Saudi Arabia	-	Leaves	Blood and heart tonic	[178]
	boiled water	Leaves	blisters dermatitis	[208]
Pakistan	Infusion	Whole plant	Diabetes, obesity, control swatting	[209]
Iran	Decoction, infusion	Aerial parts	Appetizing, vermicide, carminative	[210]

I.2.6.4. Pharmacology of *Fagonia bruguieri* DC.

Table.I.14. Pharmacological studies of *Fagonia bruguieri* DC.

Testd sample / Part used	Model	Dose / concentration	Results	Ref
Analgesic activity				
Methanol extract/ whole plant	-In vivo / Acetic acid induced writhing model and Eddy's hot plate in	250- 750 mg/kg	A 750 mg/kg dose of <i>F. bruguieri</i> methanolic extract decreased the writhing count by 62.23 %, while <i>F. bruguieri</i> improved delay in Eddy's hot plate test.	[211]
Anti-inflammatory activity				
Methanol extract/ whole plant	In vivo / Carrageenan-induced paw edema in adult male albino Wistar rats was used to assess anti-inflammatory effects	250- 750 mg/kg	The methanolic extract of <i>F. bruguieri</i> at 750 mg/kg showed anti-inflammatory effects in carrageenan-induced edema after 2, 3, and 4th hours.	[211]
Anti-pyretic activity				
Methanol extract/ whole plant	In vivo / Brewer's yeast induced pyrexia model.	250- 750 mg/kg	The yeast treatment increased rectal temperature and decreased the methanolic extract of <i>F.bruguieri</i> (98.3±0.07) at 500 and 750 mg/kg compared to diseased rats.	[211]
Antidiabetic activity				
Crude extract / Aerial part	In vitro / amylase inhibition assay	-	Important inhibition of alpha amylase (75.5±0.5 %)	[212]
Histopathological and biochemical hepatoprotective effect				
Ethanollic extract / Aerial part	In vitro/ Pre-treatment with ethanollic extract against CCl4-intoxicated rabbits was investigated biochemically and histologically	500 and 750 mg/kg/day PO	The ethanollic extract of <i>F.bruguieri</i> showed Hepatoprotection at 500 and 750 mg/kg, which considerably restored SGOT, SGPT, and ALP levels, whereas TB levels did not increase appreciably. Moreover, these findings were confirmed	[213]

Table.I.14 continued....


			by a histopathological study of the liver tissue.	
Anti-allergic activity				
Boiling water, freeze-dried / whole plant	in vivo / Albino guinea pigs administered the extract orally antagonized with 20 µg/kg i.v. of histamine and 100 µg/kg i.v. of capsaicin and produced bronchoconstriction without affecting ACh and 5-HT.	200 mg/kg	Antagonisms against histamine and capsaicin were 72 % and 65 %, respectively. Treatment of guinea pigs with <i>F. bruguieri</i> for 20 minutes or orally for 2 hours prevented histamine toxicity, gasps and loss of consciousness.	[205]
Acetylcholinesterase Activity				
Methanolic, petroleum ether, n-butanolic extracts/ Aerial part	In vivo / The haemolymph and fat body of nymphs in their last instar and adult females were tested to assess the AchE activity.	-Methanolic (7.5-3.7%) -Petroleum ether (30 -15%) -n-butanolic (30 -15%)	The petroleum ether and n-butanolic extracts showed the strongest inhibitory impact with respect to the enzyme activity in the fat body of <i>S. gregaria</i> nymphs, particularly in the early nymphs.	[214]
Antioxidant activity				
Methanolic extract/ Aerial part	In vitro / DPPH radical scavenging assay	11-100 µg/mL	IC ₅₀ = 32.733 µM	[215]
Methanolic extract/ Aerial part	In vitro / Total antioxidant capacity(phosphomolybdenum method)	-	IC ₅₀ =120 µg AA Equivalent /mg methanol extract	[215]
Methanolic extract/ Aerial part	In vitro / Reducing power assay	-	IC ₅₀ =141 µg AA equivalent/ mg methanol extract	[215]
Antifungal activity				
Methanolic extract/ Aerial part	In vivo / - <i>Aspergillus niger</i> - <i>Aspergillus Fumigatus</i> - <i>Aspergillus Flavus</i> - <i>Mucor mycosis</i>	100- 400 mg/kg, b.w.	The methanolic extract had antifungal effect against all of the microorganisms that were examined.	[215]

I.2.6.5. Secondary metabolites isolated from the *Fagonia* genus

I.2.6.5.1. Flavonoids

The most abundant secondary metabolites in the genus *Fagonia* are flavonoids, predominantly O-glycosylated flavonols at the 3 and/or 7 position, including Kaempferol, Isorhamnetin, Quercetin, and Herbacetin. On the other hand, Flavones are not very common in the genus *Fagonia*. Only three derivatives of aepenin and acetin have been isolated from the species *F. taekholmiana* and *F. arabica*. Table.I.15→ Table.I.20 illustrate the various flavonic structures isolated from the genus *Fagonia*.


✓ Flavonols and its derivatives

Table.I.15. Quercetin derivatives isolated from the genus *Fagonia*.


Isolated Compound	R ₁	R ₂	Species	Ref
Quercetin	H	H	<i>F. taeckholmiana</i>	[216]
			<i>F. indica</i>	[217]
Quercetin-3-O-rhamnogalactoside	Rha-Gal	H	<i>F. kassasii</i>	[218]
			<i>F. bruguieri</i>	
			<i>F. schimperi</i>	
			<i>F. olivieri</i>	
			<i>F. microphylla</i>	[219]
			<i>F. glutinosa</i>	
Quercetin-3-O-glucoside	Glc	H	<i>F. indica</i>	[220]
			<i>F. paulayana</i>	
			<i>F. scabra</i>	
			<i>F. cretica</i>	
			<i>F. thebaica</i>	[221]
Quercetin-3-O-galactoside	Gal	H	<i>F. taeckholmiana</i>	[216]
			<i>F. kassasii</i>	[218]
			<i>F. bruguieri</i>	[218, 220]
			<i>F. schimperi</i>	
			<i>F. olivieri</i>	
Quercetin-3-O-gentiobioside	β -D-Glc ⁶ -D-Glc	H	<i>F. latifolia</i>	[219]
			<i>F. isotricha</i>	
			<i>F. microphylla</i>	[219]
			<i>F. glutinosa</i>	
			<i>F. latifolia</i>	
			<i>F. isotricha</i>	
Quercetin-3-O-gentiobioside-7-O-glucoside	β -D-Glc ⁶ -D-Glc	Glu	<i>F. kassasii</i>	[218]
			<i>F. bruguieri</i>	
			<i>F. schimperi</i>	
			<i>F. olivieri</i>	
			<i>F. glutinosa</i>	[219]
Quercetin-3-O-rutinoside	Rut	H	<i>F. microphylla</i>	
			<i>F. indica</i>	[219]
			<i>F. boulosii</i>	[220, 221]

Table.I.15 continued....

			<i>F. cretica</i>	[220]
			<i>F. tenuifolia</i>	
			<i>F. thebaica</i>	
			<i>F. olivieri</i>	
			<i>F. bruguieri</i>	[218, 220]
			<i>F. schimperi</i>	
			<i>F. kassasii</i>	
Quercetin 3-O-β-D-galactopyranosyl -(1→6)- α-L-2 acetyl rhamnose-(1→3) β-D-glucopyranoside	β-D-Glc ⁶ - α-L-2 acetyl Rha ³ - D-Glc	H	<i>F. indica</i>	[217]
Quercetin-3,7-O-diglucoside	Glc	Glc	<i>F. glutinosa</i>	[219]
			<i>F. microphylla</i>	
			<i>F. isotricha</i>	
			<i>F. thebaica</i>	[220, 222]
			<i>F. boulosii</i>	
			<i>F. tenuifolia</i>	[220]
			<i>F. paulayana</i>	
Quercetin 3-O-β-D-glucopyranoside	β-D-Glc	H	<i>F. longispina</i>	[223]

Table.I.16. Kaempferol derivatives isolated from the genus *Fagonia*.

Isolated Compound	R ₁	R ₂	Species	Ref
kaempferol	H	H	<i>F. paulayana</i>	[220, 224]
			<i>F. indica</i>	
			<i>F. schweinfurthii</i>	
3-O-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyl]-kaempferol	Rha- Glc	H	<i>F. indica</i>	[225]
Kaempferol-3-O-rutinoside	Rut	H	<i>F. mollis</i>	[226]
			<i>F. tristis</i>	
			<i>F. bruguieri</i>	[218]
			<i>F. olivieri</i>	
			<i>F. schimperi</i>	
			<i>F. kassasii</i>	
			<i>F. indica</i>	[224]
			<i>F. schweinfurthii</i>	
			<i>F. isotricha</i>	[219]
			<i>F. latifolia</i>	
			<i>F. indica</i>	[220]
			<i>F. boveana</i>	
			<i>F. longispina</i>	[223]
Kaempferol-3-O-glucoside	Glc	H	<i>F. bruguieri</i>	[218]
			<i>F. kassasii</i>	
			<i>F. glutinosa</i>	[219]
			<i>F. microphylla</i>	

Table.I.16 continued....

			<i>F. schweinfurthii</i>	[220]
			<i>F. cretica</i>	
			<i>F. scabra</i>	
			<i>F. longispina</i>	
			<i>F. paulayana</i>	
			<i>F. indica</i>	
Kaempferol 3- O-rhamnogalactoside	Rha-Gal	H	<i>F. kassasii</i> ,	[218]
			<i>F. olivieri</i>	[218, 220]
			<i>F. schimperi</i>	
			<i>F. bruguieri</i>	
			<i>F. isotricha</i>	[219]
			<i>F. latifolia</i>	
kaempferol-3-gentiobioside-7- O-glucoside	Gent	Glc	<i>F. glutinosa</i>	[219]
			<i>F. microphylla</i>	
Kaempferol-7-O-rhamnoside	H	Rha	<i>F. arabica</i>	[227]
Kaempferol-3,7-O-diglucoside	Glc	Glc	<i>F. isotricha</i>	[219]
Kaempferol-7-O-glucoside	H	Glc	<i>F. microphylla</i>	[219]
			<i>F. glutinosa</i>	
Kaempferol-3,7-di-O-rhamnoside (kaempféritrine)	Rha	Rha	<i>F. taeckholmiana</i>	[216]
Kaempferol 3-O-β-L-arabinopyranosyl-(1→4)-α-L-rhamnopyranoside-7-O-α-L-rhamnopyranoside	Ara-Rha	Rha	<i>F. taeckholmiana</i>	[216]
Isokaempferide	CH ₃	H	<i>F. longispina</i>	[223]

Table.I.17. Isorhamnetin derivatives isolated from the genus *Fagonia*.


Isolated Compound	R ₁	R ₂	Species	Ref
Isorhamnetin-3-glucoside	Glc	H	<i>F. thebaica</i>	[220, 221]
			<i>F. scabra</i> Forsskal	[220]
			<i>F. cretica</i>	
			<i>F. arabica</i>	[220, 228]
			<i>F. indica</i>	[220, 224]
			<i>F. taeckholmiana</i>	[228]
Isorhamnetin-3,7-O-diglucoside	Glc	Glc	<i>F. thebaica</i>	[220, 222]
			<i>F. paulayana</i>	[220, 224]
			<i>F. cretica</i>	[220]
			<i>F. tenulfolia</i>	
			<i>F. scabra</i> Forsskal	
Isorhamnetin-3-rutinoside	Rut	H	<i>F. mollis</i>	[220, 226]
			<i>F. schweinfurthii</i>	[224]
			<i>F. indica</i>	
			<i>F. taeckholmiana</i>	[228]
			<i>F. arabica</i>	
			<i>F. olivieri</i>	[218]
			<i>F. schimperi</i>	
<i>F. kassasii</i>				

Table.I.17 continued....

			<i>F. boulosii</i>	[220, 222]
			<i>F. thebaica</i>	
			<i>F. tristis</i>	[226]
			<i>F. boveana</i>	[220]
			<i>F. bruguieri</i>	
Isorhamnetin-3-O-rhamnoside	Rha	H	<i>F. indica</i>	[217]

Table I.18. Herbacetin derivatives isolated from the genus *Fagonia*.

Isolated Compound	R ₁	R ₂	R ₃	Species	Ref
3,8- dimethoxy herbacetin	CH ₃	H	CH ₃	<i>F. bruguieri</i>	[229]
				<i>F. boveana</i>	[230]
8-methoxy-3,glucoside herbacetin	Glc	H	CH ₃	<i>F. thebaica</i>	[220]
8-methoxy-3-rutinoside-7-glucoside herbacetin	Rut	Glc	CH ₃	<i>F. taeckholmiana</i>	[228]
				<i>F. arabica</i>	[220, 228]
Herbacetin-8-O-rutinoside	H	H	Rut	<i>F. Arabica</i>	[220, 228]
				<i>F. thebaica</i>	[220, 222]
				<i>F. taeckholmiana</i>	[228]
3,7,8-trimethoxy herbacetin	CH ₃	CH ₃	CH ₃	<i>F. bruguieri</i>	[229]
8-methoxy-3-rutinoside herbacetin	Rut	H	CH ₃	<i>F. boulosii</i>	[222]
				<i>F. thebaica</i>	
				<i>F. taeckholmiana</i>	[228]
				<i>F. Arabica</i>	[187, 220]
8-methyl ether-3,7-diglucoside herbacetin	Glc	Glc	CH ₃	<i>F. arabica</i>	[220, 228]
				<i>F. taeckholmiana</i>	[228]
				<i>F. mollis</i>	[220]
8-methoxy herbacetin	H	H	CH ₃	<i>F. boveana</i>	
				<i>F. tristis</i>	[226]

Table.I.19. Flavonols isolated from the genus *Fagonia*.


Isolated Compound	R ₁	R ₂	Species	Ref
Apigenin	H	H	<i>F. taeckholmiana</i>	[216]
Acacetin 7-O-rhamnoside	Rha	CH ₃	<i>F. arabica</i>	[227]
Apigenin 7-O-glucoside	Glc	H	<i>F. taeckholmiana</i>	[216]

I.2.6.5.2. Terpenoids

✓ Triterpenoids and saponins and its derivatives


As a class, these secondary metabolites are among the most defining characteristics of the *Fagonia* genus. More than 40 new Saponin and triterpenoid compounds have been isolated from this genus. The vast majority of them are saponins that are monodesmosides or bisdesmosides, and they are distinguished by α -L- arabinopyranosyl at position 3 that is linked to structures that are of the oleanane, ursane, or taraxastane type. The research on *Fagonia* has led to the isolation and characterization of thirteen genin saponins, including oleanolic acid and ursane type 3-O-glycosides or 3,28-di-O-glycosides in the genus *Fagonia*, represented by genins: ursolic acid, 27-hydroxyursolic acid, quinovic acid. In the genus *Fagonia*, taraxastane-type saponins are rare; they are widespread among the *F. indica* species.

A novel saponin glycosylated steroid of the genus *Fagonia* 12-(4-methyl-pent-3-enoyloxy)-20-(4-methyl-pent-3-enoyloxy)-3 β ,12 β ,20 β -trihydroxypregnane-3-ylO- β -D-cymapyranosyl-(1 \rightarrow 4)-3-methoxy-6-deoxy- β -D-glucopyranoside which is capable of triggering apoptosis or necrosis in cancer cells was isolated as a consequence of research into the plant anticancer activity of the plant *Fagonia indica* [231]. We classify the triterpenes and saponins into five categories (oleananes, ursanes, taraxastane, lupane, and saponin steroids), distributed across six different species (Tableau.I.21; Figure.I.13 \rightarrow Figure.I.16).

Table.I.20. Triterpenes and saponins isolated from the genus *Fagonia*.


N°	Isolated Compound	Species	Ref
Saponins of the Oleanane type			
1	3-O-β-D-xylopyranosyl (1→2)-[β-Dglucopyranosyl (1→3)]-α-L arabinopyranosyl oleanolic acid	<i>F. arabica</i>	[232]
2	3-O-β-D-glucopyranosyl(1→2)-[β-D-glucopyranosyl(1→3)]-α-L-arabinopyranosyl oleanolic acid	<i>F. arabica</i>	[232]
3	3-O-β-D-glucopyranosyl(1→3)-α-L- arabinopyranoside oleanolic acid	<i>F. arabica</i>	[227]
		<i>F. indica</i>	[233]
4	3-O-β-D-xylopyranosyl (1→2)-[β-D glucopyranosyl (1→3)]-α-L- arabinopyranosyl 28-O-β-D-glucopyranoside oleanolic acid	<i>F. arabica</i>	[232]
5	3-O-β-D-glucopyranosyl (1→2)-[β-D-glucopyranosyl (1→3)]-α-L-arabinopyranosyl 28-O-β-D-glucopyranoside oleanolic acid	<i>F. arabica</i>	[232]
6	3-O-α-L-rhamnopyranosyl-(1→3)-6'-O-methyl-β-D-glucuronopyranoside oleanolic acid	<i>F.mollis</i>	[234]
7	3-O-α-L-rhamnopyranosyl (1→3)-6'-O-methyl-β-D-glucurono pyranosyl 28-O-β-D-glucopyranoside oleanolic acid	<i>F.mollis</i>	[234]
8	3-O-sulfonyl- acide 27-hydroxyoleanolic-28-O-β-D-glucopyranoside	<i>F.arabica</i>	[235]
9	3-O-[β-D-glucopyranosyl (1→2)] [β-D-glucopyranosyl (1→3)]-α-L-arabinopyranosyl- acide 27-hydroxy oleanolic-28-O-β-D-glucopyranosyl ester	<i>F. glutinosa</i>	[236]
10	3 β-O-[β-D-xylopyranosyl(1→2)-α-L-arabinopyranosyl] acide olean-12-èn-27-al-28-oic 28-O-[β-D-glucopyranosyl(1→6)-β-D-glycopyranosyl] ester	<i>F. cretica</i>	[237]
11	Hederagenin 3-O-β-D-glucopyranosyl	<i>F. cretica</i>	[238]
12	Hederagenin 3-O-β-Dglucopyranosyl-(1 →5)-α-L-arabinofuranosyl-(1 →4)-α-L-rhamnopyranosyl	<i>F. cretica</i>	[238]
13	hederagenin 3-O-β-D glucopyranosyl-(1 →4)-α-L-rhamnopyranosyl	<i>F. cretica</i>	[238]
Saponins of the ursane type			
Table.I.21 continued....			
14	3-O-{[β-D-glucopyranosyl-(1→2)]-[α-L-arabinopyranosyl-(1→3)]-α-L-arabinopyranosyl} ursolic-28-O-[β-Dglucopyranosyl] ester	<i>F. arabica</i>	[233]
15	3-O-[β-Dglucopyranosyl(1→2)][β-D-glucopyranosyl(1→3)]-α-L arbinopyranosyl ursolic-28-O-β-Dglucopyranosyl ester	<i>F. glutinosa</i>	[236]
16	ursolic 3-O-[β-D-glucopyranosyl(1→3)]-α-L-arabinopyranosyl	<i>F. glutinosa</i>	[236]
17	3-O-β-D-glucopyranosyl-(1→3)-α-L-arabinopyranosyl ursolic-28-O-β-D-glucopyranosyl ester	<i>F. indica</i>	[236]
18	3-O-β-Dxylopyranosyl(1→2)-[β-D-glucopyranosyl (1→3)-α-L arabinopyranosyl - 27-hydroxy ursolic28-O-β-D-glucopyranoside	<i>F.arabica</i>	[232]
19	3-O-[2-O-sulfo-α-L-arabinopyranosyl] 27-hydroxyursolic 28-O-β-D-glucopyranoside	<i>F.arabica</i>	[235]

20	3-O-[2-O-sulfo- α -L-arabinopyranosyl] -27-hydroxyursolique	<i>F.arabica</i>	[235]
21	3-O- β -D-glucopyranosyl-(1 \rightarrow 3)- α -L-arabinopyranosyl quinovic 28-O- β -D-glucopyranoside	<i>F. arabica</i>	[227]
22	3-O- β -D-glucopyranosyl quinovic 28-O- β -D-glucopyranoside	<i>F.cretica</i>	[239]
23	3-O- β -D-2-O-sulfonyl glucopyranosyl quinovic	<i>F. indica</i>	[240]
Triterpenes and saponins of the taraxastane type			
24	3 β ,O- β -D-glucopyranosyl-23-hydroxytaraxer-20-en-28-oic	<i>F. indica</i>	[177]
25	23,28-di-O- β -D-glucopyranosyl taraxer-20-en-28-oic	<i>F. indica</i>	[177]
26	3 β , 28-di-O- β -D-glucopyranosyl-23- hydroxytaraxer-20-en-28-oic	<i>F.mollis</i>	[241]
27	21,22 α -epoxy-23-O- β -D-glucopyranosyl-nahagenin	<i>F. indica</i>	[177]
28	3 β ,23-disulfonyl-nahagenin	<i>F. indica</i>	[235]
29	fagonicin	<i>F. indica</i>	[242]
30	3 β - hydroxy-23-O- β -Dglucopyranosyl-taraxer-20-en-28-carboxy-O- β -D-glucopyranosyl	<i>F. indica</i>	[242]
31	3 β - hydroxy-23,28-di-O- β -D-glucopyranosyl-acide taraxer-20-en-28-oic	<i>F. indica</i>	[242]
Lupane-type triterpenes			
32	3 β , 19, 21-trihydroxy-20(29)-lupéne	<i>F. indica</i>	[243]
33	Lupeol	<i>F. indica</i>	[243]
Saponin Steroid			
34	12-(4-methyl-pent-3-enoyloxy)-20-(4-methyl-pent-3-enoyloxy)-3 β ,12 β ,20 β -trihydroxypregnane-3-ylO- β -Dcymapyranosyl-(1 \rightarrow 4)-3-methoxy-6-deoxy- β -D-glucopyranoside	<i>F. indica</i>	[231]



	R₁	R₂	R₃	R₄
1	β -D-xylyl ² - β -D-Glc ³ - α -L-Ara	H	CH ₃	H
2	β -D-Glc ² - β -D-Glc ³ - α -L-Ara	H	CH ₃	H
3	β -D-Glc ³ - α -L-Ara	H	CH ₃	H
4	β -D-xylyl ² - β -D-Glc ³ - α -L-Ara	H	CH ₃	β -D-Glc
5	β -D-Glc ² - β -D-Glc ³ - α -L-Ara	H	CH ₃	β -D-Glc
6	α -L-Rha ³ -6'-O-Me- β -D-GlcA	H	CH ₃	H
7	α -L-Rha ³ -6'-O-Me- β -D-GlcA	H	CH ₃	β -D-Glc
8	SO ₃ H	H	CH ₂ OH	β -D-Glc
9	β -D-Glc ² - β -D-Glc ³ - α -L-Ara	H	CH ₂ OH	β -D-Glc
10	β -D-Glc ² - α -L-Ara	H	CHO	β -D-Glc ⁶ - β -D-Glc
11	β -D-Glc	OH	CH ₃	H
12	β -D-Glc ⁴ - α -L-Ara ^{4f} - α -L-Rha	OH	CH ₃	H
13	β -D-Glc ⁴ - α -L-Rha	OH	CH ₃	H

Figure.I.13. Oleanane saponins isolated from the genus *Fagonia*.



	R₁	R₂	R₃
14	β -D-Glc ² - α -L-Ara ³ - α -L-Ara	CH ₃	β -D-Glc
15	β -D-Glc ² - β -D-Glc ³ - α -L-Ara	CH ₃	β -D-Glc
16	β -D-Glc ³ - α -L-Ara	CH ₃	H
17	β -D-Glc ³ - α -L-Ara	CH ₃	β -D-Glc
18	β -D-xylyl ² - β -D-Glc ³ - α -L-Ara	CH ₂ OH	β -D-Glc
19	2-O-Sulfonyl- α -L-Ara	CH ₂ OH	β -D-Glc
20	2-O-Sulfonyl- α -L-Ara	CH ₂ OH	H
21	β -D-Glc ³ - α -L-Ara	COOH	β -D-Glc

22	β -D-Glc	COOH	β -D-Glc
23	2-O-Sulfonyl- β -D-Glc	COOH	H

Figure.I.14. Ursan saponins isolated from the genus *Fagonia*.





Figure.I.15. Triterpenes and saponins of the taraxastane type isolated from the genus *Fagonia*

Figure.I.16. Lupan-type triterpenes isolated from *Fagonia*.

➤ **Steroids and its derivatives**

Table.I.21. Steroids isolated from *Fagonia* genus.

Isolated Compound	Structure	Species	Ref
Stigmasterol		<i>F.indica</i>	[217]
β -sitosterol-3-O- β -D-glucoside		<i>F.indica</i> <i>F.cretica</i>	[239] [244]

➤ **Diterpene and its derivatives**


Table.I.22. Diterpenes isolated from *Fagonia* genus.

Isolated Compound	Structure	Species	Ref
7- β -hydroxyfagonene		<i>F.bruguieri</i>	[229]

Table.I.23 continued....

15,16-dihydroxy-7-oxo-cis-ent-erythro-3-ene (fagonone)		<i>F. bruguieri</i>	[245]
7- α -hydroxyfagonene		<i>F. glutinosa</i>	[245]
2,7-Dioxofagonene		<i>F. glutinosa</i>	[245]
16-O-acetyl-2,7-dioxofagonene		<i>F. glutinosa</i>	[245]
7-O-acetyl-2-oxo-5-epi-fagonene		<i>F. glutinosa</i>	[245]
1 α ,10 α -epoxy-2-oxofagonene		<i>F. glutinosa</i>	[246]
1 β ,10 β -epoxy-2-oxofagonene		<i>F. glutinosa</i>	[246]
2-oxofagonene		<i>F. glutinosa</i>	[246]
3 β ,15,16-trihydroxy-erythro-4(18)-ene		<i>F. boveana</i>	[230]

Table.I.23 continued....

7 β -Hydroxy-5-epifagonene*F.mollis*

[240]






➤ Sesquiterpene and its derivatives

Table.I.23. Sesquiterpene isolated from *Fagonia* genus.

Isolated Compound	Structure	Species	Ref
6,10-epoxy-4 α -hydroxy guaiane		<i>F. boveana</i>	[230]
α -cedrol		<i>F.cretica</i>	[247]
α -curcumen		<i>F.cretica</i>	[247]

➤ Monoterpene and its derivatives

Table.I.24. Monoterpene isolated from *Fagonia* genus.

Isolated Compound	Structure	Species	Ref
Geraniol acetate		<i>F.cretica</i>	[247]
o-Cymene		<i>F.cretica</i>	[247]
α -citral		<i>F.cretica</i>	[247]
β -phellandrene		<i>F.cretica</i>	[230]
α -limonene diepoxide		<i>F.cretica</i>	[230]

*Chapter II: Valorisation of
Bioactive Compounds*

II.1. Introduction

Each plant species has a multitude of substances, which proceed from primary or secondary metabolism. Primary metabolism is responsible for the production of carbohydrates, proteins, lipids, minerals, and nucleic acids [248], all of which are directly engaged in the significant pathways of basal cell metabolism [249]. Secondary metabolites are a category of compounds distinguished by their complexity, a large number of metabolites (at least 30,000 have been characterized), and subsequent categorization into distinct chemical classes [250]. These compounds include phenolic compounds, flavonoids, tannins, saponosides, essential oils, and alkaloids, all of which have many applications in the food and pharmaceutical industries.

II.2. Phenolic compounds

Phenolic compounds are secondary metabolites that are distinctive to the plant kingdom. They constitute an extensive set of more than 8,000 molecules with an extremely wide range of chemical characteristics [251] from the basic phenolic molecules, which have a low molecular weight, such phenolic acids, through the most highly polymerized compounds, such as tannins [252]. The distinguishing structural feature of all these substances is the existence of at least one benzene nucleus directly linked to at least one hydroxyl group, whether free or performing some other function: ether, ester, or heteroside [253]. The basic structures of phenolic compounds allow for the categorization of these compounds into a variety of different classes, the most important of which are tannins, flavonoids, and phenolic acids [254].

II.2.1. Phenolic acids

Acid-phenols are a class of organic compounds characterized by the presence of both a carboxylic function and a phenolic hydroxyl [255]. In the field of phytochemistry, the use of this word is restricted to the derivatives of benzoic acid or cinnamic acid, which together make up the two subclasses:

➤ Hydroxybenzoic acid

Hydroxybenzoic acids are typically found in the form of esters or glycosides [256]. Hydroxybenzoic acid, protocatechuic acid, vanillic acid, gallic acid, and salicylic acid are plants' most common hydroxybenzoic acids (Figure II.1) [257].

➤ Hydroxycinnamic acids

Cinnamic acid derivatives (hydroxycinnamic acids) have a basic C₆-C₃ structure for example: caffeic acid, ferulic acid, p-coumaric, and sinapic acid (Figure.II.1). They are members of the phenylpropanoids family. The most common type of simple phenolic compound is a hydroxycinnamic acid. Free forms of these acids are extremely uncommon outside of frozen, sterilized, or fermented processed foods. Quinic acid, shikimic acid, and tartaric acid have glycosylated derivatives or esters that constitute the bound forms [258, 259].




Figure.II.1. Structure of principal phenolic acids [258].

II.2.1.1. Biosynthesis

The production of hydroxybenzoic acids begins with the hydroxylation of benzoic acid, which has a fundamental structure of the type C₆-C₁. Following that, these phenolic hydroxyls OH can be methylated (Figure.II.2) [260]




Figure.II.2. Biosynthesis of benzoic acid derivatives [255].

The reaction of cinnamic acid derivatives consists of the condensation of phosphoenolpyruvate (PEP) with erythrose-4-phosphate to create 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP), which leads to aromatic amino acids (phenylalanine, tyrosine) and, via deamination of the latter, to cinnamic acids and their derivatives (benzoic acid, acetophenone, lignans, coumarin, etc.) (Figure.II.3).




Figure.II.3. Biosynthesis of cinnamic acid derivatives [255].

II.2.2. Flavonoids

The term "flavonoid" is used to designate a broadly diverse group of naturally occurring compounds members of the polyphenols class. They are regarded as practically all plant peppers due to their prevalence [261]. These substances have a low atomic weight, and all have the same fundamental structure, which consists of 15 carbon atoms grouped in three cycles of C₆-C₃-C₆: A, B, and C, each of which has one or more hydroxyl groups as a substituent (Figure.II.4) [258, 262].




Figure.II.4. Structure of a flavonoid

Flavonoids are commonly found in their glycosylated form in nature. In the presence of sugar, the molecule's characteristics are altered compared to its glycosylated analog. In particular, the molecule's solubility and hydrophobicity are affected. The formation of the bond between aglycone and ose is typically accomplished by one of the phenolic hydroxyls, particularly those in position 3 (for flavonols) or position 7 (for flavones) and sometimes in positions 6 or 8 if these positions are hydroxylated. D-glucose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, L-arabinose, D-xylose, and rarely D-allose, and D-mannose are the predominant monosaccharides in their constitution. D-glucose and L-rhamnose are the most predominant sugars in flavonoids [258, 263].

Different types of flavonoids can be distinguished based on the oxidation degree of the central heterocycle C, the degree of unsaturation, and the positions of the hydroxyl groups on the nuclei A and B. The most extensively reported and well-characterized of these groups are the following six: flavonoids, flavanones, flavonols, isoflavones, flavonols, flavones, and anthocyanidins [258, 264].

II.2.2.1. Biosynthesis

This fundamental structure is the final product of the two various pathways for the synthesis of phenolic compounds. The phenylpropanoid unit, which includes the B nucleus and the carbon bridge, is produced by the shikimic acid pathway from phenylalanine, whereas the A nucleus

is formed via the condensation of 3 acetate patterns via the malonic acid pathway. The combination of these two components takes place through the condensation of a phenylpropanoid, 4-coumaryl, with three malonyl CoA molecules, which results in the formation of tetrahydrochalcone. This, in turn, will result in the formation of all flavonoids (Figure.II.5) [258, 263].




Figure.II.5. Flavonoid biosynthesis [255].

II.2.3. Tannins

Tannins are a class of polyphenols that possess a high molecular weight and may be found in nearly every part of a plant, including the bark, the wood, the leaves, and the roots [265]. These substances are highly hydroxylated molecules that, when coupled with carbohydrates, proteins, and digestive enzymes, can form insoluble complexes that decrease digestibility [266].

Hydrolyzable tannins and condensed tannins are the two categories into which natural tannins can be divided according to their chemical structure [267].

Condensed tannins or proanthocyanidins are dimers or polymers of flavan-3-ols, mainly catechin and catechols, including profisetinidin, prorobinetinidin, procyanidin, prodelphinidine, and other polysaccharides [268]. In type A proanthocyanidins, these units are bound by a single C-C bond (interflavanic) C₄-C₈ or C₄-C₆ (Figure II.6). In type B, they are linked by a double interflavanic bond (C₄-C₈ or C₄-C₆) and (C₂-O-C₇) [268, 269].

Hydrolyzable tannins are sugar-phenolic acid oligos or polyesters (Figure II.6). Sugar is commonly glucose. Gallic acid or hydroxydiphenic acid (HHDP) and its derivatives make up phenolic acid for gallic tannins and elylagic tannins, respectively [270].




Figure II.6. Basic structure of tanins. **A** : Condensed tannins ; **B** : Hydrolysable tannins [271].

II.3. Biological properties of phenolic compounds

The bioactive compounds produced by the various parts of the plant are involved in a variety of occurrences that are protective not only for the plant itself but also for the human organism. In light of the fact that the body's baseline production of free radicals is crucial to many functions and should not be eliminated, it makes sense to investigate the therapeutic potential

of naturally occurring antioxidant compounds that can act in the prevention of degenerative diseases so long as they are taken in controlled doses.

A/ . Phenolic acids play a crucial function in protecting against the oxidative stress that leads to degenerative illnesses such as cancer, cardiovascular disease, and Alzheimer's...[272, 273].

B/ . Flavonoids are among the most representative of the compounds synthesized by plants through their secondary metabolisms; these aromatic, medicinal, and cosmetic compounds give plants evolutionary advantages. It contains numerous valuable ingredients that benefit both the plant and humans.

C/ . Tannins exert their biological and pharmacological effects mainly through their capacity to precipitate proteins, such as salivary proteins, resulting in an astringent flavour [254]. Tannins are able to act as antioxidants due to the presence of phenol nuclei and hydroxyl groups in their structure. Numerous investigations have demonstrated that these bioactive compounds possess an antibacterial impact on a wide variety of pathogens (bacteria, viruses) [274]. Moreover, tannins are natural chelators that act in the digestive tract to prevent iron absorption [275].

D/ . Terpenic compounds also have antifungal and antiparasitic capabilities and well-known anticancer effects [276]. Several studies have demonstrated limonene, myrcene, and sabinene to have stimulant and anticancer properties [277].

E/ . Saponins have a function known as adjuvant activity, which affects the immune system. Additionally, saponins have the capacity to enhance the absorption of a very wide variety of different compounds [278].

II.3.1. Antioxidant properties

In recent years, natural antioxidant's medicinal properties have drawn a great deal of attention. It is the capability of a molecule to inhibit or prevent the oxidation of biological substances triggered by free radicals or other molecules that are considered pro-oxidants [279].

II.3.1.1. Free radicals

A free radical or reactive oxygen species is defined as any molecule, atom, or independent ion that contains one or more single electron(s) occupying the outer orbital space. Free radicals are extremely unstable and rapidly react with other components to acquire the electron required for

stability (Figure.II.7), producing new stable radicals through a cascade of chemical reactions [280].




Figure.II.7. Oxidizing stress mechanism.

II.3.1.2. The different reactive oxygen species

Reactive oxygen species (ROS) are free radicals derived from oxygen oxidation, such as: superoxide radical (O_2^{\bullet}), radical hydroxyl (OH^{\bullet}), OxideNitric (NO^{\bullet}), and peroxyntirite ($ONOO^{\bullet}$), and reactive nitrogen species (RNS) are a subcategory of free radicals derived from the oxidation of oxygen and nitrogen. There are additional reactive species but not free radicals like hydrogen peroxide (H_2O_2), hypochlorous acid ($HOCl$), and ozone (O_3), and these species can act as precursors to radicals [281].

II.3.1.3. Oxidative stress

Oxidizing stress is generally defined as an imbalance between an organism, organelle, or cell's oxidizing systems and antioxidant capacities [282]. Physiologically, free radicals, such as tissue mediators or energy or defense response leftovers, are constantly created in minute amounts, although defense mechanisms carefully regulate these amounts under normal conditions [283]. The balance of antioxidants to pro-oxidants is stable under physiological conditions [284].

II.3.1.4. Phenolic compounds as antioxidants

An antioxidant is any substance that delays or prevents the oxidation of biological substances; these compounds react with free radicals, rendering them harmless. The antioxidant activity of phenolic compounds is affected by several factors, including the number and position of hydroxyl groups on the aromatic ring, the binding position of the hydroxyl groups, the type of

substituent, and the glycosylation of flavonoid molecules [285]. The glycosylation of flavonoids reduces their activity compared to the corresponding aglycones, while certain hydroxyl groups on the nucleus increase antioxidant activity. Substituents in cycles A and B, as well as double binding 2,3 (instauration), and the 4-oxo group in the C nucleus, also affect flavonoid's antioxidant activity [286, 287].

Several research studies have demonstrated that phenolic compounds have the ability to act as antioxidants through a variety of modes of action, including the chelation of transition metals, the hardening of singlet oxygen, the trapping of free radicals, and the inhibition of oxidative enzymes (Figure.II.8) [288].




Figure.II.8. Simplified presentation of antioxidant mechanisms of phenolic compounds [289].

The delocalization of the free radical can be stabilized by donating a hydrogen atom, which allows the free radical to acquire an electron by first removing it from another molecule. The deactivation of the molecule's excited state might occur either through a chemical or a physical mechanism, which results in the hardness of the singular oxygen. The generation of free radicals

is inhibited or reduced as a direct result of all these reactions. They prevent free radical chain reactions from continuing, delay their initiation, or slow them ultimately [285].

In large part, free oxygen radicals are produced in living organisms due to the presence of transition metals. There are two distinct oxidation states of iron (ferrous and ferric ions).

Although ferric iron (Fe^{3+}) has no biological activity, depending on the conditions, particularly pH and oxidation via the Fenton reaction, with the production of hydroxyl radicals, Fe^{3+} can be reduced to an active form (Fe^{2+}). The formation of free radicals can result in the peroxidation of lipids, the alteration of proteins, and even damage to DNA. Phenolic compounds have the ability to inactivate metal ions and could potentially inhibit metal-dependent activities. The capacity of polyphenols to chelate metals is correlated with the existence of polyphenols ortho-dihydroxylates, which are characterized as molecules that include either a catechol or galloyl group...etc [285].

Flavonoids have the ability to block a wide variety of $\text{O}_2^{\cdot-}$ and other ROS enzymes. Some of these enzymes include xanthine oxidase, protein kinase C, cyclooxygenase, lipoxygenase, monooxygenase microsomal, and glutathione S-Transferase. Furthermore, flavonoids containing half catechol on cycle B have been shown to inhibit mitochondrial succinoxidase and NADH oxidase [290].

II.3.2. Anti-inflammatory activity

In vitro studies have shown that various flavonoids have the ability to alter the metabolism of platelet arachidonic acid. Therefore, at relatively high concentrations, myricetin and quercetin are able to inhibit the activity of cyclooxygenase as well as lipoxygenase. At low concentrations, lipoxygenase is preferentially inhibited. The results of certain studies suggest that they have potent anti-inflammatory effects without inducing ulcers [291].

In vivo, Subcutaneous administration of hesperidin had considerable anti-inflammatory effects in rats with edema caused using a model of carrageenan and dextran [261].

II.3.3. Anti-diabetic activities

Numerous research studies have shown that active biomolecules in plant extracts have anti-diabetic effects. They carry out their functions according to various mechanisms of action to regulate blood glucose, and these processes can vary depending on the category [292]. Herbal therapy is highly regarded and widely utilized to treat metabolic disorders like diabetes, obesity, and dyslipidemia in Africa [293]. The anti-diabetic effects of polyphenols and polysaccharides

have been the subject of substantial research, which has revealed that these compounds exert their effects via the following mechanisms:

II.3.3.1. Reduction of the adsorption of sugar

Several compounds prevent the transformation of starch into simple ose by preventing the activity of the digestive enzymes alpha-glucosidase and alpha-amylase. This mechanism of action has been seen in polyphenols, including alkaloids [292], tannins such as geraniin [294], flavonoids notably quercetin [295], and certain phenolic acids (curcumin, caffeic acid, p-coumaric acid), and diterpenes.

Studies have demonstrated that polysaccharides (mucilages, pectins, and proteoglycans) significantly inhibit the intestinal absorption of sugars. This is accomplished in part by increasing the viscosity, which in turn causes a delay in the reabsorption of sugars [296].

II.3.3.2. Inhibition of enzymes involved in the occurrence and complications of diabetes related to obesity

Inhibition of enzymes involved in the occurrence and complications of diabetes related to obesity including aldose reductase (AR), protein kinase C (PKC), end products of glycation (AGEs), and protein phosphatase 1B (PTP-1B). This mechanism of action has been proven by flavonoids, tannins, phenolic acids, and oligosaccharides [297].

II.3.3.3. Increase in Glucose Transport

Increase in Glucose Transport in muscle and fat cells, attributable to alkaloids, phenolic acids, polysaccharides, saponosides, and flavonoids [292].

II.3.3.4. Increase in insulin secretion

Tannins, alkaloids, and saponosides were found to have antidiabetic effects in both the pancreas and the liver. This activity was demonstrated by increased insulin secretion by the pancreas, which was associated with the regeneration of beta cells. Additionally, Flavonoids and polysaccharides also show insulin-mimetic activity [292].

II.3.4. Anti-cholinesterase activity

In humans, two cholinesterases are distinct in terms of their synthetic medium, structure, mechanism of action, physiological function, and activity indicator.

Acetylcholinesterase, also known as globular cholinesterase or real cholinesterase, itis an enzyme produced in nerve tissue and red blood cells. Specifically, it is found in the synapses of the brain, lungs, and spleen, as well as the Nervous and neuromuscular junction. Its

physiological function ensures the proper functioning of acetylcholinergic synapses by preventing neurotransmitter buildup. Additionally, it is abnormally present in amniotic fluid cases of neural tube closure failure [298].

Butyryl-cholinesterase (also known as serum cholinesterase or pseudo-cholinesterase) has a significantly broader affinity. It can hydrolyze a wide range of synthetic and natural esters, including acetylcholine and succinylcholine. The liver is the primary source of its synthesis, but it is also present in the plasma/serum, pancreas, intestine, and other organs [298].

The activity of each of these enzymes can be ascertained through the application of a colorimetric method, which involves the monitoring of the hydrolysis kinetics with the assistance of a specific substrate: Butyrylthiocholine, which is exceptionally stable at room temperature, is used for serum cholinesterase, while acetylthiocholine is used for globular cholinesterase [298].

The treatment of Alzheimer's disease has included the use of acetylcholinesterase inhibitors, often known as AChE. Anti-cholinesterase compounds primarily target the cholinergic system and are the only cure for AD [299]. AD is a neurodegenerative disorder predominantly affecting the elderly, with memory loss being the most prominent symptom [298, 300].

Several synthetic medications are available to treat cognitive dysfunction and memory loss caused by AD, such as tacrin, donepezil, and rivastigmine-based natural products, as well as galantamine. The secondary effects of these approved drugs, such as the development of gastrointestinal diseases and bioavailability issues, limit their use [301-303].

In Far Eastern countries, plants have been utilized to enhance cognition for centuries. Diverse pharmacological investigations have revealed promising leads in the search for novel anticholinesterase in these plants. Cognitive improvements were attributed to *Panax ginseng*, while the compound Huperzine A obtained from *Huperzia serrata* was reported beneficial in treating Alzheimer's disease [304, 305].

The Ellman colorimetry method was used to examine cholinesterase inhibitory effects of methanol extracts of seven herbs (*Acorus calamus*, *Acorus gramineus*, *Bupleurum facaltum*, *Dioscorea batatas*, *Epimedium E. koreanum*, *Poria cocos* et *Zizyphi jujuba*). They were used in traditional Korean medicine to promote memory and cognition in the elderly. Extracts of both *A. calamus* and *E. koreanum* were found to inhibit the enzyme significantly. In light of

recent research on these herbs' chemical and biological activity and others that have been investigated, we discuss the possible origins of their well-known properties [299].

II.4. Mineral elements

In addition to supplying the human body with protein, energy, and vitamins, plants also provide the body with minerals. Studies have shown that about half of the elements in Mendeleev's table are biologically necessary for man, making mineral elements essential, notably micro- and macronutrients, for different metabolisms. Simultaneously, both major and trace elements play an essential part in forming and repairing the physical body in both health and illness [306]. The mineral profile of plants is determined on residue using various methods (ICP-OES, INAA, RNAA, AAS...).

Besides the organic components that make up more than 90% of the dry residue by weight (C: 40-50%, O: 42-45%, H: 6-7%), the mineral elements are classified into two [307]:

- Macro-elements (Ca, Mg, P, Na, K...) with a concentration greater than 10 mmol kg⁻¹
- Micro-elements or trace elements (Mn, Zn, Cu, Mo...) Less than 10 mmol kg⁻¹

On the other hand, the chemical elements are divided in terms of importance or not into three groups [308]:

- Essential chemical elements
- Non-essential chemical elements
- The toxic elements

According to some investigations, antioxidants are thought to include minerals and trace elements, including magnesium, zinc, and selenium. Quantitative assessments of various element concentrations are important for determining the plant's effectiveness and association with secondary metabolites and treating various diseases and perceptions of their pharmacological activity [309].

PART 2:

EXPERIMENTAL

PART

*Chapter III: Extraction,
Chemical Composition,
Separation and Purification*

III.1. Plant Material

Artemisia campestris. L and *Fagonia bruguieri* DC. plants were harvested during the flowering season in March 2018 from the Oued Tifouguine and Oued Amsel regions, respectively Tamanrasset –Algeria (22°47'13" N, 5°31'38" E), in the Sahara Desert. Figure.III.1 illustrates the locations of the harvest. Taxonomically, the plants were identified by Dr. Reggani Adelmalek from the University of Tamanrasset and Dr. Halis Yousef from the Center for Scientific and Technical Research on Arid Regions on the basis identification described by Quezel and Santa [310]. Under the codes "Ac. TMT: 03/18" and "Fb. TMT: 03/18," standard samples were kept in the Herbarium of the department's Saharan Resources Valorization and Promotion Laboratory. Dry aerial parts were pounded with an electric blender and stored in paper wrappings until they were required. The weight of the dry aerial parts was 500 g for the *A.campestris*. L species and 300 g for the *F.bruguieri* DC. species, respectively.




Figure.III.1. The geographical position of the collects, Tamanrasset (Hoggar) - Algeria.

III.2. Preparation of Extracts

Aerial parts of *A.campestris*. L. and *F.bruguieri* DC. were prepared by maceration in hydro-methanolic solution (methanol / Water) (80: 20) (v / v) for 24h at room temperature. The method of extraction was conducted three times with the renovation of the solvent. Through

Whatman filter paper N°1, the mixture was separated then the filtrate was evaporated in a rotary evaporator (BUCHI, R-100, flawil, Switzerland) at 40 °C. After filtration and concentration under vacuum, the hydromethanolic extract is diluted with distilled water at the rate of 50 ml per 100 g of a dried powdered plant at room temperature for 24 hours and then filtered. The resultant solution has carried out a series of liquid-liquid extractions utilizing solvents of progressively higher polarity, commencing with the Petroleum ether, Dichloromethane, Ethyl Acetate, and finally with n-Butanol. Each extraction is repeated three times to obtain dryness to extracts. The Figure.III.2 summarizes the extraction procedure. The two investigated plants both perform the same extraction procedure.

The obtained organic phases (non-polar: Petroleum Ether, weakly polar: Dichloromethane, medium-polar: Ethyl Acetate, polar: n-Butanol), in addition to the phase Residual aqueous and hydroethanolic extracts, are all concentrated dry under reduced pressure, weighed, and then recovered with methanol. Yields of different fractions are presented in Table.III.1.

Table.III.1. Yield of different fractions of *Artemisa campestris* L. and *Fagonia bruguieri* DC.

	Extracts	Yield (%)
AcME	<i>Artemisa campestris</i> Methanol Extract	9.23 %
AcPEE	<i>Artemisa campestris</i> Petroleum Ether Extract	0.05 %
AcDE	<i>Artemisa campestris</i> Dichloromethane Extract	0.35 %
AcEAE	<i>Artemisa campestris</i> Ethyl Acetate Extract	0.79 %
AcBE	<i>Artemisa campestris</i> Butanol Extract	1.45 %
AcAE	<i>Artemisa campestris</i> Aqueous Extract	7.95 %
FbME	<i>Fagonia bruguieri</i> Methanol Extract	8.30 %
FbPEE	<i>Fagonia bruguieri</i> Petroleum Ether Extract	1.94 %
FbDE	<i>Fagonia bruguieri</i> Dichloromethane Extract	0.17 %
FbEAE	<i>Fagonia bruguieri</i> Ethyl Acetate Extract	0.11 %
FbBE	<i>Fagonia bruguieri</i> Butanol Extract	4.23 %
FbAE	<i>Fagonia bruguieri</i> Aqueous Extract	4.89 %




Figure.III.2. The protocol of extraction for different fractions of *A.campestris* L., and *F.bruguieri* DC.

III.3. Qualitative Phytochemical Screening

The process of phytochemical screening involves performing a series of straightforward tests on natural compounds derived from plants. This screening has the ability to detect the presence of products that belong to many classes of bio-phytochemically active substances that are collectively known as secondary metabolites.

These are the preliminary colorimetric, solubility, and precipitation experiments that are being performed to demonstrate the presence of broad groups of secondary metabolites. The screening for phytochemicals in this study was carried out in accordance with Harborne's methods [311, 312].

III.3.1. Flavonoids test

A few turns of magnesium were added to 5 ml of different fractions of *A.campestris* L., and *F.bruguieri* DC. (while stirring), then 5 drops of concentrated hydrochloric acid were carefully added. The appearance of red color indicates the presence of flavonoid

III.3.2. Alkaloids Test

It is accomplished by mixing 5 ml of each extract with 1 ml of diluted H_2SO_4 (1/2). Two tubes are prepared by using two different reagents, one is the Mayer reagent, and the other is the Wagner reagent. After 15 minutes, the formation of turbidity or precipitate is a clear indication that alkaloids are present.

III.3.3. Tannins Test

To demonstrate the presence of tannins, we mixed 1 ml of each extract with 1 ml of water and 1 to 2 drops of $FeCl_3$ (1%).

- The appearance of a dark green or green blue color indicates the presence of tannins.
- The appearance of a dark green color indicates the presence of catechic tannins.
- The appearance of a blue-green color indicates the presence of gallic tannins.

III.3.4. Terpenoids Test

Salkowski test: targeted for identification of terpenes, each of the extracts had five (5) ml evaporated until they were dry. After thoroughly combining the residue with 2 ml of chloroform, we continued to add 0.5 ml of concentrated sulphuric acid in order to form a

layer. The presence of terpenoids was indicated by the interface's coloring, which was a reddish brownish red.

III.3.5. Coumarins Test

The various extracts were divided between two test tubes after being diluted with distilled water by a ratio of 1/2. The first tube was employed as a control, and 0.5 ml of a solution that had been titrated to 10% NH₄OH was added to the second tube. The presence of coumarin can be detected by observing a blue or green fluorescence when exposed to an ultraviolet lamp at 365 nm.

III.3.6. Reducing compounds Test

Their confirmation is done by placing 2 ml of the different extracts in a test tube, followed by adding 2 ml of the Fehling liqueur within the same tube; the mixture is then put in a bath of boiling water for 8 minutes. Obtaining a red brick precipitate indicates the presence of reducing compounds.

III.3.7. Saponins Test

Foam test: The different extracts were brought up to their final volume of 20 ml by diluting them with distilled water. A graduated cylinder was used to shake the suspension for 15 minutes. A layer of foam measuring two centimeters high revealed the presence of saponins.

III.4. Mineral Analysis using the INAA and ICP-OES techniques

The Analysis of mineral elements was carried out at the Nuclear Research Centre of Birine (CRNB) Ain Oussera, Algeria and also at the Nuclear Research Centre of Draria (CRND).

INAA and ICP-OES were utilized in order to determine the majority of the trace elements that were detected.

III.4.1. Instrumental Neutron Activation Analysis (INAA)

The samples selected for this analysis were finely powdered and weighed on an analytical balance of 110-120 mg. We have prepared three copies for each type, which will then be packaged in high-purity aluminum envelopes. In this section, we have provided standards with the same matrix as the analyzed samples. These standards were NIST-SRM 1570a, WEPAL-IPE 172 and WEPAL-IPE 189. During each step of the analysis procedure, the certified standards are required to be with the samples that will be analyzed. The following

step, which will be the validation and quality control of the results that were achieved, will use the application of standards. Each sample and standard was arranged inside the irradiation capsule (high purity aluminum cylinder) to ensure that each target is subjected to the same amount of neutron flux [313, 314].

III.4.1.1. Irradiation and Measurement

The samples and the standards were put inside a clean capsule made of cylindrical aluminum. At the irradiation site used by the CRNB and CRND research reactors, this thermal neutron flux of $1013 \text{ n.cm}^{-2}.\text{s}^{-1}$ is applied to the irradiation capsule. The irradiation capsule is exposed to the neutron flux for a total of 6 hours during the experiment. After a decrease of 2 days, the powder was placed into new polyethylene capsules, and a gamma spectrometer was used to measure all of the samples as well as the standards. At the start, the Ge(Hp) detector was calibrated in terms of energy and efficiency (resolution of FWHM is 1.8 keV at 1332.5 keV of γ -peak of ^{60}Co and relative efficiency equal (35 %)), coupled with a digital gamma spectrometry system, after two different decay times (medium, and longtime). In order to properly adjust the peaks in the spectrum in accordance with the channels, it is essential that this step of the analysis process be performed. The first measure analyzes elements having medium half-life radionuclide's like Na, Ba, and Br, was determined after a decay time of three days, the counting time of each sample was about 5000s and the source-detector distance was 15cm. On the other hand, the activities of long life radionuclide's like Co, Eu, Fe and Zn were determined after decay time of 20 days, and different counting time comparing to the previous half-life radionuclide's which was about 7200s for each sample. After the initial measurement, the gamma spectra of the samples and standards are gathered after 20 days of degradation to determine the elements over long periods for a collecting time of 14400 seconds. At the end, we determined the concentrations of the elements (major and trace elements) using the equation of INAA given by the Equation (III.1) [315]:

$$\rho(\text{mg/kg}) = \left(\left[\frac{N_p/t_c}{DC} \right]_a / \left[\frac{N_p/t_c}{DC} \right]_s \right) * \frac{(\rho W)_s}{W_a} \quad (\text{III.1})$$

where the subscripts a and s refer to the sample and the standard, respectively, N_p is the net photo-peak counts, W is the sample mass, $D = [\exp(-\lambda t_d)]$ is the decay factor, and $C = [1 - \exp(-\lambda t_m)] / (-\lambda t_m)$ is the counting factor, λ decay constant, t_c , t_d and t_m counting, decay and measurement times, respectively.

The gamma-ray spectrometry of the irradiated samples in this study, was carried out by using the nuclear parameters listed presents in (Table.III.2) [316].

Table.III.2. Optimum experimental conditions and nuclear data employed in this study.

Elements	Radio-nuclide	Half life	γ - peaks (keV)	Cooling time
Barium	^{131}Ba	11.50 d	496.3	20 d
Bromine	^{82}Br	35.30 h	554.3, 698.08, 776.5	2-5 d
Cobalt	^{60}Co	5.2714 y	1173.2, 1332.5	20 d
Chromium	^{51}Cr	27.7025 d	320.1	20 d
Cesium	^{134}Cs	2.0648 y	604.7, 795.8	20 d
Europium	^{152}Eu	13.537 y	124.78,344.28,1408.01	20 d
Iron	^{59}Fe	44.5 d	1099.3, 1291.6	20 d
Potassium	^{42}K	12.360 h	1524.7	2-5 d
Molybdenum	^{98}Mo	65.94 d	140.51	20 d
Sodium	^{24}Na	14.9590 h	1368.6	2-5 d
Rubidium	^{86}Rb	18.631 d	1077	20 d
Antimony	^{124}Sb	60.20 d	169, 602.7	20 d
Scandium	^{46}Sc	83.83 d	889.3, 1120.5	20 d
Strontium	^{153}Sr	64.84 d	514.01	20 d
Thorium	^{233}Th	26.967 d	300.1, 311.9	20 d
Uranium	^{215}U	2.3565 d	106.13,228.18,277.60	2-5 d
Zinc	^{65}Zn	244.26 d	1115.5	20 d

III.4.1.2. Quality Control and Quality Assurance (QC/QA)

Quality control validation of analyzes is an important step of the quality of results, in this investigation, for the relative approach of the INAA, were used WEPAL-IPE 172 and WEPAL-IPE 189 were used as the standard, while NIST- SRM 1570a were used as the control samples.

To assess the quality of the obtained results, the parameters test of Z-score and U-score were determined, they were calculated according to the following equations (III.2 and III.3), the results are found to be acceptable if Z-score ≤ 3 and satisfactory if U-score ≤ 1 .

$$Z_{\text{score}} = \frac{|X_{\text{Lab}} - X_{\text{Ref}}|}{\mu_{\text{Lab}}} \dots\dots\dots\text{(III.2)}$$

$$U_{\text{score}} = \frac{|X_{\text{Lab}} - X_{\text{Ref}}|}{\sqrt{\mu_{\text{Lab}}^2 + \sigma_{\text{Ref}}^2}} \dots\dots\dots\text{(III.3)}$$

With:

X_{Lab} , μ_{Lab} , X_{Ref} and σ_{Ref} : are the laboratory results, standard deviation, the recommended and standards uncertainties, respectively [317].

III.4.2. Inductively Coupled Plasma ICP-OES Analysis

The analysis of the mineral contents was performed using ICP-OES (Inductively Coupled Plasma-Optical Emission Spectrometry) [318, 319]. Following the procedure depicted in Figure.III.3, samples are dissolved in preparation for analysis. A sample of *A. campestris* L. and *F. bruguieri* DC. is powdered and weighs 500 mg. Afterward, each powder is put into a distillation flask with a capacity of 200 mL and is equipped with an effective reflux condenser system (Figure I.3). After that, the powder was mixed with 3 mL of HNO₃ with a concentration of 65% (Sigma Aldrich-Germany), as well as 3 mL of hydrochloric acid with a concentration of 37% (Sigma Aldrich-Germany), and 1 mL of H₂O₂ with a concentration of 30%. To ensure that all of the powder was transformed into a liquid, the mixture was heated to 105°C and then agitated for 90 minutes. A 50 mL volumetric flask was used to properly filter the mixture through a membrane filter with a pore width of 0.45 m (MF-Millipore® Membrane Filter, Germany). In order to reduce microparticles made during the analysis process, they don't get in the way of taking in liquid samples or stop the nebulization of the solution by the plasma used in ICP-OES procedures. The filtered sample was then diluted with 50 mL distilled water and transferred to a new tube, where it was allowed to settle and homogenize. Finally, the supernatant was subjected to ICP-OES analysis to determine the minerals in the sample; each sample was examined in triplicate .

The concentration of chemical elements in the samples is calculated using the following equation [318, 319]:

$$C(\text{sample})(\text{mg}/\text{kg}) = \frac{C(\text{Sample per ICP}(\text{mg}/\text{L}) * V(\text{mineralisation})(\text{L}))}{\text{test sample mass}(\text{kg})} \quad (\text{III.4})$$

Where; C: concentration.




Figure.III.3. Protocol for mineral element analysis using ICP-OES.

III.5. Analytical Chromatography Techniques

The Analysis of HPLC and LC-MS-MS was carried out at the Laboratory of Valorization and Technology of Saharan Resources (VTRS) University Echahid Hamma Lakhdar El-Oued, Algeria, and Scientific & Technical Research Center in Physico-Chemical Analysis (CRAPC), Ouargla Algeria.

III.5.1. Quantitative analysis of phenolic compounds by High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV)

III.5.1.1. Preparation of extracts for HPLC-UV analysis

The various extracts of *A. campestris* L. and *F. bruguieri* DC. (10 mg) were diluted in methanol (HPLC grade). Before injecting the sample solutions into the HPLC, solutions were filtered through a Millipore nylon filter disk with a Millipore 0.45 m.

III.5.1.2. Preparation of polyphenol standard

In order to prepare a stock solution of polyphenol, 10 mg of pure polyphenol standard was first dissolved in methanol (HPLC grade). It was sonicated for about 10 min and then carried to volume with the mobile phase. Daily working standard solutions of polyphenols were prepared by proper dilution of each one with the mobile phase. After injecting each solution into the column three times with a volume of 20 μ l, the peak areas and retention times were recorded.

III.5.1.3. Chromatographic instruments and HPLC analysis conditions

High-performance liquid chromatography analysis of the extracts and standards was performed using a Shimadzu model Prominence liquid chromatography. At room temperature, a Pura disc 25 mm and a Terumo syringe with a volumetric capacity of 5 cc/ml were used to inject 20 μ l of analyte solution into an HPLC valve. On a Thermo scientific (HPLC-RP 18), column CTO-20AC (250mm x 4,6mm) packed with C18 stationary phase with a particle size of 5 μ m, phenolic compounds were separated at a flow rate 1mL/min. A binary gradient linear system consisting of acetonitrile (A) and 0.2% acetic acid in water (B) was used. The elution gradient was as follows: (0-0.1 min) 90% B; (0.01-6 min) 86% B, (6-16 min) 83% B, (16-23 min) 81% B, to 77% B in 28 min, held at 77% B in 28-35 min, to 60% B in 38 min, to 90% B in 50 min, detected by UV-SPD-20 Å detector (operating at 268 nm). In order to identify the chromatographic peaks, we compared the retention times of our analyses with those of reference chemicals (Figure.III.4). The phenolic composition were quantified by plotting a standard curve with the respective standards (Table.III.3). This procedure is required for the purpose of performing a qualitative and quantitative analysis of a different extract of *A.campestris*. L. and *F.bruguierei* DC. collected in the Saharan region of Algeria. The results of each examination were recorded in triplicate.

III.5.1.3. LOD and LOQ

The detection limit is the minimum concentration in a sample that can be estimated but not commonly quantified under the experimental requirements established. The quantitation limit is the lowest analyte concentration in a sample, which can be evaluated with adequate accuracy and precision. The values for LOD and LOQ are given in Table.III.3.




Figure.III.4. High-performance liquid chromatography (HPLC) chromatogram of phenolic compounds. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic acid; CA: Caffeic acid; V: Vanillin; *p*-CA—*p*-Coumaric Acid; RU: Rutin; NAR: Naringin and QC: Quercetin.

Table.III.3. Retention times (Rt), calibration curves, regression coefficients, Detection and quantification limits for phenolic compounds.

Compound	Rt (min)	Calibration curve	R ²	LOQ (µg/mL)	LOD (µg/mL)
Gallic acid	5.29	Y=23616x-7232	0.9986	0.36939	0.12189
Chlorogenic acid	13.392	Y=39775x-1881	0.9963	0.41308	0.13631
Vanilic Acid	15.531	Y=65077x+33	0.9885	0.09577	0.03192
Caffeic acid	16.277	Y=72328x-52	0.9992	0.44863	0.14804
Vanillin	21.46	Y=58930x+64	0.9933	0.11350	0.37833
<i>p</i> -Coumaric acid	23.817	Y=157538+122	0.9996	0.09385	0.03097
Rutin	28.37	Y=28144x-24	0.9854	0.39912	0.13304
Naringin	34.788	Y=19379x-212	0.9922	0.52711	0.17570
Quercetin	45.047	Y=45378x+177	0.9988	0.13475	0.04491

III.5.2. Quantitative analysis of phenolic compounds by high-performance liquid chromatography coupled to tandem mass spectrophotometry (LC-MS/MS)

It is a methodology of physicochemical analysis that depends on mass measurement to detect, identify, and quantify molecules of interest. The basic concept behind this technique is the separation of charged molecules (ions) in the gaseous phase according to their mass-to-charge ratios (m/z). In addition, mass spectrometry can be used to characterize the molecular chemical structure by fragmenting the molecules [320].

III.5.2.1. Preparation of extracts for LC-MS/MS analysis

Before performing an LC-MS/MS analysis, the different extracts were diluted in methanol (LC grade) at a concentration of 1mg/1mL and then filtered through a 0.2 μm syringe filter.

III.5.2.2. Chromatographic instruments and LC-MS/MS analysis conditions

A qualitative analysis of constituents present in different fractions of *A. campestris* L. and *F. bruguieri* DC. as performed using UPLC-ESI-MS-MS Shimadzu 8040 Ultra-High sensitivity with UFMS technology equipped with binary pump Nexera XR LC-20AD. Separation was achieved with an Ultra-force C18 column (I.D. 2.5 mm \times 100 mm, 1.8 μm particle size; Restek) at 25 °C oven temperature. The chromatographic separation was carried out using a mixture of 30% (water, 0.1% formic acid) as mobile phase A and 70% methanol as mobile phase B. The duration of gradient elution was applied as: 0 min 100% B; 0.10 min 5% B; 10 min 15% B; 30 min 95% B; 45 min 15% B; 50 min 5% B; 60 min 100% B. The flow rate was established at 0.3 mL/min, while the injection volume was 6 μL , passed through a Millex-LCR (PTFE) filter with 0.22 μm pore sizes. The separation was performed at room temperature, while the run lasted for 60 min.

The ESI conditions employed in the MS/MS are as follows:

- 230 KPa CID gas; -6.00 Kv conversion dynode.
- 350 °C interface temperature; 250 °C DL temperature.
- 3.00 L/min nebulizing gas flow, 400 °C heat block.
- 15.00 L/min drying gas flow.

The ion trap mass spectrometer was used in both negative and positive ions with MRM mode (multiple reaction monitoring). Accurate identification was made according to their typical fragments by comparing the mass spectra with published literature.

III.6. Separation and purification

All the extracts of *A.campestris* L. and *F.bruguieri* DC. were treated by using the thin-layer chromatography (TLC) analytical to select the rich extract and good systems for separation, elution, or elution system, and stationary phases, that would give the best results, we have compared each of the extracts of *A.campestris* L. and *F.bruguieri* DC. by using silica gel and polyamide TLC.

The comparison and the results of our analytical work led us to choose, separate, and isolate the constituents of the butanol extracts of *A.campestris* L. and *F.bruguieri* DC., for its richness.

III.6.1. Isolation of the constituents of the Butanol fraction of *Artemisia campestris* L. aerial part AcBE

The AcBE fraction (6 g) was slurried with a ½ amount of celite, dried, powdered and subjected to silica gel (150 g) [4.3 (ID) × 50 (L) cm] flash column, which was eluted with the gradient elution with CHCl₃-MeOH (98:02; V/V), (95:05; V/V), (93:07; V/V), (90:10; V/V), (85:15; V/V), (80:20; V/V), (77:23; V/V), (75:25; V/V), (70:30; V/V), (65:35; V/V), (60:40; V/V), (55:45; V/V), (50:50; V/V), (40:60; V/V), (30:70; V/V), (20:80; V/V) and finally with 100 % MeOH.

Each fraction was monitored by TLC on silica gel using different systems: CHCl₃- EtOAc-MeOH ; CHCl₃-AA-MeOH (12:0.5:1; 5:0.2:1; 3:0.2:1 V/V/V) and CHCl₃-MeOH (11:1; 9:1; 4:1 V/V) as developers. Similar fractions were combined and concentrated under reduced pressure to give six main fractions from A - F. All TLC plates were sprayed with the acidic solution. The scheme of separation and isolation of the butanol fraction of aerial part *A.campestris* is presented in Figure.III.5 and Figure.III.6.




Figure.III.5. Follow-up the TLC fractions silica gel column of AcBE after revelation with acidic solution.




Figure.III.6. Scheme of the fractionation and isolation of pure compounds from AcBE aerial parts.

Fraction A of AcBE column (290 mg) was subjected to silica gel column using $\text{CHCl}_3/\text{MeOH}$ as eluent, we obtained 20 sub-fractions.

Sub-fractions were collected and tested on a TLC plate (Figure.III.7).




Figure.III.7. Follow-up the separation of fraction A.

- **Sub-fraction A4-9:** 163.7 mg was chromatographed over by the RP-C18 column eluted by the H_2O % to MeOH % gradient system to yield non-pure fraction that have a mixture of three compounds. This mixture presented in **SF₃₋₁₅**, which is purified again many times by the RP-C18 column (H_2O % to MeOH %) to obtain pure yellow compound **PJ** (18.9 mg).

Fraction B (1.56 mg) was subjected to silica gel column using $\text{CHCl}_3/\text{MeOH}$ as an eluent (50 g) [2.7 (ID) \times 50 (L) cm] CC, we obtained 16 sub-fractions.

Some of those sub-fractions were collected and tested on a TLC plate (Figure.III.8).




Figure.III.8. Follow-up the separation of fraction B.

- **Sub-fraction B₂₅₋₅₂** (431.04 mg) underwent CC of LH Sephadex using gradient system $\text{CHCl}_3/\text{H}_2\text{O}$. The **SF₁₁₋₁₈** was separated on reversed phase RP-C18 with the system

H₂O/MeOH then, it was purified on TLC preparative with CHCl₃/AA/MeOH (5:0.5:1 ; V/V/V) ×3 to give PN (62 mg). The SF₂₀₋₃₀ was subjected to TLC preparative using the system CHCl₃/MeOH (5:1; V/V) ×5 to afford two pure compounds **PJF** (8 mg), and **PJC** (7 mg) respectively.

Fraction E (980 mg) was subjected to silica gel using gradient elution CHCl₃-MeOH (9:1 V/V), we obtained 5 sub-fractions.

- **Sub-fraction E₁₉₋₂₅** (149 mg) was separated on LH Sephadex CC using CHCl₃-MeOH (4:1 V/V). This separation produced more than 20 fractions. The fractions **SF₁₋₇** were collected and put through one more purification step on TLC preparative using the system CHCl₃/AA/MeOH (5:0.2:1; V/V/V) ×3 to afford two pure compounds **JR1** (4 mg), and **JR2** (27 mg) respectively Figure.III.9.




Figure.III.9. TLC purification of JR1 and JR2 compounds.

III.6.2. Isolation of the constituents of the Butanol fraction of *Fagonia bruguieri* DC. aerial part (FbBE)


The Butanolic fraction (5 g) was subjected to silica gel CC which was eluted with CHCl₃-MeOH systems (95:05; V/V), (90:10; V/V), (86:14; V/V), (80:20; V/V), (77:23; V/V), (75:25; V/V), (70:30; V/V), (65:35; V/V), (60:40; V/V), (55:45; V/V), (50:50; V/V), (30:70; V/V) (20:80; V/V), and 100 % MeOH.

The eluate was collected in fractions (50 ml each) to give five fractions (A - E).

The fractions were monitored by TLC on silica gel using the system: CHCl₃-MeOH (15:1 V/V), CHCl₃-MeOH (9:1 V/V), CHCl₃-MeOH (7:1 V/V) and CHCl₃-EtOAc-MeOH (10:0.5:1; 7:1:1; V/V/V).

The scheme of separation and isolation of the FbBE of leaves aerial part is presented in Figure.III.10 and Figure.III.11.

Under UV light 254 nm



Under UV light 365 nm




Figure.III.10. Follow-up the TLC fractions silica gel column of FbBE.




Figure.III.11. Scheme the fractionation and isolation of pure compounds from FbBE aerial parts.

Fraction A (95 mg) was subjected to Sephadex LH-20 column using gradient elution CHCl_3 -MeOH (7:3). We obtained a sub-fractions which is collected and tested on a TLC plate presented as A₄₋₅ (Figure.III.12).





Figure.III.12. Follow-up the separation of fraction A.

- **Sub-fraction A₄₋₅** (18 mg) was subjected to TLC preparative using the system $\text{CHCl}_3/\text{AA}/\text{MeOH}$ (5:0.5:1 ; V/V/V) $\times 4$ to afford a crystals yellowish pure compound **PFN (3 mg)**.

Fraction B (2100 mg) was subjected to CC silica gel using CHCl_3 -MeOH as an eluent (100 g [2.7 (ID) \times 50 (L) cm] CC, we obtained 29 sub-fractions.

Sub-fractions were collected and tested on a TLC plate (Figure.III.13).



After chemical spraying




Figure.III.13. Follow-up the separation of fraction B.

- **Sub-fraction SF₁₋₄** (37.3 mg) underwent RP-C18 column eluted by the 100% of H₂O.

All the fractions tested on TLC where similar ones were collected to get **B₅₋₉**.

SF₅₋₉ was purified on TLC preparative using the system CHCl₃/AA/MeOH (7:0.2:1 ; V/V/V) ×3 to afford a white crystals pure compound **Pb** (8 mg). On the other hand, the **SF₉₋₄₈** subjected to CC of Sephadex LH-20 with CHCl₃-MeOH (70 %: 30 %) and purified with TLC preparative using the system CHCl₃/MeOH (6:1 ; V/V) ×3 to give brown powder presented a pure compound **Pm** (28 mg).

Fraction C (899 mg) was subjected to CC silica gel using gradient elution CHCl₃-MeOH, we obtained 37 sub-fractions.

- **Sub-fraction C₁₋₄** (193 mg) was chromatographed by using column silica gel eluted with the CHCl₃-MeOH gradient system to yield:

SF₅₋₄₀ (98 mg) was separated on RP-C18 column using H₂O-MeOH (7:1; V/V) to obtain a subfractions **SF₂₋₂₁** contain a mixture of two compounds.

SF₂₋₂₁ was purified by CC of Sephadex LH-20 with Tol-MeOH to afford **PMV** (12.7 mg).

SF₂₅₋₃₂ was recollected from **C₁₋₄** and put through one more purification with TLC preparative using the system CHCl₃/AA/MeOH (7:0.5:1 ; V/V/V) ×5 to give pure white powder compound **PV2** (4 mg).

*Chapter IV: Biological
Activities*

IV. Biological Activities

The Biological activities were examined at Biotechnology Research Center (CRBT) Constantine, Algeria and the Laboratory of Valorization and Technology of Saharan Resources (VTRS) University Echahid Hamma Lakhdar El-Oued, Algeria.

The investigation of the biological properties and total bioactive content was performed on the various extracts of *A. campestris* L. and *F. bruguieri* DC. aerial parts:

AcME: *Artemisa campestris* L. Methanol Extract

AcPEE: *Artemisa campestris* L. Petroleum Ether Extract

AcDE: *Artemisa campestris* L. Dichloromethane Extract

AcEAE: *Artemisa campestris* L. Ethyl Acetate Extract

AcBE: *Artemisa campestris* L. Butanol Extract

AcAE: *Artemisa campestris* L. Aqueous Extract

FbPEE: *Fagonia bruguieri* DC. Petroleum Ether Extract

FbDE: *Fagonia bruguieri* DC. Dichloromethane Extract

FbEAE: *Fagonia bruguieri* DC. Ethyl Acetate Extract

FbBE: *Fagonia bruguieri* DC. Butanol Extract

FbAE: *Fagonia bruguieri* DC. Aqueous Extract

IV.1. Total bioactive components assessment

IV.1.1. Total phenolic content (TPC)

The total polyphenols content of the different extracts is determined by using the Folin-Ciocalteu reagent method. In the presence of polyphenols, the middle Alkaline is reduced to tungsten oxide and molybdenum, producing a blue color. This reagent, known as the FCR reagent, is a mixture of phosphotungstic acid ($H_3PW_{12}O_{40}$) and phosphomolybdic acid ($H_3PMO_{12}O_{40}$), which is reduced as a consequence of the oxidation of phenols to a mixture of tungsten oxides (W_8O_{23}) and molybdenum oxides (Mo_8O_{23}). The resulting blue coloration is proportional to the total phenol content and exhibits maximum absorption at 750 -765 nm [321].

Protocol

Total phenolic in the extracts of *A.campestris* L. and *F.bruguieri* DC. were carried out as stated by Singleton & Rossi. (1965) using the Folin-Ciocalteu reagent with slight modifications [322]. Briefly, 20 μL of the extract was mixed with 75 μL of sodium carbonate 7.5 % and 100 μL of (1:10) Folin-Ciocalteu reagen to adapt a microplate protocol as reported by Müller *et al.* (2010) [323]. The mixture was incubated at room temperature in the dark for 2h. The absorbance was recited at 765 nm. The calibration curve was achieved using gallic acid at increasing concentrations (0-200 $\mu\text{g} /\text{ml}$) (Figure.VI.1). The phenolic amounts were defined as (μg GAE/mg dried extract).




Figure.IV.1. Gallic acid calibration curve for TPC quantification.

IV.1.2. Total flavonoids content (TFC)

Flavonoids are quantified by the aluminum trichloride (AlCl_3) colorimetric method. The dosage of flavonoid extracts depends on forming a complex between Al^{+3} and flavonoids. The complex forms a yellow compound that absorb in the visible at 415 nm.

Protocol

Total flavonoids in the extracts of *A.campestris* L. and *F.bruguieri* DC. were evaluated by using the aluminium coluorimetric method Topçu *et al.* (2007) with some modifications [324]. Shortly, 130 μL (MeOH) was added to 50 μL of extract solution (1mg/mL), then 10 μL aluminium nitrate (10%) $\text{Al}(\text{NO}_3)_2 \cdot 9\text{H}_2\text{O}$ and 10 μL potassium acetate (1 M) (CH_3COOK) were added. The mix was allowed to attain at room temperature for 40 min. The absorbance was measured by a microplate reader (Perkin Elmer, Enspire) at 415 nm, and the standard curve

was plotted with quercetin (0-200 $\mu\text{g} / \text{ml}$) (Figure.IV.2); the total flavonoid amounts were expressed in μg quercetin equivalent per mg of dried extract (μg QE/mg).




Figure.IV.2. Quercetin calibration curve for TFC quantification.

IV.2. Antioxidant Activity

Seven methods were used to investigate the antioxidant activity of the various extracts of *A.campestris* L. and *F.bruguieri* DC: DPPH• scavenging, ABTS scavenging, β -carotene-linoleic acid bleaching, Reducing Power (RP), Cupric Reducing Antioxidant Capacity (CUPRAC), O-Phenanthroline Chelating and Galvinoxyl scavenging (GOR).

Preparation of dilutions

In order to prepare a series of dilutions of different samples, the various extracts and standards were dissolved in methanol, 500 μl of this stock solution (known concentration) were mixed with 500 μl of methanol to arrive at a 1/2 dilution, and continuing in this manner. This procedure is repeated for further dilutions until 1/64 (Figure.IV.3).




Figure.IV.3. Preparation of dilutions of different extracts.

IV.2.1. DPPH[•] Scavenging Activity

Due to its stability as free radicals and simplicity of analysis, DPPH (2,2 diphenyl-1-picrylhydrazyl) is the most widely utilized substrate for rapid and direct assessment of antioxidant activity. It absorbs in the visible region between 515 and 520 nm in wavelength. The fundamental concept behind this approach is the transformation of violet DPPH (2,2-diphenyl-1-picrylhydrazyl) into yellow 2,2-diphenyl-1-picrylhydrazine (Figure.IV.4). However, when an antioxidant reduces it, this wavelength becomes less efficient. The intensity of the colour is inversely related to the medium's antioxidants' ability to produce H⁺ protons [325].




Figure.IV.4. The mechanism for reducing the DPPH[•] radical by an antioxidant [326].

Protocol

The capacity of *A.campestris* L. and *F.bruguieri* DC. to inhibit the 2,2-diphenyl-1-picrylhydrazyl free radical was performed according to the procedure reported by Blois (1958) [327]. In a 96-wells microplate, 160 μL of a DPPH solution (0,4 mM) were placed in the presence of 40 μL of different concentrations. For 30 min, the microplate was kept at room temperature in the darkness. Using a microplate reader (Perkin Elmer Enspire, Singapore), the absorbance was recited at 517 nm, and BHT, α -Tocopherol, and BHA were used as standards. Free radical trapping activity increased when the reaction mixture had a lower absorbance. The capacity to scavenge DPPH in percentage (%) was calculated using the following equation (IV.1):

$$\% \text{ Inhibition} = [(Ab_{\text{SCN}} - Ab_{\text{EXT}})/Ab_{\text{SCN}}] \times 100 \quad (\text{IV.1})$$

Where; Ab_{SCN} : is the absorbance of the control reaction.

Ab_{EXT} : is the absorbance of the extract.

IV.2.2. ABTS^{•+} Scavenging Activity

2,2'-azino-bis (3-ethyl-benzothiazoline-6-sulfonic acid) is a radical cation that is readily formed by oxidation in the presence of potassium persulfate, resulting in a blue-green-coloured solution. Absorbance measurements at the appropriate wavelength allowed for determining this radical's concentration (Figure.IV.5). The absorbance at 734 nm decreases when an antioxidant is added to a solution containing these radical cations. This decrease frequently depends on time, concentration, and the examined samples' antioxidant activity [328].




Figure.IV.5. Formation and trapping of the radical ABTS^{•+} by an antioxidant donor of H[•] [329].

Protocol

According to the procedure described by Re *et al.* [328], the extracts of *A. campestris* L. and *F. bruguieri* DC. were conducted to determine their ability to scavenge free radicals in the presence of ABTS (2,2'-azinobis (3-ethylbenzothiazoline)-6-sulfonic). After reacting an aqueous solution of ABTS at 7 mM with 2.45 mM of potassium persulfate ($K_2S_2O_8$) for 16 hours, the cation $ABTS^{*+}$ was generated during storage of the mixture in the dark at room temperature. Following dilution, the absorbance of the $ABTS^{*+}$ solution was 0.700 ± 0.020 . In a 96-well microplate reader, PerkinElmer Multi-mode Plate Reader EnSpire, USA, 40 μ l of each sample prepared in methanol at various concentrations was combined with 160 μ l of the $ABTS^{*+}$ mixture and kept in the darkness for 10 min. A wavelength of 734 nm was used to measure the absorbance. The antioxidant standards were BHT and BHA, respectively. The following equation was utilized to calculate the inhibition percentage of $ABTS^{*+}$:

$$\% \text{ inhibition} = [Ab_{S734 \text{ plank}} - Ab_{S734 \text{ sample}} / Ab_{S734 \text{ plank}}] \times 100 \quad (\text{IV.2})$$

$Ab_{S734 \text{ blank}}$: absorbance of control reaction. $Ab_{S734 \text{ sample}}$: absorbance of test sample.

IV.2.3. β -Carotene-Linoleic Acid Bleaching Activity

This system is founded on the idea; when yellow beta-carotene's color is destroyed by its reactivity with the radicals generated during the oxidation of linoleic acid in an emulsion. Antioxidants slow the bleaching of β -carotene, which is determined by spectrophotometric monitoring at 470 nm. Therefore, the absorbance value is obtained by reading it at time 0 and then again during two hours. This approach is sensitive because of the high absorption of beta-carotene, despite being slower than DPPH. The use of 96-well microplates has recently allowed for improvements in the methodology. This technique is frequently used for testing the antioxidant potential of a wide variety of samples, including pure chemicals, plant extracts, seeds, fruits, and vegetables [330].

Protocol

Using a model system (β -carotene/linoleic acid), we evaluated the ability of *A. campestris* L. and *F. bruguieri* DC. extracts to inhibit β -carotene [331]. β -carotene/linoleic acid emulsion was obtained by dissolving 0.5 mg of β -carotene in 1 ml of chloroform. This mixture was transferred to a flask containing 20 μ L linoleic acid and 200 μ L tween 40. A vacuum evaporator was utilized to remove the chloroform, and [50-70 ml] of hydrogen peroxide H_2O_2 was added for *A. campestris* L.; *F. bruguieri* DC.; respectively, followed by vigorous agitation. At 470 nm,

the absorbance of the combination was adapted to between 0.8 and 0.9. then, 160 μL of the emulsion was mixed with 40 μL of the plant extracts or synthetic antioxidants (BHA and BHA) at diverse concentrations. This mixture sets in each well of the 96-well microplate. After incubating the microplate at 50 $^{\circ}\text{C}$, The absorbance was determined using a wavelength of 470 nm and a range of times beginning at $t=0$ min and finishing at $t=120$ min, each having 30 min intervals. The percentage of inhibition was expressed using the following equation:

$$I \% = 1 - [(A_{S0} - A_{St}) / (A_{C0} - A_{Ct})] \times 100 \quad (\text{IV.3})$$

I (%): percentage of inhibition

A_{S0} : absorbance value of β -carotene content in the presence of the extract measured at $t = 0$.

A_{C0} : absorbance value of β -carotene content in the presence of negative control measured at $t=0$.

A_{St} : absorbance value of β -carotene content in the presence of the extract measured at $t = 120$ min.

A_{Ct} : absorbance value of β -carotene content in the presence of negative control measured at $t = 120$ min.

IV.2.4. Cupric Reducing Antioxidant Capacity (CUPRAC) Activity

The assay is a follow-up on the decreased enhanced absorbance of the copper-neocuproin complex $[\text{Nc}_2 - \text{Cu}^{2+}]$ due to the reduced copper-neocuproin once an antioxidant is present (Figure II.6). At a wavelength of 450 nm, this reaction is determined by measuring the absorbance [332]. The principle of this test is based on the transformation of phenolic hydroxides into quinones, which takes place as a result of the reduction of the Cu^{+2} -Nc complex, resulting in the formation of a chromogenic complex of Cu^{+2} -Nc that absorbs light at 450 nm (Figure.IV.5)




Figure.IV.6. Reduction of the Cu^{+2} -Nc chromogenic complex [332].

Protocol

In the CUPRAC method, the measurement is based on reducing copper ions (Cu^{2+}) [332]. A solution was assembled by mixing the following volumes: 50 μL of Cu (II) (10 mM), 50 μL of neocuprin (7.5 mM), and 60 μL of $\text{CH}_3\text{COONH}_4$ buffer solution (1 M, $\text{pH} = 7.0$). Then 40 μL of samples at different concentrations were added to the initial mixture. The resulting mixture was put in darkness at room temperature for 1 hour. The absorbance was measured at 450 nm using the microplate reader (Perkin Elmer Enspire, Singapore). The antioxidant standards were BHA and BHT. The concentration given an absorbance of 0.5 ($A_{0.5}$) was calculated from the absorbance curve at different concentrations.

IV.2.5. Reducing Power Assay

The presence of reducers in plant extracts causes the reduction of ferric iron (Fe^{3+}) in the ferricyanide complex to the ferrous iron form (Fe^{2+}); this is the iron form considered more stable (Figure.IV.7). It is a colorimetric reaction characterized by a color change. It can be determined by spectrophotometric detection as having a high absorbance (green colour) at 593 nm [333].

Thus, the formation of this complex will demonstrate the reducing power that determines the antioxidant capacity of a compound [334].




Figure.IV.7. Reduction of Fe^{+3} by an antioxidant in the reducing power test [333].

Protocol

The capacity of the samples to reduce Fe^{3+} contained in the complex $\text{K}_3\text{Fe}(\text{CN})_6$ to Fe^{2+} was assessed by reducing iron ions. The Oyaizu method (1986) was used to perform the study that established the reducing power [335]. In brief, 10 μL of each extract or standard at various concentrations was mixed with 40 μL of phosphate buffer solution (0.2 M, $\text{pH} 6.6$) and 50 μL 1% potassium ferricyanide. The mixture was then kept at 50°C for 20 minutes. Afterwards, 10

μL of a 0.1% ferric chloride solution, 50 μL of 10% trichloroacetic acid, and 40 μL of distilled water were added. The absorbance measurement at 700 nm was recorded with the assistance of a microplate reader (Perkin Elmer, EnSpire, Singapore). In the experiment, the reference points utilized were BHA and ascorbic acid.

IV.2.6. Galvinoxyl (GOR) Scavenging Activity

Galvinoxyl is a relatively stable free radical commonly used in antioxidant tests (Figure.IV.8). The decrease of this radical can be easily detected using a spectrophotometer since its characteristic maximum absorption in the visible range ($\lambda_{\text{max}} = 432 \text{ nm}$) disappears when trapped. Galvinoxyl has a higher reactivity towards phenolic compounds than DPPH [336].




Figure II.8. Chemical structure of galvinoxyl [337].

Free radical traps such as hydrogen donors are responsible for the reduction of galvinoxyl, as shown in the following reaction :




Where; **G[•]**: Galvinoxyl; **GH**: Reduced galvinoxyl; **IH**: free radical donor of hydrogen; and **I[•]** Corresponding IH radical [336].

Protocol

Shi *et al.* (2001) method was used to determine Galvinoxyl radical (GOR) antioxidant assay [336]. For this investigation, 40 μl of various extract concentrations in methanol were combined with 160 μl of a galvinoxyl solution in methanol at a concentration of 0.1 mM. After 120 minutes of incubation at room temperature in darkness, the absorbance of the resultant solution was determined using spectrophotometry at 428 nm. The standards were BHT and BHA and the methanolic solution of galvinoxyl was used as a control. The inhibition percentage I (%) was expressed as formula (IV.1)

IV.2.7. O-Phenanthroline Activity

It is a colorimetric antioxidant activity of iron reduction that is utilized for the purpose of determining the antioxidant capacity. It is based on the formation of the ferrous complex-phenanthroline in the presence of polyphenols (Equation .IV.5), which has a color of red [338].



Protocol

According to Szydowska-Czerniak *et al.* approach, the O-phenanthroline chelating activities of the extracts were determined [338]. A mixture of 30 μL O- phenanthroline (0.5 % in methanol), 110 μL methanol, 50 μL FeCl_3 (0.2 %), and 10 μL of samples or standards at varying concentrations was prepared (BHA; BHT), then the mixture was incubated at room temperature for 20 minutes before the examination. A 96-well microplate reader was used to measure the absorbance of an orange-red solution at 510 nm.

IV.2.8. Antioxidant Activity Evaluation via Electrochemical Method

IV.2.8.1. $\text{O}_2^{\cdot-}$ free radical scavenging assay

Cyclic voltammetry (VC) is one of the most important experimental techniques for studying redox systems intended to be employed as rechargeable energy sources. This technique is differentiated by its benefits of simplicity, sensitivity, and rapidity in collecting data on redox processes, the kinetics of charge transfer reactions, or the reversibility of the electrochemical system that has been investigated. The antioxidant capacity of plants may be estimated with the technique (VC).

Cyclic voltammetry (VC) is an electrochemical inversion technique controlled by the potential. It is usually used for the purpose of studying reactions and mechanisms. The procedure involves measuring the current intensity produced by applying a linear ramp in potential at a positive or negative scan rate. The potentials are swept in a cycle at a constant speed; after sweeping towards the anode potentials and performing oxidation. The cathodic potential is exploited by switching the direction of potential variation. Voltammograms therefore record the anodic and cathodic polarization curves, also referred to as cyclic voltammograms (Figure.IV.9).

The electrochemical cell was saturated with high-purity commercial oxygen for 15 minutes before each experiment to study the interaction of superoxide anion free radicals. Each assay, extract or standard volume was added to 15 ml of 0.1 M DMF/nTbUNBF₄ solution. Afterwards, the voltammograms were recorded in the absence and presence of progressively increasing concentrations of the different extracts that were investigated. Voltammograms were obtained in cyclic voltammetry extracts of *A.campestris* L. and *F.bruguieri* DC. with a sweep speed of 0.1 V.s⁻¹; region d'électro-activity (0, -1,6 V). The Free O₂⁻ radical scavenging data of *A.campestris* L. and *F.bruguieri* DC. extracts were used to determine IC₅₀ values. The IC₅₀ value was defined as the sample concentration (mg/mL) that inhibits O[•] radical formation at 50%.

$$I(\%) = \frac{I_{pa0} - I_{pas}}{I_{pa0}} \times 100 \quad (\text{IV.6})$$

Where; I_{pa0} and I_{pas} are the anodic peak current densities of the superoxide anion radical in the absence and presence of *A. campestris* L. and *F.bruguieri* DC. extracts respectively.

IV.3. Enzymes Inhibitory Activity

IV.3.1. Evaluation of anti-Alzheimer activity

IV.3.1.1. Cholinesterase Inhibitory Activity

Cholinesterases are enzymes that degrade acetylcholine, a cholinergic neurotransmitter involved in cognitive activities. Inhibition of these enzymes will reduce acetylcholine and consequently increase cholinergic effects [339]. The inhibitory effect of the aerial parts of *A.campestris* L. and *F.bruguieri* DC. on butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) was evaluated by employing the method of Ellman *et al.*, [340] (Figure.IV.10).




Figure.IV.10. Chemical mechanism of the Ellman *et al.*, method [340].

Protocol

Both acetylcholinesterase (AChE) from electric eels and butyrylcholinesterase (BChE) from horse serum were utilized. As substrates, iodide acetylthiocholin and butyrylthiocholin chloride were used. DTNB [5,5-dithio-bis (2-nitrobenzoïc)] was employed in the measurement of anti-cholinesterase activity. Methanol was the selected solvent for dissolving both the test samples and the controls. Briefly, a mixture composed of 150 μL sodium phosphate buffer (100 mM, pH:8.0), 10 μL of sample test or galantamine (reference molecule), and 20 μL BChE (6.85×10^{-3} U) AChE or (5.32×10^{-3} U) solution were added. Incubation at 25 $^{\circ}\text{C}$ for 15 min was realized; then 10 μL of 0.5mM DTNB was added along with 10 μL of acetylthiocholine iodide or butyrylthiocholine iodide. Using a 96-well microplate reader, Perkin Elmer Multimode Plate Reader EnSpire (National Center of Biotechnology Research; Constantine, Algeria), the absorbance was recited at 412 nm for 15 min. The hydrolysis of these substrates was monitored by spectrophotometry via the formation of a yellow 5-thio-2-nitrobenzoate anion, the product of DTNB's interaction with thiocholine. This anion was released by the enzymatic hydrolysis of acetylthiocholine iodide or butyrylthiocholine chloride, and the reaction was measured at a wavelength of 412 nm.

The inhibitory activity was measured by comparing the reaction rates of samples relative to the blank samples using the formula:

$$\text{Inhibition \%} = [(E - S) / E] \times 100 \quad (\text{IV.7})$$

E: activity of the enzyme without sample, S: activity of the enzyme with the sample. Galantamine was used as a reference compound (positive control).

IV.3.2. Evaluation of anti-diabetic activity

The antidiabetic activity of the various extracts of *A. campestris* L. and *F. bruguieri* DC., aerial part, was evaluated using the alpha-amylase inhibition method.

IV.3.2.1. Alpha -amylase Inhibitory activity

Alpha-amylase is a digestive enzyme generated by the glands in the salivary glands and pancreas. It is one of the most important endo-amylases. Its function is to hydrolyze the (1-4) glycosidic bonds inside the starch chains to generate maltose molecules, also known as α -glucose disaccharides. This enzyme is important for absorbing and breaking down the carbohydrates in food. This enzyme can be a target for treating type 2 diabetes [341].

Acarbose is a well-known medication employed in the drug industry as an inhibitor of the enzyme alpha-amylase. It delays carbohydrate digestion and reduces postprandial plasma glucose levels [342]. On the other hand, it might produce undesirable side effects such as diarrhea, gastrointestinal obstructions, and ulcers [343]. Plants' naturally occurring α -amylase inhibitors, such as flavonoids and phenolic compounds, are recommended as a safe and effective approach for treating and preventing type 2 diabetes [344].

Protocol

The α -amylase inhibitory activity was investigated according to Zengin *et al.*, 2014 [345], using the iodine/potassium iodide method, with slight modifications. The reaction mixture was prepared in a 96-well microplate by adding 25 μ L of the sample at various concentrations with amylase solution in 1U of sodium phosphate buffer (pH = 6.9 with 6 Mm NaCl). After incubating the resultant solution at 37 C° for 10 min, the reaction was initiated by adding 50 μ L of 1% starch solution. A control was simultaneously prepared without the enzyme solution. Re-incubation for 20 min at 37 °C was done, followed by the addition of 25 μ L 1M HCl and 100 μ L of iodine-potassium iodide solution to stop the reaction.

The absorbance was measured at 630 nm, and the % inhibition of α -amylase was estimated as follows:

$$I \% = 1 - [(Abs_a - Abs_b) - (Abs_c - Abs_d) / (Abs_a - Abs_b)] \quad (IV.8)$$

- Abs_c = Absorbance (Extract, Starch, Enzyme, IKI, HCl).
- Abs_d = Absorbance (Extract, sodium phosphate buffer, IKI).
- Abs_b = Absorbance (solvent vol Extract, Enzyme, Starch, HCl, IKI).
- Abs_a = Absorbance (solvent vol Extract, sodium phosphate buffer, Starch, HCl, IKI).

IV.3.3. Evaluation of anti-obesity activity

IV.3.3.1. Pancreatic Lipase Inhibitory Activity

Protocol

For determining lipase inhibitory activity against pancreatic lipase, the method of Souza *et al.*, (2011) was performed to determine the inhibitory capacity with slight change [346]. In this experiment, the studies extracts were diluted in dimethyl sulfoxide (DMSO) at the concentration of 4 mM. An aliquot containing 100 μ L of pancreatic Lipase solution in Tris-HCl buffer (pH = 8) was mixed with 50 μ L of each sample at various concentrations. After incubation of 20 min at 37 $^{\circ}$ C. Subsequently, the addition of 50 μ L of p-NPP (p-Nitrophenol Palmitate) drove the reaction to initiated after incubation at 37 $^{\circ}$ C for 120 min. Orlistat was used as a positive control. A blank with DMSO as a substitute for enzyme solution was prepared. The absorbance of lipase products (p-nitrophenol) was read at 410 nm at t=0 min and t=120 min using a 96-well microplate reader (Perkin Elmer, Enspire). All samples were analyzed in triplicate. Percent pancreatic lipase inhibition was determined using the following formula [35]:

$$I (\%) = [(AbsA - Absa) - (AbsB - Absb) / (AbsA - Absa)] \times 100 \quad (IV.9)$$

Where:

AbsA: The activity in the absence of an inhibitor.

Absa : the negative control in the absence of an inhibitor.

AbsB: the activity in the presence of an inhibitor.

Absb: the negative control in the presence of an inhibitor.

IV.3.4. Anti-inflammatory Activity (BSA denaturation inhibition)

The BSA denaturation inhibition method was used to establish the anti-inflammatory activity of the different extracts of *A. campestris* L. and *F. bruguieri* DC. aerial parts.

The fundamental concept of BSA denaturation inhibition is to prevent BSA from being denaturated by heating at (72°C).

The heat-induced denaturation of albumin causes a reaction that mimics the production of antigens associated with Type III hypersensitivity. This reaction is involved in the pathogenesis of disorders such as serum diseases, glomerulonephritis...etc [347].

Protocol

The in vitro anti-inflammatory efficacy of the *A. campestris* L. and *F. bruguieri* DC. extracts was determined using the method described by Kandikattu *et al.*, (2013), with slight modifications [348]. After adding 0.5 ml of 0.2 % BSA solution in Tris Buffer (pH 6.8) to 0.5 ml of each extract concentration or standard (Diclofenac), the mixture was then placed in an incubator at 37 ° C for 15 min. It was then placed in a water bath at 72 °C for 5 min. After cooling the tubes, the turbidity (protein precipitation) was read at 660 nm using a spectrophotometer. In order to calculate the percentage of the amount to which the proteins were prevented from denaturation, the following equation was applied:

$$\% \text{ Inhibition} = \frac{[\text{Abs}_{\text{control}} - (\text{Abs}_{\text{sample}} - \text{Abs}_{\text{white}})]}{\text{Abs}_{\text{control}}} * 100 \quad (\text{IV.10})$$

Abs_{sample}: Sample (0.5 ml extract + 0.5 ml BSA), Abs_{white}: White (0.5 ml extract + 0.5 ml Tris-phosphate (pH: 6.8)).

IV.3.5. Photoprotective Activity

IV.3.5.1. Sun protection factor activity (SPF)

The skin is the biggest organ in the body, covering 1.5-2 m². It protects the body from UV radiation; the latter is found in three subclasses: UVA, UVB, and UVC. UVB is the most dangerous radiation; it can trigger skin diseases like melanoma [349]. Natural compounds such as polyphenols and vitamins have an impact that is beneficial and preventive against the ROS which is produced by these rays [350].

The sun protection factor, abbreviated SPF, is a quantitative measure of the effectiveness of a sunscreen formulation. Sunscreen representatives are identified using an in vitro methodology

based on spectrophotometric measurement of diluted solutions as described by Mansur *et al.*, (1986) [351].

Protocol

The SPF of *A. campestris* L. and *F. bruguieri* DC. extracts was determined in vitro to investigate its ability to protect against UV damage (SPF) [351]. First, the samples were diluted in absolute methanol to a concentration of 2 mg/mL (2000 ppm). As shown in Table 1, the absorbances were measured at different wavelengths, starting with 290 nm to 320 nm, each 5 nm using a multimode microplate reader (Perkin Elmer Enspire, Singapore). Each measurement was performed in triplicate, and the SPF value was calculated by applying the below mathematic equation:

$$\text{SPF spectrophotometric} = \text{CF} * \sum_{290}^{320} \text{EE}(\lambda) * \text{I}(\lambda) * \text{Abs}(\lambda) \quad (\text{IV.11})$$

CF: correction factor (= 10); EE: erythemal effect spectrum; I: solar intensity spectrum; Abs: absorbance of sunscreen product, EE* I: is a constant calculated by Sayre *et al.* and is displayed in Table.IV.1 [352].

Table.IV.1. The Normalized product function used in the calculation of sun protection factor (SPF).

Longueur d'onde λ (nm)	EE (λ)x I(λ) (Normes)
290	0,0150
295	0,0817
300	0,2874
305	0,3278
310	0,1864
315	0,0837
320	0,0180
Total	1

According to the recommendations of the European Commission in 2006 [353], Table.IV.2 illustrates the different protection categories displayed on the products, as well as the sun protection factor values which correspond to all those protection categories.

Table.IV.2. Protection categories displayed on solar products according to the measured protection factors, as recommended by the European Commission, 2006.

Indicated category	Protection factor indicated	Sun protective factor measured	Recommended minimum UVA protection factor	Recommended minimum critical wavelength
«Minimum protection »	6	6 - 9,9	1/3 of the sun protection factor indicated on the label	370 nm
	10	10 - 14,9		
«Medium Protection »	15	15 - 19,9		
	20	20 - 24,9		
	25	25 - 29,9		
«High » « protection »	30	30 - 49,9		
	50	50 - 59,9		
«Very high protection»	50+	60 ≤		

Statistical Data Analysis

All tests were carried out in triplicate. Data were recorded as mean±standard variation (SD) of three measurements. The obtained results were statistically analyzed using SPSS descriptive statistics (IBM SPSS Statistics, version 21 PL) and one-way ANOVA (GraphPad Prism 5 program), followed by Turkey's post hoc test for multiple comparisons and differences with *p* Values are considered significantly different at $p < 0.05$.

PART 3:

RESULTS &

DISCUSSION

*Chapter V: Quantitative
analysis and Structural
Elucidation*

V.1. Qualitative phytochemical screening

Artemisia campestris L.

Based on the information shown in the Table.V.1 below, it can be stated that *A. campestris* L. is an extremely rich source of flavonoids, particularly in the AcEAE and AcDE extracts. Similarly, both the AcAE and the AcBE showed a significant content of reducing chemicals and saponins. Coumarin has a moderately positive effect on AcEAE, but it has a substantial positive content in AcME and AcDE. Terpenoids have a moderately positive appearance in AcME, AcDE and AcPEE but a negatively appearance in AcAE. An abundance of saponins can be detected in various *A. campestris* L. extracts. Conversely, tannins are present but in low concentrations. All *A. campestris* L. extracts were negative for the presence of alkaloids in a precipitation test using the Dragendorff reagent.

Table.V.1. Phytochemical screening results of *Acampestris* L.

Extracts	secondary metabolites						
	Flavonoids	Alkaloids	Tannins	Terpenoids	Coumarins	Reducing compounds	Saponins
AcME	++	-	+	++	+++	+++	+++
AcPEE	+	-	+	++	+	+	++
AcDE	++	-	+	++	+++	++	+++
AcEAE	+++	-	+	+	++	+++	+++
AcBE	++	-	+	+	+	+++	+++
AcAE	+	-	-	-	-	+	+

(+++): Strongly positive; (++): Moderately positive; (+): Weakly positive; (-): Negative.

Fagonia bruguieri DC.

The data presented in the Table.V.2 below demonstrate that the aerial part of *F.bruguieri* DC.is abundant in flavonoids, except FbPEE and FbAE, which showed a low flavonoid content. Salkowski's reaction confirms the presence of Terpenoids in FbME, FbPEE, FbDE, and FbEAE and negative in FbBE and FbAE. Catechins tannins show a significant positive reaction in the FbME, FbPEE, FbDE, and FbEAE tests; however, the FbBE and FbAE showed a weak positive reaction. For the coumarin test, there is a strong presence in FbME and FbDE; there is also a low presence of Reducing compounds in the various extracts. The same is for saponins; all of the different extracts of the *F.bruguieri* DC. plant have shown positive test outcomes. The presence of alkaloids in FbME and FbPEE was confirmed by precipitation processes using the Dragendorff reagent.

Table.V.2. Phytochemical screening results of *F.bruguieri* DC.

Extracts	secondary metabolites						
	Flavonoids	Alkaloids	Catechins tannins	Terpenoids	Coumarins	Reducing compounds	Saponins
FbME	+++	+	++	+++	+++	+	+++
FbPEE	+	+	++	+++	+	+	+++
FbDE	+++	+	++	+++	+++	+	+++
FbEAE	+++	-	++	+++	+	+	++
FbBE	+++	-	+	-	-	+	++
FbAE	+	-	+	-	-	+	++

(+++): Strongly positive; (++) : Moderately positive; (+): Weakly positive; (-): Negative

The fact that the classes of secondary metabolites found in the chosen species have the potential to have a correlation with the therapeutic properties of those species justifies the widespread use of those species in traditional medicine practiced by the inhabitants of the Tamanrasset region.

Several investigations were carried out on the phytochemical investigation of *Artemisia campestris* L. plant; according to the findings of Douaouya and al., (2022), the plant *Artemisia campestris* L. from the Aures-Algerie region contains flavonoids, saponins, tannins, alkaloids, reducing compounds, and coumarin [354]; however, terpenes were not found in the sample. These findings are almost identical to our own. Similarly, the study by Naili *et al.* (2010) revealed that the methanolic crude extract of this species contains saponosides, Alkaloids, tannins, terpenes, and flavonoids [355].

Few phytochemical studies have been conducted on the species *Fagonia bruguieri* DC. Irshad *et al.* (2022) demonstrated different classes of secondary metabolites, such as alkaloids, flavonoids, terpenoids, and saponin, were found in the methanol extract of *Fbruguieri* throughout a chemical screening [211]. In contrast, several phytochemical studies on the genus *Fagonia* have demonstrated its richness in secondary metabolites, with a distinct predominance of flavonoids [218, 220], and diterpenes [245].

V.2. Mineral Analysis

The ICP-OES and INAA analytical methods were used to identify the major, minor, trace, and ultra-trace element concentrations in the samples selected for further investigation.

V.2.1. Calculation Of Elementary (Mineral) Concentrations

The element concentrations in the plants studied with NAA and ICP-OES were determined using Equations (III.1) and (III.4), respectively in Part 2: Chapter III.

Table.V.3 shows the main concentrations of mineral elements found in *A. campestris* L. and *F.bruguieri* DC.using two techniques (INAA and ICP-OES). The results obtained were arranged in values as mean and standard error (\pm SD), based on assessment measured on the basis of triplicate analyses. twenty one elements were found in our samples as reported.

Table.V.3. Concentrations in mg/kg of the chemical elements in the plant *A. campestris* L. and *F.bruguieri* DC.

Elements	<i>A. campestris</i> L.		<i>F.bruguieri</i> DC.	
	Mean \pm SD*		Mean \pm SD*	
	ICP-OES Mean \pm SD	INAA Mean \pm SD	ICP-OES Mean \pm SD	INAA Mean \pm SD
Br	Nd	16.1409 \pm 14.4970	Nd	85.4020 \pm 119.2283
Ca	10538.1 \pm 69.9	Nd	Nd	Nd
Cd	0.0988 \pm 0.0098	Nd	0.0999 \pm 0.0199	Nd
Co	1.28 \pm 0.148	1.4625 \pm 0.2267	0.899 \pm 0.099	0.8208 \pm 0.0545
Cr	1.083 \pm 0.551	1.1982 \pm 0.3272	Nd	1.1392 \pm 0.2418
Cs	Nd	0.1566 \pm 0.0414	Nd	0.2211 \pm 0.0557
Cu	70.22 \pm 0.94	Nd	37.81 \pm 0.39	Nd
Eu	Nd	0.0393 \pm 0.0181	Nd	0.0202 \pm 0.0095
Fe	1181.8 \pm 82.37	1264.2366 \pm 56.3983	490.7 \pm 10.51	512.7699 \pm 16.3994
Li	46.6 \pm 4.45	Nd	25.5 \pm 1.10	Nd
Mg	990.7 \pm 3.14.5	Nd	933.8 \pm 253.5	Nd
Mn	41.06 \pm 6.51	Nd	9.25 \pm 3.68	Nd
Mo	0.29 \pm 0.068	Nd	0.498 \pm 0.059	Nd
Na	298.41 \pm 1.319	311.7137 \pm 19.0049	762.55 \pm 13.33	752.5544 \pm 11.1111
Ni	2.75 \pm 0.43	Nd	1.690 \pm 0.248	Nd
Pb	0.68 \pm 0.305	Nd	0.59 \pm 0.099	Nd
Sc	Nd	0.0220 \pm 0.0024	Nd	0.0059 \pm 0.0007
Se	Nd	0.1680 \pm 0.0925	Nd	0.3244 \pm 0.1746
Sr	23.93 \pm 0.768	25.3373 \pm 6.9346	168.55 \pm 14.03	157.6644 \pm 16.1226
Ti	20.38 \pm 1.61	Nd	6.26 \pm 0.66	Nd
Zn	47.07 \pm 0.797	43.7270 \pm 3.3415	38.12 \pm 0.358	36.3133 \pm 1.2809

*SD: standard deviation n=3 (All values expressed on dry weight basis). Nd: Not detected

Based on this research, it can be deduced that our samples contain three different groups of chemical components, some of which are major, minor, and trace. The components found in the studied plants can be grouped into three categories based on their biological properties:

- 1) Essential elements and nutrients: Ca; Fe; Na ; Zn ; Cr ; Mg ; Mn ; Co; Cr.
- 2) Potentially toxic elements in the top-down content model such as Pb; Cd.
- 3) The remaining chemical elements are non-essential.

V.2.2. Evaluation of Results and Quality – Quality Assurance / Control (QC / QA)

The results of the mineral compounds in the plants analyzed were validated using the following standards: NIST-SRM 1570a, WEPAL-IPE 172 and WEPAL-IPE 189 irradiated simultaneously with the samples studied. This methodology enables us to evaluate the effectiveness of the analyses and the relevance of the results obtained on the other hand and to validate the entire analytical procedure employed in this study, from sample preparation through irradiation and measurement. Table.V.4 to Table.V.6 provides an overview of these latter items. Note that the statistical parameters for evaluating the results acquired by U-score and Z-score were computed for the QC/QA concept by equations III.2 and III.3 respectively (Prat 2: Chapter III). Their assessments indicate that the majority of concentration values are located in the allowable ranges: $\leq |1|$, and $\leq |3|$ U-score and Z-score parameters, respectively.

Table.V.4. Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of NIST-SRM 1570a; values express means \pm standard error (n = 3).

Elements mg/kg	NIST-SRM 1570a			
	measured values	certified values	U- score	Z- Score
Ba	-	-	-	-
Br	-	-	-	-
Ca	15128 \pm 0.2	15260 \pm 66	0.07	1.99
Co	0.394 \pm 0.078	0.393 \pm 0.03	0.01	0.03
Cr	-	-	-	-
Cs	-	-	-	-
Fe	-	-	-	-
K	28511 \pm 500	29000 \pm 260	0.87	1.88
Na	17600 \pm 0.12	18210 \pm 230	0.5	2.65
Rb	12.45 \pm 0.985	12.7 \pm 1.6	0.13	0.15
Sb	-	-	-	-
Sr	54.54 \pm 4.66	55.54 \pm 0.5	0.21	1.99
Zn	82.65 \pm 5.68	82.3 \pm 3.9	0.05	0.09

(-): not reported

Table.V.5. Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of WEPAL-IPE 172 ; values express means \pm standard error (n = 3).

Elements mg/kg	WEPAL-IPE 172			
	measured values	certified values	U- Score	Z- Score
Ba	17.62 \pm 2.37	16.4 \pm 0.99	0.48	1.24
Br	1.763 \pm 0.361	2.1 \pm 1.265	0.26	0.27
Ca	-	-	-	-
Co	17.62 \pm 2.37	16.4 \pm 0.99	0.48	1.24
Cr	1.763 \pm 0.361	2.1 \pm 1.265	0.26	0.27
Cs	17.62 \pm 2.37	16.4 \pm 0.99	0.48	1.24
Fe	67.84 \pm 6.51	64.4 \pm 6.55	0.37	0.53
K	-	-	-	-
Na	-	-	-	-
Rb	8.763 \pm 1.167	9.07 \pm 0.536	0.23	0.56
Sb	0.0372 \pm 0.0105	0.0482 \pm 0.005	0.92	2.03
Sr	43.77 \pm 3.14	42.2 \pm 2.11	0.42	0.75
Zn	33.21 \pm 2.31	31.6 \pm 2.19	0.51	0.74

(-): not reported

Table.V.6. Assessment of the quality of the analytical results based on the comparison between the calculated and certified values in standard reference of WEPAL-IPE 189; values express means \pm standard error (n = 3).

Elements mg/kg	WEPAL-IPE 189			
	measured values	certified values	U-Score	Z-score
Ba	74.52 \pm 9.518	80.1 \pm 5.96	0.5	0.94
Br	48.34 \pm 29.64	40.6 \pm 6.9	0.25	1.12
Ca	6346.5 \pm 30.2	6730 \pm 402	0.95	0.95
Co	0.0775 \pm 0.0159	0.0789 \pm 0.0132	0.06	0.1
Cr	0.919 \pm 0.267	1.18 \pm 0.228	0.74	1.14
Cs	0.0903 \pm 0.0236	0.089 \pm 0.0157	0.04	0.07
Fe	104.4 \pm 12.8	110 \pm 7.4	0.38	0.76
K	36500.4 \pm 4213.1	37100 \pm 2160	0.13	0.28
Na	-	-	-	-
Rb	7.91 \pm 0.59	7.5 \pm 0.501	0.52	0.82
Sb	0.013 \pm 0.007	0.0095 \pm 0.0019	0.5	1.88
Sr	-	-	-	-
Zn	19.12 \pm 1.39	20.1 \pm 1.32	0.51	0.74

(-): not reported

V.2.3. Assessment of dietary intake of trace elements according to the RDA

The Recommended dietary allowances (RDA) are determined using scientific evidence to establish the minimum and maximum amounts of nutrients a human needs to maintain optimal health [356]. Macronutrients and micronutrients, often known as trace elements, compose the majority of the mineral elements required in the body's metabolism. These can be divided into three groups based on their nutritional value:

- Essential trace elements, also called micronutrients, are parts of hormones, vitamins, and catalysts for the enzymatic systems of the metabolic process inside cells.
- The mainly essential elements.
- Toxic and non-toxic elements that have no metabolic function in a living organism make up the non-essential trace elements [357].

From a nutritional perspective, there is a growing interest in determining the levels of macro-elements and oligo-elements in foods like calcium, iron, potassium, sodium, selenium, and zinc, all of which play a significant role in human health. Furthermore, one of the most important sources of toxic elements for the human body is its consumption of unhealthy foods and drinkable water. In light of this, it must be careful monitoring of their intake.

Plants used for medicinal purposes can be an excellent source of several essential elements. On the other hand, the amount of consumption must be carefully controlled and monitored. In the case of the investigated plants, the values for daily intake and average intake per person for essential and toxic elements must be controlled.

In this study, the amounts of some essential or toxic elements were determined by calculating the assumption that a person consumes 10 g (dry weight) per person. The recommended nutrient intake values are listed in Table.V.7, along with the recommended daily requirement/tolerance limits and the estimated values.

Table.V.7. Intake values (mg/day, person) of certain essential elements and tolerable daily intake for adults (70 kg) (Tolerable Daily Intake) of certain toxic elements according to the food and agricultural organization (FAO/WHO; 2011).

Plants studied; Person-age	RDA and AI of essential chemical elements									TDI (70 kg adult (BW)) of potentially toxic chemicals		
	Ca* (mg/day)	Na ^a (mg/day)	Fe* (mg/day)	Mg* (mg/day)	Se* (µg/day)	Mn ^a (mg/day)	Mo* (µg/day)	Zn* (mg/day)	Cr* (µg/day)	Pb (mg/day/person)	Cd (µg/day/person)	Br (mg/day/person)
<i>A.campestris</i> L.	105.38	2.98	11.81	9.90	1.68	0.41	2.9	0.47	10.83	0.06	0.988	0.16
<i>F.bruguieri</i> DC.	Nd	7.62	4.90	9.33	3.24	0.09	4.9	0.38	Nd	0.05	0.999	0.85
Children 1–3 years	600	1000	9	50	20	1.2	17	5	11	Nd	Nd	Nd
Men 19-50 years	600	1500	17	340	55	2.3	45	12	35	0.3	60	70
Women 19-50 years	600	1500	21	310	55	1.6	45	10	25	0.3	60	70
Pregnant women 19-50 years	1200	1500	35	310	60	2.0	50	12	30	0.3	60	70
Lactation 19-50 years	1200	1500	21	310	70	2.6	50	12	45	0.3	60	70

*RDA: Recommended daily allowance, expressed in mg/day per person for adult men. All values are expressed on the dry weight. Nd: Not determined.

^aAI: Adequate intake, expressed in mg/day, per person for adult men and women).

As a preliminary observation, the assessment of the probable intake values for consumption of these samples reveals that the levels of toxic elements are lower than the reference toxicological values (Figure.V.1 and Figure.V.2). This was determined by comparing the levels of toxic elements to the reference toxicological values [358]. They were discovered to conform with

dietary recommendations, with the exception of iron, when they consumed 10 grams per day of the plant *A.campestris* L. According to the findings, the average daily consumption of iron is higher than the amount advised for Children 1–3 years (9 mg/day) [359].

Regarding the remaining essential components, each one is well below the permissible limits recommended by the WHO/FAO commission. It is important to note that the amount of toxic elements present is significantly lower than the reference toxicological values and agrees with the nutritional recommendations[358] (Table.V.7).




Figure.V.1. Comparison between measured values and the limit tolerance of essential elements.




Figure.V.2. Comparison between measured values and the Tolerable Daily Intake of toxic elements.

According to the World Health Organization, traditional herbal treatments are natural substances used to cure and alleviate a wide range of diseases [360]. Monitoring the mineral content of medicinal plants is considered one of the most critical aspects of safety before evaluating pharmaceutical use. This report provides the content of mineral concentrations found in the aerial part of the two plants studied and assesses the potential risks that these concentrations represent to human health.

There is currently no research available at this time concerning the multi-element content (mineral compounds) of the plants *A.campestris* L. and *F.bruguieri* DC. This research tries to fill this gap by utilizing the ICP-OES and Instrumental Neutron Activation Analysis (INAA) techniques to provide scientific evidence on the mineral composition of *A.campestris* L. and *F.bruguieri* DC., as well as their elemental concentrations.

Description and inputs of essential trace elements for the human body:

- **Calcium:** Ca is the only mineral most abundant in the human body, with approximately 1 to 1.2 kilograms in adults. The main function of this element is building and renewing the skeleton. Indeed, 99% of calcium contributes to the formation and strength of bones and teeth [361]. In this investigation, the amounts of calcium were found to have a level

of 10538.1 mg/kg in *A. campestris* L., on the other hand, *F.bruguieri* DC. shows no evidence of the presence of Ca. In contrast, the *A. campestris* L. plant is calcium-rich. A daily dose of 10 grams of this plant provides 105.38 mg of calcium/per person, recommended by the World Health Organization WHO [359].

- **Chromium:** Cr is an oligo-element that plays a significant role in the body's operation. Its principal function is to control insulin secretion by the pancreas, which allows for stable levels of blood sugar to be maintained (blood sugar) [362]. The concentration of Cr in the plant *A. campestris* L. measures 1.083 mg/kg in content. It is necessary to mention that the plant *F.bruguieri* DC. does not detect even a trace of Cr; hence it is regarded as Cr poor. When consuming the plant *A. campestris* L., the WHO/FAO recommended RDA value must be considered [359].
- **Iron:** Fe is one of the essential oligo-elements for blood; therefore, it is important to consume iron daily. It is involved in many physiological functions. As a constituent of hemoglobin and the red pigment found in blood cells, it plays a role in various tasks crucial to the body's physiology. One of these functions is the transportation and storage of oxygen in the blood [363]. The iron concentrations in the plants examined ranged from 490.7 to 1181.8 mg/kg; according to the results of the analyses carried out on the plants, *A. campestris* L. has the highest concentration of iron, whereas the plant *F.bruguieri* DC. has the lowest concentration of iron. The Joint Committee on Food and Agriculture (FAW) and the World Health Organization (WHO) recommend that an individual's iron consumption should not exceed safe limits, even though iron is essential to human health . The recommended daily dose of *A. campestris* L. is less than 9 mg to reduce or eliminate the risk of iron toxicity [359].
- **Zinc:** Zn is an essential trace element for human health. It is involved in many enzyme reactions and plays a critical role in immune function [364]. The zinc (Zn) contents in the investigated plants ranged from 38.12 to 47.07 mg/kg. The plant *A. campestris* L. has the highest concentration, while the species *F.bruguieri* DC. has the lowest concentration. This nutritional intake is much less critical than that recommended by the DRA (5-12 mg/ day) [359].
- **Molybdenum:** Mo is also an essential oligo-element in the body. It is The key organs responsible for its storage are the liver as well as the kidneys and it found in minimal amounts in the body, Insufficiency of Mo in the body leads to dysfunction in the liver, in addition to dental problems and inflammation of a tooth [365]. The results of this analysis demonstrated that the concentrations of molybdenum (Mo) ranged from 0.29

to 0.498 mg/kg. The *A. campestris* L. plant contained the lowest concentrations of the chemical under inquiry.

- **Manganese:** Mn is one of the essential oligo-elements, non-synthetic by the body. It contributes to the process through which our body metabolizes lipids and carbohydrates. In addition to these benefits, it helps regulate blood sugar levels and fights free radicals [366]. In contrast, When present in excessive concentrations, it becomes toxic. The human body has approximately 20 mg of manganese, primarily distributed in the bones, liver, and kidneys [367]. This study's manganese concentrations range from 9.25 to 41.06 mg/kg. The lowest and highest concentrations are for plant *A. campestris* L. and plant *F.bruguieri* DC., respectively.
- **Magnesium:** Mg is an essential mineral for many human body functions. However, it is best known for preserving nervous and muscular balance. Mg is a cofactor in more than three hundred enzyme activities necessary for physiological function [368]. According to our research findings, magnesium levels vary from 933.8 to 990.7 mg/kg. The magnesium concentrations of both *A.campestris* L. and *F.bruguieri* DC. are nearly the same, and both are excellent sources of magnesium.
- **Sodium:** The crust of the Earth contains a total of 2.83% sodium in its many forms, which makes sodium the sixth most prevalent element on the planet [369]. Seawater, salt lakes, alkali lakes, and mineral spring waters all contain trace amounts of sodium salts. The levels of Na that were recorded throughout this research ranged from 299.41 to 762.55 mg/kg. The *A.campestris* L. plant has the least amount of concentration. The largest concentration of sodium is found in the *F.bruguieri* DC. plant.
- **Cobalt:** Co is a necessary element for human health. It owes its crucial feature as a central binding atom to vitamin B12 (also known as cobalamin), which is required for folate and fatty acid metabolism. Vitamin B12, which contains cobalt, is a potent tool against anemia and iron deficiency in the blood. However, high levels of Co can have very adverse health effects [370, 371]. Co values ranged from 0.89 to 1.28 mg/kg in our study. *A. campestris* L. has the most cobalt and *F.bruguieri* DC. The least concentration (Table.V.7). The recommended dietary allowance for cobalt has not been established because vitamin B12 is the only form in which it can be found. Adults in the United Kingdom were recommended to consume 2.4 µg per day of vitamin B12, pregnant women were recommended to consume 2.6 µg per day, and lactating women were recommended to have 2.8 µg per day [359].

According to the results of the experiments, the following is the order in which the other mineral concentrations were found in *A. campestris* L.: Cu (70.22 mg/Kg) > Li (46.6 mg/Kg) > Sr (23.93 mg/Kg) > Ti (20.38 mg/Kg) > Ni (2.75 mg/Kg) and for *F.bruguieri* DC. The concentration of the other mineral decreased in the order: Sr (168.55 mg/Kg) > Cu (37.81 mg/Kg) > Li (25.5 mg/Kg) > Ti (6.26 mg/Kg) > Ni (1.690 mg/Kg).

A.campestris L. and *F.bruguieri* DC. showed Cu content (70.22; 37.81 mg/Kg, respectively) outside the WHO permissible limits. The maximum allowable level of copper in fruit samples, according to FAO/WHO, is 4.5 mg/kg [372]. Although the plant is typically taken in lower quantities, there is still a potential for overexposure to Cu. Therefore it is important for people that consume *A. campestris* L. or *F.bruguieri* DC. to take that into consideration.

V.2.5. Potentially toxic elements and tolerable daily intake (TDI)

Considerable research has focused on toxicological concerns and the adverse effect that trace metals have on human health. Adopting maximum acceptable limits for their daily consumption can have negative health effects. Among these toxic chemicals harmful to human health are lead (Pb), (Br) brom, and cadmium (Cd). Table.V.7 shows that these potentially toxic elements (Pb, Br and Cd) are present at trace levels, as are the remaining non-essential chemical elements [358, 359].

✚ To validate the outcomes of our attempts, we analyzed the following reference standards : NIST-SRM 1570a, WEPAL-IPE 172, and WEPAL-IPE 189.

For this type of analysis, the judicious choice of these standards and conditions of irradiation, decay, and measurement would unquestionably increase the quality of the results. U-score and Z-score are two statistical parameters commonly used in this context, along with comparisons to certified, calculated findings from these standards.

The U-score evaluation considers both the measurement uncertainties and the uncertainty of the value that was found. Nevertheless, in the case of the Z-score, the measurement's uncertainty is not considered in the performance evaluation. In contrast, the approach's performance is significantly improved when the U-score is used.

In these contexts, we observe that the calculated values match the verified values for the majority of the analyzed elements. According to the statistical evaluation parameters, the results obtained can be interpreted as satisfactory from an analysis perspective. The values of the Z-

score and U-score statistical parameters reveal that CRM validation is the most recommended approach in ISO17025:2005. Most elements have close calculated and certified values.

V.3. Quantitative analysis of phenolic compounds by High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV)

The chemical profiles of *A. campestris* L. and *F. bruguieri* DC. extracts are examined by HPLC-UV/Vis analysis shown from Figure.V.3 to Figures.V.12, respectively. Table.V.8 and Table.V.9 illustrate the quantitative concentrations of different phenolic compounds present in *A. campestris* L. and *F. bruguieri* DC., respectively. Identified compounds in *A. campestris* L. extracts were mainly flavonoids and phenolic acids: Gallic Acid, Chlorogenic Acid, and Vanillic Acid. Caffeic Acid, Vanillin, p-Coumaric Acid, Rutin, Naringin, and Quercetin, respectively. While for *F. bruguieri* DC. The predominantly phenolic compounds present were: Chlorogenic Acid, Vanillin and Caffeic Acid.

Artemisia .campestris L.

Table.V.8. Identification and quantification of phenolic compounds in *A. campestris* L. extracts by HPLC analysis.

Compounds	AcME	AcPEE	AcDE	AcEAE	AcBE	AcAE
	µg/g ^a	µg/g ^a	µg/g ^a	µg/g ^a	µg/g ^a	µg/g ^a
Gallic Acid	1334.055	Nd	278.442	802.691	3154.304	1334.055
Chlorogenic Acid	Nd	117.585	39204.708	235792.291	13226.078	16142.949
Vanillic Acid	545.453	Nd	2344.484	21345.290	1626.680	545.453
Caffeic Acid	899.929	Nd	11863.529	57950.598	782.706	647.164
Vanillin	1033.090	20.151	53735.058	29910.325	29.976	92.957
p-Coumaric Acid	772.620	22.229	40586.604	23532.508	5514.425	772.620
Rutin	9563.946	167.193	45582.77	722742.147	2681.402	1597.944
Naringin	66.334	Nd	28051.266	40755.792	11334.485	66.334
Quercetin	Nd	Nd	84370.322	Nd	Nd	38023.359

^a **Concentration:** µg/g, **Nd:** Not Detected.




Figure.V.3. Phenolic compounds content identified by HPLC chromatogram in AcME. Detected Constituents are: GA: Gallic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.




Figure.V.4. Phenolic compounds content identified HPLC chromatogram in AcPEE. Detected compounds are: CGA: Chlorogenic Acid; V: Vanillin; p-CA: p-Coumaric Acid and RU: Rutin.




Figure.V.5. Phenolic compounds content identified by HPLC chromatogram in AcDE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin; NAR: Naringin and QC: Quercetin.




Figure.V.6. Phenolic compounds content identified by HPLC chromatogram in AcEAE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.




Figure.V.7. Phenolic compounds content identified by HPLC chromatogram in AcBE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin and NAR: Naringin.





Figure.V.8. Phenolic compounds content identified by HPLC chromatogram in AcAE. Detected compounds are: GA: Gallic Acid; CGA: Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; RU: Rutin; NAR: Naringin and QC—Quercetin.

Fagonia bruguieri DC.**Table.V.9.** Identification and quantification of phenolic compounds in *F.bruguieri* DC. extracts by HPLC analysis.

Compounds	FbDE	FbEAE	FbBE	FbAE
	$\mu\text{g/g}^a$	$\mu\text{g/g}^a$	$\mu\text{g/g}^a$	$\mu\text{g/g}^a$
Gallic Acid	36.319	6069.119	443.929	Nd
Chlorogenic Acid	39204.708	16744.195	11546.326	506.254
Vanilic Acid	314.296	2120.357	3843.992	Nd
Caffeic Acid	2364.374	4427.20	12138.486	941.260
Vanillin	2884.439	4793.101	13234.030	880.688
p-Coumaric Acid	Nd	4469.027	88.332	Nd
Rutin	7486.977	19288.402	Nd	3016.557
Naringin	8906.54	10997.703	24190.309	Nd
Quercetin	Nd	2533.959	38023.359	Nd

^a Concentration: $\mu\text{g/g}$, Nd: Not Detected.**Figure.V.9.** Phenolic compounds content identified by HPLC chromatogram in FbDE. Detected compounds are: GA: Gallic Acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid. and NAR: Naringin.




Figure.V.10. Phenolic compounds content identified by HPLC chromatogram in FbEAE. Detected compounds are: GA: Gallic acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid; NAR: Naringin and QC: Quercetin.




Figure.V.11. Phenolic compounds content identified by HPLC chromatogram in FbBE. Detected compounds are: GA: Gallic Acid; CGA : Chlorogenic Acid; VA: Vanillic Acid; CA: Caffeic Acid; V: Vanillin; p-CA: p-Coumaric Acid and NAR: Naringin.




Figure.V.12. Phenolic compounds content identified HPLC chromatogram in FbAE. Detected compounds are: CGA : Chlorogenic Acid; CA: Caffeic Acid; p-CA: p-Coumaric Acid and RU: Rutin.

In order to characterize the chemical components that medicinal plants contain, emergence analysis techniques were specifically designed to perform chemical analysis.

According to the HPLC- UV/Vis profile of *A. campestris* L. extracts, the most abundant compounds in terms of flavonoids and phenolic acids were AcEAE and AcDE (Table.V.8). In contrast to the above, the AcEAE contained a high amount of Chlorogenic Acid, Vanillic Acid, Caffeic Acid, Rutin, and Naringin (235792.291, 21345.290, 57950.598, 722742.147, 40755.792 $\mu\text{g/g}$, respectively). In terms of flavonoids, AcDE exhibited an interesting amount of Vanillin, p-Coumaric Acid, and Quercetin (53735.058, 40586.604, and 84370.322 $\mu\text{g/g}$, respectively) were the flavonoids identified in the AcDE in the greatest abundance.

Interestingly, Gallic Acid was prominent in the AcBE (3154.304 $\mu\text{g/g}$). On the other hand, the flavonoids and phenolic acids identified in the AcBE, AcME, and AcAE were present in a concentration that was considered to be medium. The AcPEE was poor in flavonoids and phenolic acid constituents, and it contained only a minimum of Chlorogenic Acid, Vanillin, p-Coumaric Acid, and Rutin (117.585; 20.151; 22.229 and 167.193 $\mu\text{g/g}$, respectively).

Based on the HPLC-UV/Vis profiling of *F. bruguieri* DC. extracts, the compounds with the highest concentration of flavonoids and phenolic acids are classified as FbBE and FbEAE, respectively (Table.V.9). Compared to those above, the FbBE has a significant amount of Vanillic Acid, Caffeic Acid, Vanillin, Naringin, and Quercetin (3843.992, 12138.486, 13234.030, 24190.309, 38023.359 $\mu\text{g/g}$, respectively). Gallic Acid (6069.119 $\mu\text{g/g}$) and p-Coumaric Acid (4469.027 $\mu\text{g/g}$) were abundant in FbEAE with regards to phenolic acid concentration, where the phenolic acid identified in the FbEAE in the greatest abundance. While the flavonoids Rutin identified in the FbEAE (19288.402 $\mu\text{g/g}$) in the greatest abundance. Chlorogenic Acid (39204.708 $\mu\text{g/g}$) was remarkably abundant in the FbDE. On the contrary, the concentration of flavonoids and phenolic acids detected in FbDE was regarded as moderate. Minimal phenolic acids and flavonoids were found in the FbAE; Chlorogenic Acid, Caffeic Acid, Vanillin, and Rutin (506.254, 941.260, 880.688, 3016.557 $\mu\text{g/g}$, respectively).



V.4. Quantitative analysis of phenolic compounds by high-performance liquid chromatography coupled to tandem mass spectrophotometry (LC-MS/MS)

Following optimization of the UPLC-ESI-MS-MS conditions, analysis of AcDE; AcEAE; AcBE; FbDE; FbEAE and FbBE were performed in full scan with negative and positive ions mode. The UPLC-ESI-MS-MS and mass spectra of the compounds identified from the various extracts of *A. campestris* L. and *F. bruguieri* DC. are shown in Figure.V.13 and Figure.V.15, respectively. Table.V.10 and Table.V.10 provides the retention times (Rt), mass to charge ratios (m/z), and chemical formulas of substances that have been proposed based on data that has been previously identified in the genus *Artemisia* and *Fagonia*, respectively.

Artemisia campestris L.**Table.V.10.** Phenolic profile determined by LC-MS-MS in fractions from *A.campestris* compared with literature (retention time (Rt), not identify (NI)).

Extract	t_R (min)	Ionisati on mode (m/z)	m/z	Tentatively identified compound	Molecular formula	Ref
AcDE	0.645					
AcEAE	0.627	[M+H] ⁺	172	NI	NI	-
AcBE	0.646					
AcDE	0.983					
AcEAE	0.986	[M+H] ⁺	481	15-O- β -D-glucopyranosyl- 11 β ,13-dihydro urospermal A	C ₂₁ H ₃₀ O ₁₀	[373]
AcBE	0.987	[M+H] ⁺	437	NI	NI	-
AcEAE	1.629	[M+H] ⁺	365	NI	NI	-
AcDE	1.998					
AcEAE	1.764	[M+H] ⁻	353	5-O-caffeoylquinic acid	C ₁₆ H ₁₈ O ₉	[374]
AcBE	1.995					
AcDE	2.564					
AcEAE	2.144	[M+H] ⁺	381	NI	NI	-
AcBE	2.568					
AcDE	41.787					
AcEAE	41.831	[M+H] ⁺	331	Jaceosidin	C ₁₇ H ₁₄ O ₇	[375]
AcBE	41.805					
AcDE	43.128					
AcEAE	43.130	[M+H] ⁺	367	NI	NI	-
AcBE	43.083					
AcDE	44.107					
AcEAE	44.133	[M+H] ⁺	447	Pelargonidin-3-O-glucuronide	C ₂₁ H ₁₉ O ₁₁	[376]
AcBE	44.115					
AcDE	47.738					
AcEAE	47.771	[M+H] ⁺	449	Cyanidin-3-O-glucoside	C ₂₁ H ₂₀ O ₁₁	[376]

AcDE	52.406					
AcEAE	52.432	[M+H] ⁺	413	Arteminin B	C ₂₁ H ₁₆ O ₉	[377]
AcBE	52.427					
AcBE	47.747	[M+H] ⁺	493	Malvidin 3-O-glucoside	C ₂₃ H ₂₅ ClO ₁₂	[376]
AcDE	0.978					
AcEAE	0.974	[M-H] ⁻	239	NI	NI	-
AcBE	0.970					
AcDE	1.600					
AcBE	1.597	[M-H] ⁻	369	NI	NI	-
AcDE	1.854					
AcEAE	1.646	[M-H] ⁻	339	Esculetin-6-O-glucoside	C ₁₅ H ₁₆ O ₉	[378]
AcBE	1.871					
AcDE	2.387					
AcEAE	2.134	[M-H] ⁻	403	NI	NI	-
AcBE	2.565					
AcEAE	0.218	[M-H] ⁻	453	3-hydroxyphloretin 6'-O-hexoside	C ₂₁ H ₂₄ O ₁₁	[375]
AcDE	45.530					
AcBE	45.522	[M-H] ⁻	269	Apigenin	C ₁₅ H ₁₀ O ₅	[379]
AcDE	46.137					
AcEAE	46.135	[M-H] ⁻	283	Acacetin	C ₁₆ H ₁₂ O ₅	[380]
AcBE	46.112					
AcEAE	3.552	[M-H] ⁻	198	NI	NI	-










Figure.V.13. Total ion current (TIC) profile of AcDE (A) AcEAE (B) and AcBE (C).






Figure.V.14. Mass spectra of detected compounds from *A. campestris* L. extracts.

The outcomes of LC-MS-MS analysis based phytochemical investigation on the aerial parts of AcDE, AcEAE, and AcBE (Table.V.10) conducted to the tentative identification of 11 compounds Figure.V.14. Flavonoids make up the vast majority of these molecules, which can be found in the various extracts of *A.campestris* L. Flavonoids were present as flavones, including Apigenin [379], Acacetin [380], and Jaceosidin (trihydroxy-3, 6-dimethoxyflavone) [375]. Recently, Carazzone *et al.*, reported Cyanidin 3-O-galactoside, Pelargonidin-3-O-glucuronide and Malvidin 3-O-glucoside in *Cichorium intybus*, a species from the family Asteraceae[376], which were determined based on their m/z values (Table.V.10). These three anthocyanidins have m/z values of 449 (AcDE, AcBE), 447 (AcDE, AcEAE, AcBE) and 493



(AcBE), respectively. Full scan and MS spectra of AcDE, AcEAE, and AcBE confirmed the presence of derivative coumarins in all three fractions: 3-hydroxy-6'-dimethoxy-7-(6'-methoxy-7'-coumarinyloxy) coumarin (Arteminorin B); produced protonated molecular ions at 413 m/z . This compound was found in *Artemisia minor* and its identity was verified to be bicoumarin by He *et al.*, [377]. In addition to a $[M-H]^-$ ion at 339 m/z , which was assigned as Esculetin-6-O-glucoside [378]. Moreover, AcDE, AcEAE, and AcBE chromatograms revealed consistency at m/z 353 in the negative ion mode, which led to the tentative identification of quinic acid derivative as 5-O-caffeoylquinic acid [374]. The dihydrochalcone derivative that was identified in AcEAE gave a positive ionisation at m/z 453; therefore, 3-hydroxyphloretin 6'-O-hexoside was proposed to be the identity of the compound [375].

Fagonia bruguieri DC.

Table.V.11. Phenolic profile determined by LC-MS-MS in fractions from *F. bruguieri* DC. compared with literature (retention time (Rt), not identified (NI)).

Extract	t_R (min)	Ionisation mode (m/z)	m/z	Tentatively identified compound	Molecular formula	Ref
FbBE	1.019	$[M+H]^+$	351	Andrographolide	$C_{20}H_{30}O_5$	[381]
FbDE	47.769	$[M+H]^+$	449	Kaempferol-7-O-glucoside	$C_{21}H_{20}O_{11}$	[382]
						[383]
FbBE	52.183	$[M+H]^+$	317	Isorhamnetin	$C_{16}H_{12}O_7$	[382] [383] [384]
FbBE	1.397	$[M+H]^+$	353	3-caffeoylquinic acid	$C_{16}H_{17}O_9$	[384]
FbDE	0.633					
FbEAE	0.477	$[M+H]^+$	171	NI	NI	-
FbBE	0.549					
FbBE	1.690	$[M+H]^+$	382	Atricarpan D	$C_{23}H_{26}O_5$	[385]

FbDE	28.306	[M+H] ⁺	205	NI	NI	-
FbEAE	2.176	[M-H] ⁻	393	Xanthoangelol	C ₂₅ H ₂₈ O ₄	[386]
FbEAE	43.007	[M-H] ⁻	443	5-Methoxy- podophyllotoxin	C ₂₃ H ₂₄ O ₉	[381]
FbDE	52.450					
FbEAE	51.076	[M-H] ⁻	413	Podophyllotoxin	C ₂₂ H ₂₂ O ₈	[381]
FbBE	1.943					
FbEAE	51.461	[M-H] ⁻	610	Herbacetin 8-rutinoside	C ₂₇ H ₃₀ O ₁₆	[382] [383]
FbEAE	46.504	[M-H] ⁻	577	Isovitexin 2''- O-rhamnoside	C ₂₇ H ₃₀ O ₁₄	[387]
FbDE	48.088					
FbEAE	48.120	[M-H] ⁻	306	Epigallocatechin	C ₁₅ H ₁₄ O ₇	[388]
FbBE	48.117					
FbDE	42.901					
FbEAE	42.866	[M-H] ⁻	911	Oleanolic acid-3-O-β-D-glucopyranosyl-(1→3)-[(β-D-glucopyranosyl- (1→2))-α-L-arabinopyranoside	C ₄₇ H ₇₆ O ₁₇	[389] [232]
FbBE	42.869					
FbDE	40.064					[390]
FbEAE	40.048	[M-H] ⁻	541	Feruloyl N-tryptophan hexoside	-	[391]










Figure.V.15. Total ion current (TIC) profile of FbDE (A) FbEAE (B) and FbBE (C).






Figure.V.16. Mass spectra of detected compounds from *F. bruguieri* DC. extracts.

The findings of a phytochemical investigation based on LC-MS-MS analysis that was conducted on the aerial parts of FbDE, FbEAE, and FbBE (Table 3), led to the tentative identification of 13 constituents Figure.V.16.

To our knowledge, no previous information regarding the phenolic composition of *Fagonia bruguieri* DC. has been published. Although the phenolic composition of *Fagonia cretica* and *Fagonia indica*, particularly in plants from Pakistan origins, has only been described in a limited number of studies.

Chromatographic profiles of the plants' aerial parts are shown in Figure.V.15 and a summary of the retention times and MSn spectral data of the discovered compounds are provided in Table.V.11, together with a description of where in the various *Fagonia bruguieri* DC. extracts they can be found.

Wide varieties of metabolites were found in the different organic extracts, which may be associated with the various functions they served. Andrographolide, Atricarpan D, and 3-caffeoylquinic acid, in addition to Isorhamnetin, were exclusively identified in FbBE, whereas 5-Methoxy-podophyllotoxin was only found in FbEAE.

The preponderance of these compounds, known as flavonoids, are present in the different extracts of *F. bruguieri* DC. plant. The extracts of *F. bruguieri* DC. included four flavones, three of which were C-glycosylated flavones and one of which was a monomethoxy flavone.

An intense $[M+H]^+$ (449 m/z) ion could be seen in FbDE's full mass spectrum when measured at RT=47.7 min. Kaempferol-7-O-glucoside was determined to be the identity of this Compound through a comparison of its mass spectrometric data with published research; in fact, it has been identified in *F. cretica* by Miranda *et al.*, (2022) and Yadano Kumbi *et al.*, [383] (2019) [382]. Kaempferol-7-O-glucoside has been previously isolated in *F. microphylla* and *F. glutinosa* by Saleh al-Wakeel *et al.*, (1992) [219].

Peaks with $[M-H]^-$ ions at 577 m/z and $[M-H]^-$ ions at 610 m/z in the FbEAE chromatogram, respectively, suggested the chemical formulae $C_{27}H_{30}O_{14}$ and $C_{27}H_{30}O_{16}$, respectively. These findings led us to conclude that the compounds in the discussion were isovitexin 2'-O-rhamnoside (577 m/z) [387] and herbacetin 8-rutinoside (610 m/z) [382], [383], based on their chromatographic profiles and the molecular ions referenced in the

literature . Therefore, based on the comparison of its UV spectrum and the reported accurate masses with those obtained from another species of *Fagonia*, these peaks have been provisionally classified as O or C-glycosylated flavones.

The protonated ion $[M+H]^+$ at m/z 317 was obtained from the eluting peak in FbBE at 52.18 min. The preliminary analysis led to the identification of this chemical as Isorhamnetin. As far as we can tell, this is the first tentative identification of this monomethoxyflavone in *F. bruguieri* DC., while it has been reported in other *Fagonia* species [382-384], notably *F. indica* and *F. cretica* .

Epigallocatechin; produced deprotonated molecular ions at 306 m/z ; this molecule was identified in *Fagonia cretica*, and its identity was confirmed by Tabassum *et al.*, (2022) [388]. Full scan and MS spectra of FbDE, FbEAE, and FbBE revealed the presence of flavan 3-ol in all three fractions.

The current study was able to identify one quinic acid derivative. The protonated molecular ion $[M+H]^+$ at m/z 353, which was observed in the eluting peak's mass spectra with a retention time of 1.39 min, enabled the formula $C_{16}H_{17}O_9$ to be determined. Therefore, the identity of this compound attributed to 3-caffeoylquinic acid. This substance was previously identified in a *Zygophyllaceae* family species, *cuneifolia* L., and potentially identified in *F. bruguieri* DC. for the first time [4].

According to their MS spectra, two lignans were discovered in the aerial part of *F. bruguieri* DC. extracts. The first compounds with the attribute eluted in FbDE at 52.45 min, FbEAE at 51.07 min, and FbBE at 1.94 min had the same characteristic. In addition, the mass spectra of these compounds showed similarities in the existence of $[M-H]^-$ ions at m/z 413. On the basis of this, it has been provisionally identified as podophyllotoxin. Despite this, they are being reported for the first time in *F. bruguieri* DC.

The second lignan was detected in the FbEAE chromatogram at 43.01 min, producing a $[M-H]^-$ ion at 443 m/z . This peak's UV and full MS spectra enabled the estimation of the chemical formula, which was found to be $C_{22}H_{24}O_8$. These results are in agreement with data that had been previously reported for 5-Methoxy-podophyllotoxin [1].

The existence of feruloyl derivatives (feruloyl N-tryptophan hexoside) was confirmed by the mass spectra of peaks that eluted at 40.06 and 40.04 min in FbDE and FbEAE respectively.

These mass spectra exhibited $[M-H]^-$ ions at m/z 541. The MS spectra are in agreement with the data that was already reported for feruloyl N-tryptophan hexoside [390] [391]. According to our best knowledge, this is the first time the *Fagonia* genus has been mentioned.

In addition, the FbBE chromatogram showed consistency at m/z 393 in the negative ion mode, which led to the tentative designation of prenylated chalcones as xanthoangelol [6].

FbBE chromatogram recorded at $RT = 1.01$ min produced $[M+H]^+$ ions at m/z 351, which were used to confirm a tentative identity of Andrographolide by comparing the relevant published data [381]. It is the first time that this labdane diterpenoid has been tentatively determined to be present in this species.

At RT 1.69 min, the chromatogram of FbBE yielded $[M+H]^+$ ions at m/z 382 and was tentatively identified as Atricarpan D ($C_{23}H_{26}O_5$) based on data from Viqar Uddin Ahmad *et al.*, (2006), who isolated this pterocarpan from a BuOH extract of the whole plant of *Zygophyllum eurypterum* (Zygophyllaceae) [5].

An intense $[M-H]^-$ ion was detected in the full mass spectrum of FbDE, FbEAE, and FbBE at $RT = 42.9, 42.86,$ and 42.86 , respectively. This compound was identified as Oleanolic acid-3-O- β -D-glucopyranosyl-(1 \rightarrow 3)-[(β -D-glucopyranosyl-(1 \rightarrow 2))- α -L-arabinopyranoside (triterpenoid saponins) by comparison of its MS data with literature [389] [232]; in fact, it was previously isolated and identified in *Fagonia arabica* by Toshio Miyase *et al.*, (1995) [232].

V.5. Structural Elucidation

This part concerns the structural's elucidation of 3 compounds among the 11 isolated as part of our work. The structures of our compounds were elucidated by using the spectrophotometer RMN, mono-dimensional ($^1H, ^{13}C, DEPT$), and bi-dimensional (HSQC, COSY, and HMBC).

V.5.1. Identification of compounds isolated from of *Artemisia campestris* L. aerial parts (AcBE)

V.5.1.1. Compound I: (PN)

The compound was obtained as a brown amorphous powder soluble in the methanol. Using an acid solution and heating makes a black spot. This product is not visible under UV light.

An examination of the ^1H NMR spectrum (Figure.V.17, Figure.V.18) of this compound reveals the presence of signals only in the osidic region from δ_{H} 3.26 ppm to 5.32 ppm with intensities indicating that this compound PN is a polysaccharide, which distributed as follows:

- A doublets at $\delta_{\text{H}} = 5.30$ ppm (d, $J = 3.8$ Hz) integrated 1H attributable to H-1 proton corresponds to the anomeric proton, with a small coupling constant indicating the presence of sugar in the α configuration.
- Peaks at $\delta_{\text{H}} = 3.33$ ppm (dd, $J = 9.8; 3.8$ Hz) integrated 1H attributable to H-2 proton.
- Peaks at $\delta_{\text{H}} = 3.60$ ppm (dd, $J = 9.3; 4.3$ Hz) integrated 1H attributable to H-3 proton.
- A doublets at $\delta_{\text{H}} = 3.26$ ppm (d, $J = 9.6$ Hz) integrated 1H attributable to H-4 proton.
- Peaks at $\delta_{\text{H}} = 3.82$ ppm (d, $J = 2.4$ Hz) integrated 1H attributable to H-5 proton.
- A doublet of doublet integration at $\delta_{\text{H}} = 3.60$ ppm (dd, $J = 9.3; 4.3$ Hz) attributable to H_a-6 proton.
- A doublet of doublet signal at $\delta_{\text{H}} = 3.69$ ppm (dd, $J = 9.3, 3.1$ Hz) attributable to H_b-6 proton.
- A doublet of doublet signal at $\delta_{\text{H}} = 3.45$ ppm (dd, $J = 7.0, 2.6$ Hz) attributable to H_a-1' proton.
- A doublet integration at $\delta_{\text{H}} = 3.54$ ppm (d, $J = 8.6$ Hz) attributable to H_b-1' proton.
- Peaks at $\delta_{\text{H}} = 3.99$ ppm (d, $J = 8.2$ Hz) integrated 2H attributable to H-3' proton.
- A doublet of doublet integration at $\delta_{\text{H}} = 3.93$ ppm (dd, $J = 9; 6.7$ Hz) attributable to H-4' proton.
- A doublet of doublet signal at $\delta_{\text{H}} = 3.74$ ppm (dd, $J = 6.9; 2.0$ Hz) was attributed to H-5'.
- A doublet integration signal at $\delta_{\text{H}} = 3.66$ ppm; $J = 3.9$ Hz was attributed to H-6'.

The presence of only one anomeric proton in this polysaccharide indicates another sugar that does not contain an anomeric proton regarding the number of signals in the osidic region. Regarding its chemical shifts, we proposed that this polysaccharide contains fructose because this latter does not have an anomeric proton.




Figure.V.17. ^1H NMR spectrum of compound PN (400 MHz, Methanol- d_4).




Figure.V.18. ^1H NMR spectrum spread out (3.25-4.15 ppm) of compound PN (400 MHz, Methanol- d_4).

The ^{13}C NMR (Figure.V.19) and DEPT 135° spectrum (Figure.V.20) indicated the presence of twelve carbons, including [392]:

- Two anomeric carbons.
- Three carbons in group (CH_2) are linked to alcohol function.
- Eight carbons in group (CH) are linked to alcohol function.

The combined analysis of spectra ^{13}C RMN, and DEPT 135° reveals the presence of two sugar residues in the form of two hexoses located in the osidic region. The first hexose contains an anomeric proton at $\delta_{\text{H}} = 5.30$ ppm ($J = 3.8$ Hz), and the small coupling constant indicates the presence of a sugar of configuration α ; as a proposition, we suggest that this first hexose is the type of α -glucose.

The second sugar residue has shown the characteristic signal of quaternary carbon. We supposed that this residue could be fructose from their chemical shifts and $J_{1,2}$ (^{13}C RMN, and DEPT 135°).




Figure.V.19. ^{13}C NMR Spectrum of compound PN (Methanol- d_4 , 100 MHz).




Figure.V.20. DEPT 135 ° Spectrum of compound PN (Methanol-*d*4, 100 MHz).

In the HMBC experiment (Figure.V.21), the connectivity was observed from correlation between H-1_a ($\delta_{\text{H}} = 5.30$ ppm) with a coupling constant (3.8 Hz) and C-2 carbon ($\delta_{\text{C}} 71.81$ ppm) as well as another correlation with C-3 ($\delta_{\text{C}} 73.22$ ppm), respectively. The identified C-3 also shows a correlation spot with proton resonant at 3.26 ppm (d, $J = 9.1$ Hz), corresponding to H-4. This last show a correlation with carbon resonant at 72.24 ppm attributable to C-5.




Figure.V.21. HMBC spectrum spread out of the first hexose.




Figure.V.22. The HMBC correlations of the first hexose.

By examining the complete analyses HSQC spectrum (Figure.V.23) of this hexose, it is feasible to identify the corresponding protons and carbons:

- C-1 to δ_C 92.28 ppm due to its correlation with H-1 (d, $J= 3.8$ Hz).
- C-2 to δ_C 71.81 ppm due to its correlation with H-2 (dd, $J= 9.8; 3.8$ Hz).
- C-3 to δ_C 73.22 ppm due to its correlation with H-3 (dd, $J= 9.3; 4.3$ Hz).
- C-4 to δ_C 70.00 ppm due to its correlation with H-4 (d, $J= 9.6$ Hz).
- C-5 to δ_C 72.24 ppm due to its correlation with H-5 (d, $J= 2.4$ Hz) .
- C-6 to δ_C 60.84 ppm due to its correlation with H-6_a (dd, $J= 9.3; 4.3$ Hz) and H-6_b (dd, $J= 9.3; 3.1$ Hz).

The full chemical shift assignment of all the protons and carbons in this hexose and the coupling constants measured are in full agreement with those reported in the literature. Thus deduced to be α -glucose.




Figure.V.23. HSQC spectrum spread out of first hexose.

The HMBC spectrum has allowed to assign the position of quaternary carbon C-2' of the second hexose, the spectrum shows correlations between the protons $H_b -1'$ ($\delta_H = 3.54$ ppm (d, $J = 8.6$ Hz), and the quaternary carbon resonating at $\delta_C = 103.94$ ppm, thus attributable to the C-2' position. In the same spot of this $H_b -1'$ which also shows correlations with H-3' protons, to allocate the carbons C-1' and C-3' respectively, resonant at δ_C 62.67 and 78.05 ppm respectively. The proton H-6', resonant at $\delta_H = 3.66$ ppm in form doublet integration therefore attributable to the C-6' ($\delta_C = 61.99$) position, which shows correlations with C-5' resonant at δ_C 82.39 ppm in HMBC spectrum. Moreover, the same spectrum shows a correlation spot between proton H-3' and C-4' at $\delta_C = 74.26$ ppm (Figure.V.24).




Figure.V.24. HMBC spectrum spread out of the second hexose.




Figure.V.25. The HMBC correlations of the second hexose.

The HSQC spectrum gives the following additional clues (Figure.V.26):

- C-1' to δ_C 62.67 ppm due to its correlation with H_a-1' and H_b-1'.
- C-3' to δ_C 78.05 ppm due to its correlation with H-3'.
- C-4' to δ_C 74.35 ppm due to its correlation with H-4'.
- C-5' to δ_C 82.39 ppm due to its correlation with H-5'.
- C-6' to δ_C 61.99 ppm due to its correlation with H-6'.




Figure.V.26. HSQC spectrum spread out of second hexose.

By comparing with the literature [393], the set of these NMR spectroscopic data confirms the suggested structure of the second hexose, which is β -fructose.

Linkage of α - glucose to β -fructose was established by an HMBC experiment. A cross-peaks were observed between the anomeric proton resonant at δ_{H} 5.30 ppm with a coupling constant $J= 3.80 \text{ Hz}$ attributable to H- 1* with carbon resonant at δ_{Cq} 103.94 corresponding to C-2'. The HMBC experiment enabled the determination of the connections between sugars. Hence, alpha-glucose is linked to the O-2 of beta-fructose. The completeness of the spectroscopic data, confirmed by comparison with those in the literature and collected in the Table.V.12, led to the structure of disaccharide, it is α -D-glucopyranosyl-(1 \leftrightarrow 2)- β -D-fructofuranoside (saccharose), as shown in Figure.V.27.




Figure.V.27. Structure of α -D-glucopyranosyl-(1 \leftrightarrow 2)- β -D-fructofuranoside .

Table.V.12. ^{13}C NMR and ^1H NMR spectral data of compound PN (400 MHz, 125 MHz, Methanol- d_4).

Position	δ_{C} (ppm)	δ_{H} (ppm)	multiplicity	J (Hz)
1	92.28	5.30	d	3.8
2	71.81	3.33	dd	9.8; 3.8
3	73.22	3.60	dd	9.3; 4.3
4	70.00	3.26	d	9.6
5	72.24	3.82	d	2.4
6	60.84	H _a 3.60	dd	9.3; 4.3
		H _b 3.69	dd	9.3; 3.1
1'	62.67	H _a 3.45	dd	7.0; 2.6
		H _b 3.54	d	8.6
2'	103.94	-	-	-
3'	78.05	3.99	d	8.2
4'	74.35	3.93	dd	9; 6.7
5'	82.39	3.74	dd	6.9; 2.0
6'	61.99	3.66	d	3.9

V.5.2. Identification of compounds isolated from of *Fagonia bruguieri* DC. aerial parts (FbBE)

V.5.2.1. Compound II: Pb

The compound was obtained as a white amorphous powder soluble in the methanol. Using an acid solution and heating makes a bleu spot. This product is not visible under UV light.

The ^{13}C NMR spectrum of the compound Pb was recorded at 400 MHz in MeOH-*d*₄, as shown in Figure.V.28. This spectrum reveals multiple signals, including the following:

- $\delta_{\text{c}}=154.63$ ppm ; $\delta_{\text{c}}=104.62$ ppm ; $\delta_{\text{c}}= 134.28$ and $\delta_{\text{c}}=140.62$ ppm shows the presence of an aromatic ring.
- $\delta_{\text{c}}=130.22$ ppm et $\delta_{\text{c}}=128.58$ ppm which indicates the presence of two ethylenes (CH=CH).
- Signals: $\delta_{\text{c}}=104.15$ ppm; $\delta_{\text{c}}= 81.43$ ppm; $\delta_{\text{c}}= 76.43$ ppm; $\delta_{\text{c}}= 70.03$ ppm; $\delta_{\text{c}}= 76.96$ ppm and are present of the carbon atoms of a sugar.
- The presence of two groups of CH₂OH methylenes resonant with $\delta_{\text{c}}= 61.10$ ppm; $\delta_{\text{c}}=62.07$ ppm and a methoxyl (CHO) at $\delta_{\text{c}}=55.07$ ppm.




Figure.V.28. ^{13}C NMR Spectrum of compound Pb (100 MHz, MeOH-*d*₄).

Examination of the ^1H NMR spectrum (Figure.V.29→ Figure.V.31) of the Pb compound confirms these data by the presence of signals:

- A singlet signal with $\delta_{\text{H}} = 6.75$ ppm of 2H integration due to two equivalent protons of the aromatic nucleus ($\delta_{\text{C}} = 104.15$) points towards a tetra-substitution of this aromatic cycle.
- A doublet of doublet signal with integration of 1H at $\delta_{\text{H}} = 6.56$ ppm ($J = 14.05; 9.6$ Hz) and 1H integration triplet doublet at $\delta_{\text{H}} = 6.33$ ppm ($J = 15.8; 5.6$ Hz). The multiplicity of this signal and the values of the chemical shift and coupling constants confirm the presence of a trans-configuration double ethylene bond in this molecule and place a CH_2 group in a vicinal position relative to this ethylene CH.
- A doublet of doublets at $\delta_{\text{H}} = 4.22$ ppm ($J = 5.56; 1.47$ Hz). The values of the coupling constants indicate that this grouping is close to the previous ethylene CH. Chemical shift value indicates that this CH_2 group is oxygenated ($\delta_{\text{C}} = 62.07$).
- One singlet $\delta_{\text{H}} = 3.86$ ppm 6H integration ($\delta_{\text{C}} = 56.07$ ppm) due to two equivalent methoxyl groups, therefore, two aromatic carbon cores ($\delta_{\text{C}} = 154.63$ ppm).
- A doublet at $\delta_{\text{H}} = 4.87$ ppm ($J = 7.44$) is attributable to an anomeric proton of sugar configuration β .



Figure.V.29. ^1H NMR spectrum of compound Pb (400 MHz, Methanol- d_4).




Figure.V.30. ^1H NMR spectrum spread out (6.00-7.10 ppm) of compound Pb (400 MHz, Methanol- d_4).




Figure.V.31. ^1H NMR spectrum spread out (3.1-5.0 ppm) of compound Pb (400 MHz, Methanol- d_4).

By examining the complete analyses HSQC spectrum (Figure.V.33), it is feasible to identify the corresponding protons and carbons:

- C-7 to δ_C 130.22 ppm due to its correlation with H-7.
- C-8 to δ_C 128.58 ppm due to its correlation with H-8.
- C-9 to δ_C 62.07 ppm due to its correlation with H-9.
- C-1' to δ_C 104.18 ppm due to its correlation with H-1'.
- C-2' to δ_C 81.43 ppm due to its correlation with H-2'.
- C-3' to δ_C 76.43 ppm due to its correlation with H-3'.
- C-4' to δ_C 70.03 ppm due to its correlation with H-4'.
- C-5' to δ_C 76.96 ppm due to its correlation with H-5'.
- C-6' to δ_C 61.10 ppm due to its correlation with H-6'a and H-6'b.




Figure.V.32. HSQC spectrum spread out of compound Pb.

These correlations allow for the identification of a hexose. It's a glucose of Configuration β . Configuration assumed out from the coupling constant $J_{1'-2'} = 7.4 \text{ Hz}$.

Starting from this first identification, the other protons and carbons are gradually identified by two-dimensional experiments COSY, and HMBC.

The COSY spectrum clearly highlights the expected correlations between (Figure.V.32):

- The anomeric proton H-1' ($\delta_{\text{H}} = 4.87$; $J = 7.44$ Hz; d) and the resonant proton H-2' at $\delta_{\text{H}} = 3.48$, in multiplet form.
- The proton H-5' ($\delta_{\text{H}} = 3.23$; $J = 2.96$ Hz; d) and H-4' proton ($\delta_{\text{H}} = 3.40$; $J = 1.99$ Hz; d).
- The proton H-5' ($\delta_{\text{H}} = 3.23$; $J = 2.96$ Hz; d) and H-6_a' proton (3.78; dd; $J = 12.1$; 2.2 Hz).
- proton H-5' ($\delta_{\text{H}} = 3.23$; $J = 2.96$ Hz; d) and proton H-6_b' (3.67; dd; $J = 11.1$; 4.2 Hz).
- The proton H-4' ($\delta_{\text{H}} = 3.40$; $J = 1.99$; d) and H-3' proton ($\delta_{\text{H}} = 3.42$; $J = 1.99$; d).
- The proton H-8 (6.33; dt; $J = 15.8$; 5.6 Hz) and proton H-7 (6.56; dd; $J = 9.06$; 14.05 Hz).
- The proton H-8 and proton H-9 ($\delta_{\text{H}} = 4.22$; dd; $J = 1.47$; 5.56).




Figure.V.33. COSY spectrum spread out of compound Pb.

The analysis of the HMBC spectrum (Figure.V.34) allows for identifying additional carbons in the phenyl skeleton. Indeed, this spectrum also reveals:

- H-2 and H-3 (δ_{H} 6.75 ppm) shows two spot of correlations with
 - C-1 (δ_{C} 134.28 ppm).
 - C-3 and C-5 (δ_{C} 154.63 ppm).
- O-CH₃ (δ_{H} 3.86 ppm) shows one spot of correlations with
 - C-3/C-5 (δ_{C} 154.63 ppm).




Figure.V.34. HMBC spectrum spread out of compound Pb.

The HMBC experiment confirms the C-1 glycosylation site by observing a $^3J_{\text{C-H}}$ coupling between the anomeric proton H-1' (4.87 ppm) of glucose and C-4 carbon (140.62 ppm).




Figure.V.35. The HMBC and COSY correlations of compound Pb.

All these assignments by examining the ^1H - ^1H COSY spectrum and the HSQC spectrum confirm the previous assignments that were made by examining the NMR spectrum. All of this information leads to the structure of phenylpropanoid glycoside as shown in Figure.V.36.

The results are consistent with the Syringing data reported in the literature [394].




Figure.V.36. Structure of Syringing.

Table.V.13. ^{13}C NMR and ^1H NMR spectral data of compound Pb (400 MHz, 125 MHz, Methanol- d_4).

Position	δ_C (ppm)	δ_H (ppm)	multiplicity	J (Hz)
1	134.28	-	-	-
2	104.15	6.75	s	-
3	154.63	-	-	-
4	140.62	-	-	-
5	154.63	-	-	-
6	104.15	6.75	s	-
7	130.22	6.56	dd	9.06; 14.05
8	128.58	6.33	dt	15.8; 5.6
9	62.07	4.22	dd	5.56; 1.47
1'	104.18	4.87	d	7.44

2'	81.43	3.48	m	-	
3'	76.43	3.42	d	1.99	
4'	70.03	3.40	d	1.99	
5'	76.96	3.23	d	2.96	
6'	61.10	H _a	3.78	dd	12.1; 2.2
		H _b	3.67	dd	11.1; 4.2
(2 -OCH ₃)	56.07	3.86	s	-	

V.5.2.2. Compound III: PV2

The compound was obtained as a white amorphous powder soluble in methanol. Using an acid solution and heating makes a purple spot. This product is visible under UV light as a dark spot.

The ¹³C NMR (Figure.V.37) and DEPT 135° (Figure.V.38) spectra show the presence of the 13 carbon atoms of this molecule and allow them to be distributed in: 1 CH₂, 9 CH, and 3 Cq. This spectrum reveals multiple signals, including the following:

- $\delta_c=115.86$ ppm and $\delta_c= 130.24$ shows the presence of an aromatic ring.
- $\delta_c=163.68$ ppm which indicates the presence one carbonyl engaged in link carbonyl (C=O).
- signals: $\delta_c= 100.20$ ppm; $\delta_c= 73.40$ ppm; $\delta_c= 76.91$ ppm; $\delta_c= 69.89$ ppm; $\delta_c= 76.54$ ppm and $\delta_c= 61.05$ ppm are present of the carbon of a sugar.




Figure.V.37. ^{13}C NMR spectrum of compound PV2 (100 MHz, Methanol- d_4).




Figure.V.38. DEPT 135° spectrum of compound PV2 (100 MHz, Methanol- d_4).

The ^1H NMR spectrum (400 MHz in Methanol- d_4) (Figure.V.39) shows the presence of a tetrasubstituted aromatic core in positions 2, 6, 3, and 5. Indeed, the four aromatic protons present as follows:

- A doublet signal with $\delta_{\text{H}} = 7.88$ ppm ($J = 9.0$ Hz) of 2H integration due to two equivalent protons of the aromatic nucleus ($\delta_{\text{C}} = 130.24$).
- A doublet signal with integration of 2H at $\delta_{\text{H}} = 7.07$ ppm ($J = 9.0$ Hz) points towards a para-substituted aromatic ring.

The examination of the ^1H NMR spectrum (Figure.V.39→Figure.V.41) of this compound also reveals the presence of signals in the osidic region from δ_{H} 3.31 ppm to 4.93 ppm with intensities indicating that this sugar moiety is glucose, which distributed as follows:

- A doublets at $\delta_{\text{H}} = 4.93$ ppm (d, $J = 7.6$ Hz) integrated 1H attributable to H-1' proton corresponds to the anomeric proton, with an intense coupling constant indicating the presence of sugar in the β configuration.
- Peaks at $\delta_{\text{H}} = 3.39$ ppm (dd, $J = 6.2; 2.1$ Hz) integrated 1H attributable to H-2' proton.
- Peaks at $\delta_{\text{H}} = 3.31$ ppm (dd, $J = 6.0; 3.1$ Hz) integrated 1H attributable to H-3' proton.
- A doublets at $\delta_{\text{H}} = 3.56$ ppm (d, $J = 5.6$ Hz) integrated 1H attributable to H-4' proton.
- Peaks at $\delta_{\text{H}} = 3.39$ ppm (dd, $J = 6.2; 2.1$ Hz) integrated 1H attributable to H-5' proton.
- A doublet of doublet integration at $\delta_{\text{H}} = 3.60$ ppm (dd, $J = 12.1; 5.6$ Hz) attributable to H-6_a' proton.
- A doublet of doublet integration at $\delta_{\text{H}} = 3.80$ ppm (dd, $J = 12.0; 2.2$ Hz) attributable to H-6_b' proton.



Figure.V.39. ^1H NMR spectrum of compound PV2 (400 MHz, Methanol- d_4).




Figure.V.40. ^1H NMR spectrum spread out (6.7-8.4 ppm) of compound PV2 (400 MHz, Methanol- d_4).




Figure.V.41. ^1H NMR spectrum spread out (3.2-5.1 ppm) of compound PV2 (400 MHz, Methanol- d_4).

Starting from this first identification, the other protons and carbons are gradually identified by two-dimensional experiments HSQC, COSY, and HMBC.

By examining the complete analyses HSQC spectrum (Figure.V.42), it is feasible to identify the corresponding protons and carbons:

- C-2 to δ_{C} 130.24 ppm due to its correlation with H-2.
- C-3 to δ_{C} 115.86 ppm due to its correlation with H-3.
- C-5 to δ_{C} 115.86 ppm due to its correlation with H-5.
- C-6 to δ_{C} 130.24 ppm due to its correlation with H-6.
- C-1' to δ_{C} 100.20 ppm due to its correlation with H-1'.
- C-2' to δ_{C} 73.40 ppm due to its correlation with H-2'.
- C-3' to δ_{C} 76.91 ppm due to its correlation with H-3'.
- C-4' to δ_{C} 69.89 ppm due to its correlation with H-4'.
- C-5' to δ_{C} 76.54 ppm due to its correlation with H-5'.
- C-6' to δ_{C} 61.05 ppm due to its correlation with H_a-6' and H_b-6'.




Figure.V.42. HSQC spectrum of spread out of compound PV2.

These correlations allow for the identification of a hexose. It's a glucose of Configuration β . Configuration assumed out from the coupling constant $J_{1'-2'} = 7.4 \text{ Hz}$.

The COSY spectrum (Figure.V.43) clearly highlights the expected correlations between:

- the aromatic protons:
 - H-2,6 ($\delta_{\text{H}} = 7.88$; $J = 9 \text{ Hz}$; d) and the resonant proton H-3.5 at $\delta_{\text{H}} = 7.07$; $J = 9 \text{ Hz}$, in doublet form.
- The anomeric proton H-1' ($\delta_{\text{H}} = 4.93$; $J = 7.6 \text{ Hz}$; d) and the resonant proton H-5' at $\delta_{\text{H}} = 3.39$; $J = 6.2$; 2.1 Hz , in doublet of doublet form.
- The proton H-5' ($\delta_{\text{H}} = 3.39$; $J = 6.2$; 2.1 Hz ; dd) and H-6'a proton (3.60 ; dd; $J = 12.1$; 5.6 Hz).
- The proton H_a-6' ($\delta_{\text{H}} = 12.1$; $J = 5.6 \text{ Hz}$; dd) and proton H_b-6' (3.80 ; dd; $J = 12.0$; 2.2 Hz).
- The proton H-2' ($\delta_{\text{H}} = 3.39$; $J = 6.2$; 2.1 Hz ; dd) and H-1' proton ($\delta_{\text{H}} = 4.93$; $J = 7.6$; d).




Figure.V.43. COSY spectrum of spread out of compound PV2.

The assignments of the remaining carbons were completed by the study of the correlation spectrum heteronuclear HMBC recorded in methanol, the HMBC correlation experiment makes it to identify the H/C correlation en 2J and 3J which are:

- The carbon C-1 at $\delta_C = 133.61$ ppm correlates with H-2 and H-6 resonant at $\delta_H = 7.88$ ppm.
- The carbon C-4 at $\delta_C = 140.92$ ppm shows a correlation spots with H-1'.
- The quaternary carbon C-7 at $\delta_C = 163.68$ ppm shows a correlation spots with H-2 and H-6.

The positions for the carbonyl fonction and glucosyl moieties were confirmed by HMBC to be at C-1 and C-4, respectively (Figure.V.44).




Figure.V.44. HMBC spectrum spread out of compound PV2.




Figure.V.45. The HMBC and COSY correlations of compound PV2.

All these assignments by examining the ^1H - ^1H COSY spectrum, HMBC spectrum and the HSQC spectrum confirm the previous assignments that were made by examining the NMR spectrum. All of this information leads to the structure of di-substituted benzoic acid and glucose moieties as shown in Figure.V.46.

the new benzoic acid derivative was identified as 4-O- β -D-glucopyranosyl benzoic acid by comparison of their NMR data with those reported in the literature [395-397]. Table.V.14 summarizes all NMR spectroscopy data.




Figure.V.46. Structure of 4-*O*- β -D-glucopyranosyl benzoic acid.

Table.V.14. ^{13}C NMR and ^1H NMR spectral data of compound PV2 (400 MHz, 125 MHz, Methanol- d_4).

Position	δ_C (ppm)	δ_H (ppm)	Multiplicity	J (Hz)	
1	133.61	-	-	-	
2	130.24	7.88	d	9.0	
3	115.86	7.07	d	9.0	
4	140.92	-	-	-	
5	115.86	7.07	d	9.0	
6	130.24	7.88	d	9.0	
7	163.68	-	-	-	
1'	100.20	4.93	d	7.6	
2'	73.40	3.39	dd	6.2; 2.1	
3'	76.91	3.31	dd	6.0; 3.1	
4'	69.89	3.56	d	5.6	
5'	76.54	3.39	dd	6.2; 2.1	
6'	61.05	H _a	3.60	dd	12.1; 5.6
		H _b	3.80	dd	12.0; 2.2

*Chapter VI : results and
disscussion of Biological
Activities*

VI. Biological activities

VI.1. Total bioactive components assessment

In the current study, the amounts of bioactive components present in *A.campestris* and *F.bruguieri* extracts are shown from Table.VI.1 to Table.VI.4 .Total phenol and flavonoid contents were defined respectively in ($\mu\text{g GAE/mg}$) and ($\mu\text{g QE/mg}$) of extract by using calibration curve (Phenol: $y = 0.0034x + 0.1044$; $R^2 = 0.9972$, Flavonoid: $y = 0.0048x$; $R^2 = 0.997$).

Artemisa campestris L. extracts

For *A.campestris*, the highest successive contents of AcEAE for phenolic compounds and flavonoid were $527.333 \pm 0.61 \mu\text{g GAE/mg}$ and $203.4194 \pm 0.14 \mu\text{g QE/mg}$, respectively. In contrast, when compared to the other extracts, AcEAE demonstrated that it contained a high concentration of phenolic and flavonoids components Figure.VI.1. It was followed by the AcDE, which showed high contents of phenolic compounds and flavonoids at $203.607 \pm 0.67 \mu\text{g GAE/mg}$ and $69.444 \pm 0.147 \mu\text{g QE/mg}$, respectively.

Total phenolic content (TPC)

Table.VI.1. Total phenolics of different extracts of *A.campestris* L.

Extracts	Total phenolic compounds content	
	($\mu\text{g GAE/mg}$) *	
AcME	<i>Artemisa campestris</i> Methanol Extract	135.37 ± 1.35^a
AcPEE	<i>Artemisa campestris</i> Petroleum Ether Extract	30.27 ± 0.33^b
AcDE	<i>Artemisa campestris</i> Dichloromethane Extract	203.60 ± 0.67^c
AcEAE	<i>Artemisa campestris</i> Ethyl Acetate Extract	527.33 ± 0.61^d
AcBE	<i>Artemisa campestris</i> Butanol Extract	130.27 ± 0.33^e
AcAE	<i>Artemisa campestris</i> Aqueous Extract	141.64 ± 1.52^f

Results are expressed as means \pm SEM of three measures, Tukey test. Values with different letters in the same column are significantly different at $p < 0.05$. * $\mu\text{g AGE/ mg}$: microgram Gallic acid equivalent/milligram of extract.

Total flavonoids content (TFC)

Table.VI.2. Total flavonoids contents of different extracts of *A.campestris* L.

Extracts		Flavonoids content ($\mu\text{g QE/mg}$)*
AcME	<i>Artemisa campestris</i> Methanol Extract	61.59 \pm 0.58 ^a
AcPEE	<i>Artemisa campestris</i> Petroleum Ether Extract	65.69 \pm 0.29 ^b
AcDE	<i>Artemisa campestris</i> Dichloromethane Extract	69.44 \pm 1.47 ^c
AcEAE	<i>Artemisa campestris</i> Ethyl Acetate Extract	203.19 \pm 0.14 ^d
AcBE	<i>Artemisa campestris</i> Butanol Extract	66.87 \pm 0.29 ^e
AcAE	<i>Artemisa campestris</i> Aqueous Extract	63.4 \pm 0.14 ^f

Results are expressed as means \pm SEM of three measures, Tukey test. Values with different letters in the same column are significantly different at $p < 0.05$. * $\mu\text{g QE/ mg}$: microgram Quercetin equivalent/milligram of extract.




Figure.VI.1. Total phenolic and flavonoids contents of different extracts of *A.campestris*.

***Fagonia bruguieri* DC. Extracts**

Maximum phenolic and Flavonoid contents in *F.bruguieri* reached (444.49 \pm 0.84 $\mu\text{g GAE/mg}$) and (266.458 \pm 0.44 $\mu\text{g QE/mg}$) successively for FbBE. Whereas, the FbBE indicated that it was very rich in phenolic and flavonoid compounds relative to the other extracts, followed by FbEAE, which demonstrated a high content of phenolics, flavonoids with a value 178.902 \pm 0.74 $\mu\text{g GAE/mg}$ and 116.25 \pm 0.88 $\mu\text{g QE/mg}$ respectively Figure.VI.2. The FbDE also gave an interesting phenolic content with a 376.82 \pm 0.29 $\mu\text{g GAE/mg}$ value.

Total phenolic content (TPC)**Table.VI.3.** Total phenolics of contents of different extracts of *F.bruguieri* DC.

Extracts		Total phenolic compounds content ($\mu\text{g GAE/mg}$) *
FbPEE	<i>Fagonia bruguieri</i> Petroleum Ether Extract	57.62 \pm 0.44 ^a
FbDE	<i>Fagonia bruguieri</i> Dichloromethane Extract	376.82 \pm 0.29 ^b
FbEAE	<i>Fagonia bruguieri</i> Ethyl Acetate Extract	178.902 \pm 0.74 ^c
FbBE	<i>Fagonia bruguieri</i> Butanol Extract	444.49 \pm 0.84 ^d
FbAE	<i>Fagonia bruguieri</i> Aqueous Extract	147.52 \pm 1.060 ^e

Results are expressed as means \pm SEM of three measures, Tukey test. Values with different letters in the same column are significantly different at $p < 0.05$. * $\mu\text{g AGE/ mg}$: microgram Gallic acid equivalent/milligram of extract.

Total flavonoids content (TFC)**Table.VI.4.** Total flavonoids contents of different extracts of *F.bruguieri* DC.

Extracts		Flavonoids content ($\mu\text{g QE/mg}$) *
FbPEE	<i>Fagonia bruguieri</i> Petroleum Ether Extract	53.611 \pm 0.24 ^a
FbDE	<i>Fagonia bruguieri</i> Dichloromethane Extract	91.73 \pm 0.73 ^b
FbEAE	<i>Fagonia bruguieri</i> Ethyl Acetate Extract	116.25 \pm 0.88 ^c
FbBE	<i>Fagonia bruguieri</i> Butanol Extract	266.458 \pm 0.44 ^d
FbAE	<i>Fagonia bruguieri</i> Aqueous Extract	72.638 \pm 0.14 ^e

Results are expressed as means \pm SEM of three measures, Tukey test. Values with different letters in the same column are significantly different at $p < 0.05$. * $\mu\text{g QE/ mg}$: microgram Quercetin equivalent/milligram of extract.




Figure.VI.2. Total phenolic and flavonoids contents of different extracts of *F. bruguieri* DC.

Discussion

Total phenolics and flavonoids represent a class of secondary metabolites widely spread in edible and inedible plants. The bioactivity of plant extracts is the common factor of these compounds [398]. They are of significant interest due to their staggering pharmacological influences on the human organism, including antioxidant; antimicrobial; antidiabetic; anti-inflammatory; anticancer, and numerous others [399].

The content of polyphenols in *A. campestris* extracts was determined by examining the extracts with solvents at different polarities. This quantitative analysis discovered various levels of polyphenols and flavonoids. The total phenolics and flavonoids produced by the AcEAE and AcDE were the greatest (Table.VI.1 and Table.VI.2). Our findings were significantly more remarkable when compared to the results obtained by Megdiche-Ksouri et al., 2015 and Djeridane et al., 2006 [400, 401].

The contents of the total phenolic flavonoids of *F. bruguieri* extracts are outlined in (Table.VI.3 and Table.VI.4). The FbBE extract registered the highest classes of phenolic and flavonoids ($444.49 \pm 0.84 \mu\text{g GAE/mg}$; $116.25 \pm 0.88 \mu\text{g QE/mg}$, respectively). Compared to the literature, the TPC and TFC results of this study are more elevated than those obtained by Saleem *et al.*, (2019) in methanolic extract of *F. bruguieri* [215]. Other studies have reported higher findings in *F. bruguieri* and *F. Olivieri* by Alia Ahmed *et al.*, (2020) growing in Balochistan-Pakistan [402].

Our findings indicated that polar organic solvents were the most efficient in extracting phenolic flavonoid compounds. Several factors have been reported to make differences in phytochemical

content, including solvents (degrees of polarity) utilized, environmental and ecological conditions, extraction and quantification procedures, and geographic region.

VI.2. Antioxidant Activity

Phytochemicals are known for their complex nature, and the antioxidant activities of plant extracts cannot be assessed by a single method. The chemical nature of plant tissues creates a difference in antioxidant activity, so it is relatively difficult to identify each antioxidant component separately [403]. Table.VI.5 to Table.VI.18 resumed the antioxidant activity of *A.campestris* and *F.bruguieri* determined using the DPPH, ABTS, β -Carotene, Reducing Power, CUPRAC, GOR, and Phenanthroline tests. Figure.VI.3 to Figure.VI.16 illustrates the graphic of the percentage inhibition of the antioxidant activities of *A.campestris* and *F.bruguieri* to create inclusive results quickly to consider, more straightforward to comprehend and correspond with other compounds. The parameters $A_{0.5}$ and IC_{50} are employed to represent the antioxidant activity of the studied fractions. The more down value of $A_{0.5}$ or IC_{50} compromises that the fraction exhibited the most elevated antioxidant activity of a compound. Among the properties of polyphenols are their potent antioxidants, and the latter play a role as reducing agents; hydrogen donors; and singlet oxygen quenchers. They also may have a metallic chelating potential. Confirming the correlation between polyphenol concentration and antioxidant activity as reported by Rice-evans *et al.*, (1995) ([404]).

VI.2.1. DPPH' Scavenging Activity

Artemisa campestris L. extracts

The DPPH test assesses a substance's antioxidant capacity by monitoring its ability to scavenge free radicals using the hydrogen proton transfer approach [405]. *A.campestris* extracts exhibited a significant capacity for scavenging the radical DPPH. The following decreasing effectiveness for both the standards and the plant extracts: BHA (IC_{50} : 5.73 ± 0.41 $\mu\text{g/mL}$) > AcEAE (IC_{50} : $10,45 \pm 0,19$ $\mu\text{g/mL}$) > BHT (IC_{50} : 22.32 ± 1.19 $\mu\text{g/mL}$) > AcDE (IC_{50} : $73,82 \pm 1,98$ $\mu\text{g/mL}$) > AcAE (IC_{50} : $126,09 \pm 1,63$ $\mu\text{g/mL}$) > AcME (IC_{50} : $141,47 \pm 0,65$ $\mu\text{g/mL}$) > AcBE (IC_{50} : $147,09 \pm 0,17$ $\mu\text{g/mL}$). According to the results shown in Table.VI.5, AcEAE showed potent antioxidant activity in the DPPH method, in which the IC_{50} was relatively close to the IC_{50} stated by the BHA and more efficient compared with standard (BHT).

Table.VI.5. DPPH radical scavenging activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in DPPH assay							IC ₅₀ µg/mL ^a	
	Concentration µg/mL	3.125	6.25	12.5	25	50	100		200
AcME		1.01±0.65	1.22±0.33	3,94±0,49	35,77±1,34	75,69±0,12	82,78±1,34	84,82±0,37	141,47±0,65
AcPEE		10,96±0.53	11,01±0,18	11,73±0.70	13,37±0,69	13,62±1,15	18,08±1,58	24,29±0,89	>200
AcDE		10,80±1,60	14,19±0,55	20,18±0.70	24,85±1,15	39,15±0,89	60,43±0,62	87,59±0,44	73,82±1,98
AcEAE		22,90±0,09	35,15±0,98	57,71±1,07	79,55±0,53	90,21±0,09	90,41±0,09	92,77±0,15	10,45±0,19
AcBE		8,96±0,67	11,78±0,71	16,39±0.32	19,11±0,80	31,41±1,60	40,69±0,85	60,37±0,44	147,09±0,17
AcAE		NA	1,24±0,61	9,70±0,12	46,03±1,12	79,41±1,70	82,50±0,73	84,47±0,68	126,09±1,63
BHT*		11,69±1,88	22,21±1,30	37,12±1,80	52,63±2,70	56,02±0,53	83,60±0,23	87,28±0,26	22.32±1.19
BHA*		28,95±1,16	54,33±1,59	76,76±1,65	84,09±0,35	87,53±0,82	87,73±0,15	88,43±0,23	5.73±0.41

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.3. Comparison of DPPH capacity between extracts of *A.campestris* L. and BHA and BHT.

Fagonia bruguieri DC. extracts

The DPPH scavenging effect of both standards and plants extracts decreasing in the order of BHA (IC₅₀: 6.14±0.41 µg/mL) > BHT (IC₅₀: 12.99±0.41 µg/mL) > α-Tocopherol (IC₅₀:

13.02±5,17 µg/mL) > FbBE (IC₅₀: 29,21±0,10 µg/mL) > FbEAE (IC₅₀: 92,05±0,38 µg/mL) > FbDE (IC₅₀: 128,65±0,83 µg/mL) > FbAE(IC₅₀: 493,53±6,52 µg/mL) respectively. Higher radical scavenging activity towards DPPH is evidenced by a lower IC₅₀ value. According to the results presented in Table.VI.6. IC₅₀ of BHA, BHT, α-tocopherol was found to be (6.14±0.41; 12.99±0.41; 13.02±5,17) µg/mL successively whereas FbBE (29,21±0,10 µg/mL) was the most active scavenger of DPPH radical than FbEAE (IC₅₀ =92,05±0,38 µg/mL).

Table.VI.6. DPPH radical scavenging activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in DPPH assay							IC ₅₀ µg/mL ^a
	Concentration µg/MI	12.5	25	50	100	200	400	
FbPEE	NA	0,72±0,35	3,47±1,15	5,91±0,89	10,64±0,18	15,83±0,77	26,61±0,95	>800
FbDE	12,98±0,11	19,85±0,09	30,88±0,70	46,45±0,79	64,91±0,31	78,08±0,54	81,84±0,26	128,65±0,83
FbEAE	11,71±0,88	20,05±0,00	34,49±0,18	52,65±0,15	74,88±0,18	86,42±0,31	87,39±0,35	92,05±0,38
FbBE	29,21±1,19	44,11±0,70	76,55±0,18	88,46±0,09	88,61±0,21	88,91±0,54	89,52±0,09	29,21±0,10
FbAE	NA	NA	NA	0,56±1,10	24,95±0,76	52,57±1,10	67,60±0,24	493,53±6,52
BHT*	49,09± 0,76	72,63± 2,06	88.73±0,89	94.00±0,31	94.97±0,08	95.38±0,41	95.02±0,23	12.99±0.41
BHA *	76,55± 0,48	79,89± 0,26	81,73±0,10	84,18±0,10	87,13±0,17	89,36±0,19	90,14±0,00	6.14±0.41
α-Tocopherol*	37,21±1,82	81,53±1,51	89,23±0,12	89,38±0,19	89,45±0,22	89,99±0,23	89,52±0,33	13.02±5,17

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.4. Comparison of DPPH capacity between extracts of *F.bruguieri* DC. and BHA, BHT and α-Tocopherol.

VI.2.2. ABTS^{•+} Scavenging Activity*Artemisa campestris* L. extracts

Another methodology for evaluating the anti-radical activity of *A.campestris* extracts is the ABTS radicals, which function similarly to the DPPH radicals by monitoring electron transfer in the medium. The ABTS^{•+} scavenging capacities among the various extracts were in the ensuing order: BHT (IC₅₀: 1.29±0.30 µg/mL) > BHA (IC₅₀: 1.81±0.10 µg/mL) > AcEAE (IC₅₀: 9,52±0,12 µg/mL) > AcDE (IC₅₀: 23,26±0,42 µg/mL) > AcME (IC₅₀: 26,04±0,39 µg/mL) > AcAE (IC₅₀: 58,67±0,58 µg/mL) > AcBE (IC₅₀: 66,52±0,94 µg/mL). The data was obtained from a study performed at the highest concentration (Table.VI.7). AcEAE demonstrated remarkable high capacity scavenging of ABTS^{•+} radical Figure.VI.5.

Table.VI.7. ABTS scavenging activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in ABTS assay							IC ₅₀ µg/mL ^a	
	Concentration µg/MI	3.125	6.25	12.5	25	50	100		200
AcME		30,69±0,11	54,22±0,44	76,09±1,55	87,85±0,11	89,32±0,11	91,05±0,11	93,22±0,55	26,04±0,39
AcPEE		2,14±0,98	3,67±0,95	5,17±0,77	9,38±0,42	14,20±0,14	21,33±0,14	30,28±0,63	>200
AcDE		12,30±0,56	22,83±0,28	33,19±0,64	52,71±0,70	67,49±0,79	82,27±0,80	90,77±0,36	23,26±0,42
AcEAE		22,06±0,25	37,36±0,70	62,22±0,63	88,74±0,56	92,91±0,07	93,48±0,07	93,64±0,07	9,52±0,12
AcBE		8,01±0,07	11,45±0,63	20,52±0,70	31,77±0,35	46,88±0,60	61,90±0,43	77,81±0,77	66,52±0,94
AcAE		2,75±0,33	17,65±1,44	49,94±0,00	81,65±0,11	90,15±0,11	90,66±0,11	91,24±0,22	58,67±0,58
BHT*		59.22±0.59	78.55±3.43	90.36±0.00	92.18±1.27	93.37±0.86	94.87±0.87	96.68±0.39	1.29±0.30
BHA*		83.42±4.09	93.52±0.09	93.58±0.09	93.63±0.16	93.63±0.95	94.20±0.90	95.39±2.62	1.81±0.10

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.5. Comparison of ABTS^{•+} capacity between extracts of *A.campestris* L. and BHA and BHT.

Fagonia bruguieri DC. extracts

As presented in Table.VI.8 and Figure VI.6, the parameter IC₅₀ the inhibition concentration of ABTS, follows the increasing order: FbAE (IC₅₀= 200.38±1.23µg/mL) < FbDE (IC₅₀= 25.83±0.41 µg/mL) < FbBE (IC₅₀= 21.88±0.19µg/mL) < FbEAE (IC₅₀=14.03±0.47 µg/mL) < BHA (IC₅₀=1.81±0.10 µg/mL) < BHT (IC₅₀=1.29±0.30µg/mL) respectively. Similarly, According to the results FbEAE had the highest antioxydant activity.

Table.VI.8. ABTS scavenging activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in ABTS assay							IC ₅₀ µg/mL ^a	
	Concentration µg/MI	12.5	25	50	100	200	400		800
FbPEE		1,93±0,76	2,97±0,99	4,99±0,76	8,55±0,28	14,68±0,58	21,58±0,47	31,21±0,57	>800
FbDE		33,45±0,47	54,25±0,76	72,25±0,28	84,68±0,19	90,15±0,16	91,90±0,09	92,89±0,34	25.83±0.41
FbEAE		47,24±0,09	61,42±0,28	79,53±2,18	89,05±0,19	91,90±0,09	92,23±0,09	92,72±0,09	14.03±0.47
FbBE		28,03±0,66	66,29±0,38	89,05±0,09	91,19±0,09	91,63±0,28	91,68±0,09	91,90±0,09	21.88±0.19
FbAE		0.6,61±0,11	1,07±0,78	3,20±0,33	19,18±1,16	63,24±1,44	89,77±0,44	92,14±0,19	200.38±1.23
BHT*		69.21±0,40	78.23±1,34	88.12±1,28	88,76±3,07	90.85±1,74	90.95±0,51	96.68±0.39	1.29±0.30
BHA*		92.83±1,42	94.68±0,42	94.95±0,90	95.32±0,25	95.59±0,47	95.83±0,15	95,86±0,10	1.81±0.10

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.6. Comparison of ABTS^{•+} capacity between extracts of *F. bruguieri* DC. and BHA and BHT.

VI.2.3. β -carotene-linoleic Acid Bleaching Activity

Artemisa campestris L. extracts

We used the β -carotene bleaching methodology to investigate the efficacy of *A. campestris* fractions in inhibiting lipid peroxidation. The outcomes in Table.VI.9 revealed that AcBE (IC_{50} : 183.87 ± 1.30 $\mu\text{g/mL}$) had a moderate effect compared with BHT and BHA (IC_{50} : 1.05 ± 0.01 ; 0.90 ± 0.02 $\mu\text{g/mL}$, respectively). In contrast, AcME, AcPEE, AcDE, AcEAE, and AcAE were inactive against β -carotene bleaching.

Table.VI.9. β -carotene-linoleic acid bleaching activity of different extracts of *A. campestris* L.

Extracts	% Inhibition in β -carotene assay							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/MI}$	3.125	6.25	12.5	25	50	100		200
AcME	NA	NA	NA	NA	NA	NA	NA	NA	>200
AcPEE		$0,63 \pm 2,74$	$5,71 \pm 1,59$	$6,58 \pm 0,53$	$6,98 \pm 1,14$	$9,40 \pm 1,86$	$11,91 \pm 1,71$	$11,58 \pm 0,46$	>200
AcDE		$14,43 \pm 2,23$	$19,35 \pm 2,61$	$23,88 \pm 1,66$	$25,79 \pm 0,17$	$28,88 \pm 0,52$	$29,26 \pm 0,34$	$32,06 \pm 0,35$	>200
AcEAE		$24,87 \pm 3,62$	$26,42 \pm 2,17$	$27,29 \pm 1,02$	$30,59 \pm 1,31$	$31,65 \pm 1,22$	$32,91 \pm 1,84$	$32,76 \pm 2,23$	>200
AcBE		$36,40 \pm 1,70$	$39,84 \pm 0,73$	$42,74 \pm 2,03$	$45,74 \pm 1,90$	$50,82 \pm 0,55$	$51,55 \pm 0,27$	$52,70 \pm 0,58$	$183,87 \pm 1,30$
AcAE		$34,80 \pm 1,39$	$40,30 \pm 2,18$	$41,39 \pm 2,56$	$42,41 \pm 2,12$	$42,42 \pm 0,88$	$43,53 \pm 1,97$	$45,53 \pm 2,70$	>50

BHT*	81.14±0.84	86.09±1.04	87.52±4.24	91.67±0.52	94.11±0.42	94.41±0.32	95.28±3.25	1.05±0.01
BHA*	84.23±1.14	90.11±0.68	94.59±0.77	96.09±0.02	97.35±1.08	99.59±0.14	99.76±05	0.90±0.02

^a **IC₅₀**: the concentration at the 50 of inhibition. **IC₅₀** values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. **NT**: Note Tested. **NA**: Note Active.




Figure.VI.7. Comparison of β -carotene capacity between extracts of *A.campestris* L. and BHA and BHT.


Fagonia bruguieri DC. extracts

The Activity antioxidant of the *F.bruguieri* DC. extracts was assessed by the beta-carotene bleaching, as illustrated in Figure.VI.8 and Table.VI.10. According to the parameter **IC₅₀** the inhibition concentration of β -carotene, follows the increasing order: FbPEE (**IC₅₀**=174.52±1.94 μ g/mL) < FbDE (**IC₅₀**=66.99±2.39 μ g/mL) < FbEAE (**IC₅₀**=34.55±2.85 μ g/mL) < FbBE (**IC₅₀**=32.30±1.89 μ g/mL) < BHA (**IC₅₀**=1.05±0.03 μ g/mL) < BHT (**IC₅₀**=0.91±0.01 μ g/mL) respectively. Interestingly, FbBE extract had the most substantial antioxidant effect.

Table.VI.10. β -carotene-linoleic acid bleaching activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in β -carotene assay							IC ₅₀ $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/MI}$	12.5	25	50	100	200	400		800
FbPEE		26,68 \pm 0,50	30,98 \pm 0,37	32,85 \pm 1,39	48,70 \pm 1,06	50,58 \pm 0,27	56,58 \pm 1,34	57,49 \pm 0,99	174,52 \pm 1,94
FbDE		45,98 \pm 0,64	48,39 \pm 0,91	48,88 \pm 0,68	52,18 \pm 0,55	51,41 \pm 0,15	52,88 \pm 0,99	53,62 \pm 1,57	66.99 \pm 2.39
FbEAE		48,39 \pm 0,88	50,24 \pm 1,03	50,66 \pm 0,00	50,93 \pm 0,62	52,10 \pm 1,03	50,64 \pm 2,30	54,26 \pm 0,39	34.55 \pm 2.85
FbBE		44,96 \pm 1,58	47,82 \pm 0,65	52,91 \pm 0,72	55,95 \pm 1,01	56,88 \pm 1,50	57,77 \pm 0,17	59,15 \pm 1,41	32.30 \pm 1.89
FbAE		32,09 \pm 1,08	38,85 \pm 2,28	38,66 \pm 1,57	40,90 \pm 1,56	44,84 \pm 2,31	44,37 \pm 1,87	47,52 \pm 0,18	>800
BHT*		88.29 \pm 0.10	91.70 \pm 0.36	93.65 \pm 0.30	93.68 \pm 0.46	94.49 \pm 0.07	94.88 \pm 0.10	95.58 \pm 0.19	0.91 \pm 0.01
BHA*		93.48 \pm 0.44	95.52 \pm 0.33	96.34 \pm 0.55	97.56 \pm 0.19	97.64 \pm 2.22	97.85 \pm 0.32	99.66 \pm 0.52	1.05 \pm 0.03

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.

**Figure.VI.8.** Comparison of β -carotene capacity between extracts of *F.bruguieri* DC. and BHA and BHT.

VI.2.4. Cupric Reducing Antioxidant Capacity (CUPRAC) Activity

Artemisa campestris L. extracts

According to Table.VI.11, AcEAE exhibited high antioxidant activity in a CUPRAC assay, with an $A_{0.5}$ value of 9,94 \pm 0,21 $\mu\text{g/mL}$, which is very close to the value presented by BHT ($A_{0.5}$:

9.62±0.87 µg/mL). the parameter IC₅₀ the inhibition concentration of CUPRAC, follows the increasing order: AcME (A_{0.5} = 449,57±4,87 µg/mL) < AcAE (A_{0.5} = 233,33±0,58 µg/mL) < AcBE (A_{0.5} = 91,58±2,67µg/mL) < AcDE (A_{0.5} =56,44±1,11 µg/mL) < BHT (A_{0.5} =9.62±0.87 µg/mL) < BHA (A_{0.5} =3.64±0.19 µg/mL) respectively (Figure.VI.9).

Table.VI.11. Cupric reducing antioxidant capacity activity of different extracts of *A.campestris* L.

Extracts	Absorbances in CUPRAC assay							A _{0.50} µg/mL ^a	
	Concentration µg/MI	3.125	6.25	12.5	25	50	100		200
AcME		0,10±0,01	0,11±0,00	0,14±0,00	0,19±0,01	0,24±0,01	0,40±0,00	0,78±0,00	449,57±4,87
AcPEE		0,10±0,01	0,11±0,01	0,13±0,01	0,13±0,01	0,19±0,01	0,27±0,00	0,41±0,01	>200
AcDE		0,13±0,00	0,15±0,00	0,21±0,00	0,32±0,01	0,45±0,01	0,76±0,01	1,38±0,00	56,44±1,11
AcEAE		0,22±0,00	0,31±0,01	0,62±0,01	1,20±0,00	2,36±0,01	3,65±0,00	3,97±0,01	9,94±0,21
AcBE		0,12±0,02	0,13±0,00	0,15±0,01	0,22±0,01	0,37±0,01	0,54±0,00	0,98±0,01	91,58±2,67
AcAE		0,11±0,00	0,14±0,01	0,19±0,01	0,30±0,00	0,46±0,01	1,02±0,03	1,27±0,01	233,33±0,58
BHT*		0,19±0,01	0,33±0,04	0,66±0,07	1,03±0,07	1,48±0,09	2,04±0,14	2,32±0,28	9,62±0,87
BHA*		0,46±0,00	0,78±0,01	1,34±0,08	2,36±0,17	3,45±0,02	3,76±0,03	3,93±0,01	3,64±0,19

^aA_{0.5}: the concentration at the 0.50 absorption. A_{0.5} values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.9. Comparison of CUPRAC capacity between extracts of *A.campestris* L. and BHA and BHT.

***Fagonia bruguieri* DC. extracts**

The $A_{0.5}$ findings of each of the various extracts are presented in Table.VI.12 and Figure.VI.10. FbBE and FbEAE, FbDE presented the highest Antioxidant activity (CUPRAR) with ($A_{0.5}$ =38.60±1.48 ; 47.52±0.79 ; 67.22±0.51 $\mu\text{g/mL}$, respectively) compared with BHA, BHT as the positive control ($A_{0.5}$ = 5.35±0.71 and 8.97±3.94 $\mu\text{g/mL}$ respectively).

Table.VI.12. Cupric reducing antioxidant capacity activity of different extracts of *F.bruguieri* DC.

Extracts	Absorbances in CUPRAC assay							$A_{0.50}$ $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/MI}$	12.5	25	50	100	200	400		800
FbPEE		0,11±0,00	0,13±0,00	0,15±0,01	0,23±0,03	0,28±0,00	0,34±0,00	0,49±0,01	>800
FbDE		0,18±0,01	0,24±0,01	0,45±0,01	0,74±0,01	1,41±0,00	2,22±0,01	2,93±0,01	67,22±0,51
FbEAE		0,20±0,00	0,29±0,00	0,56±0,01	0,83±0,01	1,61±0,00	2,46±0,00	2,93±0,02	47,52±0,79
FbBE		0,25±0,01	0,37±0,01	0,64±0,01	1,04±0,00	1,98±0,01	3,41±0,00	3,86±0,01	38,60±1,48
FbAE		0,13±0,00	0,18±0,00	0,22±0,00	0,29±0,00	0,46±0,01	0,78±0,01	1,30±0,01	367,33±1,53
BHT*		1.41±0.03	2.22±0.05	2.42±0.02	2.50±0.01	2.56±0.05	2.86±0.07	3.38±0.13	8.97±3.94
BHA*		1,12±0,05	1,95±0,31	3,14±0,46	3,35±0,42	3,58±0,20	3,77±0,19	3,92±0,13	5,35±0,71

^a $A_{0.5}$: the concentration at the 0.50 absorption. $A_{0.5}$ values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.10. Comparison of CUPRAC capacity between extracts of *F.bruguieri* DC. and BHA and BHT.

VI.2.5. Reducing Power Assay

Artemisa campestris L. extracts

The reducing power approach depends on the transition of Fe³⁺ to Fe²⁺ [406]. AcEAE was the most effective in reducing iron ions, with the lowest A_{0.5} value (A_{0.5}: 16.05±0.16 µg/mL) (Table.VI.13). The effective concentrations at which the absorbance was 0.5 in decreasing order were as follows: BHA (8.41±0.67 µg/mL) > Ascorbic acid (9.01±1.46 µg/mL) > AcEAE (16,05±0,16 µg/mL) > AcME (54,00±0,33µg/mL) > AcDE (96,58±1,51 µg/mL) > AcAE (103,25±1,09 µg/mL).

Table.VI.13. Reducing power assay of different extracts of *A.campestris* L.

Extracts	Absorbances in Reducing power assay							A _{0.50} µg/mL ^a	
	Concentration µg/MI	0.781	1.562	3.125	6.25	12.5	25		50
AcME		0,11±0,00	0,18±0,01	0,19±0,00	0,27±0,00	0,51±0,00	0,56±0,00	0,84±0,02	54,00±0,33
AcPEE		0,05±0,00	0,06±0,00	0,07±0,01	0,09±0,00	0,10±0,00	0,16±0,01	0,24±0,00	>200
AcDE		0,10±0,00	0,11±0,00	0,13±0,03	0,20±0,01	0,33±0,01	0,51±0,00	0,59±0,01	96,58±1,51
AcEAE		0,20±0,01	0,27±0,00	0,45±0,01	0,70±0,00	1,11±0,01	1,27±0,21	1,42±0,01	16,05±0,16
AcBE		0,07±0,00	0,08±0,00	0,11±0,01	0,13±0,01	0,18±0,00	0,31±0,01	0,43±0,01	>200
AcAE		0,10±0,01	0,13±0,00	0,16±0,01	0,19±0,00	0,33±0,00	0,53±0,01	0,72±0,01	103,25±1,09
BHT*		0,07±0,00	0,08±0,00	0,10±0,01	0,13±0,02	0,22±0,04	0,28±0,05	0,43±0,02	>200
BHA*		0,09±0,00	0,11±0,01	0,18±0,02	0,36±0,04	0,78±0,07	1,74±0,07	3,53±0,19	8,41±0,67
Ascorbic acid*		0,09±0,00	0,11±0,00	0,16±0,01	0,33±0,04	0,76±0,16	2,02±0,23	3,87±0,27	9,01±1,46

^aA_{0.5}: the concentration at the 0.50 absorption. A_{0.5} values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.11. Comparison of reducing power capacity between extracts of *A.campestris* L. and BHA, BHT and ascorbic acid.

***Fagonia bruguieri* DC. extracts**

The effective concentrations at which the absorbance was 0.5 were in decreasing order: FbDE (105.58±0.88 µg/mL) > FbEAE (86.08±0.95 µg/mL) > FbAE (76±0.83 µg/mL) > FbBE (57.48±1.40 µg/mL) > α-tocopherol (34.93±2.38 µg/mL)> Ascorbic acid (6.77±1.15 µg/mL). According to the parameter A_{0.5} (µg / mL). In terms of antioxidant capability, FbBE showed the most extraordinary reducing power (Table.VI.14, Figure.VI.12).

Table.VI.14. Reducing power assay of different extracts of *F.bruguieri* DC.

Extracts	Absorbances in Reducing power assay							A _{0.50} µg/mL ^a	
	Concentration µg/MI	3.125	6.25	12.5	25	50	100		200
FbPEE		0,07±0,00	0,07±0,00	0,07±0,00	0,08±0,00	0,09±0,00	0,10±0,00	0,16±0,00	>200
FbDE		0,09±0,00	0,10±0,00	0,18±0,00	0,20±0,00	0,27±0,00	0,53±0,00	0,65±0,03	105.58±0.88
FbEAE		0,11±0,00	0,14±0,00	0,18±0,00	0,25±0,00	0,37±0,01	0,56±0,00	0,64±0,01	86.08±0.95
FbBE		0,09±0,00	0,10±0,00	0,18±0,01	0,27±0,00	0,45±0,00	0,78±0,02	1,01±0,00	57.48±1.40
FbAE		0,06±0,00	0,11±0,00	0,11±0,01	0,14±0,01	0,21±0,00	0,57±0,01	0,59±0,01	76±0.83
α-Tocopherol*		0,11±0,00	0,16±0,00	0,21±0,03	0,35±0,03	0,73±0,03	1,37±0,08	1,81±0,09	34.93±2.38
Ascorbic acid*		0,35±0,05	0,46±0,03	0,84±0,12	0,93±0,30	1,18±0,34	1,37±0,20	1,44±0,21	6.77±1.15

^aA_{0.5}: the concentration at the 0.50 absorption. A_{0.5} values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.12. Comparison of reducing power capacity between extracts of *F.bruguieri* DC. and alpha-tocopherol and ascorbic acid.

VI.2.6. Galvinoxyl (GOR) Scavenging Activity

Artemisa campestris L. extracts

Table.VI.15 demonstrated that AcEAE had high antioxydant activity for the GOR assay, where the IC_{50} (IC_{50} : 2.45 ± 0.03 $\mu\text{g/mL}$) was more potent than the values shown by the standards, followed by BHT and BHA (IC_{50} : 3.32 ± 0.18 ; 5.38 ± 0.06 $\mu\text{g/mL}$, respectively), and the rest in the following order: AcDE (IC_{50} : 16.11 ± 0.02 $\mu\text{g/mL}$) > AcBE (IC_{50} : 62.37 ± 0.16 $\mu\text{g/mL}$) > AcME (IC_{50} : 68.21 ± 0.13 $\mu\text{g/mL}$) > AcAE (IC_{50} : 152.18 ± 0.47 $\mu\text{g/mL}$).

Table.VI.15. Galvinoxyl scavenging activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in Galvinoxyl radical (GOR) scavenging assay							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	1.5625	3.125	6.25	12.5	25	50		100
AcME		6.54 ± 0.37	13.63 ± 0.35	50.55 ± 0.56	66.61 ± 0.52	69.31 ± 0.33	70.63 ± 0.04	71.11 ± 0.14	68.21 ± 0.13
AcPEE		1.91 ± 0.22	2.89 ± 0.14	6.36 ± 0.23	9.40 ± 0.31	11.86 ± 0.03	14.82 ± 0.25	23.67 ± 0.08	>100
AcDE		14.26 ± 0.39	22.54 ± 0.11	38.87 ± 0.09	75.15 ± 0.02	75.56 ± 0.03	77.50 ± 0.09	78.23 ± 0.10	16.11 ± 0.02
AcEAE		68.82 ± 1.14	75.03 ± 0.25	78.28 ± 0.11	81.43 ± 0.05	84.47 ± 0.08	86.83 ± 0.06	87.87 ± 0.05	2.45 ± 0.03
AcBE		4.50 ± 0.17	9.45 ± 0.23	20.64 ± 1.39	26.16 ± 0.06	47.30 ± 0.17	69.80 ± 0.31	76.00 ± 0.09	62.37 ± 0.16
AcAE		NA	NA	8.60 ± 0.33	41.66 ± 0.19	63.35 ± 0.29	66.27 ± 0.54	73.48 ± 1.86	152.18 ± 0.47
BHT*		$34,66 \pm 2.62$	$49,23 \pm 0.77$	$61,29 \pm 0.69$	$68,89 \pm 0,26$	$70,02 \pm 0.50$	$70,49 \pm 0,55$	$71,13 \pm 0,74$	$3.32 \pm 0,18$
BHA*		$25.99 \pm 2,56$	39.15 ± 0.88	54.16 ± 0.27	$65.02 \pm 1,26$	$70,19 \pm 0.51$	70.32 ± 0.65	$70.60 \pm 0,10$	$5.38 \pm 0,06$

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.13. Comparison of galvinoxyl radical (GOR) scavenging capacity between extracts of *A.campestris* L. and BHA and BHT.

Fagonia bruguieri DC. extracts

Using the GOR method to measure antioxidant activity, Table.VI.16 and Figure Figure.VI.14 show that the following are in order from most to least antioxidant activity: FbAE ($IC_{50}=478.67\pm 3.27 \mu\text{g/mL}$) < FbDE ($IC_{50}=195.99\pm 0.27 \mu\text{g/mL}$) < FbEAE ($IC_{50}=83.75\pm 0.49 \mu\text{g/mL}$) < FbBE ($IC_{50}=33.39\pm 0.11 \mu\text{g/mL}$) < BHA ($IC_{50}=5.38 \pm 0,06 \mu\text{g/mL}$) < BHT ($IC_{50}=3.32\pm 0,18 \mu\text{g/mL}$) respectively. In GOR scavenging activities, the FbBE exhibited the highest antioxidant capacity.

Table.VI.16. Galvinoxyl (GOR) scavenging activity of different extracts of *Fagonia bruguieri* DC.

Extracts	% Inhibition in Galvinoxyl radical (GOR) scavenging assay							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	1.5625	3.125 μg	6.25 μg	12.5 μg	25 μg	50 μg		100 μg
FbPEE		2,65 \pm 0,19	2,98 \pm 0,19	3,41 \pm 0,52	4,39 \pm 0,08	4,91 \pm 0,05	6,03 \pm 0,24	11,02 \pm 0,13	>100
FbDE		6,83 \pm 0,14	9,66 \pm 0,24	11,99 \pm 0,11	28,00 \pm 0,19	50,37 \pm 0,13	68,43 \pm 0,25	72,10 \pm 0,05	195.99 \pm 0.27
FbEAE		9,58 \pm 0,24	18,87 \pm 0,19	34,50 \pm 0,27	57,77 \pm 0,43	74,09 \pm 0,16	76,77 \pm 0,14	82,77 \pm 0,20	83.75 \pm 0.49
FbBE		18,28 \pm 0,21	41,28 \pm 0,19	70,89 \pm 0,19	72,35 \pm 0,03	74,94 \pm 0,02	75,93 \pm 0,03	76,21 \pm 0,25	33.39 \pm 0.11
FbAE		NA	NA	NA	1,22 \pm 0,23	19,11 \pm 0,14	63,82 \pm 0,14	64,88 \pm 1,06	478.67 \pm 3.27
BHT*		34,66 \pm 2.62	49,23 \pm 0.77	61,29 \pm 0.69	68,89 \pm 0,26	70,02 \pm 0.50	70,49 \pm 0,55	71,13 \pm 0,74	3.32 \pm 0,18
BHA*		25.99 \pm 2,56	39.15 \pm 0.88	54.16 \pm 0.27	65.02 \pm 1,26	70,19 \pm 0.51	70.32 \pm 0.65	70.60 \pm 0,10	5.38 \pm 0,06

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.14. Comparison of galvinoxyl radical (GOR) scavenging capacity between extracts of *F.bruguieri* DC. and BHA and BHT.

VI.2.7. O-Phenanthroline Activity


Artemisa campestris L. extracts

Based on the o-phenanthroline method, Table.VI.17 shows that *A.campestris* is able to lower the amount of the Fe^{3+} ion [338]. Likewise, AcEAE displayed the greatest chelating activity ($A_{0.5}$: 7.12 ± 0.15 µg/mL). According to the results of the O-phenanthroline assay, the order of decreasing antioxidant activity is as follows: BHA > BHT > AcEAE > AcDE > AcBE > AcAE (Figure.VI.15).

Table.VI.17. O-Phenanthroline Activity of different extracts of *A.campestris* L.

Extracts	Absorbances in phenanthroline assay							$A_{0.5}$ $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	0.78125	1.5625	3.125	6.25	12.5	25		50
AcME		0,23±0,00	0,24±0,01	0,25±0,01	0,26±0,01	0,27±0,01	0,28±0,01	0,29±0,00	>50
AcPEE		0,22±0,00	0,24±0,00	0,24±0,00	0,25±0,00	0,27±0,00	0,28±0,00	0,33±0,00	>50
AcDE		0,26±0,00	0,31±0,00	0,35±0,02	0,48±0,00	0,65±0,01	1,02±0,02	1,47±0,01	31,95±0,22
AcEAE		0,34±0,00	0,47±0,03	0,72±0,02	1,38±0,00	1,98±0,01	3,85±0,00	4,25±0,02	7,12±0,15
AcBE		0,28±0,00	0,29±0,01	0,38±0,01	0,44±0,00	0,62±0,00	0,88±0,01	1,42±0,00	35,56±1,51
AcAE		0,24±0,01	0,26±0,01	0,28±0,01	0,30±0,00	0,37±0,01	0,52±0,00	0,62±0,01	136,67±1,53
BHT*		0,47±0,01	0,47±0,01	0,53±0,03	1,23±0,02	1,84±0,01	3,48±0,03	4,84±0,01	2,24±0,17
BHA*		0,49±0,01	0,59±0,01	0,73±0,02	0,93±0,01	1,25±0,04	2,10±0,05	4,89±0,06	0,93±0,07

^a $A_{0.5}$: the concentration at the 0.50 absorption. $A_{0.5}$ values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.

**Figure.VI.15.** Comparison of O-Phenanthroline capacity between extracts of *A.campestris* L. and BHA and BHT.

Fagonia bruguieri DC. extracts

Table.VI.18 shows *F.bruguieri's* capacity to reduce Fe^{3+} ions via O-Phenanthroline. The antioxidant activity measured by the o-phenanthroline assay is listed below in decreasing order: BHA ($A_{0.5}$: 0,93±0,07 $\mu\text{g/mL}$) > BHT ($A_{0.5}$: 2,24±0,17 $\mu\text{g/mL}$) > FbBE ($A_{0.5}$: 20,52±1.72

$\mu\text{g/mL}$) > FbDE ($A_{0.5}$: $21,14 \pm 1,76 \mu\text{g/mL}$) > FbEAE ($A_{0.5}$: $21.91 \pm 1.97 \mu\text{g/mL}$) > FbAE ($A_{0.5}$: $74,00 \pm 1,33 \mu\text{g/mL}$) respectively. Even when compared with BHA and BHT standards, the chelation activity level shown by FbBE ($A_{0.5}$: $20,52 \pm 1.72 \mu\text{g/mL}$) was the highest achievable (Figure.VI.16).

Table.VI.18. O-Phenanthroline Activity of different extracts of *F.bruguieri* DC.

Extracts	Absorbances in phenanthroline assay							$A_{0.5}$ $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	0.78125	1.5625	3.125	6.25	12.5	25		50
FbPEE		0,24 \pm 0,00	0,24 \pm 0,00	0,25 \pm 0,01	0,24 \pm 0,00	0,25 \pm 0,01	0,26 \pm 0,01	0,26 \pm 0,01	>50
FbDE		0,29 \pm 0,01	0,32 \pm 0,00	0,42 \pm 0,03	0,53 \pm 0,02	0,89 \pm 0,02	1,13 \pm 0,14	1,61 \pm 0,34	21,14 \pm 1,76
FbEAE		0,29 \pm 0,00	0,33 \pm 0,01	0,38 \pm 0,01	0,59 \pm 0,01	0,79 \pm 0,03	1,42 \pm 0,09	2,75 \pm 0,34	21.91 \pm 1.97
FbBE		0,28 \pm 0,00	0,33 \pm 0,01	0,42 \pm 0,01	0,58 \pm 0,01	0,82 \pm 0,05	1,36 \pm 0,05	2,42 \pm 0,27	20,52 \pm 1.72
FbAE		0,28 \pm 0,01	0,28 \pm 0,00	0,29 \pm 0,03	0,36 \pm 0,01	0,47 \pm 0,00	0,63 \pm 0,03	1,02 \pm 0,08	74,00 \pm 1,33
BHT*		0,47 \pm 0,01	0,47 \pm 0,01	0,53 \pm 0,03	1,23 \pm 0,02	1,84 \pm 0,01	3,48 \pm 0,03	4,84 \pm 0,01	2,24 \pm 0,17
BHA*		0,49 \pm 0,01	0,59 \pm 0,01	0,73 \pm 0,02	0,93 \pm 0,01	1,25 \pm 0,04	2,10 \pm 0,05	4,89 \pm 0,06	0,93 \pm 0,07

^a $A_{0.5}$: the concentration at the 0.50 absorption. $A_{0.5}$ values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p < 0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.16. Comparison of O-Phenanthroline capacity between extracts of *F.bruguieri* DC. and BHA and BHT .

Discussion

Different mechanisms considering the multifaceted in the antioxidant activity, these assays can roughly be divided into different mechanisms, those that evaluate lipid peroxidation radical scavenging, binding of transition metal ion catalysts, hydrogen abstraction, chain initiation prevention, and reducing capacity [401]. Accordingly, we combined a variety of methods assays complementary to evaluate the antioxidant effect.

Due to the high levels of phenolics and flavonoids in AcEAE, the above techniques show that this extract has a strong ability to scavenge free radicals, which gives AcEAE its distinctive properties. In fact, phenolic compounds, which include hydroxyl groups in their structure that enable hydrogen or electrons to be transferred to a reactive molecule, are considered the most potent antioxidants.

Similarly, for *F.bruigueri*, the results obtained by the overhead strategies demonstrated that FbBE and FbEAE extracts have a potential antioxidant activity due to the presence of phenolics and flavonoids in elevated amounts. Subsequently, the close relationship between antioxidant activity and phenol content became widely comprehended [401].

DPPH and ABTS are synthetic free radicals frequently employed to assess plant extracts and pure compounds for their potential anti-radical effects [407]. Both the AcEAE and the FbEAE have shown significant antioxidant activity against the radical DPPH as well as the radical ABTS. Electrons' reception leads to a change from a purple colour (DPPH⁻) to a yellow colour (DPPH-H), which reveals properties measured at 515 nm. The blue-green chromophore known as 2,2'-azinobis-3 ethylbenzothiazoline-6-sulfonic acid (ABTS⁺⁺) is subjected to the ABTS decolourization procedure to assess which its colour is changed as a result of the addition of an antioxidant.

The outcomes obtained for *A.campestris* appear to be in better correlation with the findings that Akrouf *et al.*, (2009) reported in *A.campestris* [408], using infusion and ethanol 50%. On the other hand, the findings acquired using DPPH are similar to those reported by Megdich *et al.*, (2015), which used the decoction of *A.campestris* from southern Tunisia [400].

The antioxidant activity of *F.bruigueri* extracts, notably FbEAE and FbBE, was significant, with DPPH and ABTS findings greater than those reported by Satpute *et al.*, 2012, for the alcoholic and acetone extract of *Fagonia arabica* growing in India [409].

Recently, Saleem *et al.*, (2019) demonstrated that the methanol fraction of *F. bruguieri* exhibited powerful activity with an IC₅₀ value of 32.733 mM [215]. Furthermore, El-Amier and Aisha (2019) reported high DPPH antioxidant activity of the *F. mollis* species (IC₅₀ = 0.74 mg/mL) was followed by *F. arabica* and *F. cretica* (IC₅₀ = 0.76 and 0.82 mg/mL, respectively) [410].

The antioxidant activities of AcBE were the only ones that moderately reduced the oxidation of β -carotene due to free radicals generated as a by-product of linoleic acid oxidation in *A.campestris*. The capability of acting on lipid peroxidation products is a feature that gives a significant benefit and is thus very important [330]. Compared to the findings published in the previous studies, ours show that AcBE is astoundingly effective in β -carotene [125].

The beta-carotene and linoleic acid system are now being reported for *F.bruguieri* for the first time. The lack of antioxidants is responsible for the fast discolouration of beta-carotene. As observed, our results showed that these obtained IC₅₀ values of FbBE and FbEAE presented a powerful protector on β -carotene. This may be due to various antioxidants; those neutralizing radicals peroxy generated the free radical of linoleate and other compounds in the system. The results of the present study demonstrated that FbBE and FbEAE exhibited a significant effect on beta-carotene, which delayed and reduced lipoperoxidation and, consequently, the oxidation of beta-carotene. These results could be explained that these compounds are drawn to solvents with high polarity.

AcEAE and FbBE showed exceptional effectiveness in reducing iron and copper ion, which may be due to their ability to rebuild oxidized molecules and therefore broke the hydrogen subtract. The O-phenanthroline test can be assessed by the reduction of Fe(III), resulting in a bright red colour. This applied methodology has been exposed to an oversized field of relevancy and applied to fruit juices, vinegar, and wines [411]. The AcEAE and FbBE were identified to have the most outstanding efficiency, which aids in understanding why the highlights of the Fe³⁺ ions reducing donor potency were found in these fractions. For the first time, we evaluated antioxidant activity utilizing CUPRAC and O-Phenanthroline for *A.campestris* and *F.bruguieri* extracts.

Table.VI.13 shows the ferric reducing power (A_{0.5}) of *A.campestris* extracts. It explains the rate at which Fe³⁺(CN)₆ is reduced to Fe²⁺(CN)₆ by direct electron donation. Then the complexes of ferric ferrous from the reaction mixture were accompanied by a high absorption at 700 nm [412]. Comparable to that reported by Boulanouar *et al.*, (2013), *A.campestris* oil has a strong

reducing power activity [101], with an IC_{50} of $0.305 \pm 0.006 \text{ mg/mL}^{-1}$, which is higher than our findings.

Saleem *et al.*, (2019), claimed that the methanol extract of *F.bruguieri* utilizing total reducing power assay (TRP) was lower than our results [215]. However, FbBE also demonstrates a remarkable capacity to donate an electron for *F.bruguieri*.

Galvinoxyl free radical scavenging experiment is a novel technique applied for the first time to *A.campestris* and *F.bruguieri*. Similarly, Both AcEAE and FbBE exhibit strong antioxidant activity, which is higher compared to the standards. Consequently, when hydrogen donors interact with the free radical $Gox\bullet$, it is reduced to $GoxH$ [336]. This reduction was monitored spectrophotometrically as a disappearance of colour when they were quenched.

VI.2.8. Antioxidant Activity Evaluation via Electrochemical Method

VI.2.8.1. $O_2^{\bullet-}$ free radical scavenging assay

Electrochemical tests are a relatively new approach that has been selected to determine the extract's antioxidant capacity. A sweeping examination of the relevant literature revealed that no previous investigation focused on the antioxidant activity of the cyclic voltammetry test of *A. campestris* and *F. bruguieri* extracts. In the current study, the antioxidant activity of *A. campestris* and *F. bruguieri* extracts was evaluated based on their ability to scavenge $O_2^{\bullet-}$ radicals By electrochemical method.

Voltamograms were obtained in the absence of an antioxidant in order to determine the values of the i_{pa0} current, which is used to determine the anodic $O_2^{\bullet-}$ oxidation current. This current is directly related to the concentration of $O_2^{\bullet-}$ on the electrode surface, the oxygen solubility in the DMF, and the selected experimental parameters.

The Voltammogram and a calibration curve of the Ascorbic Acid (standard antioxidant) were recorded to assess the antioxidant's ability to react when it reacts against the form of $O_2^{\bullet-}$. the first step is to achieve various concentrations at each injection into the cell for the purpose of plotting their calibration curve; the standard antioxidant is dissolved in DMF in varying concentrations (Figure.VI.17).






Figure.VI.17. Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of Ascorbic acid, recorded at 0.1V s^{-1} potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF₄ 0.1 M.

All voltammograms recorded to reduce the superoxide anion radical (Figure.VI.18 and Figure.VI.19) in the presence of samples of different extracts of *A.campestris* and *F.bruguieri* to assess antioxidant activity for free radical scavenging reveal obvious oxidation and reduction peaks. Sample extracts decreased anode current peaks but did not affect cathode current peaks.


Artemisa campestris L. extracts




A



B



C



D




**E**

Figure.VI.18. Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of *A. campestris* L. extracts (**A**): AcPEE; (**B**): AcDE; (**C**): AcEAE (**D**): AcBE; (**E**): AcAE, recorded at 0.1V s^{-1} potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF₄


Fagonia bruguieri DC. extracts




A




B



C



D



E

Figure.VI.19. Cyclic voltammograms of an oxygen-saturated cell in the presence of various concentrations of *F. bruguieri* DC. extracts (A): FbPEE; (B): FbDE; (C): FbEAE (D): FbBE; (E): FbAE, recorded at 0.1V s^{-1} potential sweep rate on GC disk electrode at 298K in DMF/nTBuNBF₄ 0.1 M.

The anodic peak current was found to have significantly decreased, as shown by the experimental data for each investigated sample.

➤ Half-maximal inhibitory concentration (IC_{50})

Inhibition curves expressed as a percentage (%) are derived from the concentrations of the tested extracts to get IC_{50} values (Figure.VI.20 and Figure.VI.21).

These values represent the concentration of the studied extracts needed to reduce the free radical concentration table by 50 %. The equation obtained from the linear calibration graph shown in Figure.VI.122, where y represents the value of the oxidation peak current density of $O_2^{\bullet-}$ and x represents the value of the concentration of the extracts expressed in mg/mL.

Artemisa campestris L. extracts

Using the Superoxide Anion $O_2^{\bullet-}$ method to measure antioxidant activity, Table.VI.19 shows that the following are in order from most to least antioxidant activity: AcEAE ($IC_{50}= 0.27$ mg/mL) < AcME ($IC_{50}= 0.22$ mg/mL) < AcPEE ($IC_{50}= 0.18$ mg/mL) < AcAE ($IC_{50}= 0.12$ Mg/mL) < Ascorbic acid ($IC_{50}= 00.05$ mg/mL) respectively. In Superoxide Anion $O_2^{\bullet-}$ Scavenging activities, the AcAE exhibited the highest antioxidant capacity.

Table.VI.19. Superoxide Anion $O_2^{\bullet-}$ Scavenging of different extracts of *A.campestris* L.

Superoxide anion $O_2^{\bullet-}$ scavenging assay				
Extracts	Equation	R ² Value	IC ₅₀ mg/mL ^a	
AcME	NT	NT	NT	
AcPEE	$y = 222.42x + 1.0188$	0.9991	0.22	
AcDE	$y = 291.96x - 2.5847$	0.9958	0.18	
AcEAE	$y = 200.07x - 5.3199$	0.997	0.27	
AcBE	$y = 290.36x - 3.0766$	0.9968	0.18	
AcAE	$y = 393.95x - 1.1461$	0.9963	0.12	
Ascorbic acid*	$y = 234.11x + 0.6611$	0.9903	0.0596	

^a IC₅₀: the concentration at the 50 of inhibition. *Standard compounds. NT: Note Tested.




Figure.VI.20. Comparison of superoxide anion radical $O_2^{\bullet-}$ according to I % values between extracts of *A.campestris* L. and Ascorbic acid.

***Fagonia bruguieri* DC. extracts**

Table.VI.20 shows *F.bruguieri's* capacity to reduce $O_2^{\bullet-}$ ions via superoxide anion $O_2^{\bullet-}$. The antioxidant activity measured by the electrochemical assay is listed below in decreasing order: Ascorbic acid (IC_{50} : 0.0596 mg/mL) > FbAE (IC_{50} : 0.43 mg/mL) > FbDE (IC_{50} : 0.89 mg/mL) > FbPEE (IC_{50} : 0.96 mg/mL) > FbBE (IC_{50} : 1.08 mg/mL) > FbEAE (IC_{50} : 1.13 mg/mL) respectively. Even when compared with Ascorbic acid standards, the $O_2^{\bullet-}$ radical scavenging activity level shown by FbAE (IC_{50} : 0.43 mg/mL μ g/mL) was the highest achievable.

Table.VI.20. Superoxide Anion $O_2^{\bullet-}$ Scavenging of different extracts of *F.bruguieri* DC.

Superoxide anion $O_2^{\bullet-}$ scavenging assay			
Extracts	Equation	R ² Value	IC ₅₀ mg/mL ^a
FbPEE	$y = 53.077x - 1.4839$	0.9971	0.96
FbDE	$y = 55.507x + 0.4354$	0.998	0.89
FbEAE	$y = 47.853x - 4.1945$	0.9921	1.13
FbBE	$y = 47.395x - 1.3803$	0.9977	1.08
FbAE	$y = 119.15x - 1.3448$	0.9955	0.43
Ascorbic acid*	$y = 234.11x + 0.6611$	0.9903	0.0596

*IC₅₀: the concentration at the 50 of inhibition. *Standard compounds. NT: Note Tested.









Figure.VI.21. Comparison of superoxide anion radical $O_2^{\bullet-}$ according to I % values between extracts of *F.bruguieri* DC. and Ascorbic acid.






Figure.VI.22. Plots of $(A_0 - A) / A_0 * 100$ verses the concentration for diffrents extracts of *A.campestris* L. and *F.bruguieri* DC.

The IC₅₀ values show that antioxidants are a significant component of the extracts' protection against oxidants. The ability of phenolic compounds to act as antioxidants is determined not only by the amount of hydroxyl groups present but also by the configuration of those groups and the existence of substitute electron donors in the cycle structure.

VI.3. Enzymes Inhibitory Activity

VI.3.1. Cholinesterase Inhibitory Activity

The anticholinesterase activities were determined for all fractions employing two enzymes: AChE and BChE, which reduce neurotransmitter Ach involved in Alzheimer's illness (Table.VI.21→ Table.VI.24).

VI.3.1.1. Acetylcholinesterase

Artemisa campestris L. extracts

AcEAE (IC₅₀= 23,16±0,19 µg/mL) showed a significant inhibitory effect for AChE Table.VI.21; it was more effective than AcPEE (IC₅₀=59.03±0.58 µg/mL), whilst AcDE showed the weakest inhibitory effectiveness (IC₅₀ >200 µg/mL).

Table.VI.21. Acetylcholinesterase inhibitory activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in Acetylcholinesterase inhibitory activity							IC ₅₀ µg/mL ^a	
	Concentration µg/mL	3.125	6.25	12.5	25	50	100		200
AcME	NA	NA	NA	NA	NA	NA	NA	NA	NA
AcPEE	6,87±0,12	14,07±0,12	14,77±0,09	34,95±0,58	41,15±0,32	72,83±0,09	88,01±0,68	59.03±0.58	
AcDE	1,32±0,84	1,58±0,24	1,92±0,59	2,41±0,16	2,78±0,23	3,48±0,28	4,94±0,50	>200	
AcEAE	6,34±0,96	6,51±0,33	33,84±0,60	51,54±0,56	60,11±0,24	70,83±0,27	83,25±0,39	23,16±0,19	
AcBE	NA	NA	NA	NA	NA	NA	NA	NA	NA
AcAE	NA	NA	NA	NA	NA	NA	NA	NA	NA
Galantamine	35,93 ± 2,28	43,77 ± 0,00	68,50 ± 0,31	80,69 ± 0,41	85,78 ± 1,63	91,80 ± 0,20	94,77 ± 0,34	6.27±1.15	

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.23. Comparison of acetylcholinesterase inhibition according to I % values between extracts of *A.campestris* L. and Galantamine.

Fagonia bruguieri DC. extracts

Extracts of *F.bruguieri* showed a significant inhibitory effect for ACHE it was more effective with the FbPEE ($IC_{50}=27.41\pm 1,03$ $\mu\text{g/mL}$) followed by FbBE ($IC_{50}=154,56\pm 3,03$ $\mu\text{g/mL}$) ; FbDE ($IC_{50}=163,42\pm 1,76$ $\mu\text{g/mL}$) whilst the FbEAE shown the weakest inhibitory effectiveness ($IC_{50}>200$ $\mu\text{g/mL}$) (Table.VI.22, Figure.VI.24).

Table.VI.22. Acetylcholinesterase inhibitory activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in Acetylcholinesterase inhibitory activity							IC_{50} $\mu\text{g/mL}$	
	Concentration $\mu\text{g/mL}$	3.125	6.25	12.5	25	50	100		200
FbPEE		18,47 \pm 0,35	31,07 \pm 0,88	34,51 \pm 0,20	51,28 \pm 1,50	62,08 \pm 0,50	82,14 \pm 0,77	96,50 \pm 1,15	27.41 \pm 1,03
FbDE		NA	NA	NA	0,90 \pm 1,17	7,38 \pm 0,50	35,84 \pm 0,23	55,15 \pm 0,82	163,42 \pm 1,76
FbEAE		18,82 \pm 0,40	19,92 \pm 0,56	20,50 \pm 1,14	27,78 \pm 0,74	28,33 \pm 0,28	37,58 \pm 0,88	38,73 \pm 0,70	>200
FbBE		3,33 \pm 1,20	9,06 \pm 0,76	15,56 \pm 1,04	15,58 \pm 0,43	32,46 \pm 2,05	43,01 \pm 1,44	50,90 \pm 0,70	154,56 \pm 3,03
FbAE		NA	NA	NA	NA	NA	NA	NA	NA
Galantamine		35,93 \pm 2,28	43,77 \pm 0,00	68,50 \pm 0,31	80,69 \pm 0,41	85,78 \pm 1,63	91,80 \pm 0,20	94,77 \pm 0,34	6.27 \pm 1.15

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p<0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.24. Comparison of acetylcholinesterase inhibition according to I % values between extracts of *F.bruguieri* DC. and Galantamine.

VI.3.1.2. Butyrylcholinesterase

Artemisa campestris L. extracts

On the other hand, significant inhibition was shown against BChE, where the AcPEE ($IC_{50}=93.50\pm 1.60$ µg/mL) declared the most heightened inhibitory effect; AcBE and AcAE did not affect the activities of BChE (Figure.VI.25).

Table.VI.23. Butyrylcholinesterase inhibitory activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in Butyrylcholinesterase inhibitory activity							IC_{50} µg/mL ^a	
	Concentration µg/mL	3.125	6.25	12.5	25	50	100		200
AcME	NA	NA	NA	1,08±0,26	9,10±1,63	20,03±1,52	30,51±0,29	>200	
AcPEE		11,52±2,32	18,45±0,22	22,40±0,34	35,43±1,56	38,48±1,23	51,74±0,77	56,13±1,49	93.50±1.60
AcDE	NA	NA	NA	7,88±2,47	15,55±0,59	27,61±0,22	52,49±1,52	185.11±2.51	
AcEAE	NA	NA	NA	NA	NA	10,26±0,56	26,49±1,55	>200	
AcBE	NA	NA	NA	NA	NA	NA	NA	NA	
AcAE	NA	NA	NA	NA	NA	NA	NA	NA	
Galantamine*		3,26± 0,62	6,93± 0,62	24,03± 2,94	45,13± 2,60	63,87± 2,85	73,57± 0,77	78,95± 0,58	34.75±1.99

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at $p<0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.25. Comparison of Butyrylcholinesterase inhibition according to I % values between extracts of *A.campestris* L. and Galantamine.

Fagonia bruguieri DC. extracts

The anti BChE activity (IC_{50}) of different extracts of *F.bruguieri* was obtained as follows : FbEAE ($IC_{50}=171,94\pm 3,25$ $\mu\text{g/mL}$) > FbBE ($IC_{50}=119,55\pm 1,66$ $\mu\text{g/mL}$) > FbDE ($IC_{50}=69,97\pm 0,70$ $\mu\text{g/mL}$) > FbPEE ($IC_{50}=46,14\pm 0,78$ $\mu\text{g/mL}$) > Galantamine ($IC_{50}=34.75\pm 1.99$ $\mu\text{g/mL}$).

Table.VI.24. Butyrylcholinesterase inhibitory activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in Butyrylcholinesterase inhibitory activity							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	3.125	6.25	12.5	25	50	100		200
FbPEE		29,67±0,43	29,72±0,11	32,24±0,80	40,77±1,95	51,53±0,71	53,60±0,00	57,34±0,21	46,14±0,78
FbDE		24,01±0,56	24,57±0,56	32,12±1,49	43,78±0,65	50,04±0,74	50,71±1,70	71,89±1,84	69,97±0,70
FbEAE		16,53±1,03	19,71±1,03	20,02±0,71	22,69±0,39	32,46±0,94	39,60±0,88	53,79±0,94	171,94±3,25
FbBE		25,53±1,22	32,09±0,48	35,71±0,93	39,26±0,74	43,11±0,80	47,50±0,46	58,60±0,61	119,55±1,66
FbAE		NA	NA	NA	NA	NA	NA	NA	NA
Galantamine*		3,26± 0,62	6,93± 0,62	24,03± 2,94	45,13± 2,60	63,87± 2,85	73,57± 0,77	78,95± 0,58	34.75±1.99

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p<0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.26. Comparison of Butyrylcholinesterase inhibition according to I % values between extracts of *F.bruguieri* DC. and Galantamine.

Discussion

Alzheimer's disease, such as neurodegenerative diseases, concerns public health priorities. It is a fatal neurodegenerative disease that is characterized by progressive damage to the brain and increased mental disorder [413]. Several illnesses require enzyme therapy to be effectively cured. Cholinesterase inhibitors are the main enzyme in Alzheimer's disease pathologies as the key to inhibiting the enzymes impacted in acetylcholine hydrolysis, acetylcholinesterase and butyrylcholinesterase by trying to extend the availability of acetylcholine to create the receptors in the brain [414, 415]. Galantamine is a cholinesterase inhibitor widely used in treating AD, and it represents a positive control for comparison purposes.

According to the findings shown in Table.VI.21, *A.campestris* revealed good inhibitory effectiveness for the AcEAE against AChE ($IC_{50} = 23.16 \pm 0.19 \mu\text{g/mL}$) and then AcPEE ($IC_{50} = 59.03 \pm 0.58 \mu\text{g/mL}$). The AcPEE, nonetheless, it moderately inhibited BChE activity ($IC_{50} = 93.50 \pm 1.60 \mu\text{g/mL}$). In comparison with the findings obtained for the essential oil of *A.campestris* reported in 2020 by Cherif. K *et al.*, [416], the AcPEE and AcEAE demonstrated a strong inhibitory effect on the AChE and BChE enzymes. For this reason, we may conclude that the chemical components are capable of acting as antagonists of both AChE and BChE. Szwajgier *et al.* (2015) have proven that some flavonoids and phenolic acids play this function,

such as acacetin and apigenin have a substantial effect on inhibiting activity towards AChE and BChE and whose presence has already been established according to the LC-MS/MS results [417].

Murray *et al.* (2013) have shown that naturally occurring substances, such as terpenoids and alkaloid chemicals, can inhibit the enzymes AchE and BChE. Such compounds originate from a variety of multiple sources [418]. It is conceivable that the activity of acetyl and butyrylcholinesterase in the AcPEE is due to secondary metabolites. Recently, Boukhalkhal *et al.* (2020) have previously identified these terpenoids in *A.campestris*: OH-Rubescensin BI, BII and Carnosic acid [419]. These compounds might have produced the anticholinesterase effect that was studied in this approach. In light of this, we have highlighted our results, which suggest that *A.campestris* might very well have an anti-Alzheimer effect that could be helpful in the treatment of AD.

Additionally, the extracts of *F.bruguieri* showed a considerable inhibitory effect on both AChE and BChE, as shown in Table.VI.23 and Table.VI.24. It has been found that the FbPEE exhibits the most significant activity against both BChE and AChE. As was discussed earlier, natural chemicals derived from various resources such as terpenoids, phenolic compounds, and alkaloids, can inhibit the enzymes AchE and BChE [418]. We suggest that secondary metabolites in the FbPEE may be responsible for the acetyl- and butyrylcholinesterase activity. Abdel-Kader *et al.*, (1994) demonstrated a new ent-erythroane diterpene: 15,16-dihydroxy-7-hydroxy-cis-ent-erythro-3-ene present in *F.bruguieri* [245]. In 1993 the same authors also afforded the first reported diterpenes: 15,16-dihydroxy-7-oxo-cis-ent-erythro-3-ene (fagonone) with an ent-erythroane structure 16-*O*-acetylfagonone in aerial parts of *F.bruguieri* [229]. Moreover, Maksoud & El-Hadidi., (1987) have previously identified in *F.bruguieri* seven flavonol glycosides of these Quercetin 3-rhamnogalactoside, kaempferol 3-rhamnogalactoside, and Quercetin 3-galactoside [420]. These chemicals may provide the foundation for the anticholinesterase effect investigated above. Several monoterpenes obtained from essential oils are potent inhibitors of AChE activity *in vitro* [421]. Cinéole, Camphre, trans-géranol, o-Cymène, and α -citral have all been found in the aerial fractions of *Fagonia cretica* L. in Previous research [247]. Preliminary *in vivo* studies showed that *F.bruguieri* extracts strongly inhibited AchE activity in the haemolymph of freshly emerging *S. gregaria* adults [214]. In light of this, we've consolidated our findings that the anti-Alzheimer activity in *F.bruguieri* may be beneficial in the treatment of AD.

VI.3.2. Evaluation of anti-diabetic activity

VI.3.2.1. Alpha -amylase Inhibitory activity

In order to evaluate the antidiabetic efficient of *A.campestris* and *F.bruguieri* extracts was determined by estimating the potential of the different extracts to inhibit the α -amylase enzyme.

Artemisa campestris L. extracts

Based on the findings in Table.VI.25, the reaction with *Artemisa* extracts provided the ideal response with an IC₅₀ value that was significantly lower than that of acarbose, except that the AcAE was not active against beta-amylase. The most heightened α -amylase inhibitory effect was recorded for AcPEE (IC₅₀=11.97± 0.14 μ g/mL) (Figure.VI.27) . This activity is three hundred and thirty-third times (333x) higher than acarbose (IC₅₀=3650.93±10.70 μ g/ml).

Table.VI.25. Alpha-amylase inhibitory activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in α -amylase inhibitory assay							IC ₅₀ μ g/mL ^a	
	Concentration μ g/mL	62,5	125	250	500	1000	2000		4000
AcME		37,44±0,30	38,16±0,31	39,04±0,13	39,73±0,24	40,58±0,36	41,27±0,27	45,76±0,31	>4000
AcPEE		47,42±0,00	50,21±0,27	56,46±0,18	59,40±0,45	68,75±0,39	71,95±0,72	97,91±0,63	11.79±0.14
AcDE		46,49±0,00	47,57±0,81	48,81±0,00	53,67±0,59	73,50±0,45	80,62±0,45	92,10±0,36	28.33±1.35
AcEAE		42,05±0,70	43,80±0,09	43,80±0,18	45,51±0,54	46,95±0,15	48,35±0,15	51,91±0,62	284.33±3.91
AcBE		40,54±0,30	44,90±0,07	51,99±0,07	62,32±0,15	71,34±0,63	87,57±0,15	88,98±0,07	21.55±0.66
AcAE		37,40±0,27	38,20±0,52	38,78±0,30	39,64±0,25	39,91±0,21	39,99±0,31	40,46±0,13	>4000
Acarbose *		7,76±0,17	8,08±0,30	9,46±0,11	10,70±0,96	31,81±2,89	37,21±3,54	53,05±1,59	3650,93±10,70

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.27. Comparison of alpha-amylase inhibition according to I % values between extracts of *A.campestris* L. and Acarbose.

Fagonia bruguieri DC. extracts

The α -amylase inhibitory activity of several *F.bruguieri* extracts was determined as follows: FbDE ($IC_{50}=7,12\pm0,89$ $\mu\text{g/mL}$) > FbEAE ($IC_{50}=119,55\pm1,66$ $\mu\text{g/mL}$) > FbBE ($IC_{50}=43.55\pm0.33$ $\mu\text{g/mL}$) > FbPEE ($IC_{50}=68,86\pm2,91$ $\mu\text{g/mL}$) > FbAE ($IC_{50}=97.67\pm0.33$ $\mu\text{g/mL}$) > acarbose ($IC_{50}=3650.93\pm10.70$ $\mu\text{g/ml}$). The highest α -amylase inhibitory activity was showed in FbDE . This activity is (520 x) higher than acarbose (Table.VI.26 and Figure.VI.28).

Table.VI.26. Alpha -amylase inhibitory activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in α -amylase inhibitory assay							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	62,5	125	250	500	1000	2000		4000
FbPEE		45,56 \pm 0,66	46,42 \pm 0,75	47,56 \pm 0,98	48,48 \pm 0,72	51,18 \pm 0,40	62,52 \pm 0,49	82,11 \pm 0,72	68,86 \pm 2,91
FbDE		47,84 \pm 0,55	54,92 \pm 0,63	56,54 \pm 0,35	59,88 \pm 0,44	68,64 \pm 0,55	76,13 \pm 0,38	89,70 \pm 4,13	7,12 \pm 0,89
FbEAE		45,76 \pm 0,53	48,09 \pm 0,35	51,83 \pm 0,23	54,92 \pm 0,32	62,82 \pm 0,23	80,44 \pm 0,61	104,99 \pm 0,49	19,12 \pm 0,33
FbBE		27,17 \pm 0,26	33,28 \pm 0,07	42,25 \pm 0,52	52,76 \pm 0,07	63,95 \pm 0,22	74,75 \pm 1,18	87,10 \pm 0,52	43.55 \pm 0.33
FbAE		26,38 \pm 2,04	32,86 \pm 0,71	33,95 \pm 0,20	38,72 \pm 0,34	50,71 \pm 0,53	55,18 \pm 0,27	76,66 \pm 0,60	97.67 \pm 0.33
Acarbose*		7,76 \pm 0,17	8,08 \pm 0,30	9,46 \pm 0,11	10,70 \pm 0,96	31,81 \pm 2,89	37,21 \pm 3,54	53,05 \pm 1,59	3650,93 \pm 10,70

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p<0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.28. Comparison of alpha-amylase inhibition according to I % values between extracts of *F.bruguieri* DC. and Acarbose.

Discussion

Diabetes, also known as hyperglycemia chronic, is a symptom of the metabolic. Diabetes Type 2 can be treated with a variety of medicinal approaches. Inhibiting alpha-amylase in the small intestine, which inhibits complex carbohydrates from being broken down and inhibits the body from absorbing them, is one of the strategies by which plants exert their anti-hyperglycemic impact on the body. Starch and other glucose polymers in diabetic individuals hydrolyze (1.4)-D-glycosidic linkages in the presence of this enzyme's inhibitors [422].

Both *A.campestris* and *F.bruguieri* extracts had a remarkable anti-diabetic action that was significantly more effective than acarbose (Table.VI.25; Table.VI.26 and Figure.VI.27; Figure.VI.28). Furthermore, we underlined a substantial difference in their IC₅₀ values. The ability of polyphenols to inhibit the enzymes alpha-glucosidase and alpha-amylase was investigated through molecular docking simulations, and it was expected that compounds such as caffeic acid, naringin, chlorogenic acid, quercetin and Rutin might significantly inhibit the enzymes [423]. This includes all Phenolic chemicals and flavonoids discussed in the profile phytochemicals of *A.campestris* and *F.bruguieri* extracts, which are a crucial tool in the treatment of diabetes type II in this study. On the other hand, the presence of some minerals may favourably contribute to the anti-diabetic benefits of plants, by enhancing the effects of insulin, this could be the case as specific minerals have been shown to have anti-diabetic

properties [424]. Myricetin, a common flavonol and one of the *A.campestris* and *F.bruguieri* components (Table.V.8 and Table.V.9 Part 2: Chapter V), has been validated as a potent flavonoid inhibitor of amylase, and the possibility of delivering it in concentrated form to lower postoperative hyperglycaemia has been investigated in 2015, by Gu *et al.* [425]. Our study is highlighting demonstrates that *A.campestris* and *F.bruguieri* have anti-diabetic potential in vitro by inhibiting alpha-amylase.

VI.3.3. Evaluation of anti-obesity activity

VI.3.3.1. Pancreatic Lipase Inhibitory Activity

Artemisa campestris L. extracts

The data on the Pancreatic Lipase inhibiting activity of extracts from *A.campestris* aerial parts is shown in Table.VI.27 and Figure.VI.29. *A.campestris* extracts were shown to significantly inhibit anti-lipase activity, with the AcPEE ($IC_{50}=40.15\pm 1.36\mu\text{g/mL}$) proving to be more effective compared to the reference compound. The inhibitory activity follows the decreasing order: orlistat ($IC_{50}=0.06\pm 0.001\mu\text{g/mL}$) > AcPEE ($IC_{50}=40.15\pm 1.36\mu\text{g/mL}$) > AcDE ($IC_{50}=86.29\pm 2.60\mu\text{g/mL}$) > AcEAE ($IC_{50}=155.47\pm 3.44\mu\text{g/mL}$), respectively. While the AcME did not affect pancreatic lipase.

Table.VI.27. Pancreatic lipase inhibitory activity of different extracts of *A.campestris* L.

Extracts	% Inhibition in Antilipase inhibitory activity							IC ₅₀ μg/mL ^a
	Concentration μg/mL	15.62	31.25	62.5	125	250	500	
AcME	NT	NT	NT	NT	NT	NT	NT	NT
AcPEE	23.59±0.15	35.04±0.23	35.46±0.07	44.15±0.15	54.37±0.96	56.71±0.09	75.72±1.34	40.15±1.36
AcDE	32.68±0.30	36.71±0.03	36.90±0.24	42.91±0.35	43.94±0.14	52.29±0.38	62.49±0.38	86.29±2.60
AcEAE	24.55±1.39	27.75±0.08	29.57±0.86	34.14±0.20	32.92±0.11	46.21±0.42	55.04±0.58	155.47±3.44
AcBE	13.61±0.20	17.98±0.07	19.71±0.09	23.78±0.47	25.14±0.14	27.31±0.25	31.56±0.49	>1000
AcAE	NA	NA	NA	1.01±0.22	1.22±0.94	2.43±1.06	8.98±0.50	>1000
Orlistat*	-	21,66±0,87	68,59±1,60	74,72±0,88	76,80±0,19	77,48±0,87	79,84±1,07	0,06±0,01

^a IC₅₀: the concentration at the 50 of inhibition. IC₅₀ values represent the means ±SEM of three measures. Tukey test. The differences in values were considered at p<0.05. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.29. Comparison of Antilipase inhibitory according to I % values between extracts of *A.campestris* L. and Orlistat.

Fagonia bruguieri DC. extracts

Table.VI.28 and Figure.VI.30 show data on the pancreatic lipase inhibitory activity of extracts from *F.bruguieri* aerial parts. The inhibitory activity follows the decreasing order: orlistat (79.84%)> Dichloromethane (56.76%) > Petroleum Ether (48.28%) > Butanol (34.81%) > Ethyl acetate (32.21%) respectively.

As compared to the reference ($IC_{50}=0,06\pm 0,001\mu\text{g/mL}$), FbBE have significant anti-lipase ($IC_{50} = 122.5\pm 0.93\mu\text{g/mL}$) activity to inhibit the Pancreatic Lipase.

Table.VI.28. Pancreatic lipase inhibitory activity of different extracts of *F.bruguieri* DC.

Extracts	% Inhibition in Antilipase inhibitory activity							IC_{50} $\mu\text{g/mL}^a$	
	Concentration $\mu\text{g/mL}$	15.62	31.25	62.5	125	250	500		1000
FbPEE		21,20±0,39	26,01±0,24	27,91±1,02	35,62±0,58	38,58±0,65	45,96±1,29	48,28±0,39	> 1000
FbDE		18,35±0,30	21,50±1,31	26,08±0,51	39,34±0,46	44,48±0,21	47,48±0,26	56,76±0,10	122.5±0.93
FbEAE		NA	6,41±0,31	7,91±0,12	16,15±0,56	23,39±1,81	27,94±0,04	32,21±0,36	> 1000
FbBE		NA	5,99±0,75	11,30±0,26	13,66±0,37	17,43±0,39	24,93±0,14	34,81±0,55	>1000
FbAE		NA	NA	5.66±1.01	9.12±0.32	14.12±0.65	18.95±0.76	29.88±1.50	>1000
Orlistat*		-	21,66±0,87	68,59±1,60	74,72±0,88	76,80±0,19	77,48±0,87	79,84±1,07	0,06±0,001

^a IC_{50} : the concentration at the 50 of inhibition. IC_{50} values represent the means \pm SEM of three measures. Tukey test. The differences in values were considered at $p<0.05$. *Standard compounds. NT: Note Tested. NA: Note Active.




Figure.VI.30. Comparison of Antilipase inhibitory according to I % values between extracts of *F.bruguieri* DC. and Orlistat.

Discussion

Since pancreatic lipase is the primary source of excess calories, recent advancements in absorption inhibitors and nutritional digestion are crucial for treating this disease. The search for therapeutic drugs has become an urgent matter [426]. Among the most important and latest treatment for obesity is Orlistat, a pancreatic lipase inhibitor with a remarkable effect ($IC_{50} = 0.061 \pm 0.001 \mu\text{g/mL}$) due to its long-term effectiveness. The enzyme lipase breaks down dietary triglycerides into diacylglycerol, monoglycerides, glycerol, and polyunsaturated fatty acids [427].

Our study reports for the first time the anti-lipase activity of the aerial parts of the *A.campestris* extracts. According to our results (Table.VI.27), AcPEE is more effective, providing a real chance of discovering new antiobesity drugs. Natural compounds obtained from plants have been shown to have biological activity and potential as anti-obesity drugs. In effect, saponins, polyphenolics, terpenes, and triterpenes are abundant lipase inhibitors. Thus many plants have been studied for their antilipase activity [426, 427]. In particular, terpenes, such as carnosic acid; carnosol; and oleanolic acid were reported to inhibit pancreatic lipase [428, 429], previous research has proven the existence of the mentioned substances in *A.campestris* [419, 430].

The remarkable inhibitory activity of the FbDE was the most remarkable (Table.VI.28), which presents an exciting opportunity to discover newer anti-obesity factors. As was already declared, terpenes and triterpenes are sources of lipase inhibitors, which are thought to be

promising treatments for obesity [426, 427]. The *Fagonia* plant is well-known for its abundance of terpenes, although previous studies are isolated from *F.bruguieri* DC: oleanolic acid and its derivatives (terpenes) [229, 245]. Furthermore, an important study on Wistar rats found that methanol extract of *Fagonia cretica* L. protected Wistar rats from several obesity markers produced by a cafeteria diet [431]. Additionally, it was reported that methanol/water extract of *Fagonia arabica* L., another species of *Fagonia*, possesses pancreatic lipase inhibitory effects [432]. A recent study by Patel *et al.* (2020), conducted with ethyl acetate fraction of *Fagonia cretica* L. ($IC_{50} = 83.02 \pm 2.47 \%$) [433]. Nevertheless, this is the first research to investigate the anti-lipase activity of the aerial parts of *F.bruguieri* extracts.

VI.4. Anti-inflammatory Activity

We selected to use the anti-denaturation model of BSA (bovine serum albumin) as the basis for our in vitro evaluation of the various extracts' potential anti-inflammatory effects. The effect that each of our different extracts of *A. campestris* L. and *F.bruguieri* DC. had on the thermal denaturation of BSA was measured at various concentrations, and the findings are presented in Figure.VI.31; Figure.VI.32; Table.VI.29 and Table.VI.30 below.

Artemisa campestris L. extracts


As shown in Figure.VI.31 and Table.VI.29, *A. campestris* L. extracts were evaluated in comparison to the reference compounds used in this investigation (Diclofenac). It is worth noting that extracts have a concentration dependent inhibitory effect on protein denaturation that can be influenced by high temperatures. The AcBE extract had the highest percentage (94.47%) of anti-inflammatory action at a 250 $\mu\text{g/mL}$ concentration, which is very close to that of Diclofenac (99.23%).

The order of the various extracts of *A. campestris* L. in terms of their ability to inhibit was: AcBE (94.47%) > AcDE (91.58%) > AcEAE (84.78%) > AcPEE (58.72%) > AcAE (24.17%).

Table.VI.29. Inhibition percentage in Anti-Inflammatory activity of different extracts of *A.campestris* L.

Concentration ($\mu\text{g/mL}$)	% Inhibition percentage in Anti-Inflammatory inhibition					
	AcPEE	AcDE	AcEAE	AcBE	AcAE	Dichlofenac*
250	58.72 \pm 0.86 ^a	91.58 \pm 1.00 ^a	84.78 \pm 0.26 ^a	94.47 \pm 0.27 ^a	24.17 \pm 2.82 ^a	99.23 \pm 0.41 ^a
125	34.56 \pm 1.47 ^b	82.22 \pm 0.56 ^b	83.16 \pm 1.68 ^b	85.76 \pm 0.37 ^b	6.02 \pm 0.80 ^b	76.87 \pm 1.24 ^b
62.5	14.65 \pm 1.82 ^c	53.95 \pm 0.79 ^c	73.89 \pm 0.84 ^c	29.06 \pm 0.53 ^c	NA	51.37 \pm 0.91 ^c
31.25	4.78 \pm 0.21 ^d	28.31 \pm 1.17 ^d	43.85 \pm 2.57 ^d	12.47 \pm 1.07 ^d	NA	34.11 \pm 0.50 ^d

% Inhibition values are expressed as means \pm SD of three replicates. The values with different superscripts (a, b, c, d) in the same columns are significantly different ($p < 0.05$). *Standard compounds, NA: Note Active.

**Figure.VI.31.** Effect of different extracts of *Artemisia campestris* L. and Diclofenac sodium on the inhibition of protein denaturation.***Fagonia bruguieri* DC. extracts**

The protein denaturation inhibition percentages provided by the various concentrations of the several extracts of the plant *F.bruguieri* DC. ranged from 10.78% to 92.67%. These results were not significant ($p < 0.05$). The anti-inflammatory activity of diclofenac was used as a

standard to compare to our extracts; it showed maximum inhibition of 99.23% at 250 µg/mL, demonstrating that it is more potent than the extracts investigated. At a concentration of 250 µg/mL, maximal inhibition of 92.76% for FbBE and 90.32% for FbEAE were recorded, both of which are close to the diclofenac standard. Figure.VI.31 shows that the lowest inhibition percentages are seen for FbPEE and FbDE, from 31.25 to 125 g/mL. From this concentration onwards, the percentages of inhibition for the various extracts increase steadily. We observe that the effect of the extracts depends on the concentration and that diclofenac's effect is significantly more effective than that of our extracts.

The order of the various extracts of *A. campestris* in terms of their ability to inhibit was: FbBE (92.76%) >FbEAE (80.38%) >FbDE (39.91%) >FbPEE (36.20%) >FbAE (14.81%)

Table.VI.30. Inhibition percentage in anti-inflammatory activity of different extracts of *F.bruguieri* DC.

Concentration (µg/mL)	% Inhibition percentage in anti-inflammatory inhibition					
	FbPEE	FbDE	FbEAE	FbBE	FbAE	Dichlofenac*
250	36.20±0.28 ^a	39.91±1.66 ^a	80.38±0.19 ^a	92.76±0.8 ^a	14.81±0.12 ^a	99.23±0.41 ^a
125	23.24±0.55 ^b	26.63±1.03 ^b	76.15 ±1.02 ^b	84.88±0.87 ^b	NA	76.87±1.24 ^b
62.5	12.11±0.83 ^c	17.91±2.03 ^c	60.64±0.78 ^c	66.47±1.76 ^c	NA	51.37±0.91 ^c
31.25	NA	10.78±0.20 ^d	44.04±0.19 ^d	64.18±0.53 ^d	NA	34.11±0.50 ^d

% Inhibition values are expressed as means ±SD of three replicates. The values with different superscripts (^{a, b, c, d}) in the same columns are significantly different ($p < 0.05$). *Standard compounds, NA: Note Active.




Figure.VI.32. Effect of different extracts of *Fagonia bruguieri* DC. and Diclofenac sodium on the inhibition of protein denaturation.

Discussion

Denaturation of proteins is a process in which proteins lose their tertiary and secondary structures due to exposure to external stress such as heat or by certain compounds such as acids or strong bases and organic solvents. This results in proteins losing their ability to perform their biological function [434]. The mechanism that leads to this denatured state involves a rupture of the electrostatic, hydrogen, or hydrophobic interactions as well as the disulfide bridges responsible for maintaining the three-dimensional structure of the [435]. Some forms of arthritis may be triggered by autoantigens, which can lead to the denaturing of tissue proteins. Therefore, it is possible to conclude that arthritis is characterized by the denaturing of tissue proteins [434].

The denaturation of cell-building proteins or intercellular substances is the source of a significant number of lesions that occur in the tissue. Nonsteroidal anti-inflammatory medications are widely utilized in clinical settings to treat inflammatory disorders due to their ability to reduce or prevent protein denaturation [436].

Inhibition of protein denaturation may play a significant part in NSAID (nonsteroidal anti-inflammatory drug) antirheumatic effectiveness. Still, the unavoidable and potentially fatal side effects are sometimes disastrous [437]. Mizushima & Kobayashi (1968) used protein denaturation as an in vitro screening model for potentially anti-inflammatory compounds [438]. In addition, agents that are able to inhibit or prevent the denaturation of proteins of plant origin are suitable for the development of new anti-inflammatory agents due to the fact that they are

safe, efficacious, and cost-effective as we mentioned previously, flavonoids and phenolic acids reduce inflammation [439].

In the present investigation, the protein denaturation biological test was used to evaluate the anti-inflammatory effects in vitro of the various extracts of *A. campestris* L. and *F. bruguieri* DC. Based on the results obtained, it is reasonable to assume that our extracts can prevent the formation of autoantigens by preventing the denaturation of proteins and consequently prevent the formation of autoantibodies associated with autoimmune diseases.

The increased absorbances of the test samples compared to the control show that the extracts and the reference drug diclofenac sodium stabilize the proteins by inhibiting the heat-induced protein denaturation (BSA) [440]. According to the percentages of inhibition, it is evident that AcBE, AcDE, FbBe and FbEAE were more active when compared to other extracts and effective at lower concentrations compared to diclofenac sodium.

Duganath *et al.*, (2010) found that the molecules in natural products interact with certain amino acids that make up proteins, in this case, albumin, to provide an anti-denaturation effect (model studied) [441]. Aliphatic chains at tyrosine and threonine would be the main sites of such interactions. In addition, they revealed that therapeutic compounds could reactivate the pattern-rich tyrosine receptor in conjunction with threonine, both of which regulate the biochemical mechanisms of signal transduction that are necessary for their overall biological function.

Artemisia campestris L. has been used to treat inflammatory diseases in Tunisia, Morocco, and Algeria for centuries, although its pharmacological properties are unclear [112].

In our study, an extremely high inhibition rate was recorded in the AcBE (94.74±0.27%), and even at the concentration (250 µg /mL), it had identical findings to those achieved with the anti-inflammatory drug that served as a reference (Diclofenac), and this was especially relevant at the same concentration. We suggest that this interesting response is influenced by the presence of the various bioactive substances mentioned in the preceding studies. Effectively, in 2017 Metoui *et al.* demonstrated that flavones tetrahydroxy-5'.6-dimethoxyflavone isolated from *Artemisia campestris* L. in the leaves had the best anti-inflammatory effect [115], which confirmed its existence in AcDE, AcEAE, AcBE via LC-MS/MS profil. In addition, the right hind paw oedema was successfully treated with the ethanolic extract of *A. campestris* L. leaves at doses of 150 and 300 mg/kg in rats [442]. In general, other studies, have also shown that plant extracts can have a vast variety of advantageous biological characteristics, notably properties that reduce the body's inflammatory response.

To our knowledge, no previous studies have provided findings on evaluating *Fagonia bruguieri* DC. on anti-inflammatory efficacy in vitro using the protein denaturation inhibition test in order to draw comparisons, however several researchers have reported that polyphenols and terpenes from *F.bruguieri* have anti-inflammatory effects.

Maximum inhibition of FbBE was observed at 92.76% and FbEAE at 90.32%, and the main components of the most effective FbBE and FbEAE remain phenolic acids, flavonoids, flavones, terpenes, and lignans (Table.V.9 and Table.V.11 Part 2: Chapter V). The anti-inflammatory effect may be due to a constituent or several phytochemical constituents' synergistic effect.

To validate the traditional use of *F.bruguieri* in treating inflammatory illnesses, the studies evaluated the anti-inflammatory activity of the methanol extract of the aerial part in an animal model. Irshad *et al.*, (2022) reported the in-vivo (Carrageenan-induced paw oedema in adult male albino Wistar rats model) to assess the anti-inflammatory effects of the methanol extract. In effect, the methanolic extract of *F. bruguieri* DC. at 750 mg/kg showed anti-inflammatory effects in carrageenan-induced oedema after 2, 3, and 4th hours [211].

This preliminary research suggests that the plants *A.campestris* L. and *F.bruguieri* DC. contains components that exhibit the aforementioned pharmacological (anti-inflammatory) properties and can produce bioactive molecules for the development of novel drugs.

VI.5. Sun protection factor activity (SPF)

***Artemisa campestris* L. extracts**

The Sun Protection Factor (SPF) was determined as an indicator of the photoprotective efficiency of *A.campestris* L. As illustrated in Table.VI.31 SPF values of the extracts of *A.campestris* varied from 24.79 ± 0.07 to 40.76 ± 0.1 . Based on these findings, it was determined that all of the extracts displayed indications of having photoprotective properties. Furthermore, the outcomes demonstrate that AcME, AcDE, AcEAE, and AcBE extracts all had high photoprotective effects, with SPF values: 42.07 ± 0.17 ; 40.76 ± 0.11 ; 39.51 ± 0.09 ; 38 ± 0.05 , respectively.

Table.VI.31. Photoprotective Activity of different extracts of *A.campestris* L.

	Nivea*	Vichy*	AcME	AcPEE	AcDE	AcEAE	AcBE	AcAE
SPF	50.11±0.53	44.22±0.35	42,07±0,17	24.79±0.07	40.76±0.11	39.51±0.09	38.00±0.05	26.07±0.22
Protection	High	High	High	Medium	High	High	High	medium

*Reference compounds.

***Fagonia bruguieri* DC. extracts**

As presented in Table.VI.32, SPF values of the studies extracts of *F.bruguieri* DC., ranging from 11.25±0.1 to 43.86±0.12. These findings showed that all fractions had evidenced photoprotective activity. The FbDE, FbBE, and FbEAE revealed a high photoprotective with SPF [43.86±0.12 ; 43.73±0.06; 43.07±2.06 respectively].

Table.VI.32. Photoprotective Activity of different extracts of *F.bruguieri* DC.

Extracts	Nivea*	Vichy*	FbPEE	FbDE	FbEAE	FbBE	FbAE
SPF	50,11 ±0,53	44,22 ±0,35	11.25 ±0.1	43.86 ±0.12	43.07 ±2.06	43.73 ±0.06	34.72 ±0.06
Protection	High	High	Minimum	High	High	High	High

*Reference compounds.

Discussion

The application of sunscreen as a photoprotective agent for protection against UV rays is rapidly gaining popularity. The ability of molecules to absorb, reflect, or scatter the ultraviolet light produced by the sun is essential to its functioning. Sunscreens with a higher SPF are more effective at preventing sunburn and ensure a high level of protection. [443].

Long-term exposure to ultraviolet radiation, which may be divided into three categories: UVA, UVB, and UVC, has been related to various damaging health consequences, including an increased risk of developing skin cancer [444].

In recent years, natural compounds have attracted significant attention as potential protective agents [445]. Phenolic compounds can reduce DNA damage by acting as oxy-reduction-sensitive signalling pathways. Effectively, phenolic compounds have the potential to be

effective in the prevention of UV-induced free oxygen radicals and lipid peroxidation, both of which are processes that are implicated in the development of pathological disorders such as photoaging and skin cancer [446]. Natural compounds are often used in conventional medicine and the cosmetics industry; several flavonoids, in particular, have been demonstrated to protect against the damaging effects of UV radiation [350].

Therefore, these herbal formulations, could produce several beneficial effects for the skin in addition to functioning as UV filters, which is one of the objectives of this study.

The sun protection factor, abbreviated SPF, is a quantitative rating of a sunscreen's efficacy. Considering this concept of SPF, it has newly been established that, according to the SPF ratings. The values of SPF [2 →12], [12 →30], [30 → 50] and >50 are classified as possessing a minimum, moderate and strong sun protection action, respectively.

A.campestris and *F.bruguieri* have so far not been reported to have photoprotective properties. Therefore, the facts reported in this contribution could constitute the first literature report on this species.

According to the study made by Mishra *et al.*, (2012), flavonoids and phenolic compounds possess excellent antioxidants and photoprotective properties [443]. It is common knowledge that flavonoids contain a significant amount of hydroxyl groups. Due to this, studying the phenolic components and flavonoids of plant species is essential for developing topical sunscreen formulations from these extracts. Both *A. campestris* and *F. bruguieri*, the studied plants, include phenolic compounds and flavonoids that can trap free radicals, which is directly related to their antioxidant capacity.

According to the Commission of European Communities 2006 recommendation [447], the AcME, AcDE, AcEAE, AcBE, FbDE, FbEAE, and FbBE belong to the high protection class (30→49.9). The outstanding photoprotective capacities of *A.campestris* and *F.bruguieri* extracts might well be particularly accountable to the presence of flavonoids and phenolics, which have a specific and significant feature: their ability to absorb solar radiation in the ultraviolet range.

Phytochemical analysis of *A. campestris* by LC-MS/MS and HPLC-UV described the presence of flavonoids (rutin, quercetin, acacetin, apigenin,..) and other constituents such as anthocyanidins and coumarins in the most active AcDE, AcEAE, and AcBE extracts, which are substances described with photoprotective action [448]. In contrast, triterpenoid saponins (

Oleanolic acid-3-O- β -D-glucopyranosyl-(1 \rightarrow 3)-[[β -D-glucopyranosyl-(1 \rightarrow 2)]- α -L-arabinopyranoside) was exclusively detected in FbDE, FbEAE, and FbBE based on the results of the phytochemical profiles in this study. The terpenes and its derivatives are potential agents for treating burns and accelerating skin regeneration [449].

Based on the results of this examination and what was discussed concerning the phytochemicals profiling and its richness with phenolics and flavonoid substances before, *A.campestris* and *F.bruguieri* have a substantial affinity between its photoprotective effect and its total phenolic content. The extraordinary photoprotective effects of *Fagonia bruguieri* DC. and *Artemisia campestris* L. extracts may be due to the presence of these compounds.

On the other hand, the climate and geographical region Saharan and the daily exposure of the plant to sunlight contributed to the exhibition of more bioactive compounds to protect the plant from UV damage, which enhances the photoprotective activity. Consequently, the results obtained exhibited significant antioxidant activity as a promising source for sunscreen in the cosmetic industry or pharmaceuticals formulations.

CONCLUSION

Conclusion

Our study focuses on evaluating and promoting Saharan plants to detect novel molecules with therapeutic and industrial uses.

At the outset of this study, we established for ourselves the goals of extraction, characterization, and determination of mineral elements concentration, and assessing the biological activities of extracts of two different plants: *Artemisia campestris* L. and *Fagonia bruguieri* DC from the Algerian Sahara that are utilised in traditional medicine for the treatment of several diseases. Maceration in solvents of increasing polarity was the method used to extract phenolic compounds from the two plants. Each extract was characterized by its colour and its performance.

INAA and ICP-OES were the methodologies that were utilised in our work in order to carry out the analysis of the concentrations of various mineral elements present in the plants, the outcomes from the two techniques were extremely comparable. Recently, the INAA technique has been used for the purposes of analysis of traces and ultra-traces. In effect, the primary purpose of this approach is to calibrate and validate the data produced by other methods, such as ICP and XRF, which are distinguished by their accessibility and rapidity.

The analysis of minerals carried out on two plants that were investigated using these methods revealed the richness of *Artemisia campestris* L. and their abundance in the minerals required by humans, such as calcium (10538.1mg/kg), iron (1264.2366mg/kg), sodium (311.7137 mg/kg), magnesium (990.7mg/kg), manganese (41.06mg/kg)...etc. According to the results of the analyses carried out on two plants, *Fagonia bruguieri* DC. has the highest concentration of sodium (1762.55 mg/kg). In addition, the concentrations of potentially toxic elements were significantly lower than the toxicological reference values established by the World Health Organisation (WHO), which would confer unique pharmacological and therapeutic capabilities onto these plants.

The chemical profiles of *A. campestris* L. and *F. bruguieri* DC. extracts have been examined by HPLC- UV/Vis and LC-MS/MS analysis. Identified compounds by HPLC- UV/Vis in *A. campestris* L. extracts were mainly flavonoids and phenolic acids: Gallic Acid, Chlorogenic Acid, and Vanillic Acid. Caffeic Acid, Vanillin, p-Coumaric Acid, Rutin, Naringin, and Quercetin. While for *F. bruguieri* DC., the predominantly phenolic compounds present were: Chlorogenic Acid, Vanillin, and Caffeic Acid. The outcomes of LC-MS-MS analysis based

phytochemical investigation on the aerial parts of *A. campestris* L. conducted to the identification of 11 compounds mainly flavones, anthocyanidins, coumarins...etc. For *Fagonia bruguieri* DC. The findings of a phytochemical investigation based on LC-MS-MS analysis led to the identification of 13 constituents such as flavonoids, C-glycosylated flavones, flavan 3-ol...

Upon concluding our investigations, the utilisation of various chromatographic methodologies, including an open column in normal silica gel, reverse phase, Sephadex LH-20, and TLC, guided the isolation and purification of secondary metabolites from the butanolic extract of *Artemisia campestris* L. and *Fagonia bruguieri* DC., through a process of separation and purification.

The elucidation of the structures of these compounds was accomplished through the examination and interpretation of their NMR spectra, with a particular focus on the analysis of their one-dimensional NMR: ^1H and ^{13}C , DEPT 135° NMR and two-dimensional NMR, including HSQC, HMBC, and COSY.

Eleven secondary metabolites have been identified, out of which three have been comprehensively characterised, among which:

- ✓ Polysaccharide: α -D-glucopyranosyl-(1 \leftrightarrow 2)- β -D-fructofuranoside (Saccharose) isolated for the first time from *A.campestris* L.
- ✓ Phenylpropanoid glycoside: 4-O- β -D-glucopyranosyloxyl benzoic acid isolated for the first time.
- ✓ Phenolic acids: Syringing isolated for the first time from *Fagonia bruguieri* DC.

In pharmacological terms, various activities have been conducted to assess the antioxidant, anti-inflammatory, anti-acetylcholinesterase, anti-diabetic, anti-obesity, and photoprotective effects of different extracts of *Artemisia campestris* L. and *Fagonia bruguieri* DC.

A series of antioxidant tests were carried out using DPPH, ABTS, beta-carotene, GOR, RP, CUPRAC, and O-Phenanthroline assays. The results showed that *Artemisia campestris* L. extract has strong antioxidant activity in all the test samples except for the carotene bleaching assay. The heightened concentration of phenolics and flavonoids in AcEAE and FbBE confer an outstanding antioxidant potential, consequently providing a distinctive feature to this extract, as evidenced by the abovementioned techniques.

The interaction of the various extracts of *Artemisia campestris* L. and *Fagonia bruguieri* DC. with the relatively stable superoxide anion radical $O_2^{\cdot-}$ was used to assess the antioxidant activity using cyclic voltammetry techniques. All of the fractions had an remarkable antioxidant activity comparable to that of AcAE ($IC_{50} = 0.12$ mg/mL) and FbAE ($IC_{50} = 0.43$ μ g/mL), and their IC_{50} values were extremely near to those of the reference antioxidant Ascorbic acid ($IC_{50} = 0.0596$ mg/mL).

The anti-Alzheimer action was characterized by inhibiting of the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). At $IC_{50} = 23.16 \pm 0.19$ μ g/mL, AcEAE showed the most powerful inhibitory effects on acetylcholinesterase. As to BChE, AcBE showed a significant butyrylcholinesterase inhibitory effect ($IC_{50} = 93.50 \pm 1.60$ μ g/mL). The FbPEE extract shows a potent AChE and BChE activity with $IC_{50} = 27.41 \pm 1.03$ μ g/mL and 46.14 ± 0.78 μ g/mL, respectively.

Based on our results *Artemisia campestris* L. and *Fagonia bruguieri* DC. extracts showed an outstanding anti-diabetic action that was more efficient than acarbose, The most powerful inhibitor of α -amylase was AcPEE and FbDE ($IC_{50} = 11.79 \pm 0.14$; $7,12 \pm 0,89$ μ g/mL, respectively).

Regarding the anti-lipase activity, AcEAE and FbDE demonstrated a potent inhibition against the pancreatic lipase enzyme.

The anti-inflammatory effects of various extracts of *Artemisia campestris* L. and *Fagonia bruguieri* DC. were evaluated for their efficacy in treating inflammation through the anti-denaturation model of BSA. The experimental results indicate that AcBE and FbBE exhibited a statistically significant impact compared to the reference drug Diclofenac sodium.

As for the photoprotective effect of the plant, it was measured by the sun protection factor (SPF). The species *Artemisia campestris* L. and *Fagonia bruguieri* DC. were approved to possess a robust photoprotective capacity, effectively absorbing ultraviolet radiation.

A conclusion that can be drawn from all of these relevant results is that the presence of compounds that are endowed with promising and promising biological activities within *Artemisia campestris* L. and *Fagonia bruguieri* DC. Would justifying their diverse medicinal uses.

Chemical structure of the compounds Isolated from *A.campestris* L. & *F.bruguieri* DC.

Species	Compound	Family of compound	Chemical structure	Name of compound	Report
<i>Artemisia campestris</i> L.	PN	Polysaccharide		α -D-glucopyranosyl-(1 \leftrightarrow 2)- β -D-fructofuranoside (saccharose)	Isolated for the first Time from <i>A.campestris</i> L.
<i>Fagonia bruguieri</i> DC.	Pb	phenylpropanoid glycoside		Syringing	Isolated for the first Time from <i>F.bruguieri</i> DC.
<i>Fagonia bruguieri</i> DC.	Pv 2	Phenolic Acid		4-O- β -D-glucopyranosyl benzoic acid	Isolated for the first Time

REFERENCES

REFERENCES

1. Lehmann, H., *Le médicament à base de plantes en Europe: statut, enregistrement, contrôles*. 2013, Université de Strasbourg.
2. Hostettmann, K., O. Potterat, and J.-L.J.C. Wolfender, *The potential of higher plants as a source of new drugs*. 1998. **52**(1-2): p. 10-10.
3. Newman, D.J. and G.M.J.J.o.n.p. Cragg, *Natural products as sources of new drugs over the 30 years from 1981 to 2010*. 2012. **75**(3): p. 311-335.
4. Govindappa, M.J.J.D.M., *A review on role of plant (s) extracts and its phytochemicals for the management of diabetes*. 2015. **6**(7): p. 1-38.
5. Ozenda, P., *Flore du Sahara septentrional et central*. 1958.
6. Bremer, K. and A.A. Anderberg, *Asteraceae: cladistics and classification*. 1994.
7. Quezel, P. and S. Santa, *Nouvelle flore de l'Algérie et des régions désertiques méridionales*. 1963.
8. Botineau, M., *Botanique systématique et appliquée des plantes à fleurs*. 2010: Tec & doc.
9. GIAUME, M., *Moteur de recherche des sites web traitant de botanique*. 2005.
10. Boullard, B., *Dictionnaire: plantes & champignons*. 1997: ESTEM, Editions scientifiques, techniques et médicales.
11. Bertaux, M., *Famille des Astéracées* Herbier de Lorraine 2018.
12. Marouf, A., *Dictionnaire de botanique*. 2000.
13. STEVENS, *Répartition géographique des Asteraceae* juin 2008.
14. Zdero, C., F.J.P.S. Bohlmann, and Evolution, *Systematics and evolution within the Compositae, seen with the eyes of a chemist*. 1990. **171**(1): p. 1-14.
15. Garbacki, N., et al., *Anti-inflammatory and immunological effects of Centaurea cyanus flower-heads*. 1999. **68**(1-3): p. 235-241.
16. Özçelik, B., et al., *Antiviral and antimicrobial activities of three sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis*. 2009. **164**(5): p. 545-552.
17. Ozsoy, N., et al., *Antioxidant, Anti-Inflammatory, Acetylcholinesterase Inhibitory and Antimicrobial Activities of Turkish Endemic Centaurea antiochia var. Praealta*. 2015. **39**(6): p. 771-776.
18. Dharmananda, S.J.I.f.T.M., Portland, Oregon. Available at: <http://www.itmonline.org/arts/bidens.htm>, *A Popular Remedy Escapes Notice of Western Practitioners*. 2013.
19. Eidi, A., et al., *Antinociceptive and anti-inflammatory effects of the aerial parts of Artemisia dracunculoides in mice*. 2016. **54**(3): p. 549-554.
20. Tan, P.V., T. Dimo, and E.J.J.o.E. Dongo, *Effects of methanol, cyclohexane and methylene chloride extracts of Bidens pilosa on various gastric ulcer models in rats*. 2000. **73**(3): p. 415-421.
21. Ayyanar, M. and S.J.J.o.e. Ignacimuthu, *Traditional knowledge of kani tribals in Kouthalai of Tirunelveli hills, Tamil Nadu, India*. 2005. **102**(2): p. 246-255.
22. Nadkarni, K. and A.J.B.P.M. Nadkarni, *Indian Materia Medica, Ed*. 2007. **1**: p. 691-694.
23. Phytotherapy, E.S.C.o., *ESCOMP Monographs: The Scientific Foundation for Herbal Medicinal Products*. 2003: Thieme.
24. Patočka, J. and B.J.J.A.B. Plucar, *Pharmacology and toxicology of absinthe*. 2003. **1**(4): p. 199-205.
25. Duke, J.A., *Database of phytochemical constituents of GRAS herbs and other economic plants*. 1992: CRC Press.
26. Schulze, E.-D., et al., *Long-term effects of drought on wild and cultivated plants in the Negev desert*. 1980. **45**(1): p. 11-18.
27. Floret, C. and R. Pontanier, *L'aridité en Tunisie présaharienne: climat, sol, végétation et aménagement*. 1982.
28. Akkal, S., et al., *Flavonoids from Centaurea furfuracea (Asteraceae)*. 2003. **31**(6): p. 641-643.

REFERENCES

29. Gawronska-Grzywacz, M. and T.J.A.S.B.P. Krzaczek, *Flavonoids and coumarins from Hieracium pilosella L.[Asteraceae]*. 2009. **78**(3): p. 189-195.
30. Grecco, S.d.S., et al., *Phenolic derivatives from Baccharis retusa DC.(Asteraceae)*. 2012. **42**: p. 21-24.
31. Padilla-Gonzalez, G.F., et al., *Caffeic acid derivatives and further compounds from Espeletia barclayana Cuatrec.(Asteraceae, Espeletiinae)*. 2017. **70**: p. 291-293.
32. Ambrósio, S.R., et al., *Trypanocidal activity of pimarane diterpenes from Viguiera arenaria (Asteraceae)*. 2008. **22**(10): p. 1413-1415.
33. Elso, O.G., et al., *Trypanocidal activity of four sesquiterpene lactones isolated from Asteraceae species*. 2020. **25**(9): p. 2014.
34. Okunade, A.L.J.F., *Ageratum conyzoides L.(asteraceae)*. 2002. **73**(1): p. 1-16.
35. Salido, S., et al., *Composition and infraspecific variability of Artemisia herba-alba from southern Spain*. 2004. **32**(3): p. 265-277.
36. Tutin, T., K. Persson, and W.J.F.e. Gutermann, *Artemisia L.* 1976. **4**: p. 178-186.
37. Shultz, L.M.J.S.B.M., *Monograph of Artemisia subgenus Tridentatae (Asteraceae-Anthemideae)*. 2009: p. 1-131.
38. Vallès, J., et al., *Biology, genome evolution, biotechnological issues and research including applied perspectives in Artemisia (Asteraceae)*. 2011. **60**: p. 349-419.
39. Garnock-Jones, P.J.B.j.o.t.L.S., *Floret specialization, seed production and gender in Artemisia vulgaris L.(Asteraceae, Anthemideae)*. 1986. **92**(4): p. 285-302.
40. Sanz, M., et al., *Molecular phylogeny and evolution of floral characters of Artemisia and allies (Anthemideae, Asteraceae): evidence from nrDNA ETS and ITS sequences*. 2008. **57**(1): p. 66-78.
41. Koul, B., et al., *The Artemisia genus: A review on traditional uses, phytochemical constituents, pharmacological properties and germplasm conservation*. 2018. **7**: p. 1-7.
42. Abad, M.J., et al., *The Artemisia L. genus: a review of bioactive essential oils*. 2012. **17**(3): p. 2542-2566.
43. Chhetri, B.K., N.A. Awadh Ali, and W.N.J.M. Setzer, *A survey of chemical compositions and biological activities of Yemeni aromatic medicinal plants*. 2015. **2**(2): p. 67-92.
44. Van Wyk, B.-E.J.J.o.e., *A broad review of commercially important southern African medicinal plants*. 2008. **119**(3): p. 342-355.
45. Cubukcu, B., et al., *In vitro antimalarial activity of crude extracts and compounds from Artemisia abrotanum L.* 1990. **4**(5): p. 203-204.
46. Hutchings, A., *Zulu medicinal plants: An inventory*. 1996: University of Natal press.
47. Watt, J.M., et al., *The Medicinal and Poisonous Plants of Southern and Eastern Africa being an Account of their Medicinal and other Uses, Chemical Composition, Pharmacological Effects and Toxicology in Man and Animal*. 1962(Edn 2).
48. Nurlybekova, A., et al., *Traditional Use, Phytochemical Profiles and Pharmacological Properties of Artemisia Genus from Central Asia*. 2022. **27**(16): p. 5128.
49. Karomatov, I.D.R., I.G. , *Prospects of Application of the Herb Artemisia Cina*. *Phytother. Electr. Sci. J. Biol. Integ. Med.*, 2018(9): p. 102–109.
50. Penkala-Gawęcka, D.J.C.A.S., *Mentally ill or chosen by spirits? ‘Shamanic illness’ and the revival of Kazakh traditional medicine in post-Soviet Kazakhstan*. 2013. **32**(1): p. 37-51.
51. Nabimeybodi, R., et al., *Scientific evaluation of medicinal plants used for the treatment of cervicitis (Qorohe-Rahem) in Iranian traditional medicine*. 2019. **18**(4): p. 1884.
52. Swanston-Flatt, S.K., et al., *Traditional dietary adjuncts for the treatment of diabetes mellitus*. 1991. **50**(3): p. 641-651.
53. Liu, N., F. Van der Kooy, and R.J.S.A.J.o.B. Verpoorte, *Artemisia afra: a potential flagship for African medicinal plants?* 2009. **75**(2): p. 185-195.
54. Wake, G., et al., *CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory*. 2000. **69**(2): p. 105-114.

REFERENCES

55. Guarrera, P.M.J.F., *Traditional phytotherapy in Central Italy (marche, abruzzo, and latium)*. 2005. **76**(1): p. 1-25.
56. Mueller, M.S., et al., *The potential of Artemisia annua L. as a locally produced remedy for malaria in the tropics: agricultural, chemical and clinical aspects*. 2000. **73**(3): p. 487-493.
57. Yin, Y., et al., *Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita*. 2008. **120**(1): p. 1-6.
58. Lim, B.O., et al., *Inhibition of microglial neurotoxicity by ethanol extract of Artemisia asiatica Nakai*. 2008. **22**(2): p. 279-282.
59. Kapoor, L., *CRC Handbook of ayurvedic medicinal plants*. 2018: CRC press.
60. Liu, C., et al., *Artemisia judaica L.: micropropagation and antioxidant activity*. 2004. **110**(1): p. 63-71.
61. Calderone, V., et al., *Vascular effects of aqueous crude extracts of Artemisia verlotorum Lamotte (Compositae): in vivo and in vitro pharmacological studies in rats*. 1999. **13**(8): p. 645-648.
62. Gilani, A.H., et al., *Hepatoprotective activity of aqueous-methanol extract of Artemisia vulgaris*. 2005. **19**(2): p. 170-172.
63. Temraz, A. and W.H.J.P.j.o.p.s. El-Tantawy, *Characterization of antioxidant activity of extract from Artemisia vulgaris*. 2008. **21**(4).
64. Nigam, M., et al., *Bioactive compounds and health benefits of Artemisia species*. 2019. **14**(7): p. 1934578X19850354.
65. Tariq, K., et al., *Anthelmintic activity of extracts of Artemisia absinthium against ovine nematodes*. 2009. **160**(1-2): p. 83-88.
66. Bora, K.S. and A.J.J.o.e. Sharma, *Neuroprotective effect of Artemisia absinthium L. on focal ischemia and reperfusion-induced cerebral injury*. 2010. **129**(3): p. 403-409.
67. Albasher, G., et al., *Evaluation of the neuro-protective effect of Artemisia judaica extract in a murine diabetic model*. 2020. **44**(8): p. e13337.
68. Kannan, R., et al., *Reaction of artemisinin with haemoglobin: implications for antimalarial activity*. 2005. **385**(2): p. 409-418.
69. Foglio, M.A., et al., *Antiulcerogenic activity of some sesquiterpene lactones isolated from Artemisia annua*. 2002. **68**(06): p. 515-518.
70. Boareto, A.C., et al., *Toxicity of artemisinin [Artemisia annua L.] in two different periods of pregnancy in Wistar rats*. 2008. **25**(2): p. 239-246.
71. Saddi, M., et al., *Antiherpesvirus activity of Artemisia arborescens essential oil and inhibition of lateral diffusion in Vero cells*. 2007. **6**(1): p. 1-7.
72. Jin, H., et al., *an experiment on standardized cell culture assay in assessing the activities of composite Artemisia capillaris tablets against hepatitis B virus replication in vitro*. 2005. **11**(1): p. 54-56.
73. Setzer, W.N., et al., *Antimicrobial activity of Artemisia douglasiana leaf essential oil*. 2004. **75**(2): p. 192-200.
74. VERDIAN, R.M., et al., *Chemical composition and antimicrobial activity of Artemisia annua L. essential oil from Iran*. 2008.
75. Keles, L.C., et al., *Lychnophorinae (Asteraceae): a survey of its chemical constituents and biological activities*. 2010. **33**: p. 2245-2260.
76. Kim, Y., et al., *Inhibition of 7, 12-dimethylbenz [a] anthracene induced mouse skin carcinogenesis by Artemisia capillaris*. 2008. **73**(1): p. T16-T20.
77. Islam, M., et al., *Promising anti-diabetic potential of capillin and capillinol isolated from Artemisia capillaris*. 2016. **39**(3): p. 340-349.
78. Nofal, S.M., et al., *Anti-diabetic effect of Artemisia judaica extracts*. 2009. **4**(1): p. 42-48.
79. Negahban, M., S. Moharramipour, and F.J.J.o.A.-P.E. Sefidkon, *Insecticidal activity and chemical composition of Artemisia sieben besser essential oil from Karaj, Iran*. 2006. **9**(1): p. 61-66.

REFERENCES

80. Hamza, N., et al., *A review of Algerian medicinal plants used in the treatment of diabetes*. 2019. **238**: p. 111841.
81. Quézel, P. and S.J.P. Santa, p, *Nouvelle Flore De L'Algérie et des régions désertiques méridionales. vol.[1] CNRS*. 1962.
82. Al-Snafi, A.E.J.A.J.o.P.R., *The pharmacological importance of Artemisia campestris-A review*. 2015. **5**(2): p. 88-92.
83. Dib, I., et al., *Artemisia campestris L.: Ethnomedicinal, phytochemical and pharmacological review*. 2017. **7**: p. 1-10.
84. Chalchat, J.-C., et al., *Composition of essential oil of Artemisia campestris L. from Serbia*. 2003. **15**(4): p. 251-253.
85. Kreitschitz, A. and J.J.F.-M. Vallès, *Distribution, Functional Ecology of Plants, Achene morphology and slime structure in some taxa of Artemisia L. and Neopallasia L.(Asteraceae)*. 2007. **202**(7): p. 570-580.
86. Dib, I., F.E.J.B. El Alaoui-Faris, and Pharmacotherapy, *Artemisia campestris L.: review on taxonomical aspects, cytogeography, biological activities and bioactive compounds*. 2019. **109**: p. 1884-1906.
87. Nobis, M., et al., *Contribution to the flora of Asian and European countries: new national and regional vascular plant records, 2*. 2014. **161**(2): p. 209-221.
88. Noumi, Z., et al., *The status of Asteraceae in the arid and Saharan flora of North African region: case of Tunisia*. 2010. **42**(3): p. 1417-22.
89. Rebbas, K. and R.J.P. Bounar, *Études floristique et ethnobotanique des plantes médicinales de la région de M'Sila (Algérie)*. 2014. **12**(5): p. 284-291.
90. Kawada, K., et al., *Plant biodiversity in the semi-arid zone of Tunisia*. 2012. **22**(1): p. 83-86.
91. El-Mokasabi, F.M.J.A.-E.J.A.E.S., *Floristic composition and traditional uses of plant species at Wadi Alkuf, Al-Jabal Al-Akhder, Libya*. 2014. **14**(8): p. 685-697.
92. Minami, M., et al., *Preliminary survey of taxonomical problems, pharmacognostical characteristics, and chloroplast DNA polymorphisms of the folk medicinal herb Artemisia campestris from the Ryukyu Islands, Japan*. 2010. **64**(2): p. 239-244.
93. Emery, S.M. and J.A.J.R.E. Rudgers, *Ecological assessment of dune restorations in the Great Lakes region*. 2010. **18**: p. 184-194.
94. Al-Douri, N.A.J.I.J.A.H.A.M., *Some important medicinal plants in Iraq*. 2014. **2**: p. 10-20.
95. Bammou, M., et al., *Étude Ethnobotanique des Astéracées dans la Région Meknès-Tafilalet (Maroc)/[Ethnobotanical Survey of Asteraceae Family used in Meknes-Tafilalet Region (Morocco)]*. 2015. **13**(4): p. 789.
96. Kujawska, M. and N.I.J.J.o.E. Hilgert, *Phytotherapy of Polish migrants in Misiones, Argentina: Legacy and acquired plant species*. 2014. **153**(3): p. 810-830.
97. Shemluck, M.J.J.o.e., *Medicinal and other uses of the Compositae by Indians in the United States and Canada*. 1982. **5**(3): p. 303-358.
98. Farah, R., et al., *Ethnobotanical study of some medicinal plants from Hoggar, Algeria*. 2015. **9**(30): p. 820-827.
99. Aniya, Y., et al., *Antioxidant and hepatoprotective actions of the medicinal herb Artemisia campestris from the Okinawa Islands*. 2000. **23**(3): p. 309-312.
100. Ferchichi, L., et al., *Occurrence of isocoumarinic and phenolic derivatives in Artemisia campestris L. subsp. campestris*. 2006.
101. Boulanouar, B., et al., *Antioxidant activities of eight Algerian plant extracts and two essential oils*. 2013. **46**: p. 85-96.
102. Sassi, A.B., F. Harzallah-Skhiri, and M.J.P.b. Aouni, *Investigation of some medicinal plants from Tunisia for antimicrobial activities*. 2007. **45**(5): p. 421-428.
103. Benarba, B., et al., *Ethnobotanical study of medicinal plants used by traditional healers in Mascara (North West of Algeria)*. 2015. **175**: p. 626-637.

REFERENCES

104. Benítez, G., M. González-Tejero, and J.J.J.o.E. Molero-Mesa, *Pharmaceutical ethnobotany in the western part of Granada province (southern Spain): Ethnopharmacological synthesis*. 2010. **129**(1): p. 87-105.
105. HassaniM, E., et al., *Plantes médicinales de la Moyenne Moulouya (nord-est du Maroc)*. 2013. **50**: p. 39.
106. Djidel, S., et al. *Medicinal plants used traditionally in the Algerian folk medicine for gastrointestinal disorders and hypertension: total polyphenols, flavonoids and antioxidant activity*. in *XIII International Conference on Medicinal and Aromatic Plants 854*. 2009.
107. Benchelah, A.-C., H. Bouziane, and M.J.P. Maka, *Fleurs du Sahara, arbres et arbustes, voyage au coeur de leurs usages avec les Touaregs du Tassili*. 2004. **2**(6): p. 191-197.
108. Bnouham, M., et al., *Medicinal plants used in the treatment of diabetes in Morocco*. 2002. **10**: p. 33-50.
109. Bahekar, S., R. Kale, and S.J.M.J.P.M.S. Nagpure, *A review on medicinal plants used in scorpion bite treatment in India*. 2012. **1**(1): p. 1-6.
110. Popović, Z., et al., *Phytotherapeutical plants from the Deliblato Sands (Serbia): Traditional pharmacopoeia and implications for conservation*. 2012.
111. De Natale, A., A.J.J.o.E. Pollio, and Ethnomedicine, *A forgotten collection: the Libyan ethnobotanical exhibits (1912-14) by A. Trotter at the Museum O. Comes at the University Federico II in Naples, Italy*. 2012. **8**(1): p. 1-19.
112. Leporatti, M.L., K.J.J.o.e. Ghedira, and ethnomedicine, *Comparative analysis of medicinal plants used in traditional medicine in Italy and Tunisia*. 2009. **5**(1): p. 1-8.
113. Jaouadi, I., et al., *Anti-hemolytic and Anti-cytotoxic Effect of Two Artemisia Species (A. campestris and A. herba-alba) Essential Oil against Snake Venom*. 2016. **18**(4).
114. Ben, N.H., et al., *Aqueous leaves extract of Artemisia campestris inhibition of the scorpion venom induced hypertension*. 2014. **8**(13): p. 538-542.
115. Metoui, R., et al., *Bioactive flavones isolated from Tunisian Artemisia campestris L. Leaves*. 2017. **63**(11): p. 86-91.
116. Ghlissi, Z., et al., *Antioxidant, antibacterial, anti-inflammatory and wound healing effects of Artemisia campestris aqueous extract in rat*. 2016. **84**: p. 115-122.
117. Pereira, C.G., et al., *Health promoting potential of herbal teas and tinctures from Artemisia campestris subsp. maritima: from traditional remedies to prospective products*. 2018. **8**(1): p. 1-13.
118. Sefi, M., et al., *Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, advanced glycation end products and oxidative stress in alloxan-induced diabetic rats*. 2010. **48**(7): p. 1986-1993.
119. Younsi, F., et al., *Essential oil variability in natural populations of Artemisia campestris (L.) and Artemisia herba-alba (Asso) and incidence on antiacetylcholinesterase and antioxidant activities*. 2017. **14**(7): p. e1700017.
120. Dib, I., et al., *Chemical composition, vasorelaxant, antioxidant and antiplatelet effects of essential oil of Artemisia campestris L. from Oriental Morocco*. 2017. **17**(1): p. 1-15.
121. Kadi, I., et al., *Synergistic antinociceptive activity of combined aqueous extracts of Artemisia campestris and Artemisia herba-alba in several acute pain models*. 2019. **33**(6): p. 875-878.
122. Essid, R., et al., *Antileishmanial and cytotoxic potential of essential oils from medicinal plants in Northern Tunisia*. 2015. **77**: p. 795-802.
123. Saoudi, M., et al., *Protective effects of aqueous extract of Artemisia campestris against puffer fish Lagocephalus lagocephalus extract-induced oxidative damage in rats*. 2010. **62**(6): p. 601-605.
124. Jabri, M.-A., et al., *Protective effects of Artemisia campestris extract against gastric acid reflux-induced esophageal mucosa injuries*. 2018. **25**(1): p. 63-69.
125. Akrou, A., et al., *Antioxidant and antitumor activities of Artemisia campestris and Thymelaea hirsuta from southern Tunisia*. 2011. **49**(2): p. 342-347.

REFERENCES

126. Barkat, L., et al., *Artemisia campestris* leaf aqueous extract alleviates methidathion-induced nephrotoxicity in rats. 2015. **32**(2): p. 200-09.
127. Aloui, Z., et al., Asteraceae *Artemisia campestris* and *Artemisia herba-alba* essential oils trigger apoptosis and cell cycle arrest in *Leishmania infantum* promastigotes. 2016. **2016**.
128. Hoffmann, B. and K.J.Z.f.L.-U.u.F. Herrmann, *Flavonolglykoside des Beifuß (Artemisia vulgaris L.), Estragon (Artemisia dracunculus L.) und Wermut (Artemisia absinthium L.)*. 1982. **174**(3): p. 211-215.
129. Saleh, N.A., et al., *Flavonoid glycosides of Artemisia monosperma and A. herba-alba*. 1985. **24**(1): p. 201-203.
130. Saleh, N.A., S.I. El-Negoumy, and M.M.J.P. Abou-zaid, *Flavonoids of Artemisia judaica, A. monosperma and A. herba-alba*. 1987. **26**(11): p. 3059-3064.
131. Rodriguez, E., et al., *Methoxylated flavonoids from Artemisia*. 1972. **11**(12): p. 3509-3514.
132. Chumbalov, T., O. Fadeeva, and I.J.C.o.N.C. Chanysheva, *Flavonoids of Artemisia transiliensis*. 1969. **5**(4): p. 201-202.
133. YONG, L. and Y.L. LIU, *FLAVANOIDS FROM ARTEMISIA LUDOVICIANAVAR. LUDOVICIANA*. 1982.
134. Liu, Y.-L. and T.J.P. Mabry, *Flavonoids from Artemisia frigida*. 1981. **20**(6): p. 1389-1395.
135. Kaneta, M., et al., *Identification of flavones in sixteen Compositae species*. 1978. **42**(2): p. 475-477.
136. Brown, D., R.O. Asplund, and V.A.J.P. McMahon, *Phenolic constituents of Artemisia tridentata spp. Vaseyana*. 1975. **14**(4): p. 1083-1084.
137. Hurabielle, M., J. Eberle, and M.J.P.m. Paris, *Etude des flavonoïdes d'Artemisia campestris sous-espèce glutinosa*. 1982. **46**(10): p. 124-125.
138. Segal, R. and Z. DV, *A NEW FLAVONE FROM ARTEMISIA HERBA-ALBA*. 1973.
139. Namba, T., et al., *A flavone from Artemisia capillaris*. 1983. **22**(4): p. 1057-1058.
140. Anderson, G.D., *I. A CHEMOTAXONOMIC STUDY OF SOME MEMBERS OF THE AMBROSIINAE (COMPOSITAE). II. THE ABSOLUTE AND RELATIVE CONFIGURATION OF AXIVALIN AND ITS CONGENERS*. 1973: The Florida State University.
141. Yoon, K.D., et al., *Separation of anti-ulcer flavonoids from Artemisia extracts by high-speed countercurrent chromatography*. 2011. **129**(2): p. 679-683.
142. Olennikov, D.J.C.o.N.C., *New flavonoids from Artemisia frigida*. 2020. **56**(4): p. 623-627.
143. Barberá, O., et al., *3-Methoxyflavones and coumarins from Artemisia incanescens*. 1986. **25**(10): p. 2357-2360.
144. Chandrasekharan, I., H.A. Khan, and A.J.P.m. Ghanim, *Flavonoids from Artemisia scoparia*. 1981. **43**(11): p. 310-311.
145. De Pascual Teresa, J., et al., *Flavonoids from Artemisia campestris ssp. glutinosa*. 1986. **49**(1): p. 177-177.
146. Vasconcelos, J.M., A.M. Silva, and J.A.J.P. Cavaleiro, *Chromones and flavanones from Artemisia campestris subsp. maritima*. 1998. **49**(5): p. 1421-1424.
147. Gonzalez, A., et al., *Phenolic derivatives from Artemisia glutinosa*. 1983. **22**(6): p. 1515-1516.
148. Aberham, A., et al., *Analysis of sesquiterpene lactones, lignans, and flavonoids in wormwood (Artemisia absinthium L.) using high-performance liquid chromatography (HPLC)- mass spectrometry, reversed phase HPLC, and HPLC- solid phase extraction- nuclear magnetic resonance*. 2010. **58**(20): p. 10817-10823.
149. Rauter, A.P., et al., *Flavonoids from Artemisia campestris subsp. maritima*. 1989. **28**(8): p. 2173-2175.
150. Xu, X.-W., et al., *Phenolic and Acid Derivatives from Artemisia sieversiana*. 2021. **57**(2): p. 250-253.
151. Tulake, A., Y. Jiang, and P.J.J.C.P.S. Tu, *Nine lignans from Artemisia absinthium L.* 2012. **21**: p. 360-364.
152. Marco, J.A.J.P., *Sesquiterpene lactones from Artemisia herba-alba subsp. Herba-alba*. 1989. **28**(11): p. 3121-3126.

REFERENCES

153. Jakupovic, J., Z.-L. Chen, and F.J.P. Bohlmann, *Artanomaloide, a dimeric guaianolide and phenylalanine derivatives from Artemisia anomala*. 1987. **26**(10): p. 2777-2779.
154. Kwak, J.H., et al., *Artekeiskeanin A: a new coumarin-monoterpene ether from Artemisia keiskeana*. 1997. **63**(05): p. 474-476.
155. De Pascual, J., et al., *2-Methyl-2-hydroxymethylchromenes from Artemisia campestris subsp. glutinosa*. 1983. **22**(11): p. 2587-2589.
156. Teresa, J.D.P., et al., *Phenolic derivatives from Artemisia campestris subsp. glutinosa*. 1984. **23**(8): p. 1819-1821.
157. de Pascual, J.-T., et al., *Aromatic compounds from Artemisia campestris subsp. Glutinosa*. 1981. **20**(10): p. 2417-2420.
158. Afshar, F.H., et al., *Phenolic derivatives of Artemisia spicigera C. Koch growing in Iran*. 2015. **14**(4): p. 1241.
159. Abegaz, B.M. and W.J.P. Herz, *A nor-monoterpene from Artemisia schimperi*. 1991. **30**(3): p. 1011-1012.
160. Segal, R., et al., *Sesquiterpene lactones from Artemisia herba Alba*. 1985. **24**(6): p. 1381-1382.
161. Marco, J.A., et al., *New germacranolides and Eudesmanolides from north African Artemisia herba-alba*. 1994. **57**(7): p. 939-946.
162. Messai, L. and D. Belkacemi, *Etude phytochimique d'une plante medicinale de l'est Algerien*. 2011.
163. Todorova, M.N. and M.L.J.P. Krasteva, *Sesquiterpene lactones from Artemisia lerchiana*. 1996. **42**(4): p. 1231-1233.
164. Geissman, T.J.P., *Sesquiterpene lactones of Artemisia—A. verlotorum and A. vulgaris*. 1970. **9**(11): p. 2377-2381.
165. Sanz, J.F., O. Barbera, and J.A.J.P. Marco, *Sesquiterpene lactones from Artemisia hispanica*. 1989. **28**(8): p. 2163-2167.
166. Mericli, A., et al., *Eudesmanolides from Artemisia santonicum*. 1988. **54**(05): p. 447-449.
167. Ruikar, A.D., et al., *Phytochemical investigation of Artemisia pallens*. 2011. **94**(1): p. 73-77.
168. Nagaki, M. and S.J.P. Matsueda, *Guaianolides from Artemisia montana*. 1989. **28**(10): p. 2731-2733.
169. Christenhusz, M.J. and J.W.J.P. Byng, *The number of known plants species in the world and its annual increase*. 2016. **261**(3): p. 201–217-201–217.
170. Quézel, P., S. Santa, and O. Schotter, *Nouvelle flore de l'Algerie et des regions desertiques meridionales-v. 1-2*. 1962.
171. Simpson, M.G.J.J.P.S., *Diversity and classification of flowering plants: eudicots*. 2019: p. 285-466.
172. Khalik, K.N.A.J.A.B.B., *A numerical taxonomic study of the family Zygophyllaceae from Egypt*. 2012. **26**: p. 165-180.
173. Sheahan, M., *Zygophyllaceae, in Flowering Plants· Eudicots*. 2007, Springer. p. 488-500.
174. Aghili, M.H.J.T.T.U.o.M.S., *Makhzan-al-Advia [in Persian]*. 2009: p. 227-228.
175. Kasture, S.B., et al., *Anticonvulsant activity of Balanites aegyptiaca (L.) Del. Stem bark*. 2014. **14**(1): p. 25-29.
176. Hammiche, V. and K.J.J.o.e. Maiza, *Traditional medicine in Central Sahara: pharmacopoeia of Tassili N'ajjer*. 2006. **105**(3): p. 358-367.
177. Saeed, M.A. and A.W.J.J.o.e. Sabir, *Effects of Fagonia cretica L. constituents on various haematological parameters in rabbits*. 2003. **85**(2-3): p. 195-200.
178. Gamal, E.E.-G., et al., *Traditional medicinal plants indigenous to Al-Rass province, Saudi Arabia*. 2010. **4**(24): p. 2680-2683.
179. Isla, M.I., et al., *Flower beverages of native medicinal plants from Argentina (Acacia caven, Geoffroea decorticans and Larrea divaricata) as antioxidant and anti-inflammatory*. 2021. **281**: p. 114490.
180. Sarkar, A., et al., *Anti-rheumatoid and anti-oxidant activity of homeopathic Guaiacum officinale in an animal model*. 2014. **103**(02): p. 133-138.

REFERENCES

181. Pareek, A., et al., *Antioxidant and hepatoprotective activity of Fagonia schweinfurthii (Hadidi) Hadidi extract in carbon tetrachloride induced hepatotoxicity in HepG2 cell line and rats*. 2013. **150**(3): p. 973-981.
182. Khlifi, D., et al., *Composition and anti-oxidant, anti-cancer and anti-inflammatory activities of Artemisia herba-alba, Ruta chalpensis L. and Peganum harmala L.* 2013. **55**: p. 202-208.
183. Speroni, E., et al., *Anti-inflammatory, anti-nociceptive and antioxidant activities of Balanites aegyptiaca (L.) Delile*. 2005. **98**(1-2): p. 117-125.
184. Ksouri, W.M., et al., *LC-ESI-TOF-MS identification of bioactive secondary metabolites involved in the antioxidant, anti-inflammatory and anticancer activities of the edible halophyte Zygophyllum album Desf.* 2013. **139**(1-4): p. 1073-1080.
185. Pedernera, A.M., et al., *Anti-ulcerogenic and anti-inflammatory activity of the methanolic extract of Larrea divaricata Cav. in rat*. 2006. **105**(3): p. 415-420.
186. El Ghoul, J., et al., *Antihyperglycemic, antihyperlipidemic and antioxidant activities of traditional aqueous extract of Zygophyllum album in streptozotocin diabetic mice*. 2012. **19**(1): p. 35-42.
187. Saleh, N.A., M.N.J.B.S. El-Hadidi, and Ecology, *An approach to the chemosystematics of the Zygophyllaceae*. 1977. **5**(2): p. 121-128.
188. Beier, B.A.J.S. and Biodiversity, *A revision of the desert shrub Fagonia (Zygophyllaceae)*. 2005. **3**(3): p. 221-263.
189. Beier, B.-A., et al., *Phylogenetic relationships and taxonomy of subfamily Zygophylloideae (Zygophyllaceae) based on molecular and morphological data*. 2003. **240**(1): p. 11-39.
190. Beier, B.-A., et al., *Phylogenetic relationships and biogeography of the desert plant genus Fagonia (Zygophyllaceae), inferred by parsimony and Bayesian model averaging*. 2004. **33**(1): p. 91-108.
191. Quézel, P. and S. Santa, *Nouvelle flore de l'Algérie et des régions désertiques méridionales*. 1962.
192. Hussain, A., M. Zia, and B.J.T.j.o.b. Mirza, *Cytotoxic and antitumor potential of Fagonia cretica L.* 2007. **31**(1): p. 19-24.
193. Baquar, S.R.J.M. and p.p.o. Pakistan., *Medicinal and poisonous plants of Pakistan*. 1989.
194. Khattak, K.F.J.R.P. and Chemistry, *Evaluation of microbial loads, physical characteristics, chemical constituents and biological properties of radiation processed Fagonia arabica*. 2012. **81**(6): p. 679-685.
195. Shad, A.A., et al., *Proximate and mineral constituents of medicinal herb Fagonia arabica*. 2002.
196. Ibrar, M. and F.J.F.o.B.i.C. Hussain, *Ethnobotanical studies of plants of Charkotli hills, Batkhela district, Malakand, Pakistan*. 2009. **4**(4): p. 539-548.
197. Soomro, A. and N.J.J.o.P.M.A. Jafarey, *Effect of Fagonia indica on experimentally produced tumours in rats*. 2003. **53**(6): p. 224-225.
198. Prasad, S., et al., *Effect of Fagonia arabica (Dhamasa) on in vitro thrombolysis*. 2007. **7**(1): p. 1-6.
199. Atiq-ur-Rehman, et al., *Postprandial Anti-Diabetic Effects of Various Fractions of Fagonia indica Burm. f. by in vitro and in vivo Studies*. 2019. **51**(1): p. 333-340.
200. Sharma, S., et al., *Analgesic and anti-microbial activity of Fagonia indica*. 2009. **3**: p. 623-632.
201. Saleh, I.A., et al., *Anti-inflammatory and wound healing activity of Fagonia schweinfurthii alcoholic extract herbal gel on albino rats*. 2011. **5**(17): p. 1996-2001.
202. Satpute, R.M., et al., *Protection of PC12 cells from chemical ischemia induced oxidative stress by Fagonia arabica*. 2009. **47**(11): p. 2689-2695.
203. Hamidi, N., et al., *Ethnopharmacology, antibacterial and antioxidant activities, phytochemical screening of bioactive extracts from the aerial parts of Fagonia longispina*. 2014. **3**: p. 3.
204. Alali, F.Q., et al., *Antioxidant activity and total phenolic content of aqueous and methanolic extracts of Jordanian plants: an ICBG project*. 2007. **21**(12): p. 1121-1131.
205. Malavika, P., V. Singh, and Y. Kumar, *THE CHEMISTRY AND PHARMACOLOGY OF FAGONIA GENUS: A REVIEW*.

REFERENCES

206. BATANOVNY, K. and M.J.P.-I.M. BATANOVNY, *Autecology of common Egyptian Fagonia species*. 1970.
207. Ozenda, P.J.F.o.t.S., *Flora of the Sahara*. 1977(ed. 2).
208. Almoshari, Y.J.S.J.o.B.S., *Medicinal plants used for dermatological disorders among the people of the kingdom of Saudi Arabia: A narrative review*. 2022: p. 103303.
209. Bibi, T., et al., *Ethnobotany of medicinal plants in district Mastung of Balochistan province-Pakistan*. 2014. **157**: p. 79-89.
210. Sadat-Hosseini, M., et al., *Ethnopharmacological studies of indigenous medicinal plants in the south of Kerman, Iran*. 2017. **199**: p. 194-204.
211. Irshad, S., et al., *Anti-Inflammatory, analgesic and anti-pyretic activity of Fagonia bruguieri DC in rats*. 2022. **35**(4 (Special)): p. 1209-1213.
212. Ahmed, A., A. Hameed, and S.J.b. Saeed, *Biochemical profile and bioactive potential of wild folk medicinal plants of Zygophyllaceae from Balochistan, Pakistan*. 2020.
213. Khalid, U., H. Shahid, and A. Rao, *Evaluation of histopathological and biochemical hepatoprotective potentials of fagonia bruguieri a plant from Cholistan desert*. 2011.
214. Ghoneim, K.E., K.S. Hamadah, and A.A.J.J.o.t.E.R.S. El-Hela, *Acetylcholinesterase activity in the desert locust Schistocerca gregaria (Acrididae)(Forsk.) as a response to the action of the wild herb Fagonia bruguieri DC.(Zygophyllaceae) extracts*. 2013. **15**(1): p. 87-97.
215. Saleem, R., et al., *Comparative in vitro anti-oxidant and anti-fungal potential profiles from methanol extract of Fagonia indica, Fagonia bruguieri and Fagonia paulayana*. 2019. **4**(5): p. 69-76.
216. Ibrahim, L.F., et al., *A new kaempferol triglycoside from Fagonia taeckholmiana: cytotoxic activity of its extracts*. 2008. **343**(1): p. 155-158.
217. Shehab, N.G., et al., *Chemical constituents and biological activities of Fagonia indica Burm F*. 2011. **5**: p. 531-546.
218. Maksoud, S.A., M.J.P.s. El-Hadidi, and evolution, *The flavonoids of the Fagonia bruguieri complex (Zygophyllaceae)*. 1987. **155**(1): p. 311-318.
219. Al-Wakeel, S.A.J.B.s. and ecology, *Significance of flavonoid chemistry in the Egyptian Fagonia glutinosa and F. isotricha complexes*. 1992. **20**(3): p. 259-264.
220. Saleh, N.A., et al., *Phytochemistry and phylogenetic affinities among Egyptian species of Fagonia*. 1990. **18**(1): p. 49-52.
221. Al-Wakeel, S., et al., *Differences in flavonoid constituents among the species of Fagonia sinaica complex (Zygophyllaceae)*. 1988. **161**(1): p. 87-89.
222. Al-Wakeel, S., et al., *Distribution of flavonoids in Fagonia thebaica complex*. 1988. **16**(1): p. 57-58.
223. Ourzeddine, W., et al., *A New Δ -2-Carene- β -D-Glucopyranoside from Fagonia Longispina*. 2017. **12**(9): p. 1934578X1701200901.
224. El-Hadidi, M., et al., *Systematic significance of the flavonoid constituents in the Fagonia indica—complex*. 1988. **16**(3): p. 293-297.
225. Shaker, K.H., et al., *New compounds from Bassia muricata and Fagonia indica*. 2013. **23**(1): p. 231-236.
226. Al-Wakeel, S., et al., *Flavonoid patterns in Fagonia mollis-complex*. 1987. **15**(4): p. 459-460.
227. El-Wakil, E.A.J.Z.f.N.C., *Phytochemical and molluscicidal investigations of Fagonia arabica*. 2007. **62**(9-10): p. 661-667.
228. El-Negoumy, S., et al., *The flavonoids of the Fagonia arabica-complex (Zygophyllaceae)*. 1986. **25**(10): p. 2423-2424.
229. Abdel-Kader, M.S., et al., *Erythrozan diterpenes and flavonoids from Fagonia bruguieri*. 1993. **33**(3): p. 718-720.
230. Gedara, S.R., et al., *New erythropane-type diterpenoids from fagonia boveana (hadidi) hadidi & graf*. 2003. **58**(1-2): p. 23-32.
231. Waheed, A., et al., *A novel steroidal saponin glycoside from Fagonia indica induces cell-selective apoptosis or necrosis in cancer cells*. 2012. **47**(2): p. 464-473.

REFERENCES

232. Miyase, T., et al., *Saponins from Fagonia arabica*. 1996. **41**(4): p. 1175-1179.
233. Shaker, K.H., et al., *Triterpenoid saponins from Fagonia indica*. 1999. **51**(8): p. 1049-1053.
234. Melek, F., et al., *Saponins from Fagonia mollis*. 1996. **42**(5): p. 1405-1407.
235. Perrone, A., et al., *Sulfated triterpene derivatives from Fagonia arabica*. 2007. **70**(4): p. 584-588.
236. Melek, F., et al., *Saponins from Fagonia glutinosa*. 2000. **55**(10): p. 772-776.
237. Abdel-Khalik, S., et al., *Further saponins from Fagonia cretica*. 2001. **56**(3): p. 247-250.
238. Boutaghane, N., et al., *Triterpene saponins from Fagonia scabra Forssk and other Fagonia species*. 2016. **67**: p. 1-6.
239. Saleem, S., et al., *Plants Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity*. 2014. **156**: p. 26-32.
240. Sallam, A., et al., *Diterpenoids from Fagonia mollis*. 2014. **9**(9): p. 1934578X1400900905.
241. Ansari, A.A. and L.J.P. Kenne, *Isolation and characterization of two saponins from Fagonia indica*. 1987. **26**(5): p. 1487-1490.
242. Farheen, R., et al., *Triterpenoids and triterpenoid saponins from the aerial parts of Fagonia indica Burm*. 2015. **13**: p. 256-261.
243. Farheen, R., I. Mahmood, and B.S.J.F.J.o.B. Siddiqui, *Fagonilin: a new triterpene from Fagonia indica burm. F. Var. Indica*. 2014. **4**(2): p. 261-264.
244. Farheen, R., et al., *GC, GC-MS Analysis of Lipophilic Fractions of Aerial Parts of Fagonia indica Burm. f. Showing Growth Inhibitory Effect on HT 29 Colorectal Cancer Cells*. 2016. **38**(4).
245. Abdel-Kader, M.S., et al., *Erythroxan diterpenes from Fagonia species*. 1994. **36**(6): p. 1431-1433.
246. Abdel-Kader, M.S., A.A. Omar, and F.R.J.P.m. Stermitz, *Erythroxan diterpenes from Fagonia glutinosa*. 1997. **63**(04): p. 374-376.
247. DASTAGIR¹, G., F. HUSSAIN¹, and I.U.J.P.J.B. Rehman, *Essential oil composition of some plants of family Zygophyllaceae and Euphorbiaceae*. 2014. **46**(6): p. 2043-2049.
248. Ghasmoune, W., *Evaluation de l'activité anti-oxydante des huiles essentielles Et d'extrait d'une plante: étude théorique et expérimentale*. 2021, Université jijel.
249. Bourgaud, F., et al., *Production of plant secondary metabolites: a historical perspective*. 2001. **161**(5): p. 839-851.
250. Judd, W.S., et al., *Botanique systématique: une perspective phylogénétique*. 2002: De Boeck Supérieur.
251. Edeas, M.J.P., *Les polyphénols et les polyphénols de thé*. 2007. **5**(5): p. 264-270.
252. Lugasi, A.J.A.b.s., *The role of antioxidant phytonutrients in the prevention of diseases*. 2003. **47**(1-4): p. 119-125.
253. Bruneton, J., *Pharmacognosie: phytochimie plantes médicinales*. 1993.
254. El Gharras, H.J.I.j.o.f.s. and technology, *Polyphenols: food sources, properties and applications—a review*. 2009. **44**(12): p. 2512-2518.
255. Bruneton, J.J.P., Tec and D.-É.m. internationales, *Pharmacognosie-Phytochimie, plantes médicinales, 4e éd., revue et augmentée*. 2009: p. 1288.
256. Macheix, J.-J., A. Fleuriet, and C. Jay-Allemand, *Les composés phénoliques des végétaux: un exemple de métabolites secondaires d'importance économique*. 2005: PPUR presses polytechniques.
257. Chanforan, C. *Stabilité de microconstituants de la tomate (composés phénoliques, caroténoïdes, vitamines C et E) au cours des procédés de transformation: études en systèmes modèles, mise au point d'un modèle stoechio-cinétique et validation pour l'étape unitaire de préparation de sauce tomate*. 2010. Avignon.
258. Chira, K., et al., *Les polyphénols du raisin*. 2008. **6**(2): p. 75-82.
259. Mattila, P., J.J.J.o.F.C. Hellström, and Analysis, *Phenolic acids in potatoes, vegetables, and some of their products*. 2007. **20**(3-4): p. 152-160.
260. Škerget, M., et al., *Phenols, proanthocyanidins, flavones and flavonols in some plant materials and their antioxidant activities*. 2005. **89**(2): p. 191-198.

REFERENCES

261. Ghedira, K.J.P., *Les flavonoïdes: structure, propriétés biologiques, rôle prophylactique et emplois en thérapeutique*. 2005. **3**(4): p. 162-169.
262. Cook, N.C. and S.J.T.J.o.n.b. Samman, *Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources*. 1996. **7**(2): p. 66-76.
263. Balasundram, N., K. Sundram, and S.J.F.c. Samman, *Phenolic compounds in plants and agri-industrial by-products: Antioxidant activity, occurrence, and potential uses*. 2006. **99**(1): p. 191-203.
264. Heim, K.E., A.R. Tagliaferro, and D.J.J.T.J.o.n.b. Bobilya, *Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships*. 2002. **13**(10): p. 572-584.
265. Cowan, M.M.J.C.m.r., *Plant products as antimicrobial agents*. 1999. **12**(4): p. 564-582.
266. Ref'at, A.A., H.R. Takruri, and H.J.J.J.o.A.S. Al-Sayyed, *Tannin contents of selected plants used in Jordan*. 2008. **4**(3): p. 265-274.
267. Celzard, A., et al., *Flammability assessment of tannin-based cellular materials*. 2011. **96**(4): p. 477-482.
268. Hoong, Y.B., et al., *Characterization of Acacia mangium polyflavonoid tannins by MALDI-TOF mass spectrometry and CP-MAS 13C NMR*. 2010. **46**(6): p. 1268-1277.
269. Khanbabaee, K. and T.J.N.p.r. Van Ree, *Tannins: classification and definition*. 2001. **18**(6): p. 641-649.
270. Derbel, S. and K.J.P. Ghedira, *Les phytonutriments et leur impact sur la santé*. 2005. **3**(1): p. 28-34.
271. Lochab, B., S. Shukla, and I.K.J.R.a. Varma, *Naturally occurring phenolic sources: monomers and polymers*. 2014. **4**(42): p. 21712-21752.
272. El-Seedi, H.R., et al., *Hydroxycinnamic acids: natural sources, biosynthesis, possible biological activities, and roles in Islamic medicine*. 2018. **55**: p. 269-292.
273. Sova, M. and L.J.N. Saso, *Natural sources, pharmacokinetics, biological activities and health benefits of hydroxycinnamic acids and their metabolites*. 2020. **12**(8): p. 2190.
274. Serrano, J., et al., *Tannins: current knowledge of food sources, intake, bioavailability and biological effects*. 2009. **53**(S2): p. S310-S329.
275. Delimont, N.M., M.D. Haub, and B.L.J.C.d.i.n. Lindshield, *The impact of tannin consumption on iron bioavailability and status: A narrative review*. 2017. **1**(2): p. 1-12.
276. Sharifi-Rad, J., et al., *Biological activities of essential oils: From plant chemoecology to traditional healing systems*. 2017. **22**(1): p. 70.
277. Djilani, A., A.J.N. Dicko, well-being, and health, *The therapeutic benefits of essential oils*. 2012. **7**: p. 155-179.
278. Bano, B., et al., *Synthesis, in vitro urease inhibitory activity, and molecular docking studies of thiourea and urea derivatives*. 2018. **80**: p. 129-144.
279. Durand, G., A. Polidori, and B.J.I.a.c. Pucci, *La vectorisation de pièges à radicaux libres*. 2003: p. 26.
280. Atta, E.M., N.H. Mohamed, and A.A.A.J.E.C.B. Silaev, *Antioxidants: An overview on the natural and synthetic types*. 2017. **6**(8): p. 365-375.
281. Agarwal, A., et al., *Oxidative stress in human reproduction: shedding light on a complicated phenomenon*. 2017: Springer.
282. Tan, B.L., et al., *Sulaiman Rahman*. 2018. **9**: p. 1162.
283. Favier, A.J.L.a.c., *Le stress oxydant*. 2003. **108**(10): p. 863-832.
284. Pincemail, J., et al., *Mécanismes physiologiques de la défense antioxydante*. 2002. **16**(4): p. 233-239.
285. Andjelković, M., et al., *Iron-chelation properties of phenolic acids bearing catechol and galloyl groups*. 2006. **98**(1): p. 23-31.
286. Cai, Y.-Z., et al., *Structure–radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants*. 2006. **78**(25): p. 2872-2888.
287. Conde, E., et al., *Low molecular weight polyphenols in cork of Quercus suber*. 1997. **45**(7): p. 2695-2700.

REFERENCES

288. Chirinos, R., et al., *Antioxidant properties of mashua (Tropaeolum tuberosum) phenolic extracts against oxidative damage using biological in vitro assays*. 2008. **111**(1): p. 98-105.
289. Leopoldini, M., N. Russo, and M.J.F.c. Toscano, *The molecular basis of working mechanism of natural polyphenolic antioxidants*. 2011. **125**(2): p. 288-306.
290. Pietta, P.-G.J.J.o.n.p., *Flavonoids as antioxidants*. 2000. **63**(7): p. 1035-1042.
291. Di Carlo, G., et al., *Flavonoids: old and new aspects of a class of natural therapeutic drugs*. 1999. **65**(4): p. 337-353.
292. Bharti, S.K., et al., *Antidiabetic phytoconstituents and their mode of action on metabolic pathways*. 2018. **9**(3): p. 81-100.
293. Abo, K., et al., *Ethnobotanical survey of plants used in the treatment of infertility and sexually transmitted diseases in southwest Nigeria*. 2000. **29**(3-4): p. 325-327.
294. Perera, A., et al., *Perspectives on geraniin, a multifunctional natural bioactive compound*. 2015. **44**(2): p. 243-257.
295. Aguirre, L., et al., *Beneficial effects of quercetin on obesity and diabetes*. 2011. **4**(1).
296. Jean, B., *Pharmacognosie, phytochimie, plantes médicinales (4e éd.)*. 2009: Lavoisier.
297. Numonov, S., et al., *Evaluation of the antidiabetic activity and chemical composition of Geranium collinum root extracts—Computational and experimental investigations*. 2017. **22**(6): p. 983.
298. Perry, N.S., et al., *In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes*. 2000. **52**(7): p. 895-902.
299. Oh, M., et al., *Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity*. 2004. **11**(6): p. 544-548.
300. Cummings, B.J., et al., *β -amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease*. 1996. **17**(6): p. 921-933.
301. Melzer, D.J.B., *New drug treatment for Alzheimer's disease: lessons for healthcare policy*. 1998. **316**(7133): p. 762-764.
302. Schulz, V.J.P., *Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider*. 2003. **10**: p. 74-79.
303. Small, G.W., et al., *Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society*. 1997. **278**(16): p. 1363-1371.
304. Huang, K.C., *The pharmacology of Chinese herbs*. 1998: CRC press.
305. Ma, T. and C.J.C.T.H.D. Yu, *Pharmacological studies on the effect of Panax ginseng in learning and memory*. 1990. **21**: p. 38-40.
306. Aziz, S., et al., *Comparative studies of elemental composition in leaves and flowers of Catharanthus roseus growing in Bangladesh*. 2016. **6**(1): p. 50-54.
307. Lehner, A.J.P.Y., *La nutrition hydrique et minérale chez les plantes*. 2014(L2).
308. Messaoudi, M. and S.J.B.t.e.r. Begaa, *Dietary intake and content of some micronutrients and toxic elements in two algerian spices (Coriandrum sativum L. and Cuminum cyminum L.)*. 2019. **188**(2): p. 508-513.
309. Gasmi, A., et al., *Phenolic profiling, sugar composition and antioxidant capacity of arta (Calligonum comosum L.), a wild Tunisian desert plant*. 2019. **130**: p. 436-442.
310. Quezel, P., S.J.N.f.o.A. Santa, and s.d. regions., *New flora of Algeria and southern desert regions*. 1962.
311. Harborne, A., *Phytochemical methods a guide to modern techniques of plant analysis*. 1998: springer science & business media.
312. Wagner, H. and S. Bladt, *Plant drug analysis: a thin layer chromatography atlas*. 1996: Springer Science & Business Media.
313. Begaa, S. and M.J.B.t.e.r. Messaoudi, *Toxicological aspect of some selected medicinal plant samples collected from Djelfa, Algeria Region*. 2019. **187**(1): p. 301-306.

REFERENCES

314. Benarfa, A., et al., *Elemental composition analysis of Pistacia lentiscus L., leaves collected from Mitidja plain in Algeria using instrumental neutron activation analysis (INAA) technique*. 2020. **108**(10): p. 821-828.
315. Khoo, K.J.J.o.N. and R. Technologies, *Overview of INAA method and its application in Malaysia*. 2011. **8**(02): p. 26-40.
316. Adams, F., R.J.J.o.R. Dams, and N. Chemistry, *A compilation of precisely determined gamma-transition energies of radionuclides produced by reactor irradiation*. 1969. **3**(1-2): p. 99-125.
317. Begaa, S., M. Messaoudi, and A.J.B.T.E.R. Benarfa, *Statistical approach and neutron activation analysis for determining essential and toxic elements in two kinds of Algerian Artemisia plant*. 2021. **199**(6): p. 2399-2405.
318. Butler, C.C., R.N. Kniseley, and V.A.J.A.c. Fassel, *Inductively coupled plasma-optical emission spectrometry. Application to the determination of alloying and impurity elements in low and high alloy steels*. 1975. **47**(6): p. 825-829.
319. Fassel, V.A. and R.N.J.A.C. Kniseley, *Inductively coupled plasma. Optical emission spectroscopy*. 1974. **46**(13): p. 1110A-1120a.
320. Watson, J.T. and O.D. Sparkman, *Introduction to mass spectrometry: instrumentation, applications, and strategies for data interpretation*. 2007: John Wiley & Sons.
321. Agbor, G.A., et al., *Folin-Ciocalteu reagent for polyphenolic assay*. 2014. **3**(8): p. 147-156.
322. Singleton, V.L., J.A.J.A.j.o.E. Rossi, and Viticulture, *Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents*. 1965. **16**(3): p. 144-158.
323. Müller, L., et al., *Antioxidant capacity and related parameters of different fruit formulations*. 2010. **43**(6): p. 992-999.
324. Topçu, G., et al., *A new flavone from antioxidant extracts of Pistacia terebinthus*. 2007. **103**(3): p. 816-822.
325. Sánchez-Moreno, C.J.F.s. and t. international, *Methods used to evaluate the free radical scavenging activity in foods and biological systems*. 2002. **8**(3): p. 121-137.
326. Endo, T., et al., *Scavenging DPPH radicals catalyzed by binary noble metal-dendrimer nanocomposites*. 2006. **302**(2): p. 516-521.
327. Blois, M.S.J.N., *Antioxidant determinations by the use of a stable free radical*. 1958. **181**(4617): p. 1199-1200.
328. Re, R., et al., *Antioxidant activity applying an improved ABTS radical cation decolorization assay*. 1999. **26**(9-10): p. 1231-1237.
329. Marc, F., et al., *Méthodes d'évaluation du potentiel antioxydant dans les aliments*. 2004. **20**(4): p. 458-463.
330. Marco, G.J.J.J.o.t.A.O.C.S., *A rapid method for evaluation of antioxidants*. 1968. **45**(9): p. 594-598.
331. Miller, H.J.J.o.t.A.O.C.S., *A simplified method for the evaluation of antioxidants*. 1971. **48**(2): p. 91-91.
332. Apak, R., et al., *Novel total antioxidant capacity index for dietary polyphenols and vitamins C and E, using their cupric ion reducing capability in the presence of neocuproine: CUPRAC method*. 2004. **52**(26): p. 7970-7981.
333. Bedlovičová, Z., et al., *A brief overview on antioxidant activity determination of silver nanoparticles*. 2020. **25**(14): p. 3191.
334. Singh, A.P., S.J.T.-s.p. Kumar, biological properties, and c. knowledge, *Applications of tannins in industry*. 2020.
335. Oyaizu, M.J.J.J.N., *Antioxidative activities of browning reaction prepared from glucosamine*. 1986. **44**: p. 307-315.
336. Shi, H., N. Noguchi, and E. Niki, *Galvinoxyl method for standardizing electron and proton donation activity*, in *Methods in enzymology*. 2001, Elsevier. p. 157-166.
337. Valcheva-Kuzmanova, S., B. Blagović, and S.J.P.M. Valić, *Electron spin resonance measurement of radical scavenging activity of Aronia melanocarpa fruit juice*. 2012. **8**(30): p. 171.

REFERENCES

338. Szydłowska-Czerniak, A., et al., *Determination of antioxidant capacities of vegetable oils by ferric-ion spectrophotometric methods*. 2008. **76**(4): p. 899-905.
339. Asghari, B., et al., *Amylase, glucosidase, tyrosinase, and cholinesterases inhibitory, antioxidant effects, and GC-MS analysis of wild mint (*Mentha longifolia* var. *calliantha*) essential oil: A natural remedy*. 2018. **22**: p. 44-49.
340. Ellman, G.L., et al., *A new and rapid colorimetric determination of acetylcholinesterase activity*. 1961. **7**(2): p. 88-95.
341. Kazeem, M., J. Adamson, and I.J.B.r.i. Ogunwande, *Modes of inhibition of α -amylase and α -glucosidase by aqueous extract of *Morinda lucida* Benth leaf*. 2013. **2013**.
342. Chiasson, J.-L., et al., *Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial*. 2002. **359**(9323): p. 2072-2077.
343. Furman, B.L., *Acarbose*. 2017.
344. Khan, M., et al., *Flurbiprofen derivatives as novel α -amylase inhibitors: Biology-oriented drug synthesis (BIODS), in vitro, and in silico evaluation*. 2018. **81**: p. 157-167.
345. Zengin, G., et al., *A comprehensive study on phytochemical characterization of *Haplophyllum myrtifolium* Boiss. endemic to Turkey and its inhibitory potential against key enzymes involved in Alzheimer, skin diseases and type II diabetes*. 2014. **53**: p. 244-251.
346. Souza, S.P.d., et al., *Inhibition of pancreatic lipase by extracts of *Baccharis trimera* (Less.) DC., Asteraceae: evaluation of antinutrients and effect on glycosidases*. 2011. **21**: p. 450-455.
347. Adarsh Verma, M., et al., *Anti-denaturation and antioxidant activities of *Annona cherimola* in-vitro*. 2011. **2**: p. 1-6.
348. Karthik, I., *Evaluation of anti-inflammatory activity of *canthium parviflorum* by in-vitro method*. 2013.
349. D’Orazio, J., et al., *UV radiation and the skin*. 2013. **14**(6): p. 12222-12248.
350. Saewan, N. and A.J.J.o.A.P.S. Jimtaisong, *Photoprotection of natural flavonoids*. 2013. **3**(9): p. 129-141.
351. Mansur, J.d.S., et al., *Determinação do fator de proteção solar por espectrofotometria*. 1986: p. 121-4.
352. Sayre, R.M., et al., *A comparison of in vivo and in vitro testing of sunscreens formulas*. 1979. **29**(3): p. 559-566.
353. Communities., C.o.E., *Recommendation of 22 September. On Sun Screen Products and Manufacturers Claims*. Off. J. Eur. Union, 2006.
354. Douaouya, L., et al., *In vitro assessment of the bioactive potential of *Artemisia campestris* L. fractions growing in Khenchela (Algeria)*. 2022. **12**(4): p. 445-455.
355. Naili, M.B., et al., *Evaluation of antibacterial and antioxidant activities of *Artemisia campestris* (Astraceae) and *Ziziphus lotus* (Rhamnaceae)*. 2010. **3**(2): p. 79-84.
356. Council, N., *Recommended Dietary Allowances*. Washington, DC. 1989, National Academy of Sciences Press.
357. KO, S., O. CO, and E.O.J.A.j.o.f.s. O, *The importance of mineral elements for humans, domestic animals and plants-A review*. 2010. **4**(5): p. 200-222.
358. Mudgal, V., et al., *Effect of toxic metals on human health*. 2010. **3**(1).
359. Council, N.R., *Recommended dietary allowances*. 1989.
360. Jamshidi-Kia, F., Z. Lorigooini, and H.J.J.o.h.p. Amini-Khoei, *Medicinal plants: Past history and future perspective*. 2018. **7**(1).
361. Intakes, I.o.M.S.C.o.t.S.E.o.D.R., *Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride*. 1997.
362. Bhattacharya, P.T., S.R. Misra, and M.J.S. Hussain, *Nutritional aspects of essential trace elements in oral health and disease: an extensive review*. 2016. **2016**.
363. Abbaspour, N., R. Hurrell, and R.J.J.o.r.i.m.s.t.o.j.o.I.U.o.M.S. Kelishadi, *Review on iron and its importance for human health*. 2014. **19**(2): p. 164.
364. Stefanidou, M., et al., *Zinc: a multipurpose trace element*. 2006. **80**(1): p. 1-9.
365. Novotny, J.A. and C.A.J.A.i.N. Peterson, *Molybdenum*. 2018. **9**(3): p. 272-273.

REFERENCES

366. Li, L., X.J.O.m. Yang, and c. longevity, *The essential element manganese, oxidative stress, and metabolic diseases: links and interactions*. 2018. **2018**.
367. O'Neal, S.L. and W.J.C.e.h.r. Zheng, *Manganese toxicity upon overexposure: a decade in review*. 2015. **2**(3): p. 315-328.
368. Kirkland, A.E., G.L. Sarlo, and K.F.J.N. Holton, *The role of magnesium in neurological disorders*. 2018. **10**(6): p. 730.
369. Li, F., et al., *Sodium-based batteries: from critical materials to battery systems*. 2019. **7**(16): p. 9406-9431.
370. Barker, A.V. and D.J. Pilbeam, *Handbook of plant nutrition*. 2015: CRC press.
371. Gambelli, L., et al., *Minerals and trace elements in some Italian dairy products*. 1999. **12**(1): p. 27-35.
372. Commission, J.F.W.C.A. and J.F.W.F.S. Programme, *Codex Alimentarius*. 1995: FAO.
373. Aissani, F., et al., *Algerian Sonchus oleraceus L.: a comparison of different extraction solvent on phytochemical composition, antioxidant properties and anti-cholinesterase activity*. 2022. **22**(2): p. 383-394.
374. Bakchiche, B., et al., *Identification, quantification, and antioxidant activity of hydroalcoholic extract of Artemisia campestris from Algeria*. 2019. **16**(2): p. 234.
375. Bourgou, S., et al., *LC-ESI-TOF-MS and GC-MS profiling of Artemisia herba-alba and evaluation of its bioactive properties*. 2017. **99**: p. 702-712.
376. Carazzone, C., et al., *Identification of phenolic constituents in red chicory salads (Cichorium intybus) by high-performance liquid chromatography with diode array detection and electrospray ionisation tandem mass spectrometry*. 2013. **138**(2-3): p. 1062-1071.
377. He, Z.-Z., et al., *Chemical constituents from the aerial parts of Artemisia minor*. 2009. **72**(6): p. 1198-1201.
378. Rechek, H., et al., *Chemical composition and antioxidant, anti-inflammatory, and enzyme inhibitory activities of an endemic species from southern algeria: Warionia saharae*. 2021. **26**(17): p. 5257.
379. Ivanescu, B., et al., *HPLC-DAD-MS study of polyphenols from Artemisia absinthium, A. annua, and A. vulgaris*. 2010. **46**(3): p. 468-470.
380. Ivanescu, B., et al., *Bioactive compounds from Artemisia campestris L. subsp. campestris*. 2018. **2**: p. 3.
381. Cuthbertson, D.J., et al., *Accurate mass–time tag library for LC/MS-based metabolite profiling of medicinal plants*. 2013. **91**: p. 187-197.
382. Kumbi, Y., *Phytochemical characterization of Fagonia indica and its effects on MCF-7 breast cancer cell line*. 2019.
383. Miranda, C.L., et al., *Phytochemical characterization and bioactivity toward breast cancer cells of unhydrolyzed and acid-hydrolyzed extracts of Fagonia indica*. 2022. **17**(7): p. 1934578X221109426.
384. Lorenzo, M.E., et al., *Phenolic Profile and Antioxidant Activity of Ethanolic Extract of Larrea cuneifolia Cav. Leaves*. 2020. **70**(1): p. 37.
385. Ahmad, V.U., et al., *Isolation of four new pterocarpanes from Zygodphyllum eurypterum (syn. Z. atriplicoides) with enzyme-inhibition properties*. 2006. **3**(9): p. 996-1003.
386. Aulifa, D.L., et al., *Inhibitory activity of xanthoangelol isolated from Ashitaba (Angelica keiskei Koidzumi) towards α -glucosidase and dipeptidyl peptidase-IV: in silico and in vitro studies*. 2022. **8**(5): p. e09501.
387. Ortiz, O.O., et al., *Cecropia telenitida Cuatrec.(Urticaceae: Cecropieae): Phytochemical diversity, chemophenetic implications and new records from Central America*. 2019. **86**: p. 103935.
388. Choudhary, D.K., et al., *Characterization, inhibitory activity and mechanism of polyphenols from faba bean (gallic-acid and catechin) on α -glucosidase: Insights from molecular docking and simulation study*. 2020. **50**(2): p. 123-132.

REFERENCES

389. Marston, A., et al., *Clarification of the saponin composition of Ranunculus ficaria tubers*. 2006. **1**(1): p. 1934578X0600100105.
390. Martins, N., et al., *Antioxidant potential of two Apiaceae plant extracts: A comparative study focused on the phenolic composition*. 2016. **79**: p. 188-194.
391. Barros, L., et al., *Phenolic profiles of in vivo and in vitro grown Coriandrum sativum L.* 2012. **132**(2): p. 841-848.
392. Bora, K.S. and A.J.P.b. Sharma, *The genus Artemisia: a comprehensive review*. 2011. **49**(1): p. 101-109.
393. Valizadeh, H., et al., *Isolation and structure elucidation of secondary metabolites from Echinophora platyloba DC from Iran*. 2014.
394. Krishnan, S.S.C., et al., *Isolation, characterization of syringin, phenylpropanoid glycoside from Musa paradisiaca tepal extract and evaluation of its antidiabetic effect in streptozotocin-induced diabetic rats*. 2014. **4**(2): p. 105-111.
395. Sang, S., et al., *New prenylated benzoic acid and other constituents from almond hulls (Prunus amygdalus Batsch)*. 2002. **50**(3): p. 607-609.
396. Manguro, L.O.A. and P.J.N.P.R. Lemmen, *Phenolics of Moringa oleifera leaves*. 2007. **21**(1): p. 56-68.
397. Lee, K.H., et al., *Isolation and identification of phenolic compounds from an Asian pear (Pyrus pyrifolia Nakai) fruit peel*. 2011. **20**: p. 1539-1545.
398. Hsouna, A.B., N.J.L.i.h. Hamdi, and disease, *Phytochemical composition and antimicrobial activities of the essential oils and organic extracts from Pelargonium graveolens growing in Tunisia*. 2012. **11**(1): p. 1-7.
399. Suwal, S. and A.J.N.J.o.B. Marciniak, *Technologies for the Extraction, Separation and Purification of polyphenols—A Review*. 2018. **6**(1): p. 74-91.
400. Megdiche-Ksouri, W., et al., *Artemisia campestris phenolic compounds have antioxidant and antimicrobial activity*. 2015. **63**: p. 104-113.
401. Djeridane, A., et al., *Antioxidant activity of some Algerian medicinal plants extracts containing phenolic compounds*. 2006. **97**(4): p. 654-660.
402. Ahmed, A., A. Hameed, and S.J.b. Saeed, *Biochemical profile and bioactive potential of wild folk medicinal plants of Zygophyllaceae from Balochistan, Pakistan*. 2020: p. 2020.03.30.016212.
403. Kähkönen, M.P., et al., *Antioxidant activity of plant extracts containing phenolic compounds*. 1999. **47**(10): p. 3954-3962.
404. Rice-evans, C.A., et al., *The relative antioxidant activities of plant-derived polyphenolic flavonoids*. 1995. **22**(4): p. 375-383.
405. Sasikumar, V., P.J.B. Kalaisezhiyen, and A. Biochemistry, *Evaluation of Free Radical Scavenging Activity of Various Leaf Extracts from Kedrostis Foetidissima (Jacq.) Cogn.* 2014. **3**(2): p. 1.
406. Alam, M.N., N.J. Bristi, and M.J.S.p.j. Rafiqzaman, *Review on in vivo and in vitro methods evaluation of antioxidant activity*. 2013. **21**(2): p. 143-152.
407. Irda, F., A.N. Sahar, and W.K.J.I.J.R.P.S. Ruslan, *Evaluation of antioxidant activities from various extracts of Dragon fruit peels using DPPH, ABTS assays and correlation with phenolic, flavonoid, carotenoid content*. 2014. **5**: p. 104-111.
408. Akrouf, A., et al., *Screening of antiradical and antibacterial activities of essential oils of Artemisia campestris L., Artemisia herba alba Asso, & Thymus capitatus Hoff. et Link. growing wild in the Southern of Tunisia*. 2009. **2**(1).
409. Satpute, R., et al., *Antioxidant potential of Fagonia arabica against the chemical ischemia-induced in PC12 cells*. 2012. **11**(1): p. 303.
410. El-Amier, Y.A. and I.A.J.P.A. Aisha, *Phytochemical constituents of common growing Fagonia species (Zygophyllaceae) in Egyptian deserts and its biological activities*. 2019. **19**(2): p. 2213-2219.
411. Saywell, L., B.J.I. Cunningham, and E.C.A. Edition, *Determination of iron: colorimetric o-phenanthroline method*. 1937. **9**(2): p. 67-69.

REFERENCES

412. Hsu, B., I.M. Coupar, and K.J.F.c. Ng, *Antioxidant activity of hot water extract from the fruit of the Doum palm, Hyphaene thebaica*. 2006. **98**(2): p. 317-328.
413. Liu, G., et al., *Circulating vitamin E levels and Alzheimer's disease: a Mendelian randomization study*. 2018. **72**: p. 189. e1-189. e9.
414. Lane, R.M., S.G. Potkin, and A.J.I.J.o.N. Enz, *Targeting acetylcholinesterase and butyrylcholinesterase in dementia*. 2006. **9**(1): p. 101-124.
415. Mesulam, M.-M., et al., *Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine*. 2002. **110**(4): p. 627-639.
416. Cheraif, K., et al., *Chemical composition, antioxidant, anti-tyrosinase, anti-cholinesterase and cytotoxic activities of essential oils of six Algerian plants*. 2020. **25**(7): p. 1710.
417. Szwajgier, D.J.A.o.A. and E. Medicine, *Anticholinesterase activity of selected phenolic acids and flavonoids-interaction testing in model solutions*. 2015. **22**(4).
418. Murray, A.P., et al., *Natural AChE inhibitors from plants and their contribution to Alzheimer's disease therapy*. 2013. **11**(4): p. 388-413.
419. Boukhalkhal, S., et al., *UHPLC-DAD-ESI-MSn profiling variability of the phenolic constituents of Artemisia campestris L. populations growing in Algeria*. 2020. **23**: p. 101483.
420. Maksoud, S.A., M.J.P.s. El-Hadidi, and evolution, *The flavonoids of the Fagonia bruguieri complex (Zygophyllaceae)*. 1987. **155**: p. 311-318.
421. Grundy, D.L., C.C.J.P.b. Still, and physiology, *Inhibition of acetylcholinesterases by pulegone-1, 2-epoxide*. 1985. **23**(3): p. 383-388.
422. WRESDIYATI, T., et al., *Alpha-glucosidase inhibition and hypoglycemic activities of Sweitenia mahagoni seed extract*. 2015. **22**(2): p. 73-78.
423. Rasouli, H., et al., *Differential α -amylase/ α -glucosidase inhibitory activities of plant-derived phenolic compounds: a virtual screening perspective for the treatment of obesity and diabetes*. 2017. **8**(5): p. 1942-1954.
424. Bljajić, K., et al., *Chemical composition, antioxidant, and α -glucosidase-inhibiting activity of aqueous and hydroethanolic extracts of traditional antidiabetics from Croatian ethnomedicine*. 2021. **7**(2): p. 15.
425. Gu, C., et al., *Evaluation of α -amylase and α -glucosidase inhibitory activity of flavonoids*. 2015. **2**(2): p. 174-9.
426. Birari, R.B. and K.K.J.D.d.t. Bhutani, *Pancreatic lipase inhibitors from natural sources: unexplored potential*. 2007. **12**(19-20): p. 879-889.
427. De La Garza, A.L., et al., *Natural inhibitors of pancreatic lipase as new players in obesity treatment*. 2011. **77**(08): p. 773-785.
428. Lunagariya, N.A., et al., *Inhibitors of pancreatic lipase: state of the art and clinical perspectives*. 2014. **13**: p. 897.
429. Ninomiya, K., et al., *Carnosic acid, a new class of lipid absorption inhibitor from sage*. 2004. **14**(8): p. 1943-1946.
430. Al-Snafi, A.E.J.I.J.o.P. and Toxicology, *Therapeutic properties of medicinal plants: a review of their antibacterial activity (part 1)*. 2015. **6**(3): p. 137-158.
431. Patel, D. and V.J.J.o.N.R. Kumar, *Protective effects of fagonia cretica L. Extract in cafeteria diet induced obesity in wistar rats*. 2020: p. 185-190.
432. Bustanji, Y., et al., *Screening of some medicinal plants for their pancreatic lipase inhibitory potential*. 2011. **4**(2): p. 81-88.
433. Patel, D. and V.J.I.J.P.S.D.R. Kumar, *Phytochemical analysis & in-vitro anti obesity activity of different fractions of methanolic extract of Fagonia Cretica L*. 2020. **12**(3): p. 282-286.
434. Angel, G., B. Vimala, and B.J.P. Nambisan, *Antioxidant and anti-inflammatory activities of proteins isolated from eight Curcuma species*. 2013. **4**(1): p. 96-105.
435. Banerjee, M., et al., *Synthesis and in-vitro protein denaturation screening of novel substituted isoxazole/pyrazole derivatives*. 2011. **4**(2): p. 413-417.

REFERENCES

436. Govindappa, M., et al., *Antimicrobial, antioxidant and in vitro anti-inflammatory activity of ethanol extract and active phytochemical screening of Wedelia trilobata (L.) Hitchc.* 2011. **3**(3): p. 43-51.
437. Osman, N.I., et al., *In vitro xanthine oxidase and albumin denaturation inhibition assay of Barringtonia racemosa L. and total phenolic content analysis for potential anti-inflammatory use in gouty arthritis.* 2016. **5**(4): p. 343.
438. Mizushima, Y., M.J.J.o.P. Kobayashi, and Pharmacology, *Interaction of anti-inflammatory drugs with serum proteins, especially with some biologically active proteins.* 1968. **20**(3): p. 169-173.
439. Chandra, S., et al., *Evaluation of in vitro anti-inflammatory activity of coffee against the denaturation of protein.* 2012. **2**(1): p. S178-S180.
440. Jagtap, V., et al., *In vitro anti-inflammatory activity of 2-amino-3-(substituted benzylidinecarbohydrazide)-4, 5, 6, 7-tetrahydrobenzothiophenes.* 2011. **4**(2): p. 378-379.
441. Duganath, N., et al., *Activity of traditionally used medicinal plants.* 2010. **1**(2): p. 1-7.
442. Ifriqya, M., et al., *Biological evaluation of anti-inflammatory activity of Artemisia campestris L. and Spitzelia coronopifolia Desf ethanolic leaves extract.* 2017. **9**(7): p. 1-4.
443. Mishra, A., A. Mishra, and P.J.J.o.Y.P. Chattopadhyay, *Assessment of in vitro sun protection factor of Calendula officinalis L.(asteraceae) essential oil formulation.* 2012. **4**(1): p. 17-21.
444. Dutra, E.A., et al., *Determination of sun protection factor (SPF) of sunscreens by ultraviolet spectrophotometry.* 2004. **40**: p. 381-385.
445. Khazaeli, P. and M.J.I.J.o.P.R. Mehrabani, *Screening of sun protective activity of the ethyl acetate extracts of some medicinal plants.* 2010(1): p. 5-9.
446. Kittiwannachot, P., et al., *Antimutagenic potentials of hydroalcoholic herbal extracts towards UV-induced mutation.* 2008. **23**(1): p. 27-27.
447. Communities, C.o.E., *On Sun Screen Products and Manufacturers Claims.* Recommendation of 22 September 2006.
448. Costa, S.C., et al., *In vitro photoprotective effects of Marcetia taxifolia ethanolic extract and its potential for sunscreen formulations.* 2015. **25**: p. 413-418.
449. Xu, F., et al., *Beneficial health effects of lupenone triterpene: A review.* 2018. **103**: p. 198-203.

ANNEX

Annex I

The gamma-ray spectra were acquired through medium neutron activation analysis and long periods of the *Artemisia campestris* L. and *Fagonia bruguieri* DC. samples.





Figure S1. The medium and long-period gamma-ray spectra of *Artemisia campestris* L.





Figure S1. The medium and long-period gamma-ray spectra of *Fagonia bruguieri* DC.

ANNEX II



Figure N.1. DPPH Assay




Figure N.2. ABTS Assay



Figure N.3. β- Carotene Assay




Figure N.4. Reducing Power Assay




Figure N.5. CUPRAC Assay




Figure N.6. Phenantroline Assay




Figure N.7. GOR Scavenging Assay




Figure N.8. Alpha-amylase Assay

